id	sid	tid	token	lemma	pos
cord-016197-y69wwy40	1	1	key	key	NN
cord-016197-y69wwy40	1	2	:	:	:
cord-016197-y69wwy40	2	1	cord-016197-y69wwy40	cord-016197-y69wwy40	CD
cord-016197-y69wwy40	2	2	authors	author	NNS
cord-016197-y69wwy40	2	3	:	:	:
cord-016197-y69wwy40	2	4	White	white	JJ
cord-016197-y69wwy40	2	5	,	,	,
cord-016197-y69wwy40	2	6	Anthony	Anthony	NNP
cord-016197-y69wwy40	2	7	R.	R.	NNP
cord-016197-y69wwy40	2	8	title	title	NN
cord-016197-y69wwy40	2	9	:	:	:
cord-016197-y69wwy40	2	10	The	the	DT
cord-016197-y69wwy40	2	11	Pharmaceutical	Pharmaceutical	NNP
cord-016197-y69wwy40	2	12	Company	Company	NNP
cord-016197-y69wwy40	2	13	Approach	Approach	NNP
cord-016197-y69wwy40	2	14	to	to	IN
cord-016197-y69wwy40	2	15	Antibiotic	antibiotic	JJ
cord-016197-y69wwy40	2	16	Policies	policy	NNS
cord-016197-y69wwy40	2	17	date	date	NN
cord-016197-y69wwy40	2	18	:	:	:
cord-016197-y69wwy40	2	19	2005	2005	CD
cord-016197-y69wwy40	2	20	journal	journal	NN
cord-016197-y69wwy40	2	21	:	:	:
cord-016197-y69wwy40	3	1	Antibiotic	antibiotic	JJ
cord-016197-y69wwy40	3	2	Policies	policy	NNS
cord-016197-y69wwy40	4	1	DOI	DOI	NNP
cord-016197-y69wwy40	4	2	:	:	:
cord-016197-y69wwy40	5	1	10.1007/0	10.1007/0	CD
cord-016197-y69wwy40	5	2	-	-	SYM
cord-016197-y69wwy40	5	3	387	387	CD
cord-016197-y69wwy40	5	4	-	-	HYPH
cord-016197-y69wwy40	5	5	22852	22852	CD
cord-016197-y69wwy40	5	6	-	-	HYPH
cord-016197-y69wwy40	5	7	7_34	7_34	CD
cord-016197-y69wwy40	5	8	sha	sha	NNP
cord-016197-y69wwy40	5	9	:	:	:
cord-016197-y69wwy40	5	10	a81a9fe70249661c5ba63115452b90390c10c7e6	a81a9fe70249661c5ba63115452b90390c10c7e6	NNS
cord-016197-y69wwy40	5	11	doc_id	doc_id	CD
cord-016197-y69wwy40	5	12	:	:	:
cord-016197-y69wwy40	5	13	16197	16197	CD
cord-016197-y69wwy40	5	14	cord_uid	cord_uid	NNS
cord-016197-y69wwy40	5	15	:	:	:
cord-016197-y69wwy40	6	1	y69wwy40	y69wwy40	NNP
cord-016197-y69wwy40	6	2	nan	nan	NNP
cord-016197-y69wwy40	7	1	The	the	DT
cord-016197-y69wwy40	7	2	word	word	NN
cord-016197-y69wwy40	7	3	"	"	``
cord-016197-y69wwy40	7	4	policy	policy	NN
cord-016197-y69wwy40	7	5	"	"	''
cord-016197-y69wwy40	7	6	is	be	VBZ
cord-016197-y69wwy40	7	7	defined	define	VBN
cord-016197-y69wwy40	7	8	as	as	IN
cord-016197-y69wwy40	7	9	"	"	``
cord-016197-y69wwy40	7	10	prudent	prudent	JJ
cord-016197-y69wwy40	7	11	conduct	conduct	NN
cord-016197-y69wwy40	7	12	,	,	,
cord-016197-y69wwy40	7	13	sagacity	sagacity	NN
cord-016197-y69wwy40	7	14	;	;	:
cord-016197-y69wwy40	7	15	course	course	NN
cord-016197-y69wwy40	7	16	or	or	CC
cord-016197-y69wwy40	7	17	general	general	JJ
cord-016197-y69wwy40	7	18	plan	plan	NN
cord-016197-y69wwy40	7	19	of	of	IN
cord-016197-y69wwy40	7	20	action	action	NN
cord-016197-y69wwy40	7	21	(	(	-LRB-
cord-016197-y69wwy40	7	22	to	to	TO
cord-016197-y69wwy40	7	23	be	be	VB
cord-016197-y69wwy40	7	24	)	)	-RRB-
cord-016197-y69wwy40	7	25	adopted	adopt	VBN
cord-016197-y69wwy40	7	26	by	by	IN
cord-016197-y69wwy40	7	27	government	government	NN
cord-016197-y69wwy40	7	28	,	,	,
cord-016197-y69wwy40	7	29	party	party	NN
cord-016197-y69wwy40	7	30	or	or	CC
cord-016197-y69wwy40	7	31	person	person	NN
cord-016197-y69wwy40	7	32	.	.	.
cord-016197-y69wwy40	7	33	"	"	''
cord-016197-y69wwy40	8	1	In	in	IN
cord-016197-y69wwy40	8	2	this	this	DT
cord-016197-y69wwy40	8	3	sense	sense	NN
cord-016197-y69wwy40	8	4	,	,	,
cord-016197-y69wwy40	8	5	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	8	6	policies	policy	NNS
cord-016197-y69wwy40	8	7	range	range	VBP
cord-016197-y69wwy40	8	8	from	from	IN
cord-016197-y69wwy40	8	9	local	local	JJ
cord-016197-y69wwy40	8	10	hospital	hospital	NN
cord-016197-y69wwy40	8	11	or	or	CC
cord-016197-y69wwy40	8	12	community	community	NN
cord-016197-y69wwy40	8	13	policies	policy	NNS
cord-016197-y69wwy40	8	14	to	to	IN
cord-016197-y69wwy40	8	15	national	national	JJ
cord-016197-y69wwy40	8	16	treatment	treatment	NN
cord-016197-y69wwy40	8	17	guidelines	guideline	NNS
cord-016197-y69wwy40	8	18	for	for	IN
cord-016197-y69wwy40	8	19	specific	specific	JJ
cord-016197-y69wwy40	8	20	infections	infection	NNS
cord-016197-y69wwy40	8	21	,	,	,
cord-016197-y69wwy40	8	22	regulatory	regulatory	JJ
cord-016197-y69wwy40	8	23	policy	policy	NN
cord-016197-y69wwy40	8	24	,	,	,
cord-016197-y69wwy40	8	25	and	and	CC
cord-016197-y69wwy40	8	26	regional	regional	JJ
cord-016197-y69wwy40	8	27	and	and	CC
cord-016197-y69wwy40	8	28	global	global	JJ
cord-016197-y69wwy40	8	29	strategies	strategy	NNS
cord-016197-y69wwy40	8	30	.	.	.
cord-016197-y69wwy40	9	1	All	all	DT
cord-016197-y69wwy40	9	2	have	have	VBP
cord-016197-y69wwy40	9	3	the	the	DT
cord-016197-y69wwy40	9	4	potential	potential	NN
cord-016197-y69wwy40	9	5	to	to	TO
cord-016197-y69wwy40	9	6	impact	impact	VB
cord-016197-y69wwy40	9	7	on	on	IN
cord-016197-y69wwy40	9	8	the	the	DT
cord-016197-y69wwy40	9	9	pharmaceutical	pharmaceutical	NN
cord-016197-y69wwy40	9	10	industries	industry	NNS
cord-016197-y69wwy40	9	11	'	'	POS
cord-016197-y69wwy40	9	12	(	(	-LRB-
cord-016197-y69wwy40	9	13	Pharma	Pharma	NNP
cord-016197-y69wwy40	9	14	)	)	-RRB-
cord-016197-y69wwy40	9	15	integrated	integrate	VBN
cord-016197-y69wwy40	9	16	activities	activity	NNS
cord-016197-y69wwy40	9	17	of	of	IN
cord-016197-y69wwy40	9	18	discovering	discover	VBG
cord-016197-y69wwy40	9	19	,	,	,
cord-016197-y69wwy40	9	20	developing	develop	VBG
cord-016197-y69wwy40	9	21	,	,	,
cord-016197-y69wwy40	9	22	and	and	CC
cord-016197-y69wwy40	9	23	marketing	marketing	NN
cord-016197-y69wwy40	9	24	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	9	25	.	.	.
cord-016197-y69wwy40	10	1	This	this	DT
cord-016197-y69wwy40	10	2	article	article	NN
cord-016197-y69wwy40	10	3	reviews	review	VBZ
cord-016197-y69wwy40	10	4	the	the	DT
cord-016197-y69wwy40	10	5	relationship	relationship	NN
cord-016197-y69wwy40	10	6	between	between	IN
cord-016197-y69wwy40	10	7	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	10	8	policies	policy	NNS
cord-016197-y69wwy40	10	9	and	and	CC
cord-016197-y69wwy40	10	10	the	the	DT
cord-016197-y69wwy40	10	11	role	role	NN
cord-016197-y69wwy40	10	12	of	of	IN
cord-016197-y69wwy40	10	13	Pharma	Pharma	NNP
cord-016197-y69wwy40	10	14	.	.	.
cord-016197-y69wwy40	11	1	For	for	IN
cord-016197-y69wwy40	11	2	almost	almost	RB
cord-016197-y69wwy40	11	3	70	70	CD
cord-016197-y69wwy40	11	4	years	year	NNS
cord-016197-y69wwy40	11	5	,	,	,
cord-016197-y69wwy40	11	6	Pharma	Pharma	NNP
cord-016197-y69wwy40	11	7	has	have	VBZ
cord-016197-y69wwy40	11	8	played	play	VBN
cord-016197-y69wwy40	11	9	a	a	DT
cord-016197-y69wwy40	11	10	major	major	JJ
cord-016197-y69wwy40	11	11	role	role	NN
cord-016197-y69wwy40	11	12	in	in	IN
cord-016197-y69wwy40	11	13	discovering	discover	VBG
cord-016197-y69wwy40	11	14	,	,	,
cord-016197-y69wwy40	11	15	developing	develop	VBG
cord-016197-y69wwy40	11	16	,	,	,
cord-016197-y69wwy40	11	17	and	and	CC
cord-016197-y69wwy40	11	18	making	make	VBG
cord-016197-y69wwy40	11	19	available	available	JJ
cord-016197-y69wwy40	11	20	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	11	21	for	for	IN
cord-016197-y69wwy40	11	22	human	human	JJ
cord-016197-y69wwy40	11	23	and	and	CC
cord-016197-y69wwy40	11	24	veterinary	veterinary	JJ
cord-016197-y69wwy40	11	25	use	use	NN
cord-016197-y69wwy40	11	26	(	(	-LRB-
cord-016197-y69wwy40	11	27	Garrod	Garrod	NNP
cord-016197-y69wwy40	11	28	et	et	NNP
cord-016197-y69wwy40	11	29	al	al	NNP
cord-016197-y69wwy40	11	30	.	.	NNP
cord-016197-y69wwy40	11	31	,	,	,
cord-016197-y69wwy40	11	32	1981	1981	CD
cord-016197-y69wwy40	11	33	)	)	-RRB-
cord-016197-y69wwy40	11	34	.	.	.
cord-016197-y69wwy40	12	1	Today	today	NN
cord-016197-y69wwy40	12	2	,	,	,
cord-016197-y69wwy40	12	3	more	more	JJR
cord-016197-y69wwy40	12	4	than	than	IN
cord-016197-y69wwy40	12	5	in	in	IN
cord-016197-y69wwy40	12	6	recent	recent	JJ
cord-016197-y69wwy40	12	7	decades	decade	NNS
cord-016197-y69wwy40	12	8	,	,	,
cord-016197-y69wwy40	12	9	there	there	EX
cord-016197-y69wwy40	12	10	are	be	VBP
cord-016197-y69wwy40	12	11	high	high	JJ
cord-016197-y69wwy40	12	12	demands	demand	NNS
cord-016197-y69wwy40	12	13	on	on	IN
cord-016197-y69wwy40	12	14	Pharma	Pharma	NNP
cord-016197-y69wwy40	12	15	to	to	TO
cord-016197-y69wwy40	12	16	deliver	deliver	VB
cord-016197-y69wwy40	12	17	to	to	IN
cord-016197-y69wwy40	12	18	patients	patient	NNS
cord-016197-y69wwy40	12	19	new	new	JJ
cord-016197-y69wwy40	12	20	,	,	,
cord-016197-y69wwy40	12	21	effective	effective	JJ
cord-016197-y69wwy40	12	22	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	12	23	to	to	TO
cord-016197-y69wwy40	12	24	replace	replace	VB
cord-016197-y69wwy40	12	25	those	those	DT
cord-016197-y69wwy40	12	26	agents	agent	NNS
cord-016197-y69wwy40	12	27	for	for	IN
cord-016197-y69wwy40	12	28	which	which	WDT
cord-016197-y69wwy40	12	29	clinical	clinical	JJ
cord-016197-y69wwy40	12	30	utility	utility	NN
cord-016197-y69wwy40	12	31	is	be	VBZ
cord-016197-y69wwy40	12	32	compromised	compromise	VBN
cord-016197-y69wwy40	12	33	by	by	IN
cord-016197-y69wwy40	12	34	emerging	emerge	VBG
cord-016197-y69wwy40	12	35	bacterial	bacterial	JJ
cord-016197-y69wwy40	12	36	resistance	resistance	NN
cord-016197-y69wwy40	12	37	.	.	.
cord-016197-y69wwy40	13	1	This	this	DT
cord-016197-y69wwy40	13	2	"	"	``
cord-016197-y69wwy40	13	3	crisis	crisis	NN
cord-016197-y69wwy40	13	4	,	,	,
cord-016197-y69wwy40	13	5	"	"	''
cord-016197-y69wwy40	13	6	with	with	IN
cord-016197-y69wwy40	13	7	the	the	DT
cord-016197-y69wwy40	13	8	daunting	daunting	JJ
cord-016197-y69wwy40	13	9	prospect	prospect	NN
cord-016197-y69wwy40	13	10	that	that	IN
cord-016197-y69wwy40	13	11	one	one	CD
cord-016197-y69wwy40	13	12	of	of	IN
cord-016197-y69wwy40	13	13	the	the	DT
cord-016197-y69wwy40	13	14	most	most	RBS
cord-016197-y69wwy40	13	15	beneficial	beneficial	JJ
cord-016197-y69wwy40	13	16	discoveries	discovery	NNS
cord-016197-y69wwy40	13	17	and	and	CC
cord-016197-y69wwy40	13	18	developments	development	NNS
cord-016197-y69wwy40	13	19	in	in	IN
cord-016197-y69wwy40	13	20	the	the	DT
cord-016197-y69wwy40	13	21	history	history	NN
cord-016197-y69wwy40	13	22	of	of	IN
cord-016197-y69wwy40	13	23	mankind	mankind	NN
cord-016197-y69wwy40	13	24	could	could	MD
cord-016197-y69wwy40	13	25	become	become	VB
cord-016197-y69wwy40	13	26	extinct	extinct	JJ
cord-016197-y69wwy40	13	27	within	within	IN
cord-016197-y69wwy40	13	28	a	a	DT
cord-016197-y69wwy40	13	29	mere	mere	JJ
cord-016197-y69wwy40	13	30	few	few	JJ
cord-016197-y69wwy40	13	31	human	human	JJ
cord-016197-y69wwy40	13	32	generations	generation	NNS
cord-016197-y69wwy40	13	33	,	,	,
cord-016197-y69wwy40	13	34	has	have	VBZ
cord-016197-y69wwy40	13	35	understandably	understandably	RB
cord-016197-y69wwy40	13	36	also	also	RB
cord-016197-y69wwy40	13	37	prompted	prompt	VBN
cord-016197-y69wwy40	13	38	a	a	DT
cord-016197-y69wwy40	13	39	wide	wide	JJ
cord-016197-y69wwy40	13	40	range	range	NN
cord-016197-y69wwy40	13	41	of	of	IN
cord-016197-y69wwy40	13	42	recommendations	recommendation	NNS
cord-016197-y69wwy40	13	43	,	,	,
cord-016197-y69wwy40	13	44	guidelines	guideline	NNS
cord-016197-y69wwy40	13	45	,	,	,
cord-016197-y69wwy40	13	46	and	and	CC
cord-016197-y69wwy40	13	47	policies	policy	NNS
cord-016197-y69wwy40	13	48	with	with	IN
cord-016197-y69wwy40	13	49	the	the	DT
cord-016197-y69wwy40	13	50	intent	intent	NN
cord-016197-y69wwy40	13	51	of	of	IN
cord-016197-y69wwy40	13	52	preserving	preserve	VBG
cord-016197-y69wwy40	13	53	and	and	CC
cord-016197-y69wwy40	13	54	protracting	protract	VBG
cord-016197-y69wwy40	13	55	the	the	DT
cord-016197-y69wwy40	13	56	utility	utility	NN
cord-016197-y69wwy40	13	57	of	of	IN
cord-016197-y69wwy40	13	58	our	-PRON-	PRP$
cord-016197-y69wwy40	13	59	current	current	JJ
cord-016197-y69wwy40	13	60	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	13	61	armamentarium	armamentarium	NN
cord-016197-y69wwy40	13	62	.	.	.
cord-016197-y69wwy40	14	1	However	however	RB
cord-016197-y69wwy40	14	2	,	,	,
cord-016197-y69wwy40	14	3	in	in	IN
cord-016197-y69wwy40	14	4	some	some	DT
cord-016197-y69wwy40	14	5	cases	case	NNS
cord-016197-y69wwy40	14	6	,	,	,
cord-016197-y69wwy40	14	7	these	these	DT
cord-016197-y69wwy40	14	8	policies	policy	NNS
cord-016197-y69wwy40	14	9	themselves	-PRON-	PRP
cord-016197-y69wwy40	14	10	are	be	VBP
cord-016197-y69wwy40	14	11	reducing	reduce	VBG
cord-016197-y69wwy40	14	12	the	the	DT
cord-016197-y69wwy40	14	13	chance	chance	NN
cord-016197-y69wwy40	14	14	of	of	IN
cord-016197-y69wwy40	14	15	success	success	NN
cord-016197-y69wwy40	14	16	of	of	IN
cord-016197-y69wwy40	14	17	Pharma	Pharma	NNP
cord-016197-y69wwy40	14	18	delivering	deliver	VBG
cord-016197-y69wwy40	14	19	the	the	DT
cord-016197-y69wwy40	14	20	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	14	21	agents	agent	NNS
cord-016197-y69wwy40	14	22	for	for	IN
cord-016197-y69wwy40	14	23	the	the	DT
cord-016197-y69wwy40	14	24	future	future	NN
cord-016197-y69wwy40	14	25	.	.	.
cord-016197-y69wwy40	15	1	In	in	IN
cord-016197-y69wwy40	15	2	order	order	NN
cord-016197-y69wwy40	15	3	to	to	TO
cord-016197-y69wwy40	15	4	succeed	succeed	VB
cord-016197-y69wwy40	15	5	,	,	,
cord-016197-y69wwy40	15	6	Pharma	Pharma	NNP
cord-016197-y69wwy40	15	7	will	will	MD
cord-016197-y69wwy40	15	8	need	need	VB
cord-016197-y69wwy40	15	9	to	to	TO
cord-016197-y69wwy40	15	10	adapt	adapt	VB
cord-016197-y69wwy40	15	11	to	to	IN
cord-016197-y69wwy40	15	12	the	the	DT
cord-016197-y69wwy40	15	13	new	new	JJ
cord-016197-y69wwy40	15	14	environment	environment	NN
cord-016197-y69wwy40	15	15	,	,	,
cord-016197-y69wwy40	15	16	but	but	CC
cord-016197-y69wwy40	15	17	there	there	EX
cord-016197-y69wwy40	15	18	is	be	VBZ
cord-016197-y69wwy40	15	19	a	a	DT
cord-016197-y69wwy40	15	20	very	very	RB
cord-016197-y69wwy40	15	21	real	real	JJ
cord-016197-y69wwy40	15	22	and	and	CC
cord-016197-y69wwy40	15	23	immediate	immediate	JJ
cord-016197-y69wwy40	15	24	danger	danger	NN
cord-016197-y69wwy40	15	25	that	that	IN
cord-016197-y69wwy40	15	26	the	the	DT
cord-016197-y69wwy40	15	27	extent	extent	NN
cord-016197-y69wwy40	15	28	of	of	IN
cord-016197-y69wwy40	15	29	change	change	NN
cord-016197-y69wwy40	15	30	in	in	IN
cord-016197-y69wwy40	15	31	the	the	DT
cord-016197-y69wwy40	15	32	environment	environment	NN
cord-016197-y69wwy40	15	33	is	be	VBZ
cord-016197-y69wwy40	15	34	presenting	present	VBG
cord-016197-y69wwy40	15	35	significant	significant	JJ
cord-016197-y69wwy40	15	36	hurdles	hurdle	NNS
cord-016197-y69wwy40	15	37	that	that	WDT
cord-016197-y69wwy40	15	38	will	will	MD
cord-016197-y69wwy40	15	39	prevent	prevent	VB
cord-016197-y69wwy40	15	40	or	or	CC
cord-016197-y69wwy40	15	41	delay	delay	VB
cord-016197-y69wwy40	15	42	the	the	DT
cord-016197-y69wwy40	15	43	discovery	discovery	NN
cord-016197-y69wwy40	15	44	and	and	CC
cord-016197-y69wwy40	15	45	delivery	delivery	NN
cord-016197-y69wwy40	15	46	of	of	IN
cord-016197-y69wwy40	15	47	new	new	JJ
cord-016197-y69wwy40	15	48	agents	agent	NNS
cord-016197-y69wwy40	15	49	.	.	.
cord-016197-y69wwy40	16	1	A	a	DT
cord-016197-y69wwy40	16	2	greater	great	JJR
cord-016197-y69wwy40	16	3	understanding	understanding	NN
cord-016197-y69wwy40	16	4	of	of	IN
cord-016197-y69wwy40	16	5	the	the	DT
cord-016197-y69wwy40	16	6	collective	collective	JJ
cord-016197-y69wwy40	16	7	impact	impact	NN
cord-016197-y69wwy40	16	8	of	of	IN
cord-016197-y69wwy40	16	9	policies	policy	NNS
cord-016197-y69wwy40	16	10	on	on	IN
cord-016197-y69wwy40	16	11	Pharma	Pharma	NNP
cord-016197-y69wwy40	16	12	's	's	POS
cord-016197-y69wwy40	16	13	ability	ability	NN
cord-016197-y69wwy40	16	14	and	and	CC
cord-016197-y69wwy40	16	15	willingness	willingness	NN
cord-016197-y69wwy40	16	16	to	to	TO
cord-016197-y69wwy40	16	17	conduct	conduct	VB
cord-016197-y69wwy40	16	18	sustainable	sustainable	JJ
cord-016197-y69wwy40	16	19	research	research	NN
cord-016197-y69wwy40	16	20	and	and	CC
cord-016197-y69wwy40	16	21	development	development	NN
cord-016197-y69wwy40	16	22	(	(	-LRB-
cord-016197-y69wwy40	16	23	R&D	r&d	NN
cord-016197-y69wwy40	16	24	)	)	-RRB-
cord-016197-y69wwy40	16	25	of	of	IN
cord-016197-y69wwy40	16	26	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	16	27	is	be	VBZ
cord-016197-y69wwy40	16	28	needed	need	VBN
cord-016197-y69wwy40	16	29	along	along	RP
cord-016197-y69wwy40	16	30	with	with	IN
cord-016197-y69wwy40	16	31	a	a	DT
cord-016197-y69wwy40	16	32	cooperative	cooperative	JJ
cord-016197-y69wwy40	16	33	partnership	partnership	NN
cord-016197-y69wwy40	16	34	approach	approach	NN
cord-016197-y69wwy40	16	35	.	.	.
cord-016197-y69wwy40	17	1	There	there	EX
cord-016197-y69wwy40	17	2	is	be	VBZ
cord-016197-y69wwy40	17	3	a	a	DT
cord-016197-y69wwy40	17	4	need	need	NN
cord-016197-y69wwy40	17	5	for	for	IN
cord-016197-y69wwy40	17	6	governments	government	NNS
cord-016197-y69wwy40	17	7	,	,	,
cord-016197-y69wwy40	17	8	nongovernmental	nongovernmental	JJ
cord-016197-y69wwy40	17	9	organizations	organization	NNS
cord-016197-y69wwy40	17	10	(	(	-LRB-
cord-016197-y69wwy40	17	11	NGOs	NGOs	NNPS
cord-016197-y69wwy40	17	12	)	)	-RRB-
cord-016197-y69wwy40	17	13	,	,	,
cord-016197-y69wwy40	17	14	policy	policy	NN
cord-016197-y69wwy40	17	15	-	-	HYPH
cord-016197-y69wwy40	17	16	makers	maker	NNS
cord-016197-y69wwy40	17	17	,	,	,
cord-016197-y69wwy40	17	18	regulators	regulator	NNS
cord-016197-y69wwy40	17	19	,	,	,
cord-016197-y69wwy40	17	20	and	and	CC
cord-016197-y69wwy40	17	21	infectious	infectious	JJ
cord-016197-y69wwy40	17	22	disease	disease	NN
cord-016197-y69wwy40	17	23	experts	expert	NNS
cord-016197-y69wwy40	17	24	to	to	TO
cord-016197-y69wwy40	17	25	collaborate	collaborate	VB
cord-016197-y69wwy40	17	26	with	with	IN
cord-016197-y69wwy40	17	27	Pharma	Pharma	NNS
cord-016197-y69wwy40	17	28	to	to	TO
cord-016197-y69wwy40	17	29	establish	establish	VB
cord-016197-y69wwy40	17	30	ways	way	NNS
cord-016197-y69wwy40	17	31	to	to	TO
cord-016197-y69wwy40	17	32	maximize	maximize	VB
cord-016197-y69wwy40	17	33	the	the	DT
cord-016197-y69wwy40	17	34	chance	chance	NN
cord-016197-y69wwy40	17	35	of	of	IN
cord-016197-y69wwy40	17	36	bringing	bring	VBG
cord-016197-y69wwy40	17	37	new	new	JJ
cord-016197-y69wwy40	17	38	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	17	39	into	into	IN
cord-016197-y69wwy40	17	40	clinical	clinical	JJ
cord-016197-y69wwy40	17	41	use	use	NN
cord-016197-y69wwy40	17	42	and	and	CC
cord-016197-y69wwy40	17	43	sustain	sustain	VB
cord-016197-y69wwy40	17	44	their	-PRON-	PRP$
cord-016197-y69wwy40	17	45	utility	utility	NN
cord-016197-y69wwy40	17	46	.	.	.
cord-016197-y69wwy40	18	1	Unfortunately	unfortunately	RB
cord-016197-y69wwy40	18	2	,	,	,
cord-016197-y69wwy40	18	3	individual	individual	JJ
cord-016197-y69wwy40	18	4	Pharma	Pharma	NNP
cord-016197-y69wwy40	18	5	companies	company	NNS
cord-016197-y69wwy40	18	6	continue	continue	VBP
cord-016197-y69wwy40	18	7	to	to	TO
cord-016197-y69wwy40	18	8	exit	exit	VB
cord-016197-y69wwy40	18	9	from	from	IN
cord-016197-y69wwy40	18	10	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	18	11	discovery	discovery	NN
cord-016197-y69wwy40	18	12	and	and	CC
cord-016197-y69wwy40	18	13	development	development	NN
cord-016197-y69wwy40	18	14	and	and	CC
cord-016197-y69wwy40	18	15	the	the	DT
cord-016197-y69wwy40	18	16	pool	pool	NN
cord-016197-y69wwy40	18	17	of	of	IN
cord-016197-y69wwy40	18	18	major	major	JJ
cord-016197-y69wwy40	18	19	companies	company	NNS
cord-016197-y69wwy40	18	20	is	be	VBZ
cord-016197-y69wwy40	18	21	likely	likely	JJ
cord-016197-y69wwy40	18	22	to	to	TO
cord-016197-y69wwy40	18	23	soon	soon	RB
cord-016197-y69wwy40	18	24	be	be	VB
cord-016197-y69wwy40	18	25	occupied	occupy	VBN
cord-016197-y69wwy40	18	26	by	by	IN
cord-016197-y69wwy40	18	27	a	a	DT
cord-016197-y69wwy40	18	28	handful	handful	NN
cord-016197-y69wwy40	18	29	or	or	CC
cord-016197-y69wwy40	18	30	less	less	JJR
cord-016197-y69wwy40	18	31	,	,	,
cord-016197-y69wwy40	18	32	severely	severely	RB
cord-016197-y69wwy40	18	33	restricting	restrict	VBG
cord-016197-y69wwy40	18	34	the	the	DT
cord-016197-y69wwy40	18	35	ability	ability	NN
cord-016197-y69wwy40	18	36	of	of	IN
cord-016197-y69wwy40	18	37	Pharma	Pharma	NNP
cord-016197-y69wwy40	18	38	to	to	TO
cord-016197-y69wwy40	18	39	meet	meet	VB
cord-016197-y69wwy40	18	40	the	the	DT
cord-016197-y69wwy40	18	41	medical	medical	JJ
cord-016197-y69wwy40	18	42	needs	need	NNS
cord-016197-y69wwy40	18	43	of	of	IN
cord-016197-y69wwy40	18	44	infectious	infectious	JJ
cord-016197-y69wwy40	18	45	diseases	disease	NNS
cord-016197-y69wwy40	18	46	,	,	,
cord-016197-y69wwy40	18	47	particularly	particularly	RB
cord-016197-y69wwy40	18	48	those	those	DT
cord-016197-y69wwy40	18	49	which	which	WDT
cord-016197-y69wwy40	18	50	require	require	VBP
cord-016197-y69wwy40	18	51	flexibility	flexibility	NN
cord-016197-y69wwy40	18	52	and	and	CC
cord-016197-y69wwy40	18	53	responsiveness	responsiveness	NN
cord-016197-y69wwy40	18	54	,	,	,
cord-016197-y69wwy40	18	55	such	such	JJ
cord-016197-y69wwy40	18	56	as	as	IN
cord-016197-y69wwy40	18	57	epidemics	epidemic	NNS
cord-016197-y69wwy40	18	58	and	and	CC
cord-016197-y69wwy40	18	59	those	those	DT
cord-016197-y69wwy40	18	60	arising	arise	VBG
cord-016197-y69wwy40	18	61	from	from	IN
cord-016197-y69wwy40	18	62	bioterrorism	bioterrorism	NN
cord-016197-y69wwy40	18	63	.	.	.
cord-016197-y69wwy40	19	1	Once	once	IN
cord-016197-y69wwy40	19	2	R&D	r&d	NN
cord-016197-y69wwy40	19	3	efforts	effort	NNS
cord-016197-y69wwy40	19	4	are	be	VBP
cord-016197-y69wwy40	19	5	terminated	terminate	VBN
cord-016197-y69wwy40	19	6	it	-PRON-	PRP
cord-016197-y69wwy40	19	7	will	will	MD
cord-016197-y69wwy40	19	8	require	require	VB
cord-016197-y69wwy40	19	9	substantial	substantial	JJ
cord-016197-y69wwy40	19	10	new	new	JJ
cord-016197-y69wwy40	19	11	investment	investment	NN
cord-016197-y69wwy40	19	12	,	,	,
cord-016197-y69wwy40	19	13	both	both	DT
cord-016197-y69wwy40	19	14	in	in	IN
cord-016197-y69wwy40	19	15	monetary	monetary	JJ
cord-016197-y69wwy40	19	16	and	and	CC
cord-016197-y69wwy40	19	17	intellectual	intellectual	JJ
cord-016197-y69wwy40	19	18	terms	term	NNS
cord-016197-y69wwy40	19	19	,	,	,
cord-016197-y69wwy40	19	20	as	as	RB
cord-016197-y69wwy40	19	21	well	well	RB
cord-016197-y69wwy40	19	22	as	as	IN
cord-016197-y69wwy40	19	23	time	time	NN
cord-016197-y69wwy40	19	24	to	to	TO
cord-016197-y69wwy40	19	25	re	re	VB
cord-016197-y69wwy40	19	26	-	-	VB
cord-016197-y69wwy40	19	27	initiate	initiate	VB
cord-016197-y69wwy40	19	28	effective	effective	JJ
cord-016197-y69wwy40	19	29	programmes	programme	NNS
cord-016197-y69wwy40	19	30	.	.	.
cord-016197-y69wwy40	20	1	Without	without	IN
cord-016197-y69wwy40	20	2	continued	continue	VBN
cord-016197-y69wwy40	20	3	,	,	,
cord-016197-y69wwy40	20	4	sustainable	sustainable	JJ
cord-016197-y69wwy40	20	5	,	,	,
cord-016197-y69wwy40	20	6	and	and	CC
cord-016197-y69wwy40	20	7	successful	successful	JJ
cord-016197-y69wwy40	20	8	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	20	9	R&D	r&d	NN
cord-016197-y69wwy40	20	10	,	,	,
cord-016197-y69wwy40	20	11	we	-PRON-	PRP
cord-016197-y69wwy40	20	12	will	will	MD
cord-016197-y69wwy40	20	13	certainly	certainly	RB
cord-016197-y69wwy40	20	14	be	be	VB
cord-016197-y69wwy40	20	15	facing	face	VBG
cord-016197-y69wwy40	20	16	the	the	DT
cord-016197-y69wwy40	20	17	prospect	prospect	NN
cord-016197-y69wwy40	20	18	of	of	IN
cord-016197-y69wwy40	20	19	"	"	``
cord-016197-y69wwy40	20	20	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	20	21	extinction	extinction	NN
cord-016197-y69wwy40	20	22	.	.	.
cord-016197-y69wwy40	21	1	"	"	``
cord-016197-y69wwy40	21	2	There	there	EX
cord-016197-y69wwy40	21	3	is	be	VBZ
cord-016197-y69wwy40	21	4	no	no	DT
cord-016197-y69wwy40	21	5	doubt	doubt	NN
cord-016197-y69wwy40	21	6	that	that	IN
cord-016197-y69wwy40	21	7	research	research	NN
cord-016197-y69wwy40	21	8	-	-	HYPH
cord-016197-y69wwy40	21	9	based	base	VBN
cord-016197-y69wwy40	21	10	Pharma	Pharma	NNS
cord-016197-y69wwy40	21	11	has	have	VBZ
cord-016197-y69wwy40	21	12	for	for	IN
cord-016197-y69wwy40	21	13	many	many	JJ
cord-016197-y69wwy40	21	14	years	year	NNS
cord-016197-y69wwy40	21	15	been	be	VBN
cord-016197-y69wwy40	21	16	instrumental	instrumental	JJ
cord-016197-y69wwy40	21	17	in	in	IN
cord-016197-y69wwy40	21	18	providing	provide	VBG
cord-016197-y69wwy40	21	19	the	the	DT
cord-016197-y69wwy40	21	20	wide	wide	JJ
cord-016197-y69wwy40	21	21	range	range	NN
cord-016197-y69wwy40	21	22	of	of	IN
cord-016197-y69wwy40	21	23	clinically	clinically	RB
cord-016197-y69wwy40	21	24	important	important	JJ
cord-016197-y69wwy40	21	25	agents	agent	NNS
cord-016197-y69wwy40	21	26	which	which	WDT
cord-016197-y69wwy40	21	27	are	be	VBP
cord-016197-y69wwy40	21	28	available	available	JJ
cord-016197-y69wwy40	21	29	today	today	NN
cord-016197-y69wwy40	21	30	.	.	.
cord-016197-y69wwy40	22	1	Garrod	Garrod	NNP
cord-016197-y69wwy40	22	2	et	et	NNP
cord-016197-y69wwy40	22	3	al	al	NNP
cord-016197-y69wwy40	22	4	.	.	.
cord-016197-y69wwy40	23	1	(	(	-LRB-
cord-016197-y69wwy40	23	2	1981	1981	CD
cord-016197-y69wwy40	23	3	)	)	-RRB-
cord-016197-y69wwy40	23	4	described	describe	VBD
cord-016197-y69wwy40	23	5	three	three	CD
cord-016197-y69wwy40	23	6	eras	era	NNS
cord-016197-y69wwy40	23	7	of	of	IN
cord-016197-y69wwy40	23	8	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	23	9	chemotherapy	chemotherapy	NN
cord-016197-y69wwy40	23	10	:	:	:
cord-016197-y69wwy40	24	1	•	•	NNP
cord-016197-y69wwy40	24	2	alkaloids	alkaloid	NNS
cord-016197-y69wwy40	24	3	:	:	:
cord-016197-y69wwy40	24	4	from	from	IN
cord-016197-y69wwy40	24	5	1619	1619	CD
cord-016197-y69wwy40	24	6	and	and	CC
cord-016197-y69wwy40	24	7	use	use	NN
cord-016197-y69wwy40	24	8	of	of	IN
cord-016197-y69wwy40	24	9	cinchona	cinchona	NN
cord-016197-y69wwy40	24	10	bark	bark	NN
cord-016197-y69wwy40	24	11	to	to	TO
cord-016197-y69wwy40	24	12	treat	treat	VB
cord-016197-y69wwy40	24	13	malaria	malaria	NN
cord-016197-y69wwy40	24	14	•	•	CD
cord-016197-y69wwy40	24	15	synthetic	synthetic	JJ
cord-016197-y69wwy40	24	16	compounds	compound	NNS
cord-016197-y69wwy40	24	17	:	:	:
cord-016197-y69wwy40	24	18	from	from	IN
cord-016197-y69wwy40	24	19	1909	1909	CD
cord-016197-y69wwy40	24	20	and	and	CC
cord-016197-y69wwy40	24	21	the	the	DT
cord-016197-y69wwy40	24	22	discovery	discovery	NN
cord-016197-y69wwy40	24	23	of	of	IN
cord-016197-y69wwy40	24	24	the	the	DT
cord-016197-y69wwy40	24	25	arsenical	arsenical	JJ
cord-016197-y69wwy40	24	26	salvarsan	salvarsan	NNP
cord-016197-y69wwy40	24	27	by	by	IN
cord-016197-y69wwy40	24	28	Ehrlich	Ehrlich	NNP
cord-016197-y69wwy40	24	29	,	,	,
cord-016197-y69wwy40	24	30	and	and	CC
cord-016197-y69wwy40	24	31	including	include	VBG
cord-016197-y69wwy40	24	32	Prontosil	Prontosil	NNP
cord-016197-y69wwy40	24	33	/	/	SYM
cord-016197-y69wwy40	24	34	sulfonamides	sulfonamide	NNS
cord-016197-y69wwy40	24	35	in	in	IN
cord-016197-y69wwy40	24	36	1935	1935	CD
cord-016197-y69wwy40	25	1	•	•	NNP
cord-016197-y69wwy40	25	2	antibiotics	antibiotic	NNS
cord-016197-y69wwy40	25	3	:	:	:
cord-016197-y69wwy40	25	4	from	from	IN
cord-016197-y69wwy40	25	5	1929	1929	CD
cord-016197-y69wwy40	25	6	with	with	IN
cord-016197-y69wwy40	25	7	the	the	DT
cord-016197-y69wwy40	25	8	discovery	discovery	NN
cord-016197-y69wwy40	25	9	of	of	IN
cord-016197-y69wwy40	25	10	penicillin	penicillin	NN
cord-016197-y69wwy40	25	11	.	.	.
cord-016197-y69wwy40	26	1	Pharma	Pharma	NNP
cord-016197-y69wwy40	26	2	has	have	VBZ
cord-016197-y69wwy40	26	3	been	be	VBN
cord-016197-y69wwy40	26	4	predominant	predominant	JJ
cord-016197-y69wwy40	26	5	in	in	IN
cord-016197-y69wwy40	26	6	discovering	discover	VBG
cord-016197-y69wwy40	26	7	or	or	CC
cord-016197-y69wwy40	26	8	developing	develop	VBG
cord-016197-y69wwy40	26	9	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	26	10	in	in	IN
cord-016197-y69wwy40	26	11	the	the	DT
cord-016197-y69wwy40	26	12	two	two	CD
cord-016197-y69wwy40	26	13	most	most	RBS
cord-016197-y69wwy40	26	14	recent	recent	JJ
cord-016197-y69wwy40	26	15	of	of	IN
cord-016197-y69wwy40	26	16	these	these	DT
cord-016197-y69wwy40	26	17	three	three	CD
cord-016197-y69wwy40	26	18	eras	era	NNS
cord-016197-y69wwy40	26	19	.	.	.
cord-016197-y69wwy40	27	1	While	while	IN
cord-016197-y69wwy40	27	2	not	not	RB
cord-016197-y69wwy40	27	3	all	all	DT
cord-016197-y69wwy40	27	4	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	27	5	were	be	VBD
cord-016197-y69wwy40	27	6	discovered	discover	VBN
cord-016197-y69wwy40	27	7	by	by	IN
cord-016197-y69wwy40	27	8	Pharma	Pharma	NNP
cord-016197-y69wwy40	27	9	,	,	,
cord-016197-y69wwy40	27	10	many	many	JJ
cord-016197-y69wwy40	27	11	of	of	IN
cord-016197-y69wwy40	27	12	the	the	DT
cord-016197-y69wwy40	27	13	early	early	JJ
cord-016197-y69wwy40	27	14	members	member	NNS
cord-016197-y69wwy40	27	15	of	of	IN
cord-016197-y69wwy40	27	16	today	today	NN
cord-016197-y69wwy40	27	17	's	's	POS
cord-016197-y69wwy40	27	18	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	27	19	classes	class	NNS
cord-016197-y69wwy40	27	20	were	be	VBD
cord-016197-y69wwy40	27	21	brought	bring	VBN
cord-016197-y69wwy40	27	22	to	to	IN
cord-016197-y69wwy40	27	23	clinical	clinical	JJ
cord-016197-y69wwy40	27	24	use	use	NN
cord-016197-y69wwy40	27	25	through	through	IN
cord-016197-y69wwy40	27	26	the	the	DT
cord-016197-y69wwy40	27	27	development	development	NN
cord-016197-y69wwy40	27	28	and	and	CC
cord-016197-y69wwy40	27	29	scale	scale	NN
cord-016197-y69wwy40	27	30	-	-	HYPH
cord-016197-y69wwy40	27	31	up	up	RP
cord-016197-y69wwy40	27	32	activities	activity	NNS
cord-016197-y69wwy40	27	33	of	of	IN
cord-016197-y69wwy40	27	34	Pharma	Pharma	NNP
cord-016197-y69wwy40	27	35	,	,	,
cord-016197-y69wwy40	27	36	in	in	IN
cord-016197-y69wwy40	27	37	some	some	DT
cord-016197-y69wwy40	27	38	cases	case	NNS
cord-016197-y69wwy40	27	39	through	through	IN
cord-016197-y69wwy40	27	40	collaboration	collaboration	NN
cord-016197-y69wwy40	27	41	by	by	IN
cord-016197-y69wwy40	27	42	a	a	DT
cord-016197-y69wwy40	27	43	number	number	NN
cord-016197-y69wwy40	27	44	of	of	IN
cord-016197-y69wwy40	27	45	companies	company	NNS
cord-016197-y69wwy40	27	46	,	,	,
cord-016197-y69wwy40	27	47	notably	notably	RB
cord-016197-y69wwy40	27	48	in	in	IN
cord-016197-y69wwy40	27	49	the	the	DT
cord-016197-y69wwy40	27	50	development	development	NN
cord-016197-y69wwy40	27	51	of	of	IN
cord-016197-y69wwy40	27	52	penicillin	penicillin	NN
cord-016197-y69wwy40	27	53	G	g	NN
cord-016197-y69wwy40	27	54	in	in	IN
cord-016197-y69wwy40	27	55	the	the	DT
cord-016197-y69wwy40	27	56	1940s	1940	NNS
cord-016197-y69wwy40	27	57	.	.	.
cord-016197-y69wwy40	28	1	The	the	DT
cord-016197-y69wwy40	28	2	majority	majority	NN
cord-016197-y69wwy40	28	3	of	of	IN
cord-016197-y69wwy40	28	4	discoveries	discovery	NNS
cord-016197-y69wwy40	28	5	and	and	CC
cord-016197-y69wwy40	28	6	developments	development	NNS
cord-016197-y69wwy40	28	7	that	that	WDT
cord-016197-y69wwy40	28	8	have	have	VBP
cord-016197-y69wwy40	28	9	produced	produce	VBN
cord-016197-y69wwy40	28	10	the	the	DT
cord-016197-y69wwy40	28	11	major	major	JJ
cord-016197-y69wwy40	28	12	classes	class	NNS
cord-016197-y69wwy40	28	13	of	of	IN
cord-016197-y69wwy40	28	14	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	28	15	,	,	,
cord-016197-y69wwy40	28	16	as	as	RB
cord-016197-y69wwy40	28	17	well	well	RB
cord-016197-y69wwy40	28	18	as	as	IN
cord-016197-y69wwy40	28	19	the	the	DT
cord-016197-y69wwy40	28	20	many	many	JJ
cord-016197-y69wwy40	28	21	significant	significant	JJ
cord-016197-y69wwy40	28	22	developments	development	NNS
cord-016197-y69wwy40	28	23	within	within	IN
cord-016197-y69wwy40	28	24	these	these	DT
cord-016197-y69wwy40	28	25	classes	class	NNS
cord-016197-y69wwy40	28	26	,	,	,
cord-016197-y69wwy40	28	27	have	have	VBP
cord-016197-y69wwy40	28	28	been	be	VBN
cord-016197-y69wwy40	28	29	the	the	DT
cord-016197-y69wwy40	28	30	result	result	NN
cord-016197-y69wwy40	28	31	of	of	IN
cord-016197-y69wwy40	28	32	the	the	DT
cord-016197-y69wwy40	28	33	Pharma	Pharma	NNP
cord-016197-y69wwy40	28	34	industries	industry	NNS
cord-016197-y69wwy40	28	35	'	'	POS
cord-016197-y69wwy40	28	36	innovation	innovation	NN
cord-016197-y69wwy40	28	37	and	and	CC
cord-016197-y69wwy40	28	38	expertise	expertise	NN
cord-016197-y69wwy40	28	39	.	.	.
cord-016197-y69wwy40	29	1	It	-PRON-	PRP
cord-016197-y69wwy40	29	2	is	be	VBZ
cord-016197-y69wwy40	29	3	probable	probable	JJ
cord-016197-y69wwy40	29	4	that	that	IN
cord-016197-y69wwy40	29	5	without	without	IN
cord-016197-y69wwy40	29	6	the	the	DT
cord-016197-y69wwy40	29	7	efforts	effort	NNS
cord-016197-y69wwy40	29	8	of	of	IN
cord-016197-y69wwy40	29	9	research	research	NN
cord-016197-y69wwy40	29	10	-	-	HYPH
cord-016197-y69wwy40	29	11	based	base	VBN
cord-016197-y69wwy40	29	12	Pharma	Pharma	NNP
cord-016197-y69wwy40	29	13	and	and	CC
cord-016197-y69wwy40	29	14	the	the	DT
cord-016197-y69wwy40	29	15	associated	associate	VBN
cord-016197-y69wwy40	29	16	integrated	integrate	VBN
cord-016197-y69wwy40	29	17	competitive	competitive	JJ
cord-016197-y69wwy40	29	18	and	and	CC
cord-016197-y69wwy40	29	19	commercial	commercial	JJ
cord-016197-y69wwy40	29	20	aspects	aspect	NNS
cord-016197-y69wwy40	29	21	,	,	,
cord-016197-y69wwy40	29	22	many	many	JJ
cord-016197-y69wwy40	29	23	of	of	IN
cord-016197-y69wwy40	29	24	today	today	NN
cord-016197-y69wwy40	29	25	's	's	POS
cord-016197-y69wwy40	29	26	agents	agent	NNS
cord-016197-y69wwy40	29	27	would	would	MD
cord-016197-y69wwy40	29	28	not	not	RB
cord-016197-y69wwy40	29	29	yet	yet	RB
cord-016197-y69wwy40	29	30	have	have	VB
cord-016197-y69wwy40	29	31	been	be	VBN
cord-016197-y69wwy40	29	32	discovered	discover	VBN
cord-016197-y69wwy40	29	33	,	,	,
cord-016197-y69wwy40	29	34	developed	develop	VBN
cord-016197-y69wwy40	29	35	,	,	,
cord-016197-y69wwy40	29	36	or	or	CC
cord-016197-y69wwy40	29	37	available	available	JJ
cord-016197-y69wwy40	29	38	to	to	IN
cord-016197-y69wwy40	29	39	physicians	physician	NNS
cord-016197-y69wwy40	29	40	.	.	.
cord-016197-y69wwy40	30	1	The	the	DT
cord-016197-y69wwy40	30	2	now	now	RB
cord-016197-y69wwy40	30	3	somewhat	somewhat	RB
cord-016197-y69wwy40	30	4	famous	famous	JJ
cord-016197-y69wwy40	30	5	declaration	declaration	NN
cord-016197-y69wwy40	30	6	in	in	IN
cord-016197-y69wwy40	30	7	1969	1969	CD
cord-016197-y69wwy40	30	8	by	by	IN
cord-016197-y69wwy40	30	9	the	the	DT
cord-016197-y69wwy40	30	10	US	US	NNP
cord-016197-y69wwy40	30	11	Surgeon	Surgeon	NNP
cord-016197-y69wwy40	30	12	General	General	NNP
cord-016197-y69wwy40	30	13	,	,	,
cord-016197-y69wwy40	30	14	William	William	NNP
cord-016197-y69wwy40	30	15	Stewart	Stewart	NNP
cord-016197-y69wwy40	30	16	,	,	,
cord-016197-y69wwy40	30	17	testifying	testify	VBG
cord-016197-y69wwy40	30	18	before	before	IN
cord-016197-y69wwy40	30	19	US	US	NNP
cord-016197-y69wwy40	30	20	Congress	Congress	NNP
cord-016197-y69wwy40	30	21	that	that	IN
cord-016197-y69wwy40	30	22	it	-PRON-	PRP
cord-016197-y69wwy40	30	23	was	be	VBD
cord-016197-y69wwy40	30	24	time	time	NN
cord-016197-y69wwy40	30	25	to	to	TO
cord-016197-y69wwy40	30	26	,	,	,
cord-016197-y69wwy40	30	27	"	"	``
cord-016197-y69wwy40	30	28	Close	close	VB
cord-016197-y69wwy40	30	29	the	the	DT
cord-016197-y69wwy40	30	30	book	book	NN
cord-016197-y69wwy40	30	31	on	on	IN
cord-016197-y69wwy40	30	32	infectious	infectious	JJ
cord-016197-y69wwy40	30	33	diseases	disease	NNS
cord-016197-y69wwy40	30	34	,	,	,
cord-016197-y69wwy40	30	35	"	"	''
cord-016197-y69wwy40	30	36	illustrates	illustrate	VBZ
cord-016197-y69wwy40	30	37	the	the	DT
cord-016197-y69wwy40	30	38	degree	degree	NN
cord-016197-y69wwy40	30	39	of	of	IN
cord-016197-y69wwy40	30	40	success	success	NN
cord-016197-y69wwy40	30	41	that	that	WDT
cord-016197-y69wwy40	30	42	was	be	VBD
cord-016197-y69wwy40	30	43	perceived	perceive	VBN
cord-016197-y69wwy40	30	44	to	to	TO
cord-016197-y69wwy40	30	45	have	have	VB
cord-016197-y69wwy40	30	46	been	be	VBN
cord-016197-y69wwy40	30	47	achieved	achieve	VBN
cord-016197-y69wwy40	30	48	at	at	IN
cord-016197-y69wwy40	30	49	that	that	DT
cord-016197-y69wwy40	30	50	time	time	NN
cord-016197-y69wwy40	30	51	.	.	.
cord-016197-y69wwy40	31	1	Although	although	IN
cord-016197-y69wwy40	31	2	there	there	EX
cord-016197-y69wwy40	31	3	is	be	VBZ
cord-016197-y69wwy40	31	4	a	a	DT
cord-016197-y69wwy40	31	5	sector	sector	NN
cord-016197-y69wwy40	31	6	of	of	IN
cord-016197-y69wwy40	31	7	the	the	DT
cord-016197-y69wwy40	31	8	Pharma	Pharma	NNP
cord-016197-y69wwy40	31	9	industry	industry	NN
cord-016197-y69wwy40	31	10	that	that	WDT
cord-016197-y69wwy40	31	11	focuses	focus	VBZ
cord-016197-y69wwy40	31	12	on	on	IN
cord-016197-y69wwy40	31	13	the	the	DT
cord-016197-y69wwy40	31	14	sale	sale	NN
cord-016197-y69wwy40	31	15	of	of	IN
cord-016197-y69wwy40	31	16	generic	generic	JJ
cord-016197-y69wwy40	31	17	versions	version	NNS
cord-016197-y69wwy40	31	18	of	of	IN
cord-016197-y69wwy40	31	19	agents	agent	NNS
cord-016197-y69wwy40	31	20	discovered	discover	VBN
cord-016197-y69wwy40	31	21	and	and	CC
cord-016197-y69wwy40	31	22	developed	develop	VBN
cord-016197-y69wwy40	31	23	by	by	IN
cord-016197-y69wwy40	31	24	the	the	DT
cord-016197-y69wwy40	31	25	research	research	NN
cord-016197-y69wwy40	31	26	-	-	HYPH
cord-016197-y69wwy40	31	27	based	base	VBN
cord-016197-y69wwy40	31	28	companies	company	NNS
cord-016197-y69wwy40	31	29	,	,	,
cord-016197-y69wwy40	31	30	these	these	DT
cord-016197-y69wwy40	31	31	activities	activity	NNS
cord-016197-y69wwy40	31	32	mainly	mainly	RB
cord-016197-y69wwy40	31	33	require	require	VBP
cord-016197-y69wwy40	31	34	only	only	RB
cord-016197-y69wwy40	31	35	manufacturing	manufacturing	NN
cord-016197-y69wwy40	31	36	and	and	CC
cord-016197-y69wwy40	31	37	distribution	distribution	NN
cord-016197-y69wwy40	31	38	expertise	expertise	NN
cord-016197-y69wwy40	31	39	.	.	.
cord-016197-y69wwy40	32	1	Now	now	RB
cord-016197-y69wwy40	32	2	,	,	,
cord-016197-y69wwy40	32	3	as	as	IN
cord-016197-y69wwy40	32	4	in	in	IN
cord-016197-y69wwy40	32	5	the	the	DT
cord-016197-y69wwy40	32	6	past	past	NN
cord-016197-y69wwy40	32	7	,	,	,
cord-016197-y69wwy40	32	8	it	-PRON-	PRP
cord-016197-y69wwy40	32	9	is	be	VBZ
cord-016197-y69wwy40	32	10	the	the	DT
cord-016197-y69wwy40	32	11	research	research	NN
cord-016197-y69wwy40	32	12	-	-	HYPH
cord-016197-y69wwy40	32	13	based	base	VBN
cord-016197-y69wwy40	32	14	companies	company	NNS
cord-016197-y69wwy40	32	15	to	to	TO
cord-016197-y69wwy40	32	16	which	which	WDT
cord-016197-y69wwy40	32	17	we	-PRON-	PRP
cord-016197-y69wwy40	32	18	need	need	VBP
cord-016197-y69wwy40	32	19	to	to	TO
cord-016197-y69wwy40	32	20	continue	continue	VB
cord-016197-y69wwy40	32	21	to	to	TO
cord-016197-y69wwy40	32	22	look	look	VB
cord-016197-y69wwy40	32	23	to	to	IN
cord-016197-y69wwy40	32	24	for	for	IN
cord-016197-y69wwy40	32	25	the	the	DT
cord-016197-y69wwy40	32	26	provision	provision	NN
cord-016197-y69wwy40	32	27	of	of	IN
cord-016197-y69wwy40	32	28	agents	agent	NNS
cord-016197-y69wwy40	32	29	for	for	IN
cord-016197-y69wwy40	32	30	the	the	DT
cord-016197-y69wwy40	32	31	future	future	NN
cord-016197-y69wwy40	32	32	.	.	.
cord-016197-y69wwy40	33	1	The	the	DT
cord-016197-y69wwy40	33	2	discovery	discovery	NN
cord-016197-y69wwy40	33	3	,	,	,
cord-016197-y69wwy40	33	4	development	development	NN
cord-016197-y69wwy40	33	5	,	,	,
cord-016197-y69wwy40	33	6	and	and	CC
cord-016197-y69wwy40	33	7	appropriate	appropriate	JJ
cord-016197-y69wwy40	33	8	use	use	NN
cord-016197-y69wwy40	33	9	of	of	IN
cord-016197-y69wwy40	33	10	new	new	JJ
cord-016197-y69wwy40	33	11	agents	agent	NNS
cord-016197-y69wwy40	33	12	is	be	VBZ
cord-016197-y69wwy40	33	13	a	a	DT
cord-016197-y69wwy40	33	14	key	key	JJ
cord-016197-y69wwy40	33	15	theme	theme	NN
cord-016197-y69wwy40	33	16	in	in	IN
cord-016197-y69wwy40	33	17	the	the	DT
cord-016197-y69wwy40	33	18	major	major	JJ
cord-016197-y69wwy40	33	19	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	33	20	strategies	strategy	NNS
cord-016197-y69wwy40	33	21	and	and	CC
cord-016197-y69wwy40	33	22	policies	policy	NNS
cord-016197-y69wwy40	33	23	to	to	IN
cord-016197-y69wwy40	33	24	combat	combat	NN
cord-016197-y69wwy40	33	25	resistance	resistance	NN
cord-016197-y69wwy40	33	26	which	which	WDT
cord-016197-y69wwy40	33	27	have	have	VBP
cord-016197-y69wwy40	33	28	been	be	VBN
cord-016197-y69wwy40	33	29	reviewed	review	VBN
cord-016197-y69wwy40	33	30	by	by	IN
cord-016197-y69wwy40	33	31	Carbon	Carbon	NNP
cord-016197-y69wwy40	33	32	et	et	NNP
cord-016197-y69wwy40	33	33	al	al	NNP
cord-016197-y69wwy40	33	34	.	.	.
cord-016197-y69wwy40	34	1	(	(	-LRB-
cord-016197-y69wwy40	34	2	2002	2002	CD
cord-016197-y69wwy40	34	3	)	)	-RRB-
cord-016197-y69wwy40	34	4	.	.	.
cord-016197-y69wwy40	35	1	Against	against	IN
cord-016197-y69wwy40	35	2	this	this	DT
cord-016197-y69wwy40	35	3	background	background	NN
cord-016197-y69wwy40	35	4	it	-PRON-	PRP
cord-016197-y69wwy40	35	5	may	may	MD
cord-016197-y69wwy40	35	6	be	be	VB
cord-016197-y69wwy40	35	7	considered	consider	VBN
cord-016197-y69wwy40	35	8	surprising	surprising	JJ
cord-016197-y69wwy40	35	9	or	or	CC
cord-016197-y69wwy40	35	10	even	even	RB
cord-016197-y69wwy40	35	11	alarming	alarming	JJ
cord-016197-y69wwy40	35	12	that	that	IN
cord-016197-y69wwy40	35	13	the	the	DT
cord-016197-y69wwy40	35	14	Interscience	Interscience	NNP
cord-016197-y69wwy40	35	15	Conference	Conference	NNP
cord-016197-y69wwy40	35	16	on	on	IN
cord-016197-y69wwy40	35	17	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	35	18	Agents	Agents	NNPS
cord-016197-y69wwy40	35	19	and	and	CC
cord-016197-y69wwy40	35	20	Chemotherapy	Chemotherapy	NNP
cord-016197-y69wwy40	35	21	for	for	IN
cord-016197-y69wwy40	35	22	2003	2003	CD
cord-016197-y69wwy40	35	23	(	(	-LRB-
cord-016197-y69wwy40	35	24	ICAAC	ICAAC	NNP
cord-016197-y69wwy40	35	25	,	,	,
cord-016197-y69wwy40	35	26	2003	2003	CD
cord-016197-y69wwy40	35	27	)	)	-RRB-
cord-016197-y69wwy40	35	28	includes	include	VBZ
cord-016197-y69wwy40	35	29	a	a	DT
cord-016197-y69wwy40	35	30	symposium	symposium	NN
cord-016197-y69wwy40	35	31	entitled	entitle	VBN
cord-016197-y69wwy40	36	1	Why	why	WRB
cord-016197-y69wwy40	36	2	is	be	VBZ
cord-016197-y69wwy40	36	3	Big	big	JJ
cord-016197-y69wwy40	36	4	Pharma	Pharma	NNP
cord-016197-y69wwy40	36	5	Getting	get	VBG
cord-016197-y69wwy40	36	6	Out	out	IN
cord-016197-y69wwy40	36	7	of	of	IN
cord-016197-y69wwy40	36	8	Anti	Anti	NNP
cord-016197-y69wwy40	36	9	-	-	NNP
cord-016197-y69wwy40	36	10	Infective	Infective	NNP
cord-016197-y69wwy40	36	11	Drug	Drug	NNP
cord-016197-y69wwy40	36	12	Discovery	Discovery	NNP
cord-016197-y69wwy40	36	13	?	?	.
cord-016197-y69wwy40	37	1	A	a	DT
cord-016197-y69wwy40	37	2	review	review	NN
cord-016197-y69wwy40	37	3	of	of	IN
cord-016197-y69wwy40	37	4	abstracts	abstract	NNS
cord-016197-y69wwy40	37	5	on	on	IN
cord-016197-y69wwy40	37	6	new	new	JJ
cord-016197-y69wwy40	37	7	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	37	8	agents	agent	NNS
cord-016197-y69wwy40	37	9	or	or	CC
cord-016197-y69wwy40	37	10	targets	target	NNS
cord-016197-y69wwy40	37	11	/	/	SYM
cord-016197-y69wwy40	37	12	methods	method	NNS
cord-016197-y69wwy40	37	13	presented	present	VBN
cord-016197-y69wwy40	37	14	at	at	IN
cord-016197-y69wwy40	37	15	ICAAC	ICAAC	NNP
cord-016197-y69wwy40	37	16	2002	2002	CD
cord-016197-y69wwy40	37	17	indicates	indicate	VBZ
cord-016197-y69wwy40	37	18	some	some	DT
cord-016197-y69wwy40	37	19	47	47	CD
cord-016197-y69wwy40	37	20	companies	company	NNS
cord-016197-y69wwy40	37	21	involved	involve	VBN
cord-016197-y69wwy40	37	22	in	in	IN
cord-016197-y69wwy40	37	23	this	this	DT
cord-016197-y69wwy40	37	24	field	field	NN
cord-016197-y69wwy40	37	25	including	include	VBG
cord-016197-y69wwy40	37	26	10	10	CD
cord-016197-y69wwy40	37	27	of	of	IN
cord-016197-y69wwy40	37	28	the	the	DT
cord-016197-y69wwy40	37	29	"	"	``
cord-016197-y69wwy40	37	30	top	top	JJ
cord-016197-y69wwy40	37	31	12	12	CD
cord-016197-y69wwy40	37	32	"	"	''
cord-016197-y69wwy40	37	33	companies	company	NNS
cord-016197-y69wwy40	37	34	as	as	IN
cord-016197-y69wwy40	37	35	determined	determine	VBN
cord-016197-y69wwy40	37	36	by	by	IN
cord-016197-y69wwy40	37	37	sales	sale	NNS
cord-016197-y69wwy40	37	38	(	(	-LRB-
cord-016197-y69wwy40	37	39	Table	table	NN
cord-016197-y69wwy40	37	40	1	1	CD
cord-016197-y69wwy40	37	41	)	)	-RRB-
cord-016197-y69wwy40	37	42	.	.	.
cord-016197-y69wwy40	38	1	Of	of	IN
cord-016197-y69wwy40	38	2	the	the	DT
cord-016197-y69wwy40	38	3	total	total	NN
cord-016197-y69wwy40	38	4	,	,	,
cord-016197-y69wwy40	38	5	32	32	CD
cord-016197-y69wwy40	38	6	companies	company	NNS
cord-016197-y69wwy40	38	7	presented	present	VBD
cord-016197-y69wwy40	38	8	data	datum	NNS
cord-016197-y69wwy40	38	9	from	from	IN
cord-016197-y69wwy40	38	10	established	establish	VBN
cord-016197-y69wwy40	38	11	classes	class	NNS
cord-016197-y69wwy40	38	12	(	(	-LRB-
cord-016197-y69wwy40	38	13	␤	␤	``
cord-016197-y69wwy40	38	14	-lactams/	-lactams/	NNP
cord-016197-y69wwy40	38	15	inhibitors	inhibitor	NNS
cord-016197-y69wwy40	38	16	,	,	,
cord-016197-y69wwy40	38	17	lipopeptides	lipopeptides	NNP
cord-016197-y69wwy40	38	18	/	/	SYM
cord-016197-y69wwy40	38	19	glycopeptides	glycopeptide	NNS
cord-016197-y69wwy40	38	20	,	,	,
cord-016197-y69wwy40	38	21	fluoroquinolones	fluoroquinolone	NNS
cord-016197-y69wwy40	38	22	,	,	,
cord-016197-y69wwy40	38	23	oxazolidines	oxazolidine	NNS
cord-016197-y69wwy40	38	24	,	,	,
cord-016197-y69wwy40	38	25	protein	protein	NN
cord-016197-y69wwy40	38	26	synthesis	synthesis	NN
cord-016197-y69wwy40	38	27	inhibitors	inhibitor	NNS
cord-016197-y69wwy40	38	28	)	)	-RRB-
cord-016197-y69wwy40	38	29	and	and	CC
cord-016197-y69wwy40	38	30	8	8	CD
cord-016197-y69wwy40	38	31	of	of	IN
cord-016197-y69wwy40	38	32	these	these	DT
cord-016197-y69wwy40	38	33	companies	company	NNS
cord-016197-y69wwy40	38	34	were	be	VBD
cord-016197-y69wwy40	38	35	from	from	IN
cord-016197-y69wwy40	38	36	the	the	DT
cord-016197-y69wwy40	38	37	top	top	JJ
cord-016197-y69wwy40	38	38	12	12	CD
cord-016197-y69wwy40	38	39	companies	company	NNS
cord-016197-y69wwy40	38	40	by	by	IN
cord-016197-y69wwy40	38	41	sales	sale	NNS
cord-016197-y69wwy40	38	42	.	.	.
cord-016197-y69wwy40	39	1	Twenty	twenty	CD
cord-016197-y69wwy40	39	2	-	-	HYPH
cord-016197-y69wwy40	39	3	one	one	CD
cord-016197-y69wwy40	39	4	companies	company	NNS
cord-016197-y69wwy40	39	5	presented	present	VBD
cord-016197-y69wwy40	39	6	data	datum	NNS
cord-016197-y69wwy40	39	7	on	on	IN
cord-016197-y69wwy40	39	8	targets	target	NNS
cord-016197-y69wwy40	39	9	or	or	CC
cord-016197-y69wwy40	39	10	methods	method	NNS
cord-016197-y69wwy40	39	11	,	,	,
cord-016197-y69wwy40	39	12	thirteen	thirteen	CD
cord-016197-y69wwy40	39	13	exclusively	exclusively	RB
cord-016197-y69wwy40	39	14	,	,	,
cord-016197-y69wwy40	39	15	and	and	CC
cord-016197-y69wwy40	39	16	seven	seven	CD
cord-016197-y69wwy40	39	17	on	on	IN
cord-016197-y69wwy40	39	18	novel	novel	JJ
cord-016197-y69wwy40	39	19	agents	agent	NNS
cord-016197-y69wwy40	39	20	or	or	CC
cord-016197-y69wwy40	39	21	immunomodulators	immunomodulator	NNS
cord-016197-y69wwy40	39	22	(	(	-LRB-
cord-016197-y69wwy40	39	23	Table	table	NN
cord-016197-y69wwy40	39	24	1	1	CD
cord-016197-y69wwy40	39	25	)	)	-RRB-
cord-016197-y69wwy40	39	26	.	.	.
cord-016197-y69wwy40	40	1	This	this	DT
cord-016197-y69wwy40	40	2	analysis	analysis	NN
cord-016197-y69wwy40	40	3	represents	represent	VBZ
cord-016197-y69wwy40	40	4	only	only	RB
cord-016197-y69wwy40	40	5	a	a	DT
cord-016197-y69wwy40	40	6	snapshot	snapshot	NN
cord-016197-y69wwy40	40	7	of	of	IN
cord-016197-y69wwy40	40	8	those	those	DT
cord-016197-y69wwy40	40	9	companies	company	NNS
cord-016197-y69wwy40	40	10	presenting	present	VBG
cord-016197-y69wwy40	40	11	at	at	IN
cord-016197-y69wwy40	40	12	ICAAC	ICAAC	NNP
cord-016197-y69wwy40	40	13	and	and	CC
cord-016197-y69wwy40	40	14	not	not	RB
cord-016197-y69wwy40	40	15	the	the	DT
cord-016197-y69wwy40	40	16	total	total	JJ
cord-016197-y69wwy40	40	17	discovery	discovery	NN
cord-016197-y69wwy40	40	18	programmes	programme	NNS
cord-016197-y69wwy40	40	19	currently	currently	RB
cord-016197-y69wwy40	40	20	being	be	VBG
cord-016197-y69wwy40	40	21	undertaken	undertake	VBN
cord-016197-y69wwy40	40	22	,	,	,
cord-016197-y69wwy40	40	23	some	some	DT
cord-016197-y69wwy40	40	24	on	on	IN
cord-016197-y69wwy40	40	25	areas	area	NNS
cord-016197-y69wwy40	40	26	not	not	RB
cord-016197-y69wwy40	40	27	yet	yet	RB
cord-016197-y69wwy40	40	28	disclosed	disclose	VBN
cord-016197-y69wwy40	40	29	,	,	,
cord-016197-y69wwy40	40	30	others	other	NNS
cord-016197-y69wwy40	40	31	since	since	IN
cord-016197-y69wwy40	40	32	terminated	terminate	VBN
cord-016197-y69wwy40	40	33	.	.	.
cord-016197-y69wwy40	41	1	Despite	despite	IN
cord-016197-y69wwy40	41	2	the	the	DT
cord-016197-y69wwy40	41	3	wide	wide	JJ
cord-016197-y69wwy40	41	4	range	range	NN
cord-016197-y69wwy40	41	5	of	of	IN
cord-016197-y69wwy40	41	6	presentations	presentation	NNS
cord-016197-y69wwy40	41	7	by	by	IN
cord-016197-y69wwy40	41	8	Pharma	Pharma	NNP
cord-016197-y69wwy40	41	9	at	at	IN
cord-016197-y69wwy40	41	10	ICAAC	ICAAC	NNP
cord-016197-y69wwy40	41	11	2002	2002	CD
cord-016197-y69wwy40	41	12	,	,	,
cord-016197-y69wwy40	41	13	there	there	EX
cord-016197-y69wwy40	41	14	has	have	VBZ
cord-016197-y69wwy40	41	15	undoubtedly	undoubtedly	RB
cord-016197-y69wwy40	41	16	been	be	VBN
cord-016197-y69wwy40	41	17	a	a	DT
cord-016197-y69wwy40	41	18	consolidation	consolidation	NN
cord-016197-y69wwy40	41	19	in	in	IN
cord-016197-y69wwy40	41	20	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	41	21	R&D	r&d	NN
cord-016197-y69wwy40	41	22	in	in	IN
cord-016197-y69wwy40	41	23	the	the	DT
cord-016197-y69wwy40	41	24	large	large	JJ
cord-016197-y69wwy40	41	25	Pharma	Pharma	NNP
cord-016197-y69wwy40	41	26	companies	company	NNS
cord-016197-y69wwy40	41	27	,	,	,
cord-016197-y69wwy40	41	28	and	and	CC
cord-016197-y69wwy40	41	29	a	a	DT
cord-016197-y69wwy40	41	30	dearth	dearth	NN
cord-016197-y69wwy40	41	31	of	of	IN
cord-016197-y69wwy40	41	32	novel	novel	JJ
cord-016197-y69wwy40	41	33	agents	agent	NNS
cord-016197-y69wwy40	41	34	emerging	emerge	VBG
cord-016197-y69wwy40	41	35	from	from	IN
cord-016197-y69wwy40	41	36	the	the	DT
cord-016197-y69wwy40	41	37	pipelines	pipeline	NNS
cord-016197-y69wwy40	41	38	.	.	.
cord-016197-y69wwy40	42	1	Increasing	increase	VBG
cord-016197-y69wwy40	42	2	discovery	discovery	NN
cord-016197-y69wwy40	42	3	activity	activity	NN
cord-016197-y69wwy40	42	4	in	in	IN
cord-016197-y69wwy40	42	5	smaller	small	JJR
cord-016197-y69wwy40	42	6	companies	company	NNS
cord-016197-y69wwy40	42	7	may	may	MD
cord-016197-y69wwy40	42	8	offset	offset	VB
cord-016197-y69wwy40	42	9	this	this	DT
cord-016197-y69wwy40	42	10	,	,	,
cord-016197-y69wwy40	42	11	although	although	IN
cord-016197-y69wwy40	42	12	the	the	DT
cord-016197-y69wwy40	42	13	capabilities	capability	NNS
cord-016197-y69wwy40	42	14	of	of	IN
cord-016197-y69wwy40	42	15	smaller	small	JJR
cord-016197-y69wwy40	42	16	companies	company	NNS
cord-016197-y69wwy40	42	17	to	to	TO
cord-016197-y69wwy40	42	18	develop	develop	VB
cord-016197-y69wwy40	42	19	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	42	20	to	to	IN
cord-016197-y69wwy40	42	21	market	market	NN
cord-016197-y69wwy40	42	22	may	may	MD
cord-016197-y69wwy40	42	23	be	be	VB
cord-016197-y69wwy40	42	24	limited	limit	VBN
cord-016197-y69wwy40	42	25	in	in	IN
cord-016197-y69wwy40	42	26	the	the	DT
cord-016197-y69wwy40	42	27	face	face	NN
cord-016197-y69wwy40	42	28	of	of	IN
cord-016197-y69wwy40	42	29	increasing	increase	VBG
cord-016197-y69wwy40	42	30	development	development	NN
cord-016197-y69wwy40	42	31	hurdles	hurdle	NNS
cord-016197-y69wwy40	42	32	.	.	.
cord-016197-y69wwy40	43	1	The	the	DT
cord-016197-y69wwy40	43	2	future	future	JJ
cord-016197-y69wwy40	43	3	model	model	NN
cord-016197-y69wwy40	43	4	of	of	IN
cord-016197-y69wwy40	43	5	discovery	discovery	NN
cord-016197-y69wwy40	43	6	and	and	CC
cord-016197-y69wwy40	43	7	development	development	NN
cord-016197-y69wwy40	43	8	may	may	MD
cord-016197-y69wwy40	43	9	well	well	RB
cord-016197-y69wwy40	43	10	have	have	VB
cord-016197-y69wwy40	43	11	to	to	TO
cord-016197-y69wwy40	43	12	rely	rely	VB
cord-016197-y69wwy40	43	13	on	on	IN
cord-016197-y69wwy40	43	14	collaborations	collaboration	NNS
cord-016197-y69wwy40	43	15	and	and	CC
cord-016197-y69wwy40	43	16	cooperations	cooperation	NNS
cord-016197-y69wwy40	43	17	between	between	IN
cord-016197-y69wwy40	43	18	small	small	JJ
cord-016197-y69wwy40	43	19	/	/	SYM
cord-016197-y69wwy40	43	20	discovery	discovery	NN
cord-016197-y69wwy40	43	21	and	and	CC
cord-016197-y69wwy40	43	22	large	large	JJ
cord-016197-y69wwy40	43	23	development	development	NN
cord-016197-y69wwy40	43	24	/	/	SYM
cord-016197-y69wwy40	43	25	supply	supply	NN
cord-016197-y69wwy40	43	26	Pharma	Pharma	NNS
cord-016197-y69wwy40	43	27	.	.	.
cord-016197-y69wwy40	44	1	Mergers	merger	NNS
cord-016197-y69wwy40	44	2	and	and	CC
cord-016197-y69wwy40	44	3	acquisitions	acquisition	NNS
cord-016197-y69wwy40	44	4	have	have	VBP
cord-016197-y69wwy40	44	5	resulted	result	VBN
cord-016197-y69wwy40	44	6	in	in	IN
cord-016197-y69wwy40	44	7	the	the	DT
cord-016197-y69wwy40	44	8	key	key	JJ
cord-016197-y69wwy40	44	9	players	player	NNS
cord-016197-y69wwy40	44	10	becoming	become	VBG
cord-016197-y69wwy40	44	11	significantly	significantly	RB
cord-016197-y69wwy40	44	12	fewer	few	JJR
cord-016197-y69wwy40	44	13	and	and	CC
cord-016197-y69wwy40	44	14	each	each	DT
cord-016197-y69wwy40	44	15	withdrawal	withdrawal	NN
cord-016197-y69wwy40	44	16	from	from	IN
cord-016197-y69wwy40	44	17	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	44	18	development	development	NN
cord-016197-y69wwy40	44	19	has	have	VBZ
cord-016197-y69wwy40	44	20	an	an	DT
cord-016197-y69wwy40	44	21	676	676	CD
cord-016197-y69wwy40	44	22	Anthony	Anthony	NNP
cord-016197-y69wwy40	44	23	R.	R.	NNP
cord-016197-y69wwy40	44	24	White	White	NNP
cord-016197-y69wwy40	44	25	have	have	VBP
cord-016197-y69wwy40	44	26	evolved	evolve	VBN
cord-016197-y69wwy40	44	27	from	from	IN
cord-016197-y69wwy40	44	28	some	some	RB
cord-016197-y69wwy40	44	29	20	20	CD
cord-016197-y69wwy40	44	30	to	to	TO
cord-016197-y69wwy40	44	31	30	30	CD
cord-016197-y69wwy40	44	32	companies	company	NNS
cord-016197-y69wwy40	44	33	with	with	IN
cord-016197-y69wwy40	44	34	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	44	35	R&D	r&d	NN
cord-016197-y69wwy40	44	36	heritages	heritage	NNS
cord-016197-y69wwy40	44	37	.	.	.
cord-016197-y69wwy40	45	1	Some	some	DT
cord-016197-y69wwy40	45	2	are	be	VBP
cord-016197-y69wwy40	45	3	the	the	DT
cord-016197-y69wwy40	45	4	result	result	NN
cord-016197-y69wwy40	45	5	of	of	IN
cord-016197-y69wwy40	45	6	none	none	NN
cord-016197-y69wwy40	45	7	or	or	CC
cord-016197-y69wwy40	45	8	few	few	JJ
cord-016197-y69wwy40	45	9	amalgamations	amalgamation	NNS
cord-016197-y69wwy40	45	10	while	while	IN
cord-016197-y69wwy40	45	11	others	other	NNS
cord-016197-y69wwy40	45	12	are	be	VBP
cord-016197-y69wwy40	45	13	many	many	JJ
cord-016197-y69wwy40	45	14	-	-	HYPH
cord-016197-y69wwy40	45	15	fold	fold	JJ
cord-016197-y69wwy40	45	16	.	.	.
cord-016197-y69wwy40	46	1	Of	of	IN
cord-016197-y69wwy40	46	2	the	the	DT
cord-016197-y69wwy40	46	3	top	top	JJ
cord-016197-y69wwy40	46	4	12	12	CD
cord-016197-y69wwy40	46	5	companies	company	NNS
cord-016197-y69wwy40	46	6	,	,	,
cord-016197-y69wwy40	46	7	less	less	JJR
cord-016197-y69wwy40	46	8	than	than	IN
cord-016197-y69wwy40	46	9	half	half	DT
cord-016197-y69wwy40	46	10	are	be	VBP
cord-016197-y69wwy40	46	11	believed	believe	VBN
cord-016197-y69wwy40	46	12	to	to	TO
cord-016197-y69wwy40	46	13	be	be	VB
cord-016197-y69wwy40	46	14	currently	currently	RB
cord-016197-y69wwy40	46	15	active	active	JJ
cord-016197-y69wwy40	46	16	in	in	IN
cord-016197-y69wwy40	46	17	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	47	1	R&D.	R&D.	NNP
cord-016197-y69wwy40	48	1	Within	within	IN
cord-016197-y69wwy40	48	2	the	the	DT
cord-016197-y69wwy40	48	3	remaining	remain	VBG
cord-016197-y69wwy40	48	4	companies	company	NNS
cord-016197-y69wwy40	48	5	the	the	DT
cord-016197-y69wwy40	48	6	discovery	discovery	NN
cord-016197-y69wwy40	48	7	effort	effort	NN
cord-016197-y69wwy40	48	8	has	have	VBZ
cord-016197-y69wwy40	48	9	been	be	VBN
cord-016197-y69wwy40	48	10	directed	direct	VBN
cord-016197-y69wwy40	48	11	towards	towards	IN
cord-016197-y69wwy40	48	12	either	either	DT
cord-016197-y69wwy40	48	13	defined	define	VBN
cord-016197-y69wwy40	48	14	niche	niche	NN
cord-016197-y69wwy40	48	15	disease	disease	NN
cord-016197-y69wwy40	48	16	areas	area	NNS
cord-016197-y69wwy40	48	17	,	,	,
cord-016197-y69wwy40	48	18	or	or	CC
cord-016197-y69wwy40	48	19	large	large	JJ
cord-016197-y69wwy40	48	20	"	"	``
cord-016197-y69wwy40	48	21	blockbuster	blockbuster	JJ
cord-016197-y69wwy40	48	22	"	"	''
cord-016197-y69wwy40	48	23	commercial	commercial	JJ
cord-016197-y69wwy40	48	24	areas	area	NNS
cord-016197-y69wwy40	48	25	,	,	,
cord-016197-y69wwy40	48	26	with	with	IN
cord-016197-y69wwy40	48	27	a	a	DT
cord-016197-y69wwy40	48	28	consequent	consequent	JJ
cord-016197-y69wwy40	48	29	reduction	reduction	NN
cord-016197-y69wwy40	48	30	in	in	IN
cord-016197-y69wwy40	48	31	diversity	diversity	NN
cord-016197-y69wwy40	48	32	across	across	IN
cord-016197-y69wwy40	48	33	the	the	DT
cord-016197-y69wwy40	48	34	industry	industry	NN
cord-016197-y69wwy40	48	35	.	.	.
cord-016197-y69wwy40	49	1	Individual	individual	JJ
cord-016197-y69wwy40	49	2	specializations	specialization	NNS
cord-016197-y69wwy40	49	3	within	within	IN
cord-016197-y69wwy40	49	4	Pharma	Pharma	NNP
cord-016197-y69wwy40	49	5	,	,	,
cord-016197-y69wwy40	49	6	such	such	JJ
cord-016197-y69wwy40	49	7	as	as	IN
cord-016197-y69wwy40	49	8	was	be	VBD
cord-016197-y69wwy40	49	9	the	the	DT
cord-016197-y69wwy40	49	10	case	case	NN
cord-016197-y69wwy40	49	11	when	when	WRB
cord-016197-y69wwy40	49	12	companies	company	NNS
cord-016197-y69wwy40	49	13	almost	almost	RB
cord-016197-y69wwy40	49	14	exclusively	exclusively	RB
cord-016197-y69wwy40	49	15	worked	work	VBD
cord-016197-y69wwy40	49	16	on	on	IN
cord-016197-y69wwy40	49	17	penicillins	penicillin	NNS
cord-016197-y69wwy40	49	18	(	(	-LRB-
cord-016197-y69wwy40	49	19	Beecham	Beecham	NNP
cord-016197-y69wwy40	49	20	Research	Research	NNP
cord-016197-y69wwy40	49	21	Laboratories	Laboratories	NNP
cord-016197-y69wwy40	49	22	)	)	-RRB-
cord-016197-y69wwy40	49	23	,	,	,
cord-016197-y69wwy40	49	24	cephalosporins	cephalosporin	NNS
cord-016197-y69wwy40	49	25	(	(	-LRB-
cord-016197-y69wwy40	49	26	Glaxo	Glaxo	NNP
cord-016197-y69wwy40	49	27	)	)	-RRB-
cord-016197-y69wwy40	49	28	,	,	,
cord-016197-y69wwy40	49	29	or	or	CC
cord-016197-y69wwy40	49	30	quinolones	quinolones	NNP
cord-016197-y69wwy40	49	31	(	(	-LRB-
cord-016197-y69wwy40	49	32	Bayer	Bayer	NNP
cord-016197-y69wwy40	49	33	AG	AG	NNP
cord-016197-y69wwy40	49	34	)	)	-RRB-
cord-016197-y69wwy40	49	35	,	,	,
cord-016197-y69wwy40	49	36	for	for	IN
cord-016197-y69wwy40	49	37	example	example	NN
cord-016197-y69wwy40	49	38	,	,	,
cord-016197-y69wwy40	49	39	are	be	VBP
cord-016197-y69wwy40	49	40	becoming	become	VBG
cord-016197-y69wwy40	49	41	less	less	JJR
cord-016197-y69wwy40	49	42	as	as	IN
cord-016197-y69wwy40	49	43	the	the	DT
cord-016197-y69wwy40	49	44	companies	company	NNS
cord-016197-y69wwy40	49	45	look	look	VBP
cord-016197-y69wwy40	49	46	to	to	TO
cord-016197-y69wwy40	49	47	satisfy	satisfy	VB
cord-016197-y69wwy40	49	48	commercially	commercially	RB
cord-016197-y69wwy40	49	49	attractive	attractive	JJ
cord-016197-y69wwy40	49	50	target	target	NN
cord-016197-y69wwy40	49	51	product	product	NN
cord-016197-y69wwy40	49	52	profiles	profile	NNS
cord-016197-y69wwy40	49	53	from	from	IN
cord-016197-y69wwy40	49	54	whichever	whichever	WDT
cord-016197-y69wwy40	49	55	molecular	molecular	JJ
cord-016197-y69wwy40	49	56	classes	class	NNS
cord-016197-y69wwy40	49	57	that	that	WDT
cord-016197-y69wwy40	49	58	are	be	VBP
cord-016197-y69wwy40	49	59	available	available	JJ
cord-016197-y69wwy40	49	60	through	through	IN
cord-016197-y69wwy40	49	61	their	-PRON-	PRP$
cord-016197-y69wwy40	49	62	R&D	r&d	NN
cord-016197-y69wwy40	49	63	efforts	effort	NNS
cord-016197-y69wwy40	49	64	or	or	CC
cord-016197-y69wwy40	49	65	in	in	IN
cord-016197-y69wwy40	49	66	-	-	HYPH
cord-016197-y69wwy40	49	67	licensing	licensing	NN
cord-016197-y69wwy40	49	68	.	.	.
cord-016197-y69wwy40	50	1	The	the	DT
cord-016197-y69wwy40	50	2	emphasis	emphasis	NN
cord-016197-y69wwy40	50	3	on	on	IN
cord-016197-y69wwy40	50	4	development	development	NN
cord-016197-y69wwy40	50	5	of	of	IN
cord-016197-y69wwy40	50	6	line	line	NN
cord-016197-y69wwy40	50	7	extensions	extension	NNS
cord-016197-y69wwy40	50	8	of	of	IN
cord-016197-y69wwy40	50	9	existing	exist	VBG
cord-016197-y69wwy40	50	10	molecules	molecule	NNS
cord-016197-y69wwy40	50	11	has	have	VBZ
cord-016197-y69wwy40	50	12	also	also	RB
cord-016197-y69wwy40	50	13	increased	increase	VBN
cord-016197-y69wwy40	50	14	as	as	IN
cord-016197-y69wwy40	50	15	a	a	DT
cord-016197-y69wwy40	50	16	means	means	NN
cord-016197-y69wwy40	50	17	to	to	TO
cord-016197-y69wwy40	50	18	improve	improve	VB
cord-016197-y69wwy40	50	19	patient	patient	JJ
cord-016197-y69wwy40	50	20	benefits	benefit	NNS
cord-016197-y69wwy40	50	21	such	such	JJ
cord-016197-y69wwy40	50	22	as	as	IN
cord-016197-y69wwy40	50	23	convenience	convenience	NN
cord-016197-y69wwy40	50	24	and	and	CC
cord-016197-y69wwy40	50	25	efficacy	efficacy	NN
cord-016197-y69wwy40	50	26	and	and	CC
cord-016197-y69wwy40	50	27	importantly	importantly	RB
cord-016197-y69wwy40	50	28	for	for	IN
cord-016197-y69wwy40	50	29	Pharma	Pharma	NNP
cord-016197-y69wwy40	50	30	,	,	,
cord-016197-y69wwy40	50	31	to	to	TO
cord-016197-y69wwy40	50	32	maintain	maintain	VB
cord-016197-y69wwy40	50	33	development	development	NN
cord-016197-y69wwy40	50	34	and	and	CC
cord-016197-y69wwy40	50	35	commercial	commercial	JJ
cord-016197-y69wwy40	50	36	activity	activity	NN
cord-016197-y69wwy40	50	37	to	to	TO
cord-016197-y69wwy40	50	38	offset	offset	VB
cord-016197-y69wwy40	50	39	patent	patent	NN
cord-016197-y69wwy40	50	40	loss	loss	NN
cord-016197-y69wwy40	50	41	and	and	CC
cord-016197-y69wwy40	50	42	bridge	bridge	VB
cord-016197-y69wwy40	50	43	the	the	DT
cord-016197-y69wwy40	50	44	gap	gap	NN
cord-016197-y69wwy40	50	45	to	to	IN
cord-016197-y69wwy40	50	46	the	the	DT
cord-016197-y69wwy40	50	47	introduction	introduction	NN
cord-016197-y69wwy40	50	48	of	of	IN
cord-016197-y69wwy40	50	49	new	new	JJ
cord-016197-y69wwy40	50	50	agents	agent	NNS
cord-016197-y69wwy40	50	51	.	.	.
cord-016197-y69wwy40	51	1	Critically	critically	RB
cord-016197-y69wwy40	51	2	,	,	,
cord-016197-y69wwy40	51	3	of	of	IN
cord-016197-y69wwy40	51	4	the	the	DT
cord-016197-y69wwy40	51	5	companies	company	NNS
cord-016197-y69wwy40	51	6	which	which	WDT
cord-016197-y69wwy40	51	7	have	have	VBP
cord-016197-y69wwy40	51	8	exited	exit	VBN
cord-016197-y69wwy40	51	9	or	or	CC
cord-016197-y69wwy40	51	10	severely	severely	RB
cord-016197-y69wwy40	51	11	reduced	reduce	VBN
cord-016197-y69wwy40	51	12	their	-PRON-	PRP$
cord-016197-y69wwy40	51	13	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	51	14	R&D	r&d	NN
cord-016197-y69wwy40	51	15	(	(	-LRB-
cord-016197-y69wwy40	51	16	e.g.	e.g.	RB
cord-016197-y69wwy40	51	17	,	,	,
cord-016197-y69wwy40	51	18	Aventis	Aventis	NNP
cord-016197-y69wwy40	51	19	,	,	,
cord-016197-y69wwy40	51	20	Bristol	Bristol	NNP
cord-016197-y69wwy40	51	21	-	-	HYPH
cord-016197-y69wwy40	51	22	Myers	Myers	NNP
cord-016197-y69wwy40	51	23	Squibb	Squibb	NNP
cord-016197-y69wwy40	51	24	,	,	,
cord-016197-y69wwy40	51	25	Eli	Eli	NNP
cord-016197-y69wwy40	51	26	Lilly	Lilly	NNP
cord-016197-y69wwy40	51	27	&	&	CC
cord-016197-y69wwy40	51	28	Co	Co	NNP
cord-016197-y69wwy40	51	29	,	,	,
cord-016197-y69wwy40	51	30	Roche	Roche	NNP
cord-016197-y69wwy40	51	31	-	-	HYPH
cord-016197-y69wwy40	51	32	Chugai	Chugai	NNP
cord-016197-y69wwy40	51	33	,	,	,
cord-016197-y69wwy40	51	34	and	and	CC
cord-016197-y69wwy40	51	35	Wyeth	Wyeth	NNP
cord-016197-y69wwy40	51	36	Research	Research	NNP
cord-016197-y69wwy40	51	37	)	)	-RRB-
cord-016197-y69wwy40	52	1	(	(	-LRB-
cord-016197-y69wwy40	52	2	IDSA	IDSA	NNP
cord-016197-y69wwy40	52	3	,	,	,
cord-016197-y69wwy40	52	4	2003	2003	CD
cord-016197-y69wwy40	52	5	)	)	-RRB-
cord-016197-y69wwy40	52	6	,	,	,
cord-016197-y69wwy40	52	7	these	these	DT
cord-016197-y69wwy40	52	8	decisions	decision	NNS
cord-016197-y69wwy40	52	9	have	have	VBP
cord-016197-y69wwy40	52	10	been	be	VBN
cord-016197-y69wwy40	52	11	taken	take	VBN
cord-016197-y69wwy40	52	12	relatively	relatively	RB
cord-016197-y69wwy40	52	13	recently	recently	RB
cord-016197-y69wwy40	52	14	at	at	IN
cord-016197-y69wwy40	52	15	a	a	DT
cord-016197-y69wwy40	52	16	time	time	NN
cord-016197-y69wwy40	52	17	when	when	WRB
cord-016197-y69wwy40	52	18	the	the	DT
cord-016197-y69wwy40	52	19	need	need	NN
cord-016197-y69wwy40	52	20	for	for	IN
cord-016197-y69wwy40	52	21	new	new	JJ
cord-016197-y69wwy40	52	22	effective	effective	JJ
cord-016197-y69wwy40	52	23	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	52	24	is	be	VBZ
cord-016197-y69wwy40	52	25	arguably	arguably	RB
cord-016197-y69wwy40	52	26	greater	great	JJR
cord-016197-y69wwy40	52	27	,	,	,
cord-016197-y69wwy40	52	28	but	but	CC
cord-016197-y69wwy40	52	29	also	also	RB
cord-016197-y69wwy40	52	30	at	at	IN
cord-016197-y69wwy40	52	31	a	a	DT
cord-016197-y69wwy40	52	32	time	time	NN
cord-016197-y69wwy40	52	33	when	when	WRB
cord-016197-y69wwy40	52	34	policies	policy	NNS
cord-016197-y69wwy40	52	35	and	and	CC
cord-016197-y69wwy40	52	36	regulations	regulation	NNS
cord-016197-y69wwy40	52	37	for	for	IN
cord-016197-y69wwy40	52	38	the	the	DT
cord-016197-y69wwy40	52	39	development	development	NN
cord-016197-y69wwy40	52	40	and	and	CC
cord-016197-y69wwy40	52	41	use	use	NN
cord-016197-y69wwy40	52	42	of	of	IN
cord-016197-y69wwy40	52	43	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	52	44	have	have	VBP
cord-016197-y69wwy40	52	45	proliferated	proliferate	VBN
cord-016197-y69wwy40	52	46	.	.	.
cord-016197-y69wwy40	53	1	The	the	DT
cord-016197-y69wwy40	53	2	crucial	crucial	JJ
cord-016197-y69wwy40	53	3	issue	issue	NN
cord-016197-y69wwy40	53	4	will	will	MD
cord-016197-y69wwy40	53	5	be	be	VB
cord-016197-y69wwy40	53	6	the	the	DT
cord-016197-y69wwy40	53	7	ability	ability	NN
cord-016197-y69wwy40	53	8	of	of	IN
cord-016197-y69wwy40	53	9	companies	company	NNS
cord-016197-y69wwy40	53	10	,	,	,
cord-016197-y69wwy40	53	11	big	big	JJ
cord-016197-y69wwy40	53	12	or	or	CC
cord-016197-y69wwy40	53	13	small	small	JJ
cord-016197-y69wwy40	53	14	,	,	,
cord-016197-y69wwy40	53	15	alone	alone	JJ
cord-016197-y69wwy40	53	16	or	or	CC
cord-016197-y69wwy40	53	17	in	in	IN
cord-016197-y69wwy40	53	18	collaboration	collaboration	NN
cord-016197-y69wwy40	53	19	,	,	,
cord-016197-y69wwy40	53	20	to	to	TO
cord-016197-y69wwy40	53	21	bring	bring	VB
cord-016197-y69wwy40	53	22	novel	novel	JJ
cord-016197-y69wwy40	53	23	agents	agent	NNS
cord-016197-y69wwy40	53	24	to	to	IN
cord-016197-y69wwy40	53	25	the	the	DT
cord-016197-y69wwy40	53	26	market	market	NN
cord-016197-y69wwy40	53	27	and	and	CC
cord-016197-y69wwy40	53	28	whether	whether	IN
cord-016197-y69wwy40	53	29	the	the	DT
cord-016197-y69wwy40	53	30	agents	agent	NNS
cord-016197-y69wwy40	53	31	being	be	VBG
cord-016197-y69wwy40	53	32	discovered	discover	VBN
cord-016197-y69wwy40	53	33	and	and	CC
cord-016197-y69wwy40	53	34	developed	develop	VBN
cord-016197-y69wwy40	53	35	today	today	NN
cord-016197-y69wwy40	53	36	will	will	MD
cord-016197-y69wwy40	53	37	satisfy	satisfy	VB
cord-016197-y69wwy40	53	38	both	both	CC
cord-016197-y69wwy40	53	39	the	the	DT
cord-016197-y69wwy40	53	40	medical	medical	JJ
cord-016197-y69wwy40	53	41	and	and	CC
cord-016197-y69wwy40	53	42	the	the	DT
cord-016197-y69wwy40	53	43	commercial	commercial	JJ
cord-016197-y69wwy40	53	44	needs	need	VBZ
cord-016197-y69wwy40	53	45	to	to	TO
cord-016197-y69wwy40	53	46	provide	provide	VB
cord-016197-y69wwy40	53	47	a	a	DT
cord-016197-y69wwy40	53	48	sustainable	sustainable	JJ
cord-016197-y69wwy40	53	49	future	future	NN
cord-016197-y69wwy40	53	50	for	for	IN
cord-016197-y69wwy40	53	51	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	53	52	chemotherapy	chemotherapy	NN
cord-016197-y69wwy40	53	53	.	.	.
cord-016197-y69wwy40	54	1	Continued	continue	VBN
cord-016197-y69wwy40	54	2	investment	investment	NN
cord-016197-y69wwy40	54	3	and	and	CC
cord-016197-y69wwy40	54	4	commitment	commitment	NN
cord-016197-y69wwy40	54	5	of	of	IN
cord-016197-y69wwy40	54	6	big	big	JJ
cord-016197-y69wwy40	54	7	or	or	CC
cord-016197-y69wwy40	54	8	small	small	JJ
cord-016197-y69wwy40	54	9	Pharma	Pharma	NNS
cord-016197-y69wwy40	54	10	into	into	IN
cord-016197-y69wwy40	54	11	research	research	NN
cord-016197-y69wwy40	54	12	for	for	IN
cord-016197-y69wwy40	54	13	new	new	JJ
cord-016197-y69wwy40	54	14	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	54	15	to	to	TO
cord-016197-y69wwy40	54	16	meet	meet	VB
cord-016197-y69wwy40	54	17	current	current	JJ
cord-016197-y69wwy40	54	18	and	and	CC
cord-016197-y69wwy40	54	19	future	future	JJ
cord-016197-y69wwy40	54	20	clinical	clinical	JJ
cord-016197-y69wwy40	54	21	needs	need	NNS
cord-016197-y69wwy40	54	22	is	be	VBZ
cord-016197-y69wwy40	54	23	crucial	crucial	JJ
cord-016197-y69wwy40	54	24	and	and	CC
cord-016197-y69wwy40	54	25	yet	yet	RB
cord-016197-y69wwy40	54	26	is	be	VBZ
cord-016197-y69wwy40	54	27	at	at	IN
cord-016197-y69wwy40	54	28	a	a	DT
cord-016197-y69wwy40	54	29	crisis	crisis	NN
cord-016197-y69wwy40	54	30	and	and	CC
cord-016197-y69wwy40	54	31	being	be	VBG
cord-016197-y69wwy40	54	32	impacted	impact	VBN
cord-016197-y69wwy40	54	33	by	by	IN
cord-016197-y69wwy40	54	34	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	54	35	policies	policy	NNS
cord-016197-y69wwy40	54	36	which	which	WDT
cord-016197-y69wwy40	54	37	are	be	VBP
cord-016197-y69wwy40	54	38	increasingly	increasingly	RB
cord-016197-y69wwy40	54	39	being	be	VBG
cord-016197-y69wwy40	54	40	developed	develop	VBN
cord-016197-y69wwy40	54	41	and	and	CC
cord-016197-y69wwy40	54	42	implemented	implement	VBN
cord-016197-y69wwy40	54	43	.	.	.
cord-016197-y69wwy40	55	1	The	the	DT
cord-016197-y69wwy40	55	2	Infectious	Infectious	NNP
cord-016197-y69wwy40	55	3	Disease	Disease	NNP
cord-016197-y69wwy40	55	4	Society	Society	NNP
cord-016197-y69wwy40	55	5	of	of	IN
cord-016197-y69wwy40	55	6	America	America	NNP
cord-016197-y69wwy40	55	7	(	(	-LRB-
cord-016197-y69wwy40	55	8	IDSA	IDSA	NNP
cord-016197-y69wwy40	55	9	)	)	-RRB-
cord-016197-y69wwy40	55	10	newsletter	newsletter	NN
cord-016197-y69wwy40	55	11	,	,	,
cord-016197-y69wwy40	55	12	March	March	NNP
cord-016197-y69wwy40	55	13	12	12	CD
cord-016197-y69wwy40	55	14	,	,	,
cord-016197-y69wwy40	55	15	entitled	entitle	VBN
cord-016197-y69wwy40	55	16	The	the	DT
cord-016197-y69wwy40	55	17	Future	Future	NNP
cord-016197-y69wwy40	55	18	of	of	IN
cord-016197-y69wwy40	55	19	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	55	20	Drug	Drug	NNP
cord-016197-y69wwy40	55	21	Availability	Availability	NNP
cord-016197-y69wwy40	55	22	:	:	:
cord-016197-y69wwy40	56	1	An	an	DT
cord-016197-y69wwy40	56	2	Impending	Impending	NNP
cord-016197-y69wwy40	56	3	Crisis	Crisis	NNP
cord-016197-y69wwy40	56	4	(	(	-LRB-
cord-016197-y69wwy40	56	5	IDSA	IDSA	NNP
cord-016197-y69wwy40	56	6	,	,	,
cord-016197-y69wwy40	56	7	2003	2003	CD
cord-016197-y69wwy40	56	8	)	)	-RRB-
cord-016197-y69wwy40	56	9	,	,	,
cord-016197-y69wwy40	56	10	highlights	highlight	VBZ
cord-016197-y69wwy40	56	11	the	the	DT
cord-016197-y69wwy40	56	12	current	current	JJ
cord-016197-y69wwy40	56	13	issues	issue	NNS
cord-016197-y69wwy40	56	14	facing	face	VBG
cord-016197-y69wwy40	56	15	the	the	DT
cord-016197-y69wwy40	56	16	development	development	NN
cord-016197-y69wwy40	56	17	of	of	IN
cord-016197-y69wwy40	56	18	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	56	19	drugs	drug	NNS
cord-016197-y69wwy40	56	20	.	.	.
cord-016197-y69wwy40	57	1	Infectious	infectious	JJ
cord-016197-y69wwy40	57	2	diseases	disease	NNS
cord-016197-y69wwy40	57	3	are	be	VBP
cord-016197-y69wwy40	57	4	the	the	DT
cord-016197-y69wwy40	57	5	second	second	JJ
cord-016197-y69wwy40	57	6	leading	leading	JJ
cord-016197-y69wwy40	57	7	cause	cause	NN
cord-016197-y69wwy40	57	8	of	of	IN
cord-016197-y69wwy40	57	9	death	death	NN
cord-016197-y69wwy40	57	10	and	and	CC
cord-016197-y69wwy40	57	11	the	the	DT
cord-016197-y69wwy40	57	12	leading	leading	JJ
cord-016197-y69wwy40	57	13	cause	cause	NN
cord-016197-y69wwy40	57	14	of	of	IN
cord-016197-y69wwy40	57	15	disability	disability	NN
cord-016197-y69wwy40	57	16	-	-	HYPH
cord-016197-y69wwy40	57	17	adjusted	adjust	VBN
cord-016197-y69wwy40	57	18	life	life	NN
cord-016197-y69wwy40	57	19	years	year	NNS
cord-016197-y69wwy40	57	20	worldwide	worldwide	RB
cord-016197-y69wwy40	57	21	.	.	.
cord-016197-y69wwy40	58	1	Antibacterials	antibacterial	NNS
cord-016197-y69wwy40	58	2	are	be	VBP
cord-016197-y69wwy40	58	3	key	key	JJ
cord-016197-y69wwy40	58	4	tools	tool	NNS
cord-016197-y69wwy40	58	5	in	in	IN
cord-016197-y69wwy40	58	6	treating	treat	VBG
cord-016197-y69wwy40	58	7	many	many	JJ
cord-016197-y69wwy40	58	8	globally	globally	RB
cord-016197-y69wwy40	58	9	important	important	JJ
cord-016197-y69wwy40	58	10	infectious	infectious	JJ
cord-016197-y69wwy40	58	11	diseases	disease	NNS
cord-016197-y69wwy40	58	12	,	,	,
cord-016197-y69wwy40	58	13	including	include	VBG
cord-016197-y69wwy40	58	14	meningitis	meningitis	NN
cord-016197-y69wwy40	58	15	,	,	,
cord-016197-y69wwy40	58	16	pneumonia	pneumonia	NN
cord-016197-y69wwy40	58	17	,	,	,
cord-016197-y69wwy40	58	18	diarrhoeal	diarrhoeal	NN
cord-016197-y69wwy40	58	19	illness	illness	NN
cord-016197-y69wwy40	58	20	,	,	,
cord-016197-y69wwy40	58	21	skin	skin	NN
cord-016197-y69wwy40	58	22	and	and	CC
cord-016197-y69wwy40	58	23	bone	bone	NN
cord-016197-y69wwy40	58	24	infections	infection	NNS
cord-016197-y69wwy40	58	25	,	,	,
cord-016197-y69wwy40	58	26	tuberculosis	tuberculosis	NN
cord-016197-y69wwy40	58	27	,	,	,
cord-016197-y69wwy40	58	28	sexually	sexually	RB
cord-016197-y69wwy40	58	29	transmitted	transmit	VBN
cord-016197-y69wwy40	58	30	infections	infection	NNS
cord-016197-y69wwy40	58	31	(	(	-LRB-
cord-016197-y69wwy40	58	32	gonorrhoea	gonorrhoea	NN
cord-016197-y69wwy40	58	33	,	,	,
cord-016197-y69wwy40	58	34	syphilis	syphili	NNS
cord-016197-y69wwy40	58	35	,	,	,
cord-016197-y69wwy40	58	36	and	and	CC
cord-016197-y69wwy40	58	37	chlamydia	chlamydia	NNP
cord-016197-y69wwy40	58	38	)	)	-RRB-
cord-016197-y69wwy40	58	39	,	,	,
cord-016197-y69wwy40	58	40	HIV	HIV	NNP
cord-016197-y69wwy40	58	41	/	/	SYM
cord-016197-y69wwy40	58	42	AIDS	AIDS	NNP
cord-016197-y69wwy40	58	43	-	-	HYPH
cord-016197-y69wwy40	58	44	related	relate	VBN
cord-016197-y69wwy40	58	45	bacterial	bacterial	JJ
cord-016197-y69wwy40	58	46	infection	infection	NN
cord-016197-y69wwy40	58	47	,	,	,
cord-016197-y69wwy40	58	48	and	and	CC
cord-016197-y69wwy40	58	49	diseases	disease	NNS
cord-016197-y69wwy40	58	50	that	that	WDT
cord-016197-y69wwy40	58	51	may	may	MD
cord-016197-y69wwy40	58	52	be	be	VB
cord-016197-y69wwy40	58	53	spread	spread	VBN
cord-016197-y69wwy40	58	54	as	as	IN
cord-016197-y69wwy40	58	55	a	a	DT
cord-016197-y69wwy40	58	56	result	result	NN
cord-016197-y69wwy40	58	57	of	of	IN
cord-016197-y69wwy40	58	58	bioterrorist	bioterrorist	NN
cord-016197-y69wwy40	58	59	acts	act	NNS
cord-016197-y69wwy40	58	60	.	.	.
cord-016197-y69wwy40	59	1	Withdrawal	withdrawal	NN
cord-016197-y69wwy40	59	2	from	from	IN
cord-016197-y69wwy40	59	3	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	59	4	research	research	NN
cord-016197-y69wwy40	59	5	will	will	MD
cord-016197-y69wwy40	59	6	have	have	VB
cord-016197-y69wwy40	59	7	a	a	DT
cord-016197-y69wwy40	59	8	major	major	JJ
cord-016197-y69wwy40	59	9	impact	impact	NN
cord-016197-y69wwy40	59	10	on	on	IN
cord-016197-y69wwy40	59	11	global	global	JJ
cord-016197-y69wwy40	59	12	health	health	NN
cord-016197-y69wwy40	59	13	.	.	.
cord-016197-y69wwy40	60	1	A	a	DT
cord-016197-y69wwy40	60	2	letter	letter	NN
cord-016197-y69wwy40	60	3	to	to	IN
cord-016197-y69wwy40	60	4	the	the	DT
cord-016197-y69wwy40	60	5	journal	journal	NN
cord-016197-y69wwy40	60	6	of	of	IN
cord-016197-y69wwy40	60	7	the	the	DT
cord-016197-y69wwy40	60	8	American	American	NNP
cord-016197-y69wwy40	60	9	Society	Society	NNP
cord-016197-y69wwy40	60	10	for	for	IN
cord-016197-y69wwy40	60	11	Microbiology	Microbiology	NNP
cord-016197-y69wwy40	61	1	(	(	-LRB-
cord-016197-y69wwy40	61	2	Appelbaum	Appelbaum	NNP
cord-016197-y69wwy40	61	3	,	,	,
cord-016197-y69wwy40	61	4	2003	2003	CD
cord-016197-y69wwy40	61	5	)	)	-RRB-
cord-016197-y69wwy40	61	6	states	state	VBZ
cord-016197-y69wwy40	61	7	that	that	IN
cord-016197-y69wwy40	61	8	,	,	,
cord-016197-y69wwy40	61	9	"	"	``
cord-016197-y69wwy40	61	10	A	a	DT
cord-016197-y69wwy40	61	11	crisis	crisis	NN
cord-016197-y69wwy40	61	12	has	have	VBZ
cord-016197-y69wwy40	61	13	developed	develop	VBN
cord-016197-y69wwy40	61	14	and	and	CC
cord-016197-y69wwy40	61	15	we	-PRON-	PRP
cord-016197-y69wwy40	61	16	are	be	VBP
cord-016197-y69wwy40	61	17	doing	do	VBG
cord-016197-y69wwy40	61	18	nothing	nothing	NN
cord-016197-y69wwy40	61	19	about	about	IN
cord-016197-y69wwy40	61	20	it	-PRON-	PRP
cord-016197-y69wwy40	61	21	,	,	,
cord-016197-y69wwy40	61	22	"	"	''
cord-016197-y69wwy40	61	23	highlighting	highlight	VBG
cord-016197-y69wwy40	61	24	that	that	IN
cord-016197-y69wwy40	61	25	Pharma	Pharma	NNP
cord-016197-y69wwy40	61	26	companies	company	NNS
cord-016197-y69wwy40	61	27	are	be	VBP
cord-016197-y69wwy40	61	28	reducing	reduce	VBG
cord-016197-y69wwy40	61	29	or	or	CC
cord-016197-y69wwy40	61	30	closing	close	VBG
cord-016197-y69wwy40	61	31	their	-PRON-	PRP$
cord-016197-y69wwy40	61	32	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	61	33	research	research	NN
cord-016197-y69wwy40	61	34	and	and	CC
cord-016197-y69wwy40	61	35	that	that	IN
cord-016197-y69wwy40	61	36	pipelines	pipeline	NNS
cord-016197-y69wwy40	61	37	are	be	VBP
cord-016197-y69wwy40	61	38	,	,	,
cord-016197-y69wwy40	61	39	"	"	``
cord-016197-y69wwy40	61	40	practically	practically	RB
cord-016197-y69wwy40	61	41	empty	empty	JJ
cord-016197-y69wwy40	61	42	.	.	.
cord-016197-y69wwy40	61	43	"	"	''
cord-016197-y69wwy40	62	1	Appelbaum	appelbaum	NN
cord-016197-y69wwy40	62	2	suggests	suggest	VBZ
cord-016197-y69wwy40	62	3	that	that	IN
cord-016197-y69wwy40	62	4	,	,	,
cord-016197-y69wwy40	62	5	unlike	unlike	IN
cord-016197-y69wwy40	62	6	drugs	drug	NNS
cord-016197-y69wwy40	62	7	for	for	IN
cord-016197-y69wwy40	62	8	long	long	JJ
cord-016197-y69wwy40	62	9	-	-	HYPH
cord-016197-y69wwy40	62	10	term	term	NN
cord-016197-y69wwy40	62	11	treatments	treatment	NNS
cord-016197-y69wwy40	62	12	,	,	,
cord-016197-y69wwy40	62	13	there	there	EX
cord-016197-y69wwy40	62	14	is	be	VBZ
cord-016197-y69wwy40	62	15	a	a	DT
cord-016197-y69wwy40	62	16	lack	lack	NN
cord-016197-y69wwy40	62	17	of	of	IN
cord-016197-y69wwy40	62	18	funding	funding	NN
cord-016197-y69wwy40	62	19	for	for	IN
cord-016197-y69wwy40	62	20	research	research	NN
cord-016197-y69wwy40	62	21	into	into	IN
cord-016197-y69wwy40	62	22	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	62	23	,	,	,
cord-016197-y69wwy40	62	24	one	one	CD
cord-016197-y69wwy40	62	25	of	of	IN
cord-016197-y69wwy40	62	26	the	the	DT
cord-016197-y69wwy40	62	27	reasons	reason	NNS
cord-016197-y69wwy40	62	28	for	for	IN
cord-016197-y69wwy40	62	29	this	this	DT
cord-016197-y69wwy40	62	30	being	be	VBG
cord-016197-y69wwy40	62	31	the	the	DT
cord-016197-y69wwy40	62	32	overly	overly	RB
cord-016197-y69wwy40	62	33	stringent	stringent	JJ
cord-016197-y69wwy40	62	34	approval	approval	NN
cord-016197-y69wwy40	62	35	criteria	criterion	NNS
cord-016197-y69wwy40	62	36	imposed	impose	VBN
cord-016197-y69wwy40	62	37	by	by	IN
cord-016197-y69wwy40	62	38	the	the	DT
cord-016197-y69wwy40	62	39	Federal	Federal	NNP
cord-016197-y69wwy40	62	40	Drug	Drug	NNP
cord-016197-y69wwy40	62	41	Agency	Agency	NNP
cord-016197-y69wwy40	62	42	(	(	-LRB-
cord-016197-y69wwy40	62	43	FDA	FDA	NNP
cord-016197-y69wwy40	62	44	)	)	-RRB-
cord-016197-y69wwy40	62	45	,	,	,
cord-016197-y69wwy40	62	46	making	make	VBG
cord-016197-y69wwy40	62	47	it	-PRON-	PRP
cord-016197-y69wwy40	62	48	practically	practically	RB
cord-016197-y69wwy40	62	49	impossible	impossible	JJ
cord-016197-y69wwy40	62	50	or	or	CC
cord-016197-y69wwy40	62	51	prohibitively	prohibitively	RB
cord-016197-y69wwy40	62	52	expensive	expensive	JJ
cord-016197-y69wwy40	62	53	to	to	TO
cord-016197-y69wwy40	62	54	bring	bring	VB
cord-016197-y69wwy40	62	55	new	new	JJ
cord-016197-y69wwy40	62	56	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	62	57	to	to	IN
cord-016197-y69wwy40	62	58	market	market	NN
cord-016197-y69wwy40	62	59	(	(	-LRB-
cord-016197-y69wwy40	62	60	Appelbaum	Appelbaum	NNP
cord-016197-y69wwy40	62	61	,	,	,
cord-016197-y69wwy40	62	62	2003	2003	CD
cord-016197-y69wwy40	62	63	)	)	-RRB-
cord-016197-y69wwy40	62	64	.	.	.
cord-016197-y69wwy40	63	1	For	for	IN
cord-016197-y69wwy40	63	2	those	those	DT
cord-016197-y69wwy40	63	3	who	who	WP
cord-016197-y69wwy40	63	4	have	have	VBP
cord-016197-y69wwy40	63	5	worked	work	VBN
cord-016197-y69wwy40	63	6	in	in	IN
cord-016197-y69wwy40	63	7	the	the	DT
cord-016197-y69wwy40	63	8	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	63	9	field	field	NN
cord-016197-y69wwy40	63	10	from	from	IN
cord-016197-y69wwy40	63	11	the	the	DT
cord-016197-y69wwy40	63	12	hey	hey	NNP
cord-016197-y69wwy40	63	13	-	-	HYPH
cord-016197-y69wwy40	63	14	day	day	NN
cord-016197-y69wwy40	63	15	of	of	IN
cord-016197-y69wwy40	63	16	discoveries	discovery	NNS
cord-016197-y69wwy40	63	17	in	in	IN
cord-016197-y69wwy40	63	18	the	the	DT
cord-016197-y69wwy40	63	19	1960s	1960	NNS
cord-016197-y69wwy40	63	20	and	and	CC
cord-016197-y69wwy40	63	21	1970s	1970	NNS
cord-016197-y69wwy40	63	22	it	-PRON-	PRP
cord-016197-y69wwy40	63	23	is	be	VBZ
cord-016197-y69wwy40	63	24	very	very	RB
cord-016197-y69wwy40	63	25	apparent	apparent	JJ
cord-016197-y69wwy40	63	26	that	that	IN
cord-016197-y69wwy40	63	27	the	the	DT
cord-016197-y69wwy40	63	28	number	number	NN
cord-016197-y69wwy40	63	29	of	of	IN
cord-016197-y69wwy40	63	30	new	new	JJ
cord-016197-y69wwy40	63	31	chemical	chemical	JJ
cord-016197-y69wwy40	63	32	agents	agent	NNS
cord-016197-y69wwy40	63	33	being	be	VBG
cord-016197-y69wwy40	63	34	progressed	progress	VBN
cord-016197-y69wwy40	63	35	to	to	IN
cord-016197-y69wwy40	63	36	man	man	VB
cord-016197-y69wwy40	63	37	and	and	CC
cord-016197-y69wwy40	63	38	subsequently	subsequently	RB
cord-016197-y69wwy40	63	39	marketed	market	VBD
cord-016197-y69wwy40	63	40	is	be	VBZ
cord-016197-y69wwy40	63	41	much	much	RB
cord-016197-y69wwy40	63	42	reduced	reduce	VBN
cord-016197-y69wwy40	63	43	.	.	.
cord-016197-y69wwy40	64	1	IDSA	IDSA	NNP
cord-016197-y69wwy40	64	2	reported	report	VBD
cord-016197-y69wwy40	64	3	that	that	DT
cord-016197-y69wwy40	64	4	of	of	IN
cord-016197-y69wwy40	64	5	89	89	CD
cord-016197-y69wwy40	64	6	new	new	JJ
cord-016197-y69wwy40	64	7	medicines	medicine	NNS
cord-016197-y69wwy40	64	8	reaching	reach	VBG
cord-016197-y69wwy40	64	9	the	the	DT
cord-016197-y69wwy40	64	10	US	US	NNP
cord-016197-y69wwy40	64	11	market	market	NN
cord-016197-y69wwy40	64	12	in	in	IN
cord-016197-y69wwy40	64	13	2002	2002	CD
cord-016197-y69wwy40	64	14	none	none	NN
cord-016197-y69wwy40	64	15	was	be	VBD
cord-016197-y69wwy40	64	16	an	an	DT
cord-016197-y69wwy40	64	17	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	64	18	,	,	,
cord-016197-y69wwy40	64	19	with	with	IN
cord-016197-y69wwy40	64	20	only	only	RB
cord-016197-y69wwy40	64	21	7	7	CD
cord-016197-y69wwy40	64	22	new	new	JJ
cord-016197-y69wwy40	64	23	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	64	24	being	be	VBG
cord-016197-y69wwy40	64	25	approved	approve	VBN
cord-016197-y69wwy40	64	26	since	since	IN
cord-016197-y69wwy40	64	27	1998	1998	CD
cord-016197-y69wwy40	64	28	(	(	-LRB-
cord-016197-y69wwy40	64	29	IDSA	IDSA	NNP
cord-016197-y69wwy40	64	30	,	,	,
cord-016197-y69wwy40	64	31	2003	2003	CD
cord-016197-y69wwy40	64	32	)	)	-RRB-
cord-016197-y69wwy40	64	33	.	.	.
cord-016197-y69wwy40	65	1	A	a	DT
cord-016197-y69wwy40	65	2	review	review	NN
cord-016197-y69wwy40	65	3	of	of	IN
cord-016197-y69wwy40	65	4	company	company	NN
cord-016197-y69wwy40	65	5	reports	report	NNS
cord-016197-y69wwy40	65	6	for	for	IN
cord-016197-y69wwy40	65	7	the	the	DT
cord-016197-y69wwy40	65	8	11	11	CD
cord-016197-y69wwy40	65	9	major	major	JJ
cord-016197-y69wwy40	65	10	Pharma	Pharma	NNP
cord-016197-y69wwy40	65	11	companies	company	NNS
cord-016197-y69wwy40	65	12	listed	list	VBN
cord-016197-y69wwy40	65	13	only	only	RB
cord-016197-y69wwy40	65	14	4	4	CD
cord-016197-y69wwy40	65	15	new	new	JJ
cord-016197-y69wwy40	65	16	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	65	17	in	in	IN
cord-016197-y69wwy40	65	18	the	the	DT
cord-016197-y69wwy40	65	19	drug	drug	NN
cord-016197-y69wwy40	65	20	pipeline	pipeline	NN
cord-016197-y69wwy40	65	21	out	out	IN
cord-016197-y69wwy40	65	22	of	of	IN
cord-016197-y69wwy40	65	23	290	290	CD
cord-016197-y69wwy40	65	24	agents	agent	NNS
cord-016197-y69wwy40	65	25	listed	list	VBN
cord-016197-y69wwy40	65	26	(	(	-LRB-
cord-016197-y69wwy40	65	27	1.38	1.38	CD
cord-016197-y69wwy40	65	28	%	%	NN
cord-016197-y69wwy40	65	29	)	)	-RRB-
cord-016197-y69wwy40	65	30	(	(	-LRB-
cord-016197-y69wwy40	65	31	IDSA	IDSA	NNP
cord-016197-y69wwy40	65	32	,	,	,
cord-016197-y69wwy40	65	33	2003	2003	CD
cord-016197-y69wwy40	65	34	)	)	-RRB-
cord-016197-y69wwy40	65	35	and	and	CC
cord-016197-y69wwy40	65	36	that	that	IN
cord-016197-y69wwy40	65	37	on	on	IN
cord-016197-y69wwy40	65	38	average	average	JJ
cord-016197-y69wwy40	65	39	the	the	DT
cord-016197-y69wwy40	65	40	time	time	NN
cord-016197-y69wwy40	65	41	to	to	TO
cord-016197-y69wwy40	65	42	develop	develop	VB
cord-016197-y69wwy40	65	43	new	new	JJ
cord-016197-y69wwy40	65	44	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	65	45	was	be	VBD
cord-016197-y69wwy40	65	46	7	7	CD
cord-016197-y69wwy40	65	47	-	-	SYM
cord-016197-y69wwy40	65	48	10	10	CD
cord-016197-y69wwy40	65	49	years	year	NNS
cord-016197-y69wwy40	65	50	from	from	IN
cord-016197-y69wwy40	65	51	discovery	discovery	NN
cord-016197-y69wwy40	65	52	to	to	IN
cord-016197-y69wwy40	65	53	first	first	JJ
cord-016197-y69wwy40	65	54	approval	approval	NN
cord-016197-y69wwy40	65	55	.	.	.
cord-016197-y69wwy40	66	1	Although	although	IN
cord-016197-y69wwy40	66	2	Pharma	Pharma	NNP
cord-016197-y69wwy40	66	3	has	have	VBZ
cord-016197-y69wwy40	66	4	continued	continue	VBN
cord-016197-y69wwy40	66	5	to	to	TO
cord-016197-y69wwy40	66	6	explore	explore	VB
cord-016197-y69wwy40	66	7	ways	way	NNS
cord-016197-y69wwy40	66	8	to	to	TO
cord-016197-y69wwy40	66	9	increase	increase	VB
cord-016197-y69wwy40	66	10	efficiencies	efficiency	NNS
cord-016197-y69wwy40	66	11	and	and	CC
cord-016197-y69wwy40	66	12	decrease	decrease	VB
cord-016197-y69wwy40	66	13	development	development	NN
cord-016197-y69wwy40	66	14	times	time	NNS
cord-016197-y69wwy40	66	15	,	,	,
cord-016197-y69wwy40	66	16	these	these	DT
cord-016197-y69wwy40	66	17	have	have	VBP
cord-016197-y69wwy40	66	18	largely	largely	RB
cord-016197-y69wwy40	66	19	remained	remain	VBN
cord-016197-y69wwy40	66	20	stable	stable	JJ
cord-016197-y69wwy40	66	21	due	due	IN
cord-016197-y69wwy40	66	22	to	to	IN
cord-016197-y69wwy40	66	23	the	the	DT
cord-016197-y69wwy40	66	24	increased	increase	VBN
cord-016197-y69wwy40	66	25	numbers	number	NNS
cord-016197-y69wwy40	66	26	of	of	IN
cord-016197-y69wwy40	66	27	patients	patient	NNS
cord-016197-y69wwy40	66	28	required	require	VBN
cord-016197-y69wwy40	66	29	for	for	IN
cord-016197-y69wwy40	66	30	new	new	JJ
cord-016197-y69wwy40	66	31	drug	drug	NN
cord-016197-y69wwy40	66	32	applications	application	NNS
cord-016197-y69wwy40	66	33	(	(	-LRB-
cord-016197-y69wwy40	66	34	NDAs	NDAs	NNP
cord-016197-y69wwy40	66	35	)	)	-RRB-
cord-016197-y69wwy40	66	36	,	,	,
cord-016197-y69wwy40	66	37	as	as	RB
cord-016197-y69wwy40	66	38	well	well	RB
cord-016197-y69wwy40	66	39	as	as	IN
cord-016197-y69wwy40	66	40	increased	increase	VBN
cord-016197-y69wwy40	66	41	complexity	complexity	NN
cord-016197-y69wwy40	66	42	and	and	CC
cord-016197-y69wwy40	66	43	costs	cost	NNS
cord-016197-y69wwy40	66	44	in	in	IN
cord-016197-y69wwy40	66	45	meeting	meet	VBG
cord-016197-y69wwy40	66	46	regulatory	regulatory	JJ
cord-016197-y69wwy40	66	47	approval	approval	NN
cord-016197-y69wwy40	66	48	requirements	requirement	NNS
cord-016197-y69wwy40	66	49	(	(	-LRB-
cord-016197-y69wwy40	66	50	Kaitin	Kaitin	NNP
cord-016197-y69wwy40	66	51	and	and	CC
cord-016197-y69wwy40	66	52	DiMasi	DiMasi	NNP
cord-016197-y69wwy40	66	53	,	,	,
cord-016197-y69wwy40	66	54	2000	2000	CD
cord-016197-y69wwy40	66	55	)	)	-RRB-
cord-016197-y69wwy40	66	56	.	.	.
cord-016197-y69wwy40	67	1	An	an	DT
cord-016197-y69wwy40	67	2	important	important	JJ
cord-016197-y69wwy40	67	3	consideration	consideration	NN
cord-016197-y69wwy40	67	4	for	for	IN
cord-016197-y69wwy40	67	5	Pharma	Pharma	NNP
cord-016197-y69wwy40	67	6	companies	company	NNS
cord-016197-y69wwy40	67	7	involved	involve	VBN
cord-016197-y69wwy40	67	8	in	in	IN
cord-016197-y69wwy40	67	9	R&D	r&d	NN
cord-016197-y69wwy40	67	10	and	and	CC
cord-016197-y69wwy40	67	11	commercialization	commercialization	NN
cord-016197-y69wwy40	67	12	of	of	IN
cord-016197-y69wwy40	67	13	therapies	therapy	NNS
cord-016197-y69wwy40	67	14	for	for	IN
cord-016197-y69wwy40	67	15	a	a	DT
cord-016197-y69wwy40	67	16	range	range	NN
cord-016197-y69wwy40	67	17	of	of	IN
cord-016197-y69wwy40	67	18	disease	disease	NN
cord-016197-y69wwy40	67	19	areas	area	NNS
cord-016197-y69wwy40	67	20	,	,	,
cord-016197-y69wwy40	67	21	is	be	VBZ
cord-016197-y69wwy40	67	22	that	that	IN
cord-016197-y69wwy40	67	23	other	other	JJ
cord-016197-y69wwy40	67	24	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	67	25	areas	area	NNS
cord-016197-y69wwy40	67	26	are	be	VBP
cord-016197-y69wwy40	67	27	increasingly	increasingly	RB
cord-016197-y69wwy40	67	28	more	more	RBR
cord-016197-y69wwy40	67	29	profitable	profitable	JJ
cord-016197-y69wwy40	67	30	than	than	IN
cord-016197-y69wwy40	67	31	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	67	32	.	.	.
cord-016197-y69wwy40	68	1	Today	today	NN
cord-016197-y69wwy40	68	2	,	,	,
cord-016197-y69wwy40	68	3	there	there	EX
cord-016197-y69wwy40	68	4	are	be	VBP
cord-016197-y69wwy40	68	5	fewer	few	JJR
cord-016197-y69wwy40	68	6	large	large	JJ
cord-016197-y69wwy40	68	7	companies	company	NNS
cord-016197-y69wwy40	68	8	specializing	specialize	VBG
cord-016197-y69wwy40	68	9	in	in	IN
cord-016197-y69wwy40	68	10	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	68	11	as	as	IN
cord-016197-y69wwy40	68	12	a	a	DT
cord-016197-y69wwy40	68	13	main	main	JJ
cord-016197-y69wwy40	68	14	R&D	r&d	NN
cord-016197-y69wwy40	68	15	area	area	NN
cord-016197-y69wwy40	68	16	.	.	.
cord-016197-y69wwy40	69	1	Investment	investment	NN
cord-016197-y69wwy40	69	2	decisions	decision	NNS
cord-016197-y69wwy40	69	3	are	be	VBP
cord-016197-y69wwy40	69	4	made	make	VBN
cord-016197-y69wwy40	69	5	across	across	IN
cord-016197-y69wwy40	69	6	and	and	CC
cord-016197-y69wwy40	69	7	between	between	IN
cord-016197-y69wwy40	69	8	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	69	9	areas	area	NNS
cord-016197-y69wwy40	69	10	and	and	CC
cord-016197-y69wwy40	69	11	Pharma	Pharma	NNP
cord-016197-y69wwy40	69	12	has	have	VBZ
cord-016197-y69wwy40	69	13	an	an	DT
cord-016197-y69wwy40	69	14	obligation	obligation	NN
cord-016197-y69wwy40	69	15	to	to	TO
cord-016197-y69wwy40	69	16	maintain	maintain	VB
cord-016197-y69wwy40	69	17	shareholder	shareholder	NN
cord-016197-y69wwy40	69	18	value	value	NN
cord-016197-y69wwy40	69	19	and	and	CC
cord-016197-y69wwy40	69	20	commercial	commercial	JJ
cord-016197-y69wwy40	69	21	viability	viability	NN
cord-016197-y69wwy40	69	22	or	or	CC
cord-016197-y69wwy40	69	23	else	else	RB
cord-016197-y69wwy40	69	24	no	no	DT
cord-016197-y69wwy40	69	25	new	new	JJ
cord-016197-y69wwy40	69	26	drugs	drug	NNS
cord-016197-y69wwy40	69	27	would	would	MD
cord-016197-y69wwy40	69	28	become	become	VB
cord-016197-y69wwy40	69	29	available	available	JJ
cord-016197-y69wwy40	69	30	in	in	IN
cord-016197-y69wwy40	69	31	any	any	DT
cord-016197-y69wwy40	69	32	therapy	therapy	NN
cord-016197-y69wwy40	69	33	area	area	NN
cord-016197-y69wwy40	69	34	.	.	.
cord-016197-y69wwy40	70	1	The	the	DT
cord-016197-y69wwy40	70	2	reasons	reason	NNS
cord-016197-y69wwy40	70	3	for	for	IN
cord-016197-y69wwy40	70	4	the	the	DT
cord-016197-y69wwy40	70	5	"	"	``
cord-016197-y69wwy40	70	6	crisis	crisis	NN
cord-016197-y69wwy40	70	7	"	"	''
cord-016197-y69wwy40	70	8	in	in	IN
cord-016197-y69wwy40	70	9	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	70	10	R&D	r&d	NN
cord-016197-y69wwy40	70	11	,	,	,
cord-016197-y69wwy40	70	12	manifested	manifest	VBN
cord-016197-y69wwy40	70	13	by	by	IN
cord-016197-y69wwy40	70	14	fewer	few	JJR
cord-016197-y69wwy40	70	15	new	new	JJ
cord-016197-y69wwy40	70	16	agents	agent	NNS
cord-016197-y69wwy40	70	17	or	or	CC
cord-016197-y69wwy40	70	18	classes	class	NNS
cord-016197-y69wwy40	70	19	reaching	reach	VBG
cord-016197-y69wwy40	70	20	clinical	clinical	JJ
cord-016197-y69wwy40	70	21	use	use	NN
cord-016197-y69wwy40	70	22	,	,	,
cord-016197-y69wwy40	70	23	are	be	VBP
cord-016197-y69wwy40	70	24	complex	complex	JJ
cord-016197-y69wwy40	70	25	and	and	CC
cord-016197-y69wwy40	70	26	multifactorial	multifactorial	JJ
cord-016197-y69wwy40	70	27	but	but	CC
cord-016197-y69wwy40	70	28	undoubtedly	undoubtedly	RB
cord-016197-y69wwy40	70	29	the	the	DT
cord-016197-y69wwy40	70	30	impact	impact	NN
cord-016197-y69wwy40	70	31	of	of	IN
cord-016197-y69wwy40	70	32	the	the	DT
cord-016197-y69wwy40	70	33	changing	change	VBG
cord-016197-y69wwy40	70	34	environment	environment	NN
cord-016197-y69wwy40	70	35	of	of	IN
cord-016197-y69wwy40	70	36	regulations	regulation	NNS
cord-016197-y69wwy40	70	37	,	,	,
cord-016197-y69wwy40	70	38	guidelines	guideline	NNS
cord-016197-y69wwy40	70	39	,	,	,
cord-016197-y69wwy40	70	40	and	and	CC
cord-016197-y69wwy40	70	41	policies	policy	NNS
cord-016197-y69wwy40	70	42	on	on	IN
cord-016197-y69wwy40	70	43	the	the	DT
cord-016197-y69wwy40	70	44	development	development	NN
cord-016197-y69wwy40	70	45	and	and	CC
cord-016197-y69wwy40	70	46	use	use	NN
cord-016197-y69wwy40	70	47	of	of	IN
cord-016197-y69wwy40	70	48	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	70	49	is	be	VBZ
cord-016197-y69wwy40	70	50	an	an	DT
cord-016197-y69wwy40	70	51	important	important	JJ
cord-016197-y69wwy40	70	52	contributory	contributory	JJ
cord-016197-y69wwy40	70	53	factor	factor	NN
cord-016197-y69wwy40	70	54	.	.	.
cord-016197-y69wwy40	71	1	Stated	state	VBN
cord-016197-y69wwy40	71	2	simply	simply	RB
cord-016197-y69wwy40	71	3	,	,	,
cord-016197-y69wwy40	71	4	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	71	5	are	be	VBP
cord-016197-y69wwy40	71	6	developed	develop	VBN
cord-016197-y69wwy40	71	7	and	and	CC
cord-016197-y69wwy40	71	8	used	use	VBN
cord-016197-y69wwy40	71	9	to	to	TO
cord-016197-y69wwy40	71	10	overcome	overcome	VB
cord-016197-y69wwy40	71	11	bacterial	bacterial	JJ
cord-016197-y69wwy40	71	12	infection	infection	NN
cord-016197-y69wwy40	71	13	.	.	.
cord-016197-y69wwy40	72	1	The	the	DT
cord-016197-y69wwy40	72	2	progressive	progressive	JJ
cord-016197-y69wwy40	72	3	discovery	discovery	NN
cord-016197-y69wwy40	72	4	and	and	CC
cord-016197-y69wwy40	72	5	introduction	introduction	NN
cord-016197-y69wwy40	72	6	of	of	IN
cord-016197-y69wwy40	72	7	new	new	JJ
cord-016197-y69wwy40	72	8	classes	class	NNS
cord-016197-y69wwy40	72	9	and	and	CC
cord-016197-y69wwy40	72	10	agents	agent	NNS
cord-016197-y69wwy40	72	11	extended	extend	VBD
cord-016197-y69wwy40	72	12	the	the	DT
cord-016197-y69wwy40	72	13	range	range	NN
cord-016197-y69wwy40	72	14	of	of	IN
cord-016197-y69wwy40	72	15	bacteria	bacteria	NNS
cord-016197-y69wwy40	72	16	and	and	CC
cord-016197-y69wwy40	72	17	associated	associate	VBD
cord-016197-y69wwy40	72	18	infections	infection	NNS
cord-016197-y69wwy40	72	19	that	that	WDT
cord-016197-y69wwy40	72	20	could	could	MD
cord-016197-y69wwy40	72	21	be	be	VB
cord-016197-y69wwy40	72	22	successfully	successfully	RB
cord-016197-y69wwy40	72	23	treated	treat	VBN
cord-016197-y69wwy40	72	24	.	.	.
cord-016197-y69wwy40	73	1	Antibacterial	antibacterial	JJ
cord-016197-y69wwy40	73	2	resistance	resistance	NN
cord-016197-y69wwy40	73	3	,	,	,
cord-016197-y69wwy40	73	4	which	which	WDT
cord-016197-y69wwy40	73	5	has	have	VBZ
cord-016197-y69wwy40	73	6	emerged	emerge	VBN
cord-016197-y69wwy40	73	7	from	from	IN
cord-016197-y69wwy40	73	8	the	the	DT
cord-016197-y69wwy40	73	9	beginning	beginning	NN
cord-016197-y69wwy40	73	10	of	of	IN
cord-016197-y69wwy40	73	11	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	73	12	chemotherapy	chemotherapy	NN
cord-016197-y69wwy40	73	13	,	,	,
cord-016197-y69wwy40	73	14	has	have	VBZ
cord-016197-y69wwy40	73	15	provided	provide	VBN
cord-016197-y69wwy40	73	16	a	a	DT
cord-016197-y69wwy40	73	17	key	key	JJ
cord-016197-y69wwy40	73	18	medical	medical	JJ
cord-016197-y69wwy40	73	19	reason	reason	NN
cord-016197-y69wwy40	73	20	for	for	IN
cord-016197-y69wwy40	73	21	the	the	DT
cord-016197-y69wwy40	73	22	development	development	NN
cord-016197-y69wwy40	73	23	of	of	IN
cord-016197-y69wwy40	73	24	new	new	JJ
cord-016197-y69wwy40	73	25	agents	agent	NNS
cord-016197-y69wwy40	73	26	,	,	,
cord-016197-y69wwy40	73	27	along	along	IN
cord-016197-y69wwy40	73	28	with	with	IN
cord-016197-y69wwy40	73	29	the	the	DT
cord-016197-y69wwy40	73	30	wish	wish	NN
cord-016197-y69wwy40	73	31	to	to	TO
cord-016197-y69wwy40	73	32	improve	improve	VB
cord-016197-y69wwy40	73	33	efficacy	efficacy	NN
cord-016197-y69wwy40	73	34	,	,	,
cord-016197-y69wwy40	73	35	safety	safety	NN
cord-016197-y69wwy40	73	36	and	and	CC
cord-016197-y69wwy40	73	37	tolerability	tolerability	NN
cord-016197-y69wwy40	73	38	,	,	,
cord-016197-y69wwy40	73	39	and	and	CC
cord-016197-y69wwy40	73	40	dosing	dosing	NN
cord-016197-y69wwy40	73	41	convenience	convenience	NN
cord-016197-y69wwy40	73	42	.	.	.
cord-016197-y69wwy40	74	1	Anti	Anti	NNP
cord-016197-y69wwy40	74	2	-	-	NNS
cord-016197-y69wwy40	74	3	infectives	infective	NNS
cord-016197-y69wwy40	74	4	are	be	VBP
cord-016197-y69wwy40	74	5	unique	unique	JJ
cord-016197-y69wwy40	74	6	(	(	-LRB-
cord-016197-y69wwy40	74	7	with	with	IN
cord-016197-y69wwy40	74	8	the	the	DT
cord-016197-y69wwy40	74	9	exception	exception	NN
cord-016197-y69wwy40	74	10	of	of	IN
cord-016197-y69wwy40	74	11	some	some	DT
cord-016197-y69wwy40	74	12	increasing	increase	VBG
cord-016197-y69wwy40	74	13	evidence	evidence	NN
cord-016197-y69wwy40	74	14	in	in	IN
cord-016197-y69wwy40	74	15	oncology	oncology	NN
cord-016197-y69wwy40	74	16	)	)	-RRB-
cord-016197-y69wwy40	74	17	in	in	IN
cord-016197-y69wwy40	74	18	that	that	DT
cord-016197-y69wwy40	74	19	the	the	DT
cord-016197-y69wwy40	74	20	target	target	NN
cord-016197-y69wwy40	74	21	of	of	IN
cord-016197-y69wwy40	74	22	their	-PRON-	PRP$
cord-016197-y69wwy40	74	23	action	action	NN
cord-016197-y69wwy40	74	24	can	can	MD
cord-016197-y69wwy40	74	25	change	change	VB
cord-016197-y69wwy40	74	26	and	and	CC
cord-016197-y69wwy40	74	27	provide	provide	VB
cord-016197-y69wwy40	74	28	the	the	DT
cord-016197-y69wwy40	74	29	rationale	rationale	NN
cord-016197-y69wwy40	74	30	,	,	,
cord-016197-y69wwy40	74	31	medical	medical	JJ
cord-016197-y69wwy40	74	32	need	need	NN
cord-016197-y69wwy40	74	33	,	,	,
cord-016197-y69wwy40	74	34	and	and	CC
cord-016197-y69wwy40	74	35	commercial	commercial	JJ
cord-016197-y69wwy40	74	36	incentive	incentive	NN
cord-016197-y69wwy40	74	37	for	for	IN
cord-016197-y69wwy40	74	38	the	the	DT
cord-016197-y69wwy40	74	39	development	development	NN
cord-016197-y69wwy40	74	40	of	of	IN
cord-016197-y69wwy40	74	41	new	new	JJ
cord-016197-y69wwy40	74	42	agents	agent	NNS
cord-016197-y69wwy40	74	43	.	.	.
cord-016197-y69wwy40	75	1	The	the	DT
cord-016197-y69wwy40	75	2	need	need	NN
cord-016197-y69wwy40	75	3	for	for	IN
cord-016197-y69wwy40	75	4	new	new	JJ
cord-016197-y69wwy40	75	5	agents	agent	NNS
cord-016197-y69wwy40	75	6	or	or	CC
cord-016197-y69wwy40	75	7	classes	class	NNS
cord-016197-y69wwy40	75	8	to	to	TO
cord-016197-y69wwy40	75	9	combat	combat	VB
cord-016197-y69wwy40	75	10	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	75	11	resistance	resistance	NN
cord-016197-y69wwy40	75	12	is	be	VBZ
cord-016197-y69wwy40	75	13	arguably	arguably	RB
cord-016197-y69wwy40	75	14	greater	great	JJR
cord-016197-y69wwy40	75	15	today	today	NN
cord-016197-y69wwy40	75	16	than	than	IN
cord-016197-y69wwy40	75	17	it	-PRON-	PRP
cord-016197-y69wwy40	75	18	has	have	VBZ
cord-016197-y69wwy40	75	19	been	be	VBN
cord-016197-y69wwy40	75	20	for	for	IN
cord-016197-y69wwy40	75	21	some	some	DT
cord-016197-y69wwy40	75	22	decades	decade	NNS
cord-016197-y69wwy40	75	23	.	.	.
cord-016197-y69wwy40	76	1	Concerns	concern	NNS
cord-016197-y69wwy40	76	2	about	about	IN
cord-016197-y69wwy40	76	3	emerging	emerge	VBG
cord-016197-y69wwy40	76	4	resistance	resistance	NN
cord-016197-y69wwy40	76	5	,	,	,
cord-016197-y69wwy40	76	6	increasing	increase	VBG
cord-016197-y69wwy40	76	7	loss	loss	NN
cord-016197-y69wwy40	76	8	of	of	IN
cord-016197-y69wwy40	76	9	utility	utility	NN
cord-016197-y69wwy40	76	10	of	of	IN
cord-016197-y69wwy40	76	11	existing	exist	VBG
cord-016197-y69wwy40	76	12	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	76	13	and	and	CC
cord-016197-y69wwy40	76	14	associated	associate	VBD
cord-016197-y69wwy40	76	15	negative	negative	JJ
cord-016197-y69wwy40	76	16	impacts	impact	NNS
cord-016197-y69wwy40	76	17	on	on	IN
cord-016197-y69wwy40	76	18	health	health	NN
cord-016197-y69wwy40	76	19	have	have	VBP
cord-016197-y69wwy40	76	20	given	give	VBN
cord-016197-y69wwy40	76	21	rise	rise	NN
cord-016197-y69wwy40	76	22	to	to	IN
cord-016197-y69wwy40	76	23	a	a	DT
cord-016197-y69wwy40	76	24	wide	wide	JJ
cord-016197-y69wwy40	76	25	range	range	NN
cord-016197-y69wwy40	76	26	of	of	IN
cord-016197-y69wwy40	76	27	strategies	strategy	NNS
cord-016197-y69wwy40	76	28	(	(	-LRB-
cord-016197-y69wwy40	76	29	strategic	strategic	JJ
cord-016197-y69wwy40	76	30	plans	plan	NNS
cord-016197-y69wwy40	76	31	,	,	,
cord-016197-y69wwy40	76	32	action	action	NN
cord-016197-y69wwy40	76	33	plans	plan	NNS
cord-016197-y69wwy40	76	34	)	)	-RRB-
cord-016197-y69wwy40	76	35	,	,	,
cord-016197-y69wwy40	76	36	policies	policy	NNS
cord-016197-y69wwy40	76	37	(	(	-LRB-
cord-016197-y69wwy40	76	38	rules	rule	NNS
cord-016197-y69wwy40	76	39	and	and	CC
cord-016197-y69wwy40	76	40	directives	directive	NNS
cord-016197-y69wwy40	76	41	)	)	-RRB-
cord-016197-y69wwy40	76	42	,	,	,
cord-016197-y69wwy40	76	43	and	and	CC
cord-016197-y69wwy40	76	44	guidelines	guideline	NNS
cord-016197-y69wwy40	76	45	or	or	CC
cord-016197-y69wwy40	76	46	guidance	guidance	NN
cord-016197-y69wwy40	76	47	.	.	.
cord-016197-y69wwy40	77	1	Some	some	DT
cord-016197-y69wwy40	77	2	are	be	VBP
cord-016197-y69wwy40	77	3	advisory	advisory	JJ
cord-016197-y69wwy40	77	4	and	and	CC
cord-016197-y69wwy40	77	5	others	other	NNS
cord-016197-y69wwy40	77	6	mandatory	mandatory	JJ
cord-016197-y69wwy40	77	7	but	but	CC
cord-016197-y69wwy40	77	8	all	all	DT
cord-016197-y69wwy40	77	9	constitute	constitute	VBP
cord-016197-y69wwy40	77	10	broad	broad	JJ
cord-016197-y69wwy40	77	11	policy	policy	NN
cord-016197-y69wwy40	77	12	with	with	IN
cord-016197-y69wwy40	77	13	respect	respect	NN
cord-016197-y69wwy40	77	14	to	to	IN
cord-016197-y69wwy40	77	15	the	the	DT
cord-016197-y69wwy40	77	16	development	development	NN
cord-016197-y69wwy40	77	17	and	and	CC
cord-016197-y69wwy40	77	18	use	use	NN
cord-016197-y69wwy40	77	19	of	of	IN
cord-016197-y69wwy40	77	20	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	77	21	.	.	.
cord-016197-y69wwy40	78	1	The	the	DT
cord-016197-y69wwy40	78	2	sources	source	NNS
cord-016197-y69wwy40	78	3	of	of	IN
cord-016197-y69wwy40	78	4	policy	policy	NN
cord-016197-y69wwy40	78	5	activities	activity	NNS
cord-016197-y69wwy40	78	6	range	range	VBP
cord-016197-y69wwy40	78	7	from	from	IN
cord-016197-y69wwy40	78	8	global	global	JJ
cord-016197-y69wwy40	78	9	NGOs	NGOs	NNPS
cord-016197-y69wwy40	78	10	,	,	,
cord-016197-y69wwy40	78	11	such	such	JJ
cord-016197-y69wwy40	78	12	as	as	IN
cord-016197-y69wwy40	78	13	the	the	DT
cord-016197-y69wwy40	78	14	World	World	NNP
cord-016197-y69wwy40	78	15	Health	Health	NNP
cord-016197-y69wwy40	78	16	Organization	Organization	NNP
cord-016197-y69wwy40	78	17	(	(	-LRB-
cord-016197-y69wwy40	78	18	WHO	who	WP
cord-016197-y69wwy40	78	19	)	)	-RRB-
cord-016197-y69wwy40	78	20	,	,	,
cord-016197-y69wwy40	78	21	regionally	regionally	RB
cord-016197-y69wwy40	78	22	based	base	VBN
cord-016197-y69wwy40	78	23	bodies	body	NNS
cord-016197-y69wwy40	78	24	such	such	JJ
cord-016197-y69wwy40	78	25	as	as	IN
cord-016197-y69wwy40	78	26	the	the	DT
cord-016197-y69wwy40	78	27	European	European	NNP
cord-016197-y69wwy40	78	28	Union	Union	NNP
cord-016197-y69wwy40	78	29	(	(	-LRB-
cord-016197-y69wwy40	78	30	EU	EU	NNP
cord-016197-y69wwy40	78	31	)	)	-RRB-
cord-016197-y69wwy40	78	32	and	and	CC
cord-016197-y69wwy40	78	33	European	European	NNP
cord-016197-y69wwy40	78	34	Medicines	Medicines	NNPS
cord-016197-y69wwy40	78	35	Evaluation	Evaluation	NNP
cord-016197-y69wwy40	78	36	Agency	Agency	NNP
cord-016197-y69wwy40	78	37	(	(	-LRB-
cord-016197-y69wwy40	78	38	EMEA	EMEA	NNP
cord-016197-y69wwy40	78	39	)	)	-RRB-
cord-016197-y69wwy40	78	40	,	,	,
cord-016197-y69wwy40	78	41	countrybased	countrybase	VBD
cord-016197-y69wwy40	78	42	public	public	JJ
cord-016197-y69wwy40	78	43	health	health	NN
cord-016197-y69wwy40	78	44	and	and	CC
cord-016197-y69wwy40	78	45	regulatory	regulatory	JJ
cord-016197-y69wwy40	78	46	bodies	body	NNS
cord-016197-y69wwy40	78	47	such	such	JJ
cord-016197-y69wwy40	78	48	as	as	IN
cord-016197-y69wwy40	78	49	the	the	DT
cord-016197-y69wwy40	78	50	Centres	Centres	NNPS
cord-016197-y69wwy40	78	51	for	for	IN
cord-016197-y69wwy40	78	52	Disease	Disease	NNP
cord-016197-y69wwy40	78	53	Control	Control	NNP
cord-016197-y69wwy40	78	54	(	(	-LRB-
cord-016197-y69wwy40	78	55	CDC	CDC	NNP
cord-016197-y69wwy40	78	56	)	)	-RRB-
cord-016197-y69wwy40	78	57	,	,	,
cord-016197-y69wwy40	78	58	and	and	CC
cord-016197-y69wwy40	78	59	FDA	FDA	NNP
cord-016197-y69wwy40	78	60	,	,	,
cord-016197-y69wwy40	78	61	and	and	CC
cord-016197-y69wwy40	78	62	physician	physician	NN
cord-016197-y69wwy40	78	63	associations	association	NNS
cord-016197-y69wwy40	78	64	(	(	-LRB-
cord-016197-y69wwy40	78	65	IDSA	IDSA	NNP
cord-016197-y69wwy40	78	66	)	)	-RRB-
cord-016197-y69wwy40	78	67	,	,	,
cord-016197-y69wwy40	78	68	to	to	IN
cord-016197-y69wwy40	78	69	the	the	DT
cord-016197-y69wwy40	78	70	local	local	JJ
cord-016197-y69wwy40	78	71	,	,	,
cord-016197-y69wwy40	78	72	and	and	CC
cord-016197-y69wwy40	78	73	institutional	institutional	JJ
cord-016197-y69wwy40	78	74	level	level	NN
cord-016197-y69wwy40	78	75	within	within	IN
cord-016197-y69wwy40	78	76	countries	country	NNS
cord-016197-y69wwy40	78	77	.	.	.
cord-016197-y69wwy40	79	1	A	a	DT
cord-016197-y69wwy40	79	2	comprehensive	comprehensive	JJ
cord-016197-y69wwy40	79	3	summary	summary	NN
cord-016197-y69wwy40	79	4	of	of	IN
cord-016197-y69wwy40	79	5	the	the	DT
cord-016197-y69wwy40	79	6	more	more	RBR
cord-016197-y69wwy40	79	7	influential	influential	JJ
cord-016197-y69wwy40	79	8	recommendations	recommendation	NNS
cord-016197-y69wwy40	79	9	for	for	IN
cord-016197-y69wwy40	79	10	the	the	DT
cord-016197-y69wwy40	79	11	control	control	NN
cord-016197-y69wwy40	79	12	of	of	IN
cord-016197-y69wwy40	79	13	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	79	14	resistance	resistance	NN
cord-016197-y69wwy40	79	15	has	have	VBZ
cord-016197-y69wwy40	79	16	been	be	VBN
cord-016197-y69wwy40	79	17	prepared	prepare	VBN
cord-016197-y69wwy40	79	18	by	by	IN
cord-016197-y69wwy40	79	19	Carbon	Carbon	NNP
cord-016197-y69wwy40	79	20	et	et	NNP
cord-016197-y69wwy40	79	21	al	al	NNP
cord-016197-y69wwy40	79	22	.	.	.
cord-016197-y69wwy40	80	1	(	(	-LRB-
cord-016197-y69wwy40	80	2	2002	2002	CD
cord-016197-y69wwy40	80	3	)	)	-RRB-
cord-016197-y69wwy40	81	1	(	(	-LRB-
cord-016197-y69wwy40	81	2	Toronto	Toronto	NNP
cord-016197-y69wwy40	81	3	Declaration	Declaration	NNP
cord-016197-y69wwy40	81	4	,	,	,
cord-016197-y69wwy40	81	5	2000	2000	CD
cord-016197-y69wwy40	81	6	)	)	-RRB-
cord-016197-y69wwy40	81	7	,	,	,
cord-016197-y69wwy40	81	8	and	and	CC
cord-016197-y69wwy40	81	9	one	one	CD
cord-016197-y69wwy40	81	10	from	from	IN
cord-016197-y69wwy40	81	11	the	the	DT
cord-016197-y69wwy40	81	12	WHO	WHO	NNP
cord-016197-y69wwy40	81	13	Global	Global	NNP
cord-016197-y69wwy40	81	14	Strategy	Strategy	NNP
cord-016197-y69wwy40	81	15	for	for	IN
cord-016197-y69wwy40	81	16	Containment	Containment	NNP
cord-016197-y69wwy40	81	17	of	of	IN
cord-016197-y69wwy40	81	18	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	81	19	Resistance	Resistance	NNP
cord-016197-y69wwy40	81	20	(	(	-LRB-
cord-016197-y69wwy40	81	21	2001	2001	CD
cord-016197-y69wwy40	81	22	)	)	-RRB-
cord-016197-y69wwy40	81	23	.	.	.
cord-016197-y69wwy40	82	1	All	all	PDT
cord-016197-y69wwy40	82	2	these	these	DT
cord-016197-y69wwy40	82	3	recommendations	recommendation	NNS
cord-016197-y69wwy40	82	4	date	date	NN
cord-016197-y69wwy40	82	5	from	from	IN
cord-016197-y69wwy40	82	6	1994	1994	CD
cord-016197-y69wwy40	82	7	to	to	IN
cord-016197-y69wwy40	82	8	2001	2001	CD
cord-016197-y69wwy40	82	9	with	with	IN
cord-016197-y69wwy40	82	10	the	the	DT
cord-016197-y69wwy40	82	11	majority	majority	NN
cord-016197-y69wwy40	82	12	being	be	VBG
cord-016197-y69wwy40	82	13	published	publish	VBN
cord-016197-y69wwy40	82	14	between	between	IN
cord-016197-y69wwy40	82	15	1998	1998	CD
cord-016197-y69wwy40	82	16	and	and	CC
cord-016197-y69wwy40	82	17	2000	2000	CD
cord-016197-y69wwy40	82	18	.	.	.
cord-016197-y69wwy40	83	1	Undoubtedly	undoubtedly	RB
cord-016197-y69wwy40	83	2	,	,	,
cord-016197-y69wwy40	83	3	there	there	EX
cord-016197-y69wwy40	83	4	are	be	VBP
cord-016197-y69wwy40	83	5	more	more	RBR
cord-016197-y69wwy40	83	6	or	or	CC
cord-016197-y69wwy40	83	7	updated	update	VBN
cord-016197-y69wwy40	83	8	recommendations	recommendation	NNS
cord-016197-y69wwy40	83	9	in	in	IN
cord-016197-y69wwy40	83	10	the	the	DT
cord-016197-y69wwy40	83	11	pipeline	pipeline	NN
cord-016197-y69wwy40	83	12	and	and	CC
cord-016197-y69wwy40	83	13	continuing	continue	VBG
cord-016197-y69wwy40	83	14	activities	activity	NNS
cord-016197-y69wwy40	83	15	of	of	IN
cord-016197-y69wwy40	83	16	bodies	body	NNS
cord-016197-y69wwy40	83	17	addressing	address	VBG
cord-016197-y69wwy40	83	18	the	the	DT
cord-016197-y69wwy40	83	19	topic	topic	NN
cord-016197-y69wwy40	83	20	,	,	,
cord-016197-y69wwy40	83	21	such	such	JJ
cord-016197-y69wwy40	83	22	as	as	IN
cord-016197-y69wwy40	83	23	the	the	DT
cord-016197-y69wwy40	83	24	USA	USA	NNP
cord-016197-y69wwy40	83	25	CDC	CDC	NNP
cord-016197-y69wwy40	83	26	Task	Task	NNP
cord-016197-y69wwy40	83	27	Force	Force	NNP
cord-016197-y69wwy40	83	28	(	(	-LRB-
cord-016197-y69wwy40	83	29	IDSA	IDSA	NNP
cord-016197-y69wwy40	83	30	,	,	,
cord-016197-y69wwy40	83	31	2003	2003	CD
cord-016197-y69wwy40	83	32	;	;	:
cord-016197-y69wwy40	83	33	Shlaes	Shlaes	NNP
cord-016197-y69wwy40	83	34	and	and	CC
cord-016197-y69wwy40	83	35	Ryan	Ryan	NNP
cord-016197-y69wwy40	83	36	,	,	,
cord-016197-y69wwy40	83	37	2003	2003	CD
cord-016197-y69wwy40	83	38	)	)	-RRB-
cord-016197-y69wwy40	83	39	.	.	.
cord-016197-y69wwy40	84	1	Common	common	JJ
cord-016197-y69wwy40	84	2	themes	theme	NNS
cord-016197-y69wwy40	84	3	,	,	,
cord-016197-y69wwy40	84	4	which	which	WDT
cord-016197-y69wwy40	84	5	emerge	emerge	VBP
cord-016197-y69wwy40	84	6	from	from	IN
cord-016197-y69wwy40	84	7	the	the	DT
cord-016197-y69wwy40	84	8	range	range	NN
cord-016197-y69wwy40	84	9	of	of	IN
cord-016197-y69wwy40	84	10	recommendations	recommendation	NNS
cord-016197-y69wwy40	84	11	related	relate	VBN
cord-016197-y69wwy40	84	12	to	to	IN
cord-016197-y69wwy40	84	13	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	84	14	and	and	CC
cord-016197-y69wwy40	84	15	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	84	16	resistance	resistance	NN
cord-016197-y69wwy40	84	17	,	,	,
cord-016197-y69wwy40	84	18	are	be	VBP
cord-016197-y69wwy40	84	19	the	the	DT
cord-016197-y69wwy40	84	20	need	need	NN
cord-016197-y69wwy40	84	21	for	for	IN
cord-016197-y69wwy40	84	22	:	:	:
cord-016197-y69wwy40	85	1	•	•	NNP
cord-016197-y69wwy40	85	2	surveillance	surveillance	NN
cord-016197-y69wwy40	85	3	of	of	IN
cord-016197-y69wwy40	85	4	resistance	resistance	NN
cord-016197-y69wwy40	85	5	and	and	CC
cord-016197-y69wwy40	85	6	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	85	7	usage	usage	NN
cord-016197-y69wwy40	85	8	•	•	NN
cord-016197-y69wwy40	85	9	optimizing	optimize	VBG
cord-016197-y69wwy40	85	10	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	85	11	use	use	NN
cord-016197-y69wwy40	85	12	(	(	-LRB-
cord-016197-y69wwy40	85	13	reduce	reduce	VB
cord-016197-y69wwy40	85	14	inappropriate	inappropriate	JJ
cord-016197-y69wwy40	85	15	use	use	NN
cord-016197-y69wwy40	85	16	)	)	-RRB-
cord-016197-y69wwy40	85	17	,	,	,
cord-016197-y69wwy40	85	18	guidelines	guideline	NNS
cord-016197-y69wwy40	85	19	,	,	,
cord-016197-y69wwy40	85	20	and	and	CC
cord-016197-y69wwy40	85	21	policies	policy	NNS
cord-016197-y69wwy40	86	1	•	•	NNP
cord-016197-y69wwy40	87	1	education	education	NN
cord-016197-y69wwy40	87	2	of	of	IN
cord-016197-y69wwy40	87	3	professionals	professional	NNS
cord-016197-y69wwy40	87	4	and	and	CC
cord-016197-y69wwy40	87	5	patients	patient	NNS
cord-016197-y69wwy40	87	6	into	into	IN
cord-016197-y69wwy40	87	7	judicious	judicious	JJ
cord-016197-y69wwy40	87	8	/	/	SYM
cord-016197-y69wwy40	87	9	prudent	prudent	JJ
cord-016197-y69wwy40	87	10	use	use	NN
cord-016197-y69wwy40	87	11	•	•	NNP
cord-016197-y69wwy40	87	12	prevention	prevention	NN
cord-016197-y69wwy40	87	13	through	through	IN
cord-016197-y69wwy40	87	14	infection	infection	NN
cord-016197-y69wwy40	87	15	control	control	NN
cord-016197-y69wwy40	87	16	,	,	,
cord-016197-y69wwy40	87	17	interventions	intervention	NNS
cord-016197-y69wwy40	87	18	,	,	,
cord-016197-y69wwy40	87	19	immunization	immunization	NN
cord-016197-y69wwy40	87	20	•	•	NN
cord-016197-y69wwy40	87	21	focused	focus	VBD
cord-016197-y69wwy40	87	22	development	development	NN
cord-016197-y69wwy40	87	23	of	of	IN
cord-016197-y69wwy40	87	24	new	new	JJ
cord-016197-y69wwy40	87	25	agents	agent	NNS
cord-016197-y69wwy40	87	26	,	,	,
cord-016197-y69wwy40	87	27	diagnostics	diagnostic	NNS
cord-016197-y69wwy40	87	28	,	,	,
cord-016197-y69wwy40	87	29	and	and	CC
cord-016197-y69wwy40	87	30	strategies	strategy	NNS
cord-016197-y69wwy40	87	31	•	•	NNP
cord-016197-y69wwy40	87	32	regulatory	regulatory	JJ
cord-016197-y69wwy40	87	33	/	/	SYM
cord-016197-y69wwy40	87	34	label	label	NN
cord-016197-y69wwy40	87	35	guidance	guidance	NN
cord-016197-y69wwy40	87	36	,	,	,
cord-016197-y69wwy40	87	37	prescribing	prescribe	VBG
cord-016197-y69wwy40	87	38	,	,	,
cord-016197-y69wwy40	87	39	and	and	CC
cord-016197-y69wwy40	87	40	advert	advert	NN
cord-016197-y69wwy40	87	41	restriction	restriction	NN
cord-016197-y69wwy40	88	1	•	•	NNP
cord-016197-y69wwy40	88	2	audit	audit	NN
cord-016197-y69wwy40	88	3	of	of	IN
cord-016197-y69wwy40	88	4	evaluation	evaluation	NN
cord-016197-y69wwy40	88	5	of	of	IN
cord-016197-y69wwy40	88	6	intervention	intervention	NN
cord-016197-y69wwy40	88	7	and	and	CC
cord-016197-y69wwy40	88	8	compliance	compliance	NN
cord-016197-y69wwy40	88	9	.	.	.
cord-016197-y69wwy40	89	1	The	the	DT
cord-016197-y69wwy40	89	2	objectives	objective	NNS
cord-016197-y69wwy40	89	3	of	of	IN
cord-016197-y69wwy40	89	4	most	most	JJS
cord-016197-y69wwy40	89	5	strategies	strategy	NNS
cord-016197-y69wwy40	89	6	and	and	CC
cord-016197-y69wwy40	89	7	policies	policy	NNS
cord-016197-y69wwy40	89	8	are	be	VBP
cord-016197-y69wwy40	89	9	to	to	TO
cord-016197-y69wwy40	89	10	better	well	JJR
cord-016197-y69wwy40	89	11	control	control	VB
cord-016197-y69wwy40	89	12	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	89	13	use	use	NN
cord-016197-y69wwy40	89	14	with	with	IN
cord-016197-y69wwy40	89	15	the	the	DT
cord-016197-y69wwy40	89	16	intent	intent	NN
cord-016197-y69wwy40	89	17	of	of	IN
cord-016197-y69wwy40	89	18	reducing	reduce	VBG
cord-016197-y69wwy40	89	19	or	or	CC
cord-016197-y69wwy40	89	20	preventing	prevent	VBG
cord-016197-y69wwy40	89	21	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	89	22	resistance	resistance	NN
cord-016197-y69wwy40	89	23	.	.	.
cord-016197-y69wwy40	90	1	This	this	DT
cord-016197-y69wwy40	90	2	,	,	,
cord-016197-y69wwy40	90	3	accompanied	accompany	VBN
cord-016197-y69wwy40	90	4	by	by	IN
cord-016197-y69wwy40	90	5	parallel	parallel	JJ
cord-016197-y69wwy40	90	6	activities	activity	NNS
cord-016197-y69wwy40	90	7	to	to	TO
cord-016197-y69wwy40	90	8	monitor	monitor	VB
cord-016197-y69wwy40	90	9	and	and	CC
cord-016197-y69wwy40	90	10	understand	understand	VB
cord-016197-y69wwy40	90	11	resistance	resistance	NN
cord-016197-y69wwy40	90	12	(	(	-LRB-
cord-016197-y69wwy40	90	13	such	such	JJ
cord-016197-y69wwy40	90	14	as	as	IN
cord-016197-y69wwy40	90	15	its	-PRON-	PRP$
cord-016197-y69wwy40	90	16	consequences	consequence	NNS
cord-016197-y69wwy40	90	17	and	and	CC
cord-016197-y69wwy40	90	18	relationship	relationship	NN
cord-016197-y69wwy40	90	19	to	to	IN
cord-016197-y69wwy40	90	20	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	90	21	use	use	NN
cord-016197-y69wwy40	90	22	)	)	-RRB-
cord-016197-y69wwy40	90	23	,	,	,
cord-016197-y69wwy40	90	24	improve	improve	VB
cord-016197-y69wwy40	90	25	infection	infection	NN
cord-016197-y69wwy40	90	26	control	control	NN
cord-016197-y69wwy40	90	27	,	,	,
cord-016197-y69wwy40	90	28	and	and	CC
cord-016197-y69wwy40	90	29	development	development	NN
cord-016197-y69wwy40	90	30	of	of	IN
cord-016197-y69wwy40	90	31	new	new	JJ
cord-016197-y69wwy40	90	32	agents	agent	NNS
cord-016197-y69wwy40	90	33	(	(	-LRB-
cord-016197-y69wwy40	90	34	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	90	35	and	and	CC
cord-016197-y69wwy40	90	36	vaccines	vaccine	NNS
cord-016197-y69wwy40	90	37	)	)	-RRB-
cord-016197-y69wwy40	90	38	and	and	CC
cord-016197-y69wwy40	90	39	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	90	40	approaches	approach	NNS
cord-016197-y69wwy40	90	41	,	,	,
cord-016197-y69wwy40	90	42	is	be	VBZ
cord-016197-y69wwy40	90	43	hoped	hope	VBN
cord-016197-y69wwy40	90	44	to	to	TO
cord-016197-y69wwy40	90	45	provide	provide	VB
cord-016197-y69wwy40	90	46	a	a	DT
cord-016197-y69wwy40	90	47	sustainable	sustainable	JJ
cord-016197-y69wwy40	90	48	solution	solution	NN
cord-016197-y69wwy40	90	49	in	in	IN
cord-016197-y69wwy40	90	50	combating	combat	VBG
cord-016197-y69wwy40	90	51	bacterial	bacterial	JJ
cord-016197-y69wwy40	90	52	infection	infection	NN
cord-016197-y69wwy40	90	53	.	.	.
cord-016197-y69wwy40	91	1	Carbon	carbon	NN
cord-016197-y69wwy40	91	2	et	et	NNP
cord-016197-y69wwy40	91	3	al	al	NNP
cord-016197-y69wwy40	91	4	.	.	.
cord-016197-y69wwy40	92	1	(	(	-LRB-
cord-016197-y69wwy40	92	2	2002	2002	CD
cord-016197-y69wwy40	92	3	)	)	-RRB-
cord-016197-y69wwy40	92	4	state	state	NN
cord-016197-y69wwy40	92	5	that	that	IN
cord-016197-y69wwy40	92	6	these	these	DT
cord-016197-y69wwy40	92	7	recommendations	recommendation	NNS
cord-016197-y69wwy40	92	8	rightly	rightly	RB
cord-016197-y69wwy40	92	9	focus	focus	VBP
cord-016197-y69wwy40	92	10	on	on	IN
cord-016197-y69wwy40	92	11	controlling	control	VBG
cord-016197-y69wwy40	92	12	resistance	resistance	NN
cord-016197-y69wwy40	92	13	in	in	IN
cord-016197-y69wwy40	92	14	the	the	DT
cord-016197-y69wwy40	92	15	community	community	NN
cord-016197-y69wwy40	92	16	through	through	IN
cord-016197-y69wwy40	92	17	surveillance	surveillance	NN
cord-016197-y69wwy40	92	18	of	of	IN
cord-016197-y69wwy40	92	19	resistance	resistance	NN
cord-016197-y69wwy40	92	20	and	and	CC
cord-016197-y69wwy40	92	21	usage	usage	NN
cord-016197-y69wwy40	92	22	,	,	,
cord-016197-y69wwy40	92	23	and	and	CC
cord-016197-y69wwy40	92	24	education	education	NN
cord-016197-y69wwy40	92	25	of	of	IN
cord-016197-y69wwy40	92	26	prescribers	prescriber	NNS
cord-016197-y69wwy40	92	27	and	and	CC
cord-016197-y69wwy40	92	28	the	the	DT
cord-016197-y69wwy40	92	29	public	public	NN
cord-016197-y69wwy40	92	30	in	in	IN
cord-016197-y69wwy40	92	31	judicious	judicious	JJ
cord-016197-y69wwy40	92	32	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	92	33	use	use	NN
cord-016197-y69wwy40	92	34	.	.	.
cord-016197-y69wwy40	93	1	Nevertheless	nevertheless	RB
cord-016197-y69wwy40	93	2	,	,	,
cord-016197-y69wwy40	93	3	the	the	DT
cord-016197-y69wwy40	93	4	authors	author	NNS
cord-016197-y69wwy40	93	5	point	point	VBP
cord-016197-y69wwy40	93	6	to	to	IN
cord-016197-y69wwy40	93	7	the	the	DT
cord-016197-y69wwy40	93	8	need	need	NN
cord-016197-y69wwy40	93	9	for	for	IN
cord-016197-y69wwy40	93	10	more	more	JJR
cord-016197-y69wwy40	93	11	research	research	NN
cord-016197-y69wwy40	93	12	to	to	TO
cord-016197-y69wwy40	93	13	fill	fill	VB
cord-016197-y69wwy40	93	14	substantial	substantial	JJ
cord-016197-y69wwy40	93	15	knowledge	knowledge	NN
cord-016197-y69wwy40	93	16	gaps	gap	NNS
cord-016197-y69wwy40	93	17	,	,	,
cord-016197-y69wwy40	93	18	notably	notably	RB
cord-016197-y69wwy40	93	19	the	the	DT
cord-016197-y69wwy40	93	20	reversibility	reversibility	NN
cord-016197-y69wwy40	93	21	or	or	CC
cord-016197-y69wwy40	93	22	containment	containment	NN
cord-016197-y69wwy40	93	23	of	of	IN
cord-016197-y69wwy40	93	24	resistance	resistance	NN
cord-016197-y69wwy40	93	25	with	with	IN
cord-016197-y69wwy40	93	26	the	the	DT
cord-016197-y69wwy40	93	27	optimization	optimization	NN
cord-016197-y69wwy40	93	28	of	of	IN
cord-016197-y69wwy40	93	29	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	93	30	usage	usage	NN
cord-016197-y69wwy40	93	31	has	have	VBZ
cord-016197-y69wwy40	93	32	yet	yet	RB
cord-016197-y69wwy40	93	33	to	to	TO
cord-016197-y69wwy40	93	34	be	be	VB
cord-016197-y69wwy40	93	35	definitely	definitely	RB
cord-016197-y69wwy40	93	36	established	establish	VBN
cord-016197-y69wwy40	93	37	Davey	Davey	NNP
cord-016197-y69wwy40	93	38	et	et	NNP
cord-016197-y69wwy40	93	39	al	al	NNP
cord-016197-y69wwy40	93	40	.	.	NNP
cord-016197-y69wwy40	93	41	,	,	,
cord-016197-y69wwy40	93	42	2003	2003	CD
cord-016197-y69wwy40	93	43	)	)	-RRB-
cord-016197-y69wwy40	93	44	.	.	.
cord-016197-y69wwy40	94	1	It	-PRON-	PRP
cord-016197-y69wwy40	94	2	is	be	VBZ
cord-016197-y69wwy40	94	3	suggested	suggest	VBN
cord-016197-y69wwy40	94	4	by	by	IN
cord-016197-y69wwy40	94	5	Carbon	Carbon	NNP
cord-016197-y69wwy40	94	6	et	et	NNP
cord-016197-y69wwy40	94	7	al	al	NNP
cord-016197-y69wwy40	94	8	.	.	.
cord-016197-y69wwy40	95	1	(	(	-LRB-
cord-016197-y69wwy40	95	2	2002	2002	CD
cord-016197-y69wwy40	95	3	)	)	-RRB-
cord-016197-y69wwy40	95	4	that	that	IN
cord-016197-y69wwy40	95	5	for	for	IN
cord-016197-y69wwy40	95	6	now	now	RB
cord-016197-y69wwy40	95	7	,	,	,
cord-016197-y69wwy40	95	8	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	95	9	management	management	NN
cord-016197-y69wwy40	95	10	programmes	programme	NNS
cord-016197-y69wwy40	95	11	should	should	MD
cord-016197-y69wwy40	95	12	focus	focus	VB
cord-016197-y69wwy40	95	13	on	on	IN
cord-016197-y69wwy40	95	14	ensuring	ensure	VBG
cord-016197-y69wwy40	95	15	the	the	DT
cord-016197-y69wwy40	95	16	most	most	RBS
cord-016197-y69wwy40	95	17	appropriate	appropriate	JJ
cord-016197-y69wwy40	95	18	use	use	NN
cord-016197-y69wwy40	95	19	of	of	IN
cord-016197-y69wwy40	95	20	antimicrobials	antimicrobial	NNS
cord-016197-y69wwy40	95	21	rather	rather	RB
cord-016197-y69wwy40	95	22	than	than	IN
cord-016197-y69wwy40	95	23	simply	simply	RB
cord-016197-y69wwy40	95	24	on	on	IN
cord-016197-y69wwy40	95	25	limiting	limit	VBG
cord-016197-y69wwy40	95	26	choices	choice	NNS
cord-016197-y69wwy40	95	27	.	.	.
cord-016197-y69wwy40	96	1	Interventions	intervention	NNS
cord-016197-y69wwy40	96	2	must	must	MD
cord-016197-y69wwy40	96	3	also	also	RB
cord-016197-y69wwy40	96	4	be	be	VB
cord-016197-y69wwy40	96	5	audited	audit	VBN
cord-016197-y69wwy40	96	6	for	for	IN
cord-016197-y69wwy40	96	7	effectiveness	effectiveness	NN
cord-016197-y69wwy40	96	8	/	/	SYM
cord-016197-y69wwy40	96	9	cost	cost	NN
cord-016197-y69wwy40	96	10	.	.	.
cord-016197-y69wwy40	97	1	It	-PRON-	PRP
cord-016197-y69wwy40	97	2	is	be	VBZ
cord-016197-y69wwy40	97	3	also	also	RB
cord-016197-y69wwy40	97	4	suggested	suggest	VBN
cord-016197-y69wwy40	97	5	that	that	IN
cord-016197-y69wwy40	97	6	the	the	DT
cord-016197-y69wwy40	97	7	programmes	programme	NNS
cord-016197-y69wwy40	97	8	in	in	IN
cord-016197-y69wwy40	97	9	the	the	DT
cord-016197-y69wwy40	97	10	recommendations	recommendation	NNS
cord-016197-y69wwy40	97	11	can	can	MD
cord-016197-y69wwy40	97	12	not	not	RB
cord-016197-y69wwy40	97	13	succeed	succeed	VB
cord-016197-y69wwy40	97	14	if	if	IN
cord-016197-y69wwy40	97	15	they	-PRON-	PRP
cord-016197-y69wwy40	97	16	do	do	VBP
cord-016197-y69wwy40	97	17	not	not	RB
cord-016197-y69wwy40	97	18	imply	imply	VB
cord-016197-y69wwy40	97	19	the	the	DT
cord-016197-y69wwy40	97	20	active	active	JJ
cord-016197-y69wwy40	97	21	contribution	contribution	NN
cord-016197-y69wwy40	97	22	of	of	IN
cord-016197-y69wwy40	97	23	health	health	NN
cord-016197-y69wwy40	97	24	professionals	professional	NNS
cord-016197-y69wwy40	97	25	,	,	,
cord-016197-y69wwy40	97	26	politicians	politician	NNS
cord-016197-y69wwy40	97	27	,	,	,
cord-016197-y69wwy40	97	28	consumers	consumer	NNS
cord-016197-y69wwy40	97	29	,	,	,
cord-016197-y69wwy40	97	30	and	and	CC
cord-016197-y69wwy40	97	31	Pharma	Pharma	NNP
cord-016197-y69wwy40	97	32	,	,	,
cord-016197-y69wwy40	97	33	and	and	CC
cord-016197-y69wwy40	97	34	that	that	IN
cord-016197-y69wwy40	97	35	the	the	DT
cord-016197-y69wwy40	97	36	creation	creation	NN
cord-016197-y69wwy40	97	37	of	of	IN
cord-016197-y69wwy40	97	38	optimal	optimal	JJ
cord-016197-y69wwy40	97	39	conditions	condition	NNS
cord-016197-y69wwy40	97	40	for	for	IN
cord-016197-y69wwy40	97	41	this	this	DT
cord-016197-y69wwy40	97	42	type	type	NN
cord-016197-y69wwy40	97	43	of	of	IN
cord-016197-y69wwy40	97	44	cooperation	cooperation	NN
cord-016197-y69wwy40	97	45	is	be	VBZ
cord-016197-y69wwy40	97	46	of	of	IN
cord-016197-y69wwy40	97	47	critical	critical	JJ
cord-016197-y69wwy40	97	48	importance	importance	NN
cord-016197-y69wwy40	97	49	Chahwakilian	Chahwakilian	NNP
cord-016197-y69wwy40	97	50	,	,	,
cord-016197-y69wwy40	97	51	2000	2000	CD
cord-016197-y69wwy40	97	52	)	)	-RRB-
cord-016197-y69wwy40	97	53	.	.	.
cord-016197-y69wwy40	98	1	The	the	DT
cord-016197-y69wwy40	98	2	key	key	JJ
cord-016197-y69wwy40	98	3	role	role	NN
cord-016197-y69wwy40	98	4	of	of	IN
cord-016197-y69wwy40	98	5	Pharma	Pharma	NNP
cord-016197-y69wwy40	98	6	in	in	IN
cord-016197-y69wwy40	98	7	these	these	DT
cord-016197-y69wwy40	98	8	strategies	strategy	NNS
cord-016197-y69wwy40	98	9	is	be	VBZ
cord-016197-y69wwy40	98	10	to	to	TO
cord-016197-y69wwy40	98	11	deliver	deliver	VB
cord-016197-y69wwy40	98	12	new	new	JJ
cord-016197-y69wwy40	98	13	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	98	14	,	,	,
cord-016197-y69wwy40	98	15	although	although	IN
cord-016197-y69wwy40	98	16	the	the	DT
cord-016197-y69wwy40	98	17	cumulative	cumulative	JJ
cord-016197-y69wwy40	98	18	impact	impact	NN
cord-016197-y69wwy40	98	19	of	of	IN
cord-016197-y69wwy40	98	20	the	the	DT
cord-016197-y69wwy40	98	21	parallel	parallel	JJ
cord-016197-y69wwy40	98	22	recommendations	recommendation	NNS
cord-016197-y69wwy40	98	23	may	may	MD
cord-016197-y69wwy40	98	24	present	present	VB
cord-016197-y69wwy40	98	25	significant	significant	JJ
cord-016197-y69wwy40	98	26	barriers	barrier	NNS
cord-016197-y69wwy40	98	27	to	to	IN
cord-016197-y69wwy40	98	28	achieving	achieve	VBG
cord-016197-y69wwy40	98	29	this	this	DT
cord-016197-y69wwy40	98	30	aim	aim	NN
cord-016197-y69wwy40	98	31	(	(	-LRB-
cord-016197-y69wwy40	98	32	Figure	figure	NN
cord-016197-y69wwy40	98	33	1	1	CD
cord-016197-y69wwy40	98	34	)	)	-RRB-
cord-016197-y69wwy40	98	35	.	.	.
cord-016197-y69wwy40	99	1	Surveillance	surveillance	NN
cord-016197-y69wwy40	99	2	programmes	programme	NNS
cord-016197-y69wwy40	99	3	of	of	IN
cord-016197-y69wwy40	99	4	bacterial	bacterial	JJ
cord-016197-y69wwy40	99	5	susceptibility	susceptibility	NN
cord-016197-y69wwy40	99	6	have	have	VBP
cord-016197-y69wwy40	99	7	become	become	VBN
cord-016197-y69wwy40	99	8	commonplace	commonplace	JJ
cord-016197-y69wwy40	99	9	in	in	IN
cord-016197-y69wwy40	99	10	the	the	DT
cord-016197-y69wwy40	99	11	field	field	NN
cord-016197-y69wwy40	99	12	of	of	IN
cord-016197-y69wwy40	99	13	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	99	14	over	over	IN
cord-016197-y69wwy40	99	15	the	the	DT
cord-016197-y69wwy40	99	16	last	last	JJ
cord-016197-y69wwy40	99	17	decade	decade	NN
cord-016197-y69wwy40	99	18	and	and	CC
cord-016197-y69wwy40	99	19	feature	feature	NN
cord-016197-y69wwy40	99	20	in	in	IN
cord-016197-y69wwy40	99	21	most	most	JJS
cord-016197-y69wwy40	99	22	recommendations	recommendation	NNS
cord-016197-y69wwy40	99	23	and	and	CC
cord-016197-y69wwy40	99	24	policies	policy	NNS
cord-016197-y69wwy40	99	25	relating	relate	VBG
cord-016197-y69wwy40	99	26	to	to	IN
cord-016197-y69wwy40	99	27	combating	combat	VBG
cord-016197-y69wwy40	99	28	resistance	resistance	NN
cord-016197-y69wwy40	99	29	.	.	.
cord-016197-y69wwy40	100	1	The	the	DT
cord-016197-y69wwy40	100	2	principles	principle	NNS
cord-016197-y69wwy40	100	3	of	of	IN
cord-016197-y69wwy40	100	4	surveillance	surveillance	NN
cord-016197-y69wwy40	100	5	,	,	,
cord-016197-y69wwy40	100	6	key	key	JJ
cord-016197-y69wwy40	100	7	studies	study	NNS
cord-016197-y69wwy40	100	8	,	,	,
cord-016197-y69wwy40	100	9	data	datum	NNS
cord-016197-y69wwy40	100	10	,	,	,
cord-016197-y69wwy40	100	11	and	and	CC
cord-016197-y69wwy40	100	12	issues	issue	NNS
cord-016197-y69wwy40	100	13	have	have	VBP
cord-016197-y69wwy40	100	14	been	be	VBN
cord-016197-y69wwy40	100	15	extensively	extensively	RB
cord-016197-y69wwy40	100	16	reviewed	review	VBN
cord-016197-y69wwy40	100	17	(	(	-LRB-
cord-016197-y69wwy40	100	18	Bax	Bax	NNP
cord-016197-y69wwy40	100	19	et	et	NNP
cord-016197-y69wwy40	100	20	al	al	NNP
cord-016197-y69wwy40	100	21	.	.	NNP
cord-016197-y69wwy40	100	22	,	,	,
cord-016197-y69wwy40	100	23	2001	2001	CD
cord-016197-y69wwy40	100	24	;	;	:
cord-016197-y69wwy40	100	25	Felmingham	Felmingham	NNP
cord-016197-y69wwy40	100	26	et	et	NNP
cord-016197-y69wwy40	100	27	al	al	NNP
cord-016197-y69wwy40	100	28	.	.	NNP
cord-016197-y69wwy40	100	29	,	,	,
cord-016197-y69wwy40	100	30	2002	2002	CD
cord-016197-y69wwy40	100	31	;	;	:
cord-016197-y69wwy40	100	32	Hunter	Hunter	NNP
cord-016197-y69wwy40	100	33	and	and	CC
cord-016197-y69wwy40	100	34	Reeves	Reeves	NNP
cord-016197-y69wwy40	100	35	,	,	,
cord-016197-y69wwy40	100	36	2002	2002	CD
cord-016197-y69wwy40	100	37	)	)	-RRB-
cord-016197-y69wwy40	100	38	.	.	.
cord-016197-y69wwy40	101	1	Good	good	JJ
cord-016197-y69wwy40	101	2	quality	quality	NN
cord-016197-y69wwy40	101	3	surveillance	surveillance	NN
cord-016197-y69wwy40	101	4	methodology	methodology	NN
cord-016197-y69wwy40	101	5	and	and	CC
cord-016197-y69wwy40	101	6	interpretation	interpretation	NN
cord-016197-y69wwy40	101	7	are	be	VBP
cord-016197-y69wwy40	101	8	essential	essential	JJ
cord-016197-y69wwy40	101	9	to	to	IN
cord-016197-y69wwy40	101	10	the	the	DT
cord-016197-y69wwy40	101	11	understanding	understanding	NN
cord-016197-y69wwy40	101	12	of	of	IN
cord-016197-y69wwy40	101	13	resistance	resistance	NN
cord-016197-y69wwy40	101	14	emergence	emergence	NN
cord-016197-y69wwy40	101	15	and	and	CC
cord-016197-y69wwy40	101	16	its	-PRON-	PRP$
cord-016197-y69wwy40	101	17	control	control	NN
cord-016197-y69wwy40	101	18	.	.	.
cord-016197-y69wwy40	102	1	The	the	DT
cord-016197-y69wwy40	102	2	main	main	JJ
cord-016197-y69wwy40	102	3	functions	function	NNS
cord-016197-y69wwy40	102	4	for	for	IN
cord-016197-y69wwy40	102	5	surveillance	surveillance	NN
cord-016197-y69wwy40	102	6	were	be	VBD
cord-016197-y69wwy40	102	7	described	describe	VBN
cord-016197-y69wwy40	102	8	by	by	IN
cord-016197-y69wwy40	102	9	Felmingham	Felmingham	NNP
cord-016197-y69wwy40	102	10	et	et	NNP
cord-016197-y69wwy40	102	11	al	al	NNP
cord-016197-y69wwy40	102	12	.	.	.
cord-016197-y69wwy40	103	1	(	(	-LRB-
cord-016197-y69wwy40	103	2	2002	2002	CD
cord-016197-y69wwy40	103	3	)	)	-RRB-
cord-016197-y69wwy40	103	4	as	as	IN
cord-016197-y69wwy40	103	5	:	:	:
cord-016197-y69wwy40	103	6	•	•	NN
cord-016197-y69wwy40	103	7	quantification	quantification	NN
cord-016197-y69wwy40	103	8	of	of	IN
cord-016197-y69wwy40	103	9	resistance	resistance	NN
cord-016197-y69wwy40	103	10	:	:	:
cord-016197-y69wwy40	103	11	resistance	resistance	NN
cord-016197-y69wwy40	103	12	prevalence	prevalence	NN
cord-016197-y69wwy40	103	13	/	/	SYM
cord-016197-y69wwy40	103	14	distribution	distribution	NN
cord-016197-y69wwy40	103	15	/	/	SYM
cord-016197-y69wwy40	103	16	changes	change	NNS
cord-016197-y69wwy40	103	17	over	over	IN
cord-016197-y69wwy40	103	18	time	time	NN
cord-016197-y69wwy40	104	1	•	•	NNP
cord-016197-y69wwy40	104	2	guidance	guidance	NN
cord-016197-y69wwy40	104	3	for	for	IN
cord-016197-y69wwy40	104	4	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	104	5	use	use	NN
cord-016197-y69wwy40	104	6	:	:	:
cord-016197-y69wwy40	104	7	individual	individual	JJ
cord-016197-y69wwy40	104	8	patient	patient	JJ
cord-016197-y69wwy40	104	9	level	level	NN
cord-016197-y69wwy40	104	10	/	/	SYM
cord-016197-y69wwy40	104	11	guidelines	guideline	NNS
cord-016197-y69wwy40	104	12	/	/	SYM
cord-016197-y69wwy40	104	13	policies	policy	NNS
cord-016197-y69wwy40	105	1	•	•	NNP
cord-016197-y69wwy40	105	2	research	research	NN
cord-016197-y69wwy40	105	3	/	/	SYM
cord-016197-y69wwy40	105	4	education	education	NN
cord-016197-y69wwy40	105	5	:	:	:
cord-016197-y69wwy40	105	6	epidemiology	epidemiology	NN
cord-016197-y69wwy40	105	7	of	of	IN
cord-016197-y69wwy40	105	8	resistance	resistance	NN
cord-016197-y69wwy40	106	1	/link	/link	,
cord-016197-y69wwy40	106	2	with	with	IN
cord-016197-y69wwy40	106	3	usage	usage	NN
cord-016197-y69wwy40	106	4	•	•	NN
cord-016197-y69wwy40	106	5	industry	industry	NN
cord-016197-y69wwy40	106	6	:	:	:
cord-016197-y69wwy40	107	1	R&D	r&d	NN
cord-016197-y69wwy40	107	2	/	/	SYM
cord-016197-y69wwy40	107	3	licensing	licensing	NN
cord-016197-y69wwy40	107	4	/	/	SYM
cord-016197-y69wwy40	107	5	marketing	marketing	NN
cord-016197-y69wwy40	107	6	/	/	SYM
cord-016197-y69wwy40	107	7	post	post	JJ
cord-016197-y69wwy40	107	8	-	-	JJ
cord-016197-y69wwy40	107	9	marketing	marketing	JJ
cord-016197-y69wwy40	107	10	•	•	NN
cord-016197-y69wwy40	107	11	resistance	resistance	NN
cord-016197-y69wwy40	107	12	control	control	NN
cord-016197-y69wwy40	107	13	:	:	:
cord-016197-y69wwy40	107	14	design	design	NN
cord-016197-y69wwy40	107	15	of	of	IN
cord-016197-y69wwy40	107	16	strategies	strategy	NNS
cord-016197-y69wwy40	107	17	/	/	SYM
cord-016197-y69wwy40	107	18	impact	impact	NN
cord-016197-y69wwy40	107	19	of	of	IN
cord-016197-y69wwy40	107	20	strategies	strategy	NNS
cord-016197-y69wwy40	107	21	/	/	SYM
cord-016197-y69wwy40	107	22	interventions	intervention	NNS
cord-016197-y69wwy40	107	23	.	.	.
cord-016197-y69wwy40	108	1	Pharma	Pharma	NNP
cord-016197-y69wwy40	108	2	is	be	VBZ
cord-016197-y69wwy40	108	3	both	both	CC
cord-016197-y69wwy40	108	4	a	a	DT
cord-016197-y69wwy40	108	5	generator	generator	NN
cord-016197-y69wwy40	108	6	and	and	CC
cord-016197-y69wwy40	108	7	user	user	NN
cord-016197-y69wwy40	108	8	of	of	IN
cord-016197-y69wwy40	108	9	surveillance	surveillance	NN
cord-016197-y69wwy40	108	10	.	.	.
cord-016197-y69wwy40	109	1	Additionally	additionally	RB
cord-016197-y69wwy40	109	2	,	,	,
cord-016197-y69wwy40	109	3	all	all	PDT
cord-016197-y69wwy40	109	4	the	the	DT
cord-016197-y69wwy40	109	5	functions	function	NNS
cord-016197-y69wwy40	109	6	for	for	IN
cord-016197-y69wwy40	109	7	surveillance	surveillance	NN
cord-016197-y69wwy40	109	8	described	describe	VBN
cord-016197-y69wwy40	109	9	by	by	IN
cord-016197-y69wwy40	109	10	Felmingham	Felmingham	NNP
cord-016197-y69wwy40	109	11	et	et	NNP
cord-016197-y69wwy40	109	12	al	al	NNP
cord-016197-y69wwy40	109	13	.	.	.
cord-016197-y69wwy40	110	1	(	(	-LRB-
cord-016197-y69wwy40	110	2	2002	2002	CD
cord-016197-y69wwy40	110	3	)	)	-RRB-
cord-016197-y69wwy40	110	4	have	have	VBP
cord-016197-y69wwy40	110	5	the	the	DT
cord-016197-y69wwy40	110	6	potential	potential	NN
cord-016197-y69wwy40	110	7	to	to	TO
cord-016197-y69wwy40	110	8	impact	impact	VB
cord-016197-y69wwy40	110	9	Pharma	Pharma	NNP
cord-016197-y69wwy40	110	10	's	's	POS
cord-016197-y69wwy40	110	11	development	development	NN
cord-016197-y69wwy40	110	12	strategies	strategy	NNS
cord-016197-y69wwy40	110	13	and	and	CC
cord-016197-y69wwy40	110	14	potential	potential	JJ
cord-016197-y69wwy40	110	15	success	success	NN
cord-016197-y69wwy40	110	16	in	in	IN
cord-016197-y69wwy40	110	17	delivering	deliver	VBG
cord-016197-y69wwy40	110	18	new	new	JJ
cord-016197-y69wwy40	110	19	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	110	20	.	.	.
cord-016197-y69wwy40	111	1	The	the	DT
cord-016197-y69wwy40	111	2	relationship	relationship	NN
cord-016197-y69wwy40	111	3	between	between	IN
cord-016197-y69wwy40	111	4	resistance	resistance	NN
cord-016197-y69wwy40	111	5	,	,	,
cord-016197-y69wwy40	111	6	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	111	7	usage	usage	NN
cord-016197-y69wwy40	111	8	patterns	pattern	NNS
cord-016197-y69wwy40	111	9	,	,	,
cord-016197-y69wwy40	111	10	and	and	CC
cord-016197-y69wwy40	111	11	clinical	clinical	JJ
cord-016197-y69wwy40	111	12	outcomes	outcome	NNS
cord-016197-y69wwy40	111	13	is	be	VBZ
cord-016197-y69wwy40	111	14	an	an	DT
cord-016197-y69wwy40	111	15	important	important	JJ
cord-016197-y69wwy40	111	16	factor	factor	NN
cord-016197-y69wwy40	111	17	in	in	IN
cord-016197-y69wwy40	111	18	determining	determine	VBG
cord-016197-y69wwy40	111	19	policies	policy	NNS
cord-016197-y69wwy40	111	20	for	for	IN
cord-016197-y69wwy40	111	21	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	111	22	use	use	NN
cord-016197-y69wwy40	111	23	.	.	.
cord-016197-y69wwy40	112	1	Scientifically	scientifically	RB
cord-016197-y69wwy40	112	2	robust	robust	JJ
cord-016197-y69wwy40	112	3	methodologies	methodology	NNS
cord-016197-y69wwy40	112	4	and	and	CC
cord-016197-y69wwy40	112	5	interpretations	interpretation	NNS
cord-016197-y69wwy40	112	6	are	be	VBP
cord-016197-y69wwy40	112	7	critical	critical	JJ
cord-016197-y69wwy40	112	8	but	but	CC
cord-016197-y69wwy40	112	9	have	have	VBP
cord-016197-y69wwy40	112	10	not	not	RB
cord-016197-y69wwy40	112	11	yet	yet	RB
cord-016197-y69wwy40	112	12	been	be	VBN
cord-016197-y69wwy40	112	13	fully	fully	RB
cord-016197-y69wwy40	112	14	defined	define	VBN
cord-016197-y69wwy40	112	15	or	or	CC
cord-016197-y69wwy40	112	16	attained	attain	VBN
cord-016197-y69wwy40	112	17	for	for	IN
cord-016197-y69wwy40	112	18	many	many	JJ
cord-016197-y69wwy40	112	19	surveillance	surveillance	NN
cord-016197-y69wwy40	112	20	studies	study	NNS
cord-016197-y69wwy40	112	21	(	(	-LRB-
cord-016197-y69wwy40	113	1	Bax	Bax	NNP
cord-016197-y69wwy40	113	2	et	et	NNP
cord-016197-y69wwy40	113	3	al	al	NNP
cord-016197-y69wwy40	113	4	.	.	NNP
cord-016197-y69wwy40	113	5	,	,	,
cord-016197-y69wwy40	113	6	2001	2001	CD
cord-016197-y69wwy40	113	7	)	)	-RRB-
cord-016197-y69wwy40	113	8	.	.	.
cord-016197-y69wwy40	114	1	Pharma	Pharma	NNP
cord-016197-y69wwy40	114	2	itself	-PRON-	PRP
cord-016197-y69wwy40	114	3	has	have	VBZ
cord-016197-y69wwy40	114	4	been	be	VBN
cord-016197-y69wwy40	114	5	actively	actively	RB
cord-016197-y69wwy40	114	6	involved	involve	VBN
cord-016197-y69wwy40	114	7	in	in	IN
cord-016197-y69wwy40	114	8	the	the	DT
cord-016197-y69wwy40	114	9	initiation	initiation	NN
cord-016197-y69wwy40	114	10	and	and	CC
cord-016197-y69wwy40	114	11	support	support	NN
cord-016197-y69wwy40	114	12	of	of	IN
cord-016197-y69wwy40	114	13	a	a	DT
cord-016197-y69wwy40	114	14	number	number	NN
cord-016197-y69wwy40	114	15	of	of	IN
cord-016197-y69wwy40	114	16	key	key	JJ
cord-016197-y69wwy40	114	17	surveillance	surveillance	NN
cord-016197-y69wwy40	114	18	studies	study	NNS
cord-016197-y69wwy40	114	19	over	over	IN
cord-016197-y69wwy40	114	20	many	many	JJ
cord-016197-y69wwy40	114	21	years	year	NNS
cord-016197-y69wwy40	114	22	(	(	-LRB-
cord-016197-y69wwy40	115	1	Felmingham	Felmingham	NNP
cord-016197-y69wwy40	115	2	et	et	NNP
cord-016197-y69wwy40	115	3	al	al	NNP
cord-016197-y69wwy40	115	4	.	.	NNP
cord-016197-y69wwy40	115	5	,	,	,
cord-016197-y69wwy40	115	6	2002	2002	CD
cord-016197-y69wwy40	115	7	)	)	-RRB-
cord-016197-y69wwy40	115	8	.	.	.
cord-016197-y69wwy40	116	1	These	these	DT
cord-016197-y69wwy40	116	2	studies	study	NNS
cord-016197-y69wwy40	116	3	are	be	VBP
cord-016197-y69wwy40	116	4	mostly	mostly	RB
cord-016197-y69wwy40	116	5	aligned	align	VBN
cord-016197-y69wwy40	116	6	with	with	IN
cord-016197-y69wwy40	116	7	the	the	DT
cord-016197-y69wwy40	116	8	companies	company	NNS
cord-016197-y69wwy40	116	9	'	'	POS
cord-016197-y69wwy40	116	10	discovery	discovery	NN
cord-016197-y69wwy40	116	11	and	and	CC
cord-016197-y69wwy40	116	12	marketing	marketing	NN
cord-016197-y69wwy40	116	13	interests	interest	NNS
cord-016197-y69wwy40	116	14	but	but	CC
cord-016197-y69wwy40	116	15	nevertheless	nevertheless	RB
cord-016197-y69wwy40	116	16	have	have	VBP
cord-016197-y69wwy40	116	17	provided	provide	VBN
cord-016197-y69wwy40	116	18	good	good	JJ
cord-016197-y69wwy40	116	19	quality	quality	NN
cord-016197-y69wwy40	116	20	data	datum	NNS
cord-016197-y69wwy40	116	21	in	in	IN
cord-016197-y69wwy40	116	22	many	many	JJ
cord-016197-y69wwy40	116	23	cases	case	NNS
cord-016197-y69wwy40	116	24	where	where	WRB
cord-016197-y69wwy40	116	25	data	datum	NNS
cord-016197-y69wwy40	116	26	were	be	VBD
cord-016197-y69wwy40	116	27	lacking	lack	VBG
cord-016197-y69wwy40	116	28	and	and	CC
cord-016197-y69wwy40	116	29	even	even	RB
cord-016197-y69wwy40	116	30	pre	pre	JJ
cord-016197-y69wwy40	116	31	-	-	JJ
cord-016197-y69wwy40	116	32	date	date	JJ
cord-016197-y69wwy40	116	33	the	the	DT
cord-016197-y69wwy40	116	34	recent	recent	JJ
cord-016197-y69wwy40	116	35	calls	call	NNS
cord-016197-y69wwy40	116	36	in	in	IN
cord-016197-y69wwy40	116	37	strategy	strategy	NN
cord-016197-y69wwy40	116	38	and	and	CC
cord-016197-y69wwy40	116	39	policy	policy	NN
cord-016197-y69wwy40	116	40	documents	document	NNS
cord-016197-y69wwy40	116	41	for	for	IN
cord-016197-y69wwy40	116	42	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	116	43	surveillance	surveillance	NN
cord-016197-y69wwy40	116	44	.	.	.
cord-016197-y69wwy40	117	1	Indeed	indeed	RB
cord-016197-y69wwy40	117	2	,	,	,
cord-016197-y69wwy40	117	3	global	global	JJ
cord-016197-y69wwy40	117	4	studies	study	NNS
cord-016197-y69wwy40	117	5	,	,	,
cord-016197-y69wwy40	117	6	such	such	JJ
cord-016197-y69wwy40	117	7	as	as	IN
cord-016197-y69wwy40	117	8	the	the	DT
cord-016197-y69wwy40	117	9	Alexander	Alexander	NNP
cord-016197-y69wwy40	117	10	Project	Project	NNP
cord-016197-y69wwy40	117	11	(	(	-LRB-
cord-016197-y69wwy40	117	12	Felmingham	Felmingham	NNP
cord-016197-y69wwy40	117	13	et	et	NNP
cord-016197-y69wwy40	117	14	al	al	NNP
cord-016197-y69wwy40	117	15	.	.	NNP
cord-016197-y69wwy40	117	16	,	,	,
cord-016197-y69wwy40	117	17	2002	2002	CD
cord-016197-y69wwy40	117	18	)	)	-RRB-
cord-016197-y69wwy40	117	19	,	,	,
cord-016197-y69wwy40	117	20	initiated	initiate	VBN
cord-016197-y69wwy40	117	21	in	in	IN
cord-016197-y69wwy40	117	22	1992	1992	CD
cord-016197-y69wwy40	117	23	and	and	CC
cord-016197-y69wwy40	117	24	funded	fund	VBN
cord-016197-y69wwy40	117	25	by	by	IN
cord-016197-y69wwy40	117	26	SmithKlineBeecham	SmithKlineBeecham	NNP
cord-016197-y69wwy40	117	27	(	(	-LRB-
cord-016197-y69wwy40	117	28	now	now	RB
cord-016197-y69wwy40	117	29	GlaxoSmithKline	GlaxoSmithKline	NNP
cord-016197-y69wwy40	117	30	)	)	-RRB-
cord-016197-y69wwy40	117	31	pioneered	pioneer	VBD
cord-016197-y69wwy40	117	32	the	the	DT
cord-016197-y69wwy40	117	33	standardization	standardization	NN
cord-016197-y69wwy40	117	34	and	and	CC
cord-016197-y69wwy40	117	35	quality	quality	NN
cord-016197-y69wwy40	117	36	control	control	NN
cord-016197-y69wwy40	117	37	of	of	IN
cord-016197-y69wwy40	117	38	methodology	methodology	NN
cord-016197-y69wwy40	117	39	across	across	IN
cord-016197-y69wwy40	117	40	countries	country	NNS
cord-016197-y69wwy40	117	41	and	and	CC
cord-016197-y69wwy40	117	42	laboratories	laboratory	NNS
cord-016197-y69wwy40	117	43	in	in	IN
cord-016197-y69wwy40	117	44	the	the	DT
cord-016197-y69wwy40	117	45	surveillance	surveillance	NN
cord-016197-y69wwy40	117	46	of	of	IN
cord-016197-y69wwy40	117	47	bacterial	bacterial	JJ
cord-016197-y69wwy40	117	48	resistance	resistance	NN
cord-016197-y69wwy40	117	49	in	in	IN
cord-016197-y69wwy40	117	50	community	community	NN
cord-016197-y69wwy40	117	51	-	-	HYPH
cord-016197-y69wwy40	117	52	acquired	acquire	VBN
cord-016197-y69wwy40	117	53	lower	low	JJR
cord-016197-y69wwy40	117	54	respiratory	respiratory	JJ
cord-016197-y69wwy40	117	55	tract	tract	NN
cord-016197-y69wwy40	117	56	infection	infection	NN
cord-016197-y69wwy40	117	57	and	and	CC
cord-016197-y69wwy40	117	58	provided	provide	VBD
cord-016197-y69wwy40	117	59	a	a	DT
cord-016197-y69wwy40	117	60	model	model	NN
cord-016197-y69wwy40	117	61	for	for	IN
cord-016197-y69wwy40	117	62	a	a	DT
cord-016197-y69wwy40	117	63	number	number	NN
cord-016197-y69wwy40	117	64	of	of	IN
cord-016197-y69wwy40	117	65	subsequent	subsequent	JJ
cord-016197-y69wwy40	117	66	global	global	JJ
cord-016197-y69wwy40	117	67	and	and	CC
cord-016197-y69wwy40	117	68	national	national	JJ
cord-016197-y69wwy40	117	69	studies	study	NNS
cord-016197-y69wwy40	117	70	.	.	.
cord-016197-y69wwy40	118	1	Pharma	Pharma	NNP
cord-016197-y69wwy40	118	2	involvement	involvement	NN
cord-016197-y69wwy40	118	3	and	and	CC
cord-016197-y69wwy40	118	4	funding	funding	NN
cord-016197-y69wwy40	118	5	in	in	IN
cord-016197-y69wwy40	118	6	surveillance	surveillance	NN
cord-016197-y69wwy40	118	7	may	may	MD
cord-016197-y69wwy40	118	8	be	be	VB
cord-016197-y69wwy40	118	9	a	a	DT
cord-016197-y69wwy40	118	10	continuing	continue	VBG
cord-016197-y69wwy40	118	11	necessary	necessary	JJ
cord-016197-y69wwy40	118	12	and	and	CC
cord-016197-y69wwy40	118	13	desirable	desirable	JJ
cord-016197-y69wwy40	118	14	role	role	NN
cord-016197-y69wwy40	118	15	.	.	.
cord-016197-y69wwy40	119	1	Pharma	Pharma	NNS
cord-016197-y69wwy40	119	2	need	need	VBP
cord-016197-y69wwy40	119	3	data	datum	NNS
cord-016197-y69wwy40	119	4	from	from	IN
cord-016197-y69wwy40	119	5	which	which	WDT
cord-016197-y69wwy40	119	6	to	to	TO
cord-016197-y69wwy40	119	7	establish	establish	VB
cord-016197-y69wwy40	119	8	and	and	CC
cord-016197-y69wwy40	119	9	drive	drive	VB
cord-016197-y69wwy40	119	10	the	the	DT
cord-016197-y69wwy40	119	11	need	need	NN
cord-016197-y69wwy40	119	12	for	for	IN
cord-016197-y69wwy40	119	13	R&D	r&d	NN
cord-016197-y69wwy40	119	14	activities	activity	NNS
cord-016197-y69wwy40	119	15	into	into	IN
cord-016197-y69wwy40	119	16	new	new	JJ
cord-016197-y69wwy40	119	17	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	119	18	.	.	.
cord-016197-y69wwy40	120	1	Surveillance	surveillance	NN
cord-016197-y69wwy40	120	2	data	datum	NNS
cord-016197-y69wwy40	120	3	are	be	VBP
cord-016197-y69wwy40	120	4	also	also	RB
cord-016197-y69wwy40	120	5	needed	need	VBN
cord-016197-y69wwy40	120	6	for	for	IN
cord-016197-y69wwy40	120	7	product	product	NN
cord-016197-y69wwy40	120	8	labelling	labelling	NN
cord-016197-y69wwy40	120	9	,	,	,
cord-016197-y69wwy40	120	10	such	such	JJ
cord-016197-y69wwy40	120	11	as	as	IN
cord-016197-y69wwy40	120	12	the	the	DT
cord-016197-y69wwy40	120	13	resistance	resistance	NN
cord-016197-y69wwy40	120	14	prevalences	prevalence	NNS
cord-016197-y69wwy40	120	15	required	require	VBN
cord-016197-y69wwy40	120	16	,	,	,
cord-016197-y69wwy40	120	17	for	for	IN
cord-016197-y69wwy40	120	18	example	example	NN
cord-016197-y69wwy40	120	19	,	,	,
cord-016197-y69wwy40	120	20	by	by	IN
cord-016197-y69wwy40	120	21	EMEA	EMEA	NNP
cord-016197-y69wwy40	120	22	.	.	.
cord-016197-y69wwy40	121	1	Susceptibility	susceptibility	NN
cord-016197-y69wwy40	121	2	data	datum	NNS
cord-016197-y69wwy40	121	3	from	from	IN
cord-016197-y69wwy40	121	4	surveillance	surveillance	NN
cord-016197-y69wwy40	121	5	are	be	VBP
cord-016197-y69wwy40	121	6	important	important	JJ
cord-016197-y69wwy40	121	7	to	to	TO
cord-016197-y69wwy40	121	8	support	support	VB
cord-016197-y69wwy40	121	9	product	product	NN
cord-016197-y69wwy40	121	10	differentiation	differentiation	NN
cord-016197-y69wwy40	121	11	and	and	CC
cord-016197-y69wwy40	121	12	benefits	benefit	NNS
cord-016197-y69wwy40	121	13	in	in	IN
cord-016197-y69wwy40	121	14	the	the	DT
cord-016197-y69wwy40	121	15	market	market	NN
cord-016197-y69wwy40	121	16	place	place	NN
cord-016197-y69wwy40	121	17	,	,	,
cord-016197-y69wwy40	121	18	and	and	CC
cord-016197-y69wwy40	121	19	may	may	MD
cord-016197-y69wwy40	121	20	also	also	RB
cord-016197-y69wwy40	121	21	be	be	VB
cord-016197-y69wwy40	121	22	required	require	VBN
cord-016197-y69wwy40	121	23	as	as	IN
cord-016197-y69wwy40	121	24	part	part	NN
cord-016197-y69wwy40	121	25	of	of	IN
cord-016197-y69wwy40	121	26	a	a	DT
cord-016197-y69wwy40	121	27	Phase	Phase	NNP
cord-016197-y69wwy40	121	28	IV	IV	NNP
cord-016197-y69wwy40	121	29	regulatory	regulatory	JJ
cord-016197-y69wwy40	121	30	commitment	commitment	NN
cord-016197-y69wwy40	121	31	for	for	IN
cord-016197-y69wwy40	121	32	a	a	DT
cord-016197-y69wwy40	121	33	new	new	JJ
cord-016197-y69wwy40	121	34	agent	agent	NN
cord-016197-y69wwy40	121	35	.	.	.
cord-016197-y69wwy40	122	1	Academia	academia	NN
cord-016197-y69wwy40	122	2	and	and	CC
cord-016197-y69wwy40	122	3	policy	policy	NN
cord-016197-y69wwy40	122	4	-	-	HYPH
cord-016197-y69wwy40	122	5	makers	maker	NNS
cord-016197-y69wwy40	122	6	also	also	RB
cord-016197-y69wwy40	122	7	need	need	VBP
cord-016197-y69wwy40	122	8	such	such	JJ
cord-016197-y69wwy40	122	9	data	datum	NNS
cord-016197-y69wwy40	122	10	to	to	TO
cord-016197-y69wwy40	122	11	assess	assess	VB
cord-016197-y69wwy40	122	12	the	the	DT
cord-016197-y69wwy40	122	13	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	122	14	environment	environment	NN
cord-016197-y69wwy40	122	15	and	and	CC
cord-016197-y69wwy40	122	16	the	the	DT
cord-016197-y69wwy40	122	17	appropriate	appropriate	JJ
cord-016197-y69wwy40	122	18	policy	policy	NN
cord-016197-y69wwy40	122	19	and	and	CC
cord-016197-y69wwy40	122	20	practice	practice	NN
cord-016197-y69wwy40	122	21	interventions	intervention	NNS
cord-016197-y69wwy40	122	22	and	and	CC
cord-016197-y69wwy40	122	23	outcomes	outcome	NNS
cord-016197-y69wwy40	122	24	.	.	.
cord-016197-y69wwy40	123	1	All	all	DT
cord-016197-y69wwy40	123	2	parties	party	NNS
cord-016197-y69wwy40	123	3	need	need	VBP
cord-016197-y69wwy40	123	4	good	good	JJ
cord-016197-y69wwy40	123	5	quality	quality	NN
cord-016197-y69wwy40	123	6	,	,	,
cord-016197-y69wwy40	123	7	scientifically	scientifically	RB
cord-016197-y69wwy40	123	8	valid	valid	JJ
cord-016197-y69wwy40	123	9	data	datum	NNS
cord-016197-y69wwy40	123	10	.	.	.
cord-016197-y69wwy40	124	1	However	however	RB
cord-016197-y69wwy40	124	2	,	,	,
cord-016197-y69wwy40	124	3	there	there	EX
cord-016197-y69wwy40	124	4	may	may	MD
cord-016197-y69wwy40	124	5	be	be	VB
cord-016197-y69wwy40	124	6	differences	difference	NNS
cord-016197-y69wwy40	124	7	in	in	IN
cord-016197-y69wwy40	124	8	needs	need	NNS
cord-016197-y69wwy40	124	9	regarding	regard	VBG
cord-016197-y69wwy40	124	10	the	the	DT
cord-016197-y69wwy40	124	11	scope	scope	NN
cord-016197-y69wwy40	124	12	of	of	IN
cord-016197-y69wwy40	124	13	studies	study	NNS
cord-016197-y69wwy40	124	14	,	,	,
cord-016197-y69wwy40	124	15	such	such	JJ
cord-016197-y69wwy40	124	16	as	as	IN
cord-016197-y69wwy40	124	17	the	the	DT
cord-016197-y69wwy40	124	18	organisms	organism	NNS
cord-016197-y69wwy40	124	19	that	that	WDT
cord-016197-y69wwy40	124	20	are	be	VBP
cord-016197-y69wwy40	124	21	included	include	VBN
cord-016197-y69wwy40	124	22	,	,	,
cord-016197-y69wwy40	124	23	the	the	DT
cord-016197-y69wwy40	124	24	agents	agent	NNS
cord-016197-y69wwy40	124	25	tested	test	VBN
cord-016197-y69wwy40	124	26	,	,	,
cord-016197-y69wwy40	124	27	or	or	CC
cord-016197-y69wwy40	124	28	the	the	DT
cord-016197-y69wwy40	124	29	reporting	reporting	NN
cord-016197-y69wwy40	124	30	of	of	IN
cord-016197-y69wwy40	124	31	data	datum	NNS
cord-016197-y69wwy40	124	32	(	(	-LRB-
cord-016197-y69wwy40	124	33	minimum	minimum	JJ
cord-016197-y69wwy40	124	34	inhibitory	inhibitory	JJ
cord-016197-y69wwy40	124	35	concentrations	concentration	NNS
cord-016197-y69wwy40	124	36	vs	vs	IN
cord-016197-y69wwy40	124	37	susceptible	susceptible	JJ
cord-016197-y69wwy40	124	38	/	/	SYM
cord-016197-y69wwy40	124	39	intermediate	intermediate	JJ
cord-016197-y69wwy40	124	40	/	/	SYM
cord-016197-y69wwy40	124	41	resistance	resistance	NN
cord-016197-y69wwy40	124	42	)	)	-RRB-
cord-016197-y69wwy40	124	43	,	,	,
cord-016197-y69wwy40	124	44	but	but	CC
cord-016197-y69wwy40	124	45	the	the	DT
cord-016197-y69wwy40	124	46	demand	demand	NN
cord-016197-y69wwy40	124	47	for	for	IN
cord-016197-y69wwy40	124	48	quality	quality	NN
cord-016197-y69wwy40	124	49	and	and	CC
cord-016197-y69wwy40	124	50	accuracy	accuracy	NN
cord-016197-y69wwy40	124	51	of	of	IN
cord-016197-y69wwy40	124	52	interpretation	interpretation	NN
cord-016197-y69wwy40	124	53	should	should	MD
cord-016197-y69wwy40	124	54	be	be	VB
cord-016197-y69wwy40	124	55	equal	equal	JJ
cord-016197-y69wwy40	124	56	.	.	.
cord-016197-y69wwy40	125	1	A	a	DT
cord-016197-y69wwy40	125	2	key	key	JJ
cord-016197-y69wwy40	125	3	issue	issue	NN
cord-016197-y69wwy40	125	4	is	be	VBZ
cord-016197-y69wwy40	125	5	the	the	DT
cord-016197-y69wwy40	125	6	source	source	NN
cord-016197-y69wwy40	125	7	and	and	CC
cord-016197-y69wwy40	125	8	sustainability	sustainability	NN
cord-016197-y69wwy40	125	9	of	of	IN
cord-016197-y69wwy40	125	10	funding	funding	NN
cord-016197-y69wwy40	125	11	of	of	IN
cord-016197-y69wwy40	125	12	surveillance	surveillance	NN
cord-016197-y69wwy40	125	13	,	,	,
cord-016197-y69wwy40	125	14	along	along	IN
cord-016197-y69wwy40	125	15	with	with	IN
cord-016197-y69wwy40	125	16	ownership	ownership	NN
cord-016197-y69wwy40	125	17	,	,	,
cord-016197-y69wwy40	125	18	interpretation	interpretation	NN
cord-016197-y69wwy40	125	19	,	,	,
cord-016197-y69wwy40	125	20	and	and	CC
cord-016197-y69wwy40	125	21	dissemination	dissemination	NN
cord-016197-y69wwy40	125	22	of	of	IN
cord-016197-y69wwy40	125	23	data	datum	NNS
cord-016197-y69wwy40	125	24	.	.	.
cord-016197-y69wwy40	126	1	Global	global	JJ
cord-016197-y69wwy40	126	2	or	or	CC
cord-016197-y69wwy40	126	3	regional	regional	JJ
cord-016197-y69wwy40	126	4	,	,	,
cord-016197-y69wwy40	126	5	longitudinal	longitudinal	JJ
cord-016197-y69wwy40	126	6	surveillance	surveillance	NN
cord-016197-y69wwy40	126	7	studies	study	NNS
cord-016197-y69wwy40	126	8	are	be	VBP
cord-016197-y69wwy40	126	9	extremely	extremely	RB
cord-016197-y69wwy40	126	10	expensive	expensive	JJ
cord-016197-y69wwy40	126	11	and	and	CC
cord-016197-y69wwy40	126	12	resource	resource	NN
cord-016197-y69wwy40	126	13	intensive	intensive	JJ
cord-016197-y69wwy40	126	14	.	.	.
cord-016197-y69wwy40	127	1	Individual	individual	JJ
cord-016197-y69wwy40	127	2	Pharma	Pharma	NNP
cord-016197-y69wwy40	127	3	companies	company	NNS
cord-016197-y69wwy40	127	4	have	have	VBP
cord-016197-y69wwy40	127	5	initiated	initiate	VBN
cord-016197-y69wwy40	127	6	and	and	CC
cord-016197-y69wwy40	127	7	solely	solely	RB
cord-016197-y69wwy40	127	8	sponsored	sponsor	VBN
cord-016197-y69wwy40	127	9	studies	study	NNS
cord-016197-y69wwy40	127	10	to	to	TO
cord-016197-y69wwy40	127	11	support	support	VB
cord-016197-y69wwy40	127	12	the	the	DT
cord-016197-y69wwy40	127	13	development	development	NN
cord-016197-y69wwy40	127	14	and	and	CC
cord-016197-y69wwy40	127	15	marketing	marketing	NN
cord-016197-y69wwy40	127	16	of	of	IN
cord-016197-y69wwy40	127	17	new	new	JJ
cord-016197-y69wwy40	127	18	agents	agent	NNS
cord-016197-y69wwy40	127	19	(	(	-LRB-
cord-016197-y69wwy40	127	20	Bax	Bax	NNP
cord-016197-y69wwy40	127	21	et	et	NNP
cord-016197-y69wwy40	127	22	al	al	NNP
cord-016197-y69wwy40	127	23	.	.	.
cord-016197-y69wwy40	128	1	,	,	,
cord-016197-y69wwy40	128	2	2001	2001	CD
cord-016197-y69wwy40	128	3	;	;	:
cord-016197-y69wwy40	128	4	Felmingham	Felmingham	NNP
cord-016197-y69wwy40	128	5	et	et	NNP
cord-016197-y69wwy40	128	6	al	al	NNP
cord-016197-y69wwy40	128	7	.	.	.
cord-016197-y69wwy40	129	1	,	,	,
cord-016197-y69wwy40	129	2	2002	2002	CD
cord-016197-y69wwy40	129	3	;	;	:
cord-016197-y69wwy40	129	4	Hunter	Hunter	NNP
cord-016197-y69wwy40	129	5	and	and	CC
cord-016197-y69wwy40	129	6	Reeves	Reeves	NNP
cord-016197-y69wwy40	129	7	,	,	,
cord-016197-y69wwy40	129	8	2002	2002	CD
cord-016197-y69wwy40	129	9	)	)	-RRB-
cord-016197-y69wwy40	129	10	.	.	.
cord-016197-y69wwy40	130	1	This	this	DT
cord-016197-y69wwy40	130	2	creates	create	VBZ
cord-016197-y69wwy40	130	3	a	a	DT
cord-016197-y69wwy40	130	4	situation	situation	NN
cord-016197-y69wwy40	130	5	where	where	WRB
cord-016197-y69wwy40	130	6	at	at	IN
cord-016197-y69wwy40	130	7	a	a	DT
cord-016197-y69wwy40	130	8	particular	particular	JJ
cord-016197-y69wwy40	130	9	time	time	NN
cord-016197-y69wwy40	130	10	a	a	DT
cord-016197-y69wwy40	130	11	number	number	NN
cord-016197-y69wwy40	130	12	of	of	IN
cord-016197-y69wwy40	130	13	Pharma	Pharma	NNP
cord-016197-y69wwy40	130	14	companies	company	NNS
cord-016197-y69wwy40	130	15	may	may	MD
cord-016197-y69wwy40	130	16	compete	compete	VB
cord-016197-y69wwy40	130	17	for	for	IN
cord-016197-y69wwy40	130	18	collecting	collect	VBG
cord-016197-y69wwy40	130	19	centres	centre	NNS
cord-016197-y69wwy40	130	20	for	for	IN
cord-016197-y69wwy40	130	21	key	key	JJ
cord-016197-y69wwy40	130	22	isolates	isolate	NNS
cord-016197-y69wwy40	130	23	and	and	CC
cord-016197-y69wwy40	130	24	be	be	VB
cord-016197-y69wwy40	130	25	funding	fund	VBG
cord-016197-y69wwy40	130	26	a	a	DT
cord-016197-y69wwy40	130	27	number	number	NN
cord-016197-y69wwy40	130	28	of	of	IN
cord-016197-y69wwy40	130	29	laboratories	laboratory	NNS
cord-016197-y69wwy40	130	30	to	to	TO
cord-016197-y69wwy40	130	31	screen	screen	VB
cord-016197-y69wwy40	130	32	similar	similar	JJ
cord-016197-y69wwy40	130	33	isolates	isolate	NNS
cord-016197-y69wwy40	130	34	and	and	CC
cord-016197-y69wwy40	130	35	agents	agent	NNS
cord-016197-y69wwy40	130	36	while	while	IN
cord-016197-y69wwy40	130	37	at	at	IN
cord-016197-y69wwy40	130	38	other	other	JJ
cord-016197-y69wwy40	130	39	times	time	NNS
cord-016197-y69wwy40	130	40	or	or	CC
cord-016197-y69wwy40	130	41	for	for	IN
cord-016197-y69wwy40	130	42	other	other	JJ
cord-016197-y69wwy40	130	43	pathogens	pathogen	NNS
cord-016197-y69wwy40	130	44	or	or	CC
cord-016197-y69wwy40	130	45	agents	agent	NNS
cord-016197-y69wwy40	130	46	,	,	,
cord-016197-y69wwy40	130	47	there	there	EX
cord-016197-y69wwy40	130	48	may	may	MD
cord-016197-y69wwy40	130	49	be	be	VB
cord-016197-y69wwy40	130	50	little	little	JJ
cord-016197-y69wwy40	130	51	Pharma	Pharma	NNP
cord-016197-y69wwy40	130	52	support	support	NN
cord-016197-y69wwy40	130	53	,	,	,
cord-016197-y69wwy40	130	54	or	or	CC
cord-016197-y69wwy40	130	55	data	datum	NNS
cord-016197-y69wwy40	130	56	available	available	JJ
cord-016197-y69wwy40	130	57	from	from	IN
cord-016197-y69wwy40	130	58	any	any	DT
cord-016197-y69wwy40	130	59	source	source	NN
cord-016197-y69wwy40	130	60	.	.	.
cord-016197-y69wwy40	131	1	Surveillance	surveillance	NN
cord-016197-y69wwy40	131	2	funded	fund	VBN
cord-016197-y69wwy40	131	3	by	by	IN
cord-016197-y69wwy40	131	4	government	government	NN
cord-016197-y69wwy40	131	5	,	,	,
cord-016197-y69wwy40	131	6	societies	society	NNS
cord-016197-y69wwy40	131	7	,	,	,
cord-016197-y69wwy40	131	8	or	or	CC
cord-016197-y69wwy40	131	9	other	other	JJ
cord-016197-y69wwy40	131	10	non	non	JJ
cord-016197-y69wwy40	131	11	-	-	JJ
cord-016197-y69wwy40	131	12	Pharma	pharma	JJ
cord-016197-y69wwy40	131	13	sources	source	NNS
cord-016197-y69wwy40	131	14	may	may	MD
cord-016197-y69wwy40	131	15	not	not	RB
cord-016197-y69wwy40	131	16	meet	meet	VB
cord-016197-y69wwy40	131	17	Pharma	Pharma	NNP
cord-016197-y69wwy40	131	18	's	's	POS
cord-016197-y69wwy40	131	19	specific	specific	JJ
cord-016197-y69wwy40	131	20	needs	need	NNS
cord-016197-y69wwy40	131	21	.	.	.
cord-016197-y69wwy40	132	1	Conversely	conversely	RB
cord-016197-y69wwy40	132	2	,	,	,
cord-016197-y69wwy40	132	3	Pharma	Pharma	NNP
cord-016197-y69wwy40	132	4	's	's	POS
cord-016197-y69wwy40	132	5	studies	study	NNS
cord-016197-y69wwy40	132	6	may	may	MD
cord-016197-y69wwy40	132	7	not	not	RB
cord-016197-y69wwy40	132	8	meet	meet	VB
cord-016197-y69wwy40	132	9	broader	broad	JJR
cord-016197-y69wwy40	132	10	needs	need	NNS
cord-016197-y69wwy40	132	11	(	(	-LRB-
cord-016197-y69wwy40	133	1	Bax	Bax	NNP
cord-016197-y69wwy40	133	2	et	et	NNP
cord-016197-y69wwy40	133	3	al	al	NNP
cord-016197-y69wwy40	133	4	.	.	.
cord-016197-y69wwy40	134	1	,	,	,
cord-016197-y69wwy40	134	2	2001	2001	CD
cord-016197-y69wwy40	134	3	;	;	:
cord-016197-y69wwy40	134	4	Lewis	Lewis	NNP
cord-016197-y69wwy40	134	5	,	,	,
cord-016197-y69wwy40	134	6	2002	2002	CD
cord-016197-y69wwy40	134	7	)	)	-RRB-
cord-016197-y69wwy40	134	8	,	,	,
cord-016197-y69wwy40	134	9	or	or	CC
cord-016197-y69wwy40	134	10	be	be	VB
cord-016197-y69wwy40	134	11	perceived	perceive	VBN
cord-016197-y69wwy40	134	12	as	as	IN
cord-016197-y69wwy40	134	13	"	"	``
cord-016197-y69wwy40	134	14	distorted	distorted	JJ
cord-016197-y69wwy40	134	15	"	"	''
cord-016197-y69wwy40	134	16	source	source	NN
cord-016197-y69wwy40	134	17	of	of	IN
cord-016197-y69wwy40	134	18	data	datum	NNS
cord-016197-y69wwy40	134	19	because	because	IN
cord-016197-y69wwy40	134	20	they	-PRON-	PRP
cord-016197-y69wwy40	134	21	are	be	VBP
cord-016197-y69wwy40	134	22	funded	fund	VBN
cord-016197-y69wwy40	134	23	by	by	IN
cord-016197-y69wwy40	134	24	Pharma	Pharma	NNP
cord-016197-y69wwy40	134	25	(	(	-LRB-
cord-016197-y69wwy40	134	26	Lewis	Lewis	NNP
cord-016197-y69wwy40	134	27	,	,	,
cord-016197-y69wwy40	134	28	2002	2002	CD
cord-016197-y69wwy40	134	29	)	)	-RRB-
cord-016197-y69wwy40	134	30	.	.	.
cord-016197-y69wwy40	135	1	Pharma	Pharma	NNS
cord-016197-y69wwy40	135	2	support	support	VBP
cord-016197-y69wwy40	135	3	for	for	IN
cord-016197-y69wwy40	135	4	large	large	JJ
cord-016197-y69wwy40	135	5	single	single	JJ
cord-016197-y69wwy40	135	6	-	-	HYPH
cord-016197-y69wwy40	135	7	sponsored	sponsor	VBN
cord-016197-y69wwy40	135	8	surveillance	surveillance	NN
cord-016197-y69wwy40	135	9	studies	study	NNS
cord-016197-y69wwy40	135	10	is	be	VBZ
cord-016197-y69wwy40	135	11	dependent	dependent	JJ
cord-016197-y69wwy40	135	12	on	on	IN
cord-016197-y69wwy40	135	13	successful	successful	JJ
cord-016197-y69wwy40	135	14	product	product	NN
cord-016197-y69wwy40	135	15	registrations	registration	NNS
cord-016197-y69wwy40	135	16	and	and	CC
cord-016197-y69wwy40	135	17	marketing	marketing	NN
cord-016197-y69wwy40	135	18	.	.	.
cord-016197-y69wwy40	136	1	Similarly	similarly	RB
cord-016197-y69wwy40	136	2	,	,	,
cord-016197-y69wwy40	136	3	Pharma	Pharma	NNP
cord-016197-y69wwy40	136	4	support	support	NN
cord-016197-y69wwy40	136	5	for	for	IN
cord-016197-y69wwy40	136	6	broad	broad	JJ
cord-016197-y69wwy40	136	7	regional	regional	JJ
cord-016197-y69wwy40	136	8	and	and	CC
cord-016197-y69wwy40	136	9	national	national	JJ
cord-016197-y69wwy40	136	10	studies	study	NNS
cord-016197-y69wwy40	136	11	,	,	,
cord-016197-y69wwy40	136	12	of	of	IN
cord-016197-y69wwy40	136	13	value	value	NN
cord-016197-y69wwy40	136	14	to	to	IN
cord-016197-y69wwy40	136	15	strategists	strategist	NNS
cord-016197-y69wwy40	136	16	and	and	CC
cord-016197-y69wwy40	136	17	policy	policy	NN
cord-016197-y69wwy40	136	18	-	-	HYPH
cord-016197-y69wwy40	136	19	makers	maker	NNS
cord-016197-y69wwy40	136	20	in	in	IN
cord-016197-y69wwy40	136	21	these	these	DT
cord-016197-y69wwy40	136	22	areas	area	NNS
cord-016197-y69wwy40	136	23	will	will	MD
cord-016197-y69wwy40	136	24	become	become	VB
cord-016197-y69wwy40	136	25	limited	limited	JJ
cord-016197-y69wwy40	136	26	in	in	IN
cord-016197-y69wwy40	136	27	an	an	DT
cord-016197-y69wwy40	136	28	environment	environment	NN
cord-016197-y69wwy40	136	29	of	of	IN
cord-016197-y69wwy40	136	30	reduced	reduce	VBN
cord-016197-y69wwy40	136	31	investment	investment	NN
cord-016197-y69wwy40	136	32	and	and	CC
cord-016197-y69wwy40	136	33	commercial	commercial	JJ
cord-016197-y69wwy40	136	34	success	success	NN
cord-016197-y69wwy40	136	35	.	.	.
cord-016197-y69wwy40	137	1	Collaborative	collaborative	JJ
cord-016197-y69wwy40	137	2	surveillance	surveillance	NN
cord-016197-y69wwy40	137	3	between	between	IN
cord-016197-y69wwy40	137	4	and	and	CC
cord-016197-y69wwy40	137	5	within	within	IN
cord-016197-y69wwy40	137	6	Pharma	Pharma	NNP
cord-016197-y69wwy40	137	7	and	and	CC
cord-016197-y69wwy40	137	8	academia	academia	NN
cord-016197-y69wwy40	137	9	or	or	CC
cord-016197-y69wwy40	137	10	regulators	regulator	NNS
cord-016197-y69wwy40	137	11	may	may	MD
cord-016197-y69wwy40	137	12	become	become	VB
cord-016197-y69wwy40	137	13	increasingly	increasingly	RB
cord-016197-y69wwy40	137	14	necessary	necessary	JJ
cord-016197-y69wwy40	137	15	but	but	CC
cord-016197-y69wwy40	137	16	is	be	VBZ
cord-016197-y69wwy40	137	17	difficult	difficult	JJ
cord-016197-y69wwy40	137	18	to	to	TO
cord-016197-y69wwy40	137	19	implement	implement	VB
cord-016197-y69wwy40	137	20	in	in	IN
cord-016197-y69wwy40	137	21	terms	term	NNS
cord-016197-y69wwy40	137	22	of	of	IN
cord-016197-y69wwy40	137	23	mutually	mutually	RB
cord-016197-y69wwy40	137	24	acceptable	acceptable	JJ
cord-016197-y69wwy40	137	25	objectives	objective	NNS
cord-016197-y69wwy40	137	26	,	,	,
cord-016197-y69wwy40	137	27	scope	scope	NN
cord-016197-y69wwy40	137	28	,	,	,
cord-016197-y69wwy40	137	29	methods	method	NNS
cord-016197-y69wwy40	137	30	,	,	,
cord-016197-y69wwy40	137	31	timelines	timeline	NNS
cord-016197-y69wwy40	137	32	,	,	,
cord-016197-y69wwy40	137	33	funding	funding	NN
cord-016197-y69wwy40	137	34	agreement	agreement	NN
cord-016197-y69wwy40	137	35	,	,	,
cord-016197-y69wwy40	137	36	management	management	NN
cord-016197-y69wwy40	137	37	,	,	,
cord-016197-y69wwy40	137	38	and	and	CC
cord-016197-y69wwy40	137	39	publication	publication	NN
cord-016197-y69wwy40	137	40	/	/	SYM
cord-016197-y69wwy40	137	41	presentation	presentation	NN
cord-016197-y69wwy40	137	42	rights	right	NNS
cord-016197-y69wwy40	137	43	.	.	.
cord-016197-y69wwy40	138	1	Bax	Bax	NNP
cord-016197-y69wwy40	138	2	et	et	NNP
cord-016197-y69wwy40	138	3	al	al	NNP
cord-016197-y69wwy40	138	4	.	.	.
cord-016197-y69wwy40	139	1	(	(	-LRB-
cord-016197-y69wwy40	139	2	2001	2001	CD
cord-016197-y69wwy40	139	3	)	)	-RRB-
cord-016197-y69wwy40	139	4	stated	state	VBD
cord-016197-y69wwy40	139	5	that	that	IN
cord-016197-y69wwy40	139	6	consortium	consortium	NN
cord-016197-y69wwy40	139	7	funding	funding	NN
cord-016197-y69wwy40	139	8	will	will	MD
cord-016197-y69wwy40	139	9	be	be	VB
cord-016197-y69wwy40	139	10	necessary	necessary	JJ
cord-016197-y69wwy40	139	11	for	for	IN
cord-016197-y69wwy40	139	12	large	large	JJ
cord-016197-y69wwy40	139	13	schemes	scheme	NNS
cord-016197-y69wwy40	139	14	to	to	TO
cord-016197-y69wwy40	139	15	be	be	VB
cord-016197-y69wwy40	139	16	successful	successful	JJ
cord-016197-y69wwy40	139	17	,	,	,
cord-016197-y69wwy40	139	18	and	and	CC
cord-016197-y69wwy40	139	19	that	that	IN
cord-016197-y69wwy40	139	20	there	there	EX
cord-016197-y69wwy40	139	21	is	be	VBZ
cord-016197-y69wwy40	139	22	no	no	DT
cord-016197-y69wwy40	139	23	"	"	``
cord-016197-y69wwy40	139	24	ideal	ideal	JJ
cord-016197-y69wwy40	139	25	"	"	''
cord-016197-y69wwy40	139	26	surveillance	surveillance	NN
cord-016197-y69wwy40	139	27	system	system	NN
cord-016197-y69wwy40	139	28	.	.	.
cord-016197-y69wwy40	140	1	New	new	JJ
cord-016197-y69wwy40	140	2	approaches	approach	NNS
cord-016197-y69wwy40	140	3	to	to	IN
cord-016197-y69wwy40	140	4	the	the	DT
cord-016197-y69wwy40	140	5	funding	funding	NN
cord-016197-y69wwy40	140	6	,	,	,
cord-016197-y69wwy40	140	7	conduct	conduct	NN
cord-016197-y69wwy40	140	8	,	,	,
cord-016197-y69wwy40	140	9	and	and	CC
cord-016197-y69wwy40	140	10	availability	availability	NN
cord-016197-y69wwy40	140	11	of	of	IN
cord-016197-y69wwy40	140	12	surveillance	surveillance	NN
cord-016197-y69wwy40	140	13	data	datum	NNS
cord-016197-y69wwy40	140	14	while	while	IN
cord-016197-y69wwy40	140	15	recognizing	recognize	VBG
cord-016197-y69wwy40	140	16	individual	individual	JJ
cord-016197-y69wwy40	140	17	Pharma	Pharma	NNP
cord-016197-y69wwy40	140	18	confidentiality	confidentiality	NN
cord-016197-y69wwy40	140	19	and	and	CC
cord-016197-y69wwy40	140	20	commercial	commercial	JJ
cord-016197-y69wwy40	140	21	interests	interest	NNS
cord-016197-y69wwy40	140	22	,	,	,
cord-016197-y69wwy40	140	23	include	include	VBP
cord-016197-y69wwy40	140	24	the	the	DT
cord-016197-y69wwy40	140	25	purchasing	purchasing	NN
cord-016197-y69wwy40	140	26	of	of	IN
cord-016197-y69wwy40	140	27	surveillance	surveillance	NN
cord-016197-y69wwy40	140	28	data	datum	NNS
cord-016197-y69wwy40	140	29	from	from	IN
cord-016197-y69wwy40	140	30	commercial	commercial	JJ
cord-016197-y69wwy40	140	31	surveillance	surveillance	NN
cord-016197-y69wwy40	140	32	companies	company	NNS
cord-016197-y69wwy40	140	33	or	or	CC
cord-016197-y69wwy40	140	34	entering	enter	VBG
cord-016197-y69wwy40	140	35	into	into	IN
cord-016197-y69wwy40	140	36	collaborative	collaborative	JJ
cord-016197-y69wwy40	140	37	surveillance	surveillance	NN
cord-016197-y69wwy40	140	38	studies	study	NNS
cord-016197-y69wwy40	140	39	with	with	IN
cord-016197-y69wwy40	140	40	specific	specific	JJ
cord-016197-y69wwy40	140	41	protocols	protocol	NNS
cord-016197-y69wwy40	140	42	.	.	.
cord-016197-y69wwy40	141	1	Sources	source	NNS
cord-016197-y69wwy40	141	2	of	of	IN
cord-016197-y69wwy40	141	3	purchased	purchase	VBN
cord-016197-y69wwy40	141	4	data	datum	NNS
cord-016197-y69wwy40	141	5	,	,	,
cord-016197-y69wwy40	141	6	such	such	JJ
cord-016197-y69wwy40	141	7	as	as	IN
cord-016197-y69wwy40	141	8	from	from	IN
cord-016197-y69wwy40	141	9	Focus	Focus	NNP
cord-016197-y69wwy40	141	10	Technologies	Technologies	NNP
cord-016197-y69wwy40	141	11	(	(	-LRB-
cord-016197-y69wwy40	141	12	formerly	formerly	RB
cord-016197-y69wwy40	141	13	MRL	MRL	NNP
cord-016197-y69wwy40	141	14	/	/	SYM
cord-016197-y69wwy40	141	15	TSN	TSN	NNP
cord-016197-y69wwy40	141	16	)	)	-RRB-
cord-016197-y69wwy40	142	1	(	(	-LRB-
cord-016197-y69wwy40	142	2	Bax	Bax	NNP
cord-016197-y69wwy40	142	3	et	et	NNP
cord-016197-y69wwy40	142	4	al	al	NNP
cord-016197-y69wwy40	142	5	.	.	NNP
cord-016197-y69wwy40	142	6	,	,	,
cord-016197-y69wwy40	142	7	2001	2001	CD
cord-016197-y69wwy40	142	8	;	;	:
cord-016197-y69wwy40	143	1	Hunter	Hunter	NNP
cord-016197-y69wwy40	143	2	and	and	CC
cord-016197-y69wwy40	143	3	Reeves	Reeves	NNP
cord-016197-y69wwy40	143	4	,	,	,
cord-016197-y69wwy40	143	5	2002	2002	CD
cord-016197-y69wwy40	143	6	)	)	-RRB-
cord-016197-y69wwy40	143	7	,	,	,
cord-016197-y69wwy40	143	8	may	may	MD
cord-016197-y69wwy40	143	9	provide	provide	VB
cord-016197-y69wwy40	143	10	solutions	solution	NNS
cord-016197-y69wwy40	143	11	to	to	IN
cord-016197-y69wwy40	143	12	many	many	JJ
cord-016197-y69wwy40	143	13	requirements	requirement	NNS
cord-016197-y69wwy40	143	14	although	although	IN
cord-016197-y69wwy40	143	15	the	the	DT
cord-016197-y69wwy40	143	16	extent	extent	NN
cord-016197-y69wwy40	143	17	,	,	,
cord-016197-y69wwy40	143	18	quality	quality	NN
cord-016197-y69wwy40	143	19	,	,	,
cord-016197-y69wwy40	143	20	and	and	CC
cord-016197-y69wwy40	143	21	utility	utility	NN
cord-016197-y69wwy40	143	22	of	of	IN
cord-016197-y69wwy40	143	23	the	the	DT
cord-016197-y69wwy40	143	24	data	data	NN
cord-016197-y69wwy40	143	25	is	be	VBZ
cord-016197-y69wwy40	143	26	dependent	dependent	JJ
cord-016197-y69wwy40	143	27	on	on	IN
cord-016197-y69wwy40	143	28	the	the	DT
cord-016197-y69wwy40	143	29	database	database	NN
cord-016197-y69wwy40	143	30	and	and	CC
cord-016197-y69wwy40	143	31	may	may	MD
cord-016197-y69wwy40	143	32	not	not	RB
cord-016197-y69wwy40	143	33	be	be	VB
cord-016197-y69wwy40	143	34	as	as	RB
cord-016197-y69wwy40	143	35	well	well	RB
cord-016197-y69wwy40	143	36	defined	define	VBN
cord-016197-y69wwy40	143	37	or	or	CC
cord-016197-y69wwy40	143	38	specific	specific	JJ
cord-016197-y69wwy40	143	39	for	for	IN
cord-016197-y69wwy40	143	40	a	a	DT
cord-016197-y69wwy40	143	41	purpose	purpose	NN
cord-016197-y69wwy40	143	42	as	as	IN
cord-016197-y69wwy40	143	43	a	a	DT
cord-016197-y69wwy40	143	44	pre	pre	JJ
cord-016197-y69wwy40	143	45	-	-	JJ
cord-016197-y69wwy40	143	46	defined	define	VBN
cord-016197-y69wwy40	143	47	protocol	protocol	NN
cord-016197-y69wwy40	143	48	.	.	.
cord-016197-y69wwy40	144	1	Examples	example	NNS
cord-016197-y69wwy40	144	2	of	of	IN
cord-016197-y69wwy40	144	3	collaborative	collaborative	JJ
cord-016197-y69wwy40	144	4	predefined	predefine	VBN
cord-016197-y69wwy40	144	5	protocols	protocol	NNS
cord-016197-y69wwy40	144	6	are	be	VBP
cord-016197-y69wwy40	144	7	the	the	DT
cord-016197-y69wwy40	144	8	British	British	NNP
cord-016197-y69wwy40	144	9	Society	Society	NNP
cord-016197-y69wwy40	144	10	for	for	IN
cord-016197-y69wwy40	144	11	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	144	12	Chemotherapy	Chemotherapy	NNP
cord-016197-y69wwy40	144	13	(	(	-LRB-
cord-016197-y69wwy40	144	14	BSAC	BSAC	NNP
cord-016197-y69wwy40	144	15	)	)	-RRB-
cord-016197-y69wwy40	144	16	surveillance	surveillance	NN
cord-016197-y69wwy40	144	17	projects	project	NNS
cord-016197-y69wwy40	144	18	for	for	IN
cord-016197-y69wwy40	144	19	respiratory	respiratory	JJ
cord-016197-y69wwy40	144	20	tract	tract	NN
cord-016197-y69wwy40	144	21	pathogens	pathogen	NNS
cord-016197-y69wwy40	145	1	(	(	-LRB-
cord-016197-y69wwy40	145	2	Reynolds	Reynolds	NNP
cord-016197-y69wwy40	145	3	and	and	CC
cord-016197-y69wwy40	145	4	BSAC	BSAC	NNP
cord-016197-y69wwy40	145	5	Extended	Extended	NNP
cord-016197-y69wwy40	145	6	Working	Working	NNP
cord-016197-y69wwy40	145	7	Party	Party	NNP
cord-016197-y69wwy40	145	8	on	on	IN
cord-016197-y69wwy40	145	9	Respiratory	Respiratory	NNP
cord-016197-y69wwy40	145	10	Resistance	Resistance	NNP
cord-016197-y69wwy40	145	11	Surveillance	Surveillance	NNP
cord-016197-y69wwy40	145	12	,	,	,
cord-016197-y69wwy40	145	13	2001	2001	CD
cord-016197-y69wwy40	145	14	)	)	-RRB-
cord-016197-y69wwy40	145	15	and	and	CC
cord-016197-y69wwy40	145	16	bacteraemia	bacteraemia	NNP
cord-016197-y69wwy40	145	17	pathogens	pathogen	NNS
cord-016197-y69wwy40	145	18	in	in	IN
cord-016197-y69wwy40	145	19	which	which	WDT
cord-016197-y69wwy40	145	20	a	a	DT
cord-016197-y69wwy40	145	21	number	number	NN
cord-016197-y69wwy40	145	22	of	of	IN
cord-016197-y69wwy40	145	23	Pharma	Pharma	NNP
cord-016197-y69wwy40	145	24	sponsors	sponsor	NNS
cord-016197-y69wwy40	145	25	support	support	VBP
cord-016197-y69wwy40	145	26	a	a	DT
cord-016197-y69wwy40	145	27	core	core	NN
cord-016197-y69wwy40	145	28	protocol	protocol	NN
cord-016197-y69wwy40	145	29	and	and	CC
cord-016197-y69wwy40	145	30	panel	panel	NN
cord-016197-y69wwy40	145	31	of	of	IN
cord-016197-y69wwy40	145	32	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	145	33	,	,	,
cord-016197-y69wwy40	145	34	along	along	IN
cord-016197-y69wwy40	145	35	with	with	IN
cord-016197-y69wwy40	145	36	the	the	DT
cord-016197-y69wwy40	145	37	ability	ability	NN
cord-016197-y69wwy40	145	38	to	to	TO
cord-016197-y69wwy40	145	39	have	have	VB
cord-016197-y69wwy40	145	40	research	research	NN
cord-016197-y69wwy40	145	41	agents	agent	NNS
cord-016197-y69wwy40	145	42	tested	test	VBN
cord-016197-y69wwy40	145	43	under	under	IN
cord-016197-y69wwy40	145	44	confidentiality	confidentiality	NN
cord-016197-y69wwy40	145	45	.	.	.
cord-016197-y69wwy40	146	1	The	the	DT
cord-016197-y69wwy40	146	2	results	result	NNS
cord-016197-y69wwy40	146	3	from	from	IN
cord-016197-y69wwy40	146	4	the	the	DT
cord-016197-y69wwy40	146	5	core	core	NN
cord-016197-y69wwy40	146	6	protocol	protocol	NN
cord-016197-y69wwy40	146	7	,	,	,
cord-016197-y69wwy40	146	8	which	which	WDT
cord-016197-y69wwy40	146	9	has	have	VBZ
cord-016197-y69wwy40	146	10	been	be	VBN
cord-016197-y69wwy40	146	11	developed	develop	VBN
cord-016197-y69wwy40	146	12	by	by	IN
cord-016197-y69wwy40	146	13	experts	expert	NNS
cord-016197-y69wwy40	146	14	in	in	IN
cord-016197-y69wwy40	146	15	academia	academia	NN
cord-016197-y69wwy40	146	16	,	,	,
cord-016197-y69wwy40	146	17	specialist	specialist	NN
cord-016197-y69wwy40	146	18	testing	testing	NN
cord-016197-y69wwy40	146	19	laboratories	laboratory	NNS
cord-016197-y69wwy40	146	20	,	,	,
cord-016197-y69wwy40	146	21	and	and	CC
cord-016197-y69wwy40	146	22	Pharma	Pharma	NNP
cord-016197-y69wwy40	146	23	are	be	VBP
cord-016197-y69wwy40	146	24	made	make	VBN
cord-016197-y69wwy40	146	25	available	available	JJ
cord-016197-y69wwy40	146	26	via	via	IN
cord-016197-y69wwy40	146	27	the	the	DT
cord-016197-y69wwy40	146	28	website	website	NN
cord-016197-y69wwy40	146	29	to	to	IN
cord-016197-y69wwy40	146	30	the	the	DT
cord-016197-y69wwy40	146	31	BSAC	BSAC	NNP
cord-016197-y69wwy40	146	32	membership	membership	NN
cord-016197-y69wwy40	146	33	(	(	-LRB-
cord-016197-y69wwy40	146	34	www.bsacsurv.org	www.bsacsurv.org	NN
cord-016197-y69wwy40	146	35	)	)	-RRB-
cord-016197-y69wwy40	146	36	.	.	.
cord-016197-y69wwy40	147	1	This	this	DT
cord-016197-y69wwy40	147	2	approach	approach	NN
cord-016197-y69wwy40	147	3	,	,	,
cord-016197-y69wwy40	147	4	combining	combine	VBG
cord-016197-y69wwy40	147	5	support	support	NN
cord-016197-y69wwy40	147	6	from	from	IN
cord-016197-y69wwy40	147	7	a	a	DT
cord-016197-y69wwy40	147	8	number	number	NN
cord-016197-y69wwy40	147	9	of	of	IN
cord-016197-y69wwy40	147	10	companies	company	NNS
cord-016197-y69wwy40	147	11	,	,	,
cord-016197-y69wwy40	147	12	with	with	IN
cord-016197-y69wwy40	147	13	the	the	DT
cord-016197-y69wwy40	147	14	wide	wide	JJ
cord-016197-y69wwy40	147	15	and	and	CC
cord-016197-y69wwy40	147	16	timely	timely	JJ
cord-016197-y69wwy40	147	17	dissemination	dissemination	NN
cord-016197-y69wwy40	147	18	of	of	IN
cord-016197-y69wwy40	147	19	core	core	NN
cord-016197-y69wwy40	147	20	data	data	NN
cord-016197-y69wwy40	147	21	resolves	resolve	VBZ
cord-016197-y69wwy40	147	22	some	some	DT
cord-016197-y69wwy40	147	23	of	of	IN
cord-016197-y69wwy40	147	24	the	the	DT
cord-016197-y69wwy40	147	25	issues	issue	NNS
cord-016197-y69wwy40	147	26	and	and	CC
cord-016197-y69wwy40	147	27	conflicts	conflict	NNS
cord-016197-y69wwy40	147	28	relating	relate	VBG
cord-016197-y69wwy40	147	29	to	to	IN
cord-016197-y69wwy40	147	30	quality	quality	NN
cord-016197-y69wwy40	147	31	,	,	,
cord-016197-y69wwy40	147	32	interpretation	interpretation	NN
cord-016197-y69wwy40	147	33	,	,	,
cord-016197-y69wwy40	147	34	and	and	CC
cord-016197-y69wwy40	147	35	dissemination	dissemination	NN
cord-016197-y69wwy40	147	36	associated	associate	VBN
cord-016197-y69wwy40	147	37	with	with	IN
cord-016197-y69wwy40	147	38	single	single	JJ
cord-016197-y69wwy40	147	39	-	-	HYPH
cord-016197-y69wwy40	147	40	company	company	NN
cord-016197-y69wwy40	147	41	studies	study	NNS
cord-016197-y69wwy40	147	42	and	and	CC
cord-016197-y69wwy40	147	43	also	also	RB
cord-016197-y69wwy40	147	44	is	be	VBZ
cord-016197-y69wwy40	147	45	hoped	hope	VBN
cord-016197-y69wwy40	147	46	to	to	TO
cord-016197-y69wwy40	147	47	increase	increase	VB
cord-016197-y69wwy40	147	48	sustainability	sustainability	NN
cord-016197-y69wwy40	147	49	.	.	.
cord-016197-y69wwy40	148	1	The	the	DT
cord-016197-y69wwy40	148	2	current	current	JJ
cord-016197-y69wwy40	148	3	utility	utility	NN
cord-016197-y69wwy40	148	4	of	of	IN
cord-016197-y69wwy40	148	5	this	this	DT
cord-016197-y69wwy40	148	6	programme	programme	NN
cord-016197-y69wwy40	148	7	is	be	VBZ
cord-016197-y69wwy40	148	8	,	,	,
cord-016197-y69wwy40	148	9	however	however	RB
cord-016197-y69wwy40	148	10	,	,	,
cord-016197-y69wwy40	148	11	restricted	restrict	VBN
cord-016197-y69wwy40	148	12	due	due	IN
cord-016197-y69wwy40	148	13	to	to	IN
cord-016197-y69wwy40	148	14	the	the	DT
cord-016197-y69wwy40	148	15	data	datum	NNS
cord-016197-y69wwy40	148	16	and	and	CC
cord-016197-y69wwy40	148	17	methods	method	NNS
cord-016197-y69wwy40	148	18	being	be	VBG
cord-016197-y69wwy40	148	19	specific	specific	JJ
cord-016197-y69wwy40	148	20	to	to	IN
cord-016197-y69wwy40	148	21	the	the	DT
cord-016197-y69wwy40	148	22	United	United	NNP
cord-016197-y69wwy40	148	23	Kingdom	Kingdom	NNP
cord-016197-y69wwy40	148	24	.	.	.
cord-016197-y69wwy40	149	1	In	in	IN
cord-016197-y69wwy40	149	2	conjunction	conjunction	NN
cord-016197-y69wwy40	149	3	with	with	IN
cord-016197-y69wwy40	149	4	the	the	DT
cord-016197-y69wwy40	149	5	generation	generation	NN
cord-016197-y69wwy40	149	6	and	and	CC
cord-016197-y69wwy40	149	7	use	use	NN
cord-016197-y69wwy40	149	8	of	of	IN
cord-016197-y69wwy40	149	9	susceptibility	susceptibility	NN
cord-016197-y69wwy40	149	10	surveillance	surveillance	NN
cord-016197-y69wwy40	149	11	data	datum	NNS
cord-016197-y69wwy40	149	12	,	,	,
cord-016197-y69wwy40	149	13	there	there	EX
cord-016197-y69wwy40	149	14	is	be	VBZ
cord-016197-y69wwy40	149	15	need	need	NN
cord-016197-y69wwy40	149	16	for	for	IN
cord-016197-y69wwy40	149	17	a	a	DT
cord-016197-y69wwy40	149	18	clear	clear	JJ
cord-016197-y69wwy40	149	19	understanding	understanding	NN
cord-016197-y69wwy40	149	20	of	of	IN
cord-016197-y69wwy40	149	21	the	the	DT
cord-016197-y69wwy40	149	22	limitations	limitation	NNS
cord-016197-y69wwy40	149	23	,	,	,
cord-016197-y69wwy40	149	24	validity	validity	NN
cord-016197-y69wwy40	149	25	,	,	,
cord-016197-y69wwy40	149	26	and	and	CC
cord-016197-y69wwy40	149	27	consequences	consequence	NNS
cord-016197-y69wwy40	149	28	of	of	IN
cord-016197-y69wwy40	149	29	studies	study	NNS
cord-016197-y69wwy40	149	30	to	to	TO
cord-016197-y69wwy40	149	31	correlate	correlate	VB
cord-016197-y69wwy40	149	32	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	149	33	usage	usage	NN
cord-016197-y69wwy40	149	34	with	with	IN
cord-016197-y69wwy40	149	35	resistance	resistance	NN
cord-016197-y69wwy40	149	36	.	.	.
cord-016197-y69wwy40	150	1	The	the	DT
cord-016197-y69wwy40	150	2	relationship	relationship	NN
cord-016197-y69wwy40	150	3	between	between	IN
cord-016197-y69wwy40	150	4	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	150	5	usage	usage	NN
cord-016197-y69wwy40	150	6	and	and	CC
cord-016197-y69wwy40	150	7	resistance	resistance	NN
cord-016197-y69wwy40	150	8	is	be	VBZ
cord-016197-y69wwy40	150	9	complex	complex	JJ
cord-016197-y69wwy40	150	10	,	,	,
cord-016197-y69wwy40	150	11	and	and	CC
cord-016197-y69wwy40	150	12	while	while	IN
cord-016197-y69wwy40	150	13	there	there	EX
cord-016197-y69wwy40	150	14	is	be	VBZ
cord-016197-y69wwy40	150	15	a	a	DT
cord-016197-y69wwy40	150	16	clear	clear	JJ
cord-016197-y69wwy40	150	17	association	association	NN
cord-016197-y69wwy40	150	18	between	between	IN
cord-016197-y69wwy40	150	19	use	use	NN
cord-016197-y69wwy40	150	20	and	and	CC
cord-016197-y69wwy40	150	21	resistance	resistance	NN
cord-016197-y69wwy40	150	22	,	,	,
cord-016197-y69wwy40	150	23	cause	cause	NN
cord-016197-y69wwy40	150	24	and	and	CC
cord-016197-y69wwy40	150	25	effect	effect	NN
cord-016197-y69wwy40	150	26	has	have	VBZ
cord-016197-y69wwy40	150	27	not	not	RB
cord-016197-y69wwy40	150	28	been	be	VBN
cord-016197-y69wwy40	150	29	substantially	substantially	RB
cord-016197-y69wwy40	150	30	defined	define	VBN
cord-016197-y69wwy40	150	31	Davey	Davey	NNP
cord-016197-y69wwy40	150	32	et	et	NNP
cord-016197-y69wwy40	150	33	al	al	NNP
cord-016197-y69wwy40	150	34	.	.	NNP
cord-016197-y69wwy40	150	35	,	,	,
cord-016197-y69wwy40	150	36	2003	2003	CD
cord-016197-y69wwy40	150	37	)	)	-RRB-
cord-016197-y69wwy40	150	38	.	.	.
cord-016197-y69wwy40	151	1	There	there	EX
cord-016197-y69wwy40	151	2	are	be	VBP
cord-016197-y69wwy40	151	3	a	a	DT
cord-016197-y69wwy40	151	4	number	number	NN
cord-016197-y69wwy40	151	5	of	of	IN
cord-016197-y69wwy40	151	6	confounding	confounding	JJ
cord-016197-y69wwy40	151	7	variables	variable	NNS
cord-016197-y69wwy40	151	8	that	that	WDT
cord-016197-y69wwy40	151	9	are	be	VBP
cord-016197-y69wwy40	151	10	important	important	JJ
cord-016197-y69wwy40	151	11	to	to	TO
cord-016197-y69wwy40	151	12	consider	consider	VB
cord-016197-y69wwy40	151	13	in	in	IN
cord-016197-y69wwy40	151	14	the	the	DT
cord-016197-y69wwy40	151	15	interpretation	interpretation	NN
cord-016197-y69wwy40	151	16	of	of	IN
cord-016197-y69wwy40	151	17	simple	simple	JJ
cord-016197-y69wwy40	151	18	cause	cause	NN
cord-016197-y69wwy40	151	19	and	and	CC
cord-016197-y69wwy40	151	20	effect	effect	NN
cord-016197-y69wwy40	152	1	(	(	-LRB-
cord-016197-y69wwy40	152	2	Davey	Davey	NNP
cord-016197-y69wwy40	152	3	et	et	NNP
cord-016197-y69wwy40	152	4	al	al	NNP
cord-016197-y69wwy40	152	5	.	.	NNP
cord-016197-y69wwy40	152	6	,	,	,
cord-016197-y69wwy40	152	7	2003	2003	CD
cord-016197-y69wwy40	152	8	)	)	-RRB-
cord-016197-y69wwy40	152	9	.	.	.
cord-016197-y69wwy40	153	1	Reversibility	reversibility	NN
cord-016197-y69wwy40	153	2	or	or	CC
cord-016197-y69wwy40	153	3	containment	containment	NN
cord-016197-y69wwy40	153	4	of	of	IN
cord-016197-y69wwy40	153	5	resistance	resistance	NN
cord-016197-y69wwy40	153	6	with	with	IN
cord-016197-y69wwy40	153	7	optimization	optimization	NN
cord-016197-y69wwy40	153	8	(	(	-LRB-
cord-016197-y69wwy40	153	9	or	or	CC
cord-016197-y69wwy40	153	10	reduction	reduction	NN
cord-016197-y69wwy40	153	11	)	)	-RRB-
cord-016197-y69wwy40	153	12	of	of	IN
cord-016197-y69wwy40	153	13	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	153	14	usage	usage	NN
cord-016197-y69wwy40	153	15	has	have	VBZ
cord-016197-y69wwy40	153	16	yet	yet	RB
cord-016197-y69wwy40	153	17	to	to	TO
cord-016197-y69wwy40	153	18	be	be	VB
cord-016197-y69wwy40	153	19	definitely	definitely	RB
cord-016197-y69wwy40	153	20	established	establish	VBN
cord-016197-y69wwy40	153	21	.	.	.
cord-016197-y69wwy40	154	1	Consequently	consequently	RB
cord-016197-y69wwy40	154	2	,	,	,
cord-016197-y69wwy40	154	3	policies	policy	NNS
cord-016197-y69wwy40	154	4	designed	design	VBN
cord-016197-y69wwy40	154	5	to	to	TO
cord-016197-y69wwy40	154	6	curtail	curtail	VB
cord-016197-y69wwy40	154	7	or	or	CC
cord-016197-y69wwy40	154	8	prevent	prevent	VB
cord-016197-y69wwy40	154	9	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	154	10	resistance	resistance	NN
cord-016197-y69wwy40	154	11	based	base	VBN
cord-016197-y69wwy40	154	12	on	on	IN
cord-016197-y69wwy40	154	13	reduction	reduction	NN
cord-016197-y69wwy40	154	14	or	or	CC
cord-016197-y69wwy40	154	15	change	change	NN
cord-016197-y69wwy40	154	16	in	in	IN
cord-016197-y69wwy40	154	17	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	154	18	use	use	NN
cord-016197-y69wwy40	154	19	need	need	NN
cord-016197-y69wwy40	154	20	to	to	TO
cord-016197-y69wwy40	154	21	be	be	VB
cord-016197-y69wwy40	154	22	based	base	VBN
cord-016197-y69wwy40	154	23	on	on	IN
cord-016197-y69wwy40	154	24	sound	sound	JJ
cord-016197-y69wwy40	154	25	science	science	NN
cord-016197-y69wwy40	154	26	and	and	CC
cord-016197-y69wwy40	154	27	importantly	importantly	RB
cord-016197-y69wwy40	154	28	,	,	,
cord-016197-y69wwy40	154	29	the	the	DT
cord-016197-y69wwy40	154	30	objective	objective	NN
cord-016197-y69wwy40	154	31	of	of	IN
cord-016197-y69wwy40	154	32	maintaining	maintain	VBG
cord-016197-y69wwy40	154	33	or	or	CC
cord-016197-y69wwy40	154	34	improving	improve	VBG
cord-016197-y69wwy40	154	35	patient	patient	JJ
cord-016197-y69wwy40	154	36	outcomes	outcome	NNS
cord-016197-y69wwy40	154	37	.	.	.
cord-016197-y69wwy40	155	1	Bax	Bax	NNP
cord-016197-y69wwy40	155	2	et	et	NNP
cord-016197-y69wwy40	155	3	al	al	NNP
cord-016197-y69wwy40	155	4	.	.	.
cord-016197-y69wwy40	156	1	(	(	-LRB-
cord-016197-y69wwy40	156	2	2001	2001	CD
cord-016197-y69wwy40	156	3	)	)	-RRB-
cord-016197-y69wwy40	156	4	concluded	conclude	VBD
cord-016197-y69wwy40	156	5	that	that	IN
cord-016197-y69wwy40	156	6	for	for	IN
cord-016197-y69wwy40	156	7	surveillance	surveillance	NN
cord-016197-y69wwy40	156	8	:	:	:
cord-016197-y69wwy40	156	9	1	1	LS
cord-016197-y69wwy40	156	10	.	.	.
cord-016197-y69wwy40	156	11	decisions	decision	NNS
cord-016197-y69wwy40	156	12	need	need	VBP
cord-016197-y69wwy40	156	13	to	to	TO
cord-016197-y69wwy40	156	14	be	be	VB
cord-016197-y69wwy40	156	15	made	make	VBN
cord-016197-y69wwy40	156	16	regarding	regard	VBG
cord-016197-y69wwy40	156	17	the	the	DT
cord-016197-y69wwy40	156	18	critical	critical	JJ
cord-016197-y69wwy40	156	19	populations	population	NNS
cord-016197-y69wwy40	156	20	to	to	TO
cord-016197-y69wwy40	156	21	be	be	VB
cord-016197-y69wwy40	156	22	monitored	monitor	VBN
cord-016197-y69wwy40	156	23	for	for	IN
cord-016197-y69wwy40	156	24	both	both	CC
cord-016197-y69wwy40	156	25	local	local	JJ
cord-016197-y69wwy40	156	26	and	and	CC
cord-016197-y69wwy40	156	27	national	national	JJ
cord-016197-y69wwy40	156	28	comparisons	comparison	NNS
cord-016197-y69wwy40	156	29	of	of	IN
cord-016197-y69wwy40	156	30	resistance	resistance	NN
cord-016197-y69wwy40	156	31	rates	rate	NNS
cord-016197-y69wwy40	156	32	,	,	,
cord-016197-y69wwy40	156	33	that	that	RB
cord-016197-y69wwy40	156	34	is	is	RB
cord-016197-y69wwy40	156	35	,	,	,
cord-016197-y69wwy40	156	36	what	what	WDT
cord-016197-y69wwy40	156	37	level	level	NN
cord-016197-y69wwy40	156	38	of	of	IN
cord-016197-y69wwy40	156	39	resistance	resistance	NN
cord-016197-y69wwy40	156	40	warrants	warrant	NNS
cord-016197-y69wwy40	156	41	intervention	intervention	NN
cord-016197-y69wwy40	156	42	,	,	,
cord-016197-y69wwy40	156	43	and	and	CC
cord-016197-y69wwy40	156	44	what	what	WP
cord-016197-y69wwy40	156	45	should	should	MD
cord-016197-y69wwy40	156	46	be	be	VB
cord-016197-y69wwy40	156	47	the	the	DT
cord-016197-y69wwy40	156	48	nature	nature	NN
cord-016197-y69wwy40	156	49	of	of	IN
cord-016197-y69wwy40	156	50	the	the	DT
cord-016197-y69wwy40	156	51	intervention	intervention	NN
cord-016197-y69wwy40	156	52	;	;	:
cord-016197-y69wwy40	156	53	2	2	CD
cord-016197-y69wwy40	156	54	.	.	.
cord-016197-y69wwy40	157	1	quantitative	quantitative	JJ
cord-016197-y69wwy40	157	2	data	datum	NNS
cord-016197-y69wwy40	157	3	are	be	VBP
cord-016197-y69wwy40	157	4	more	more	RBR
cord-016197-y69wwy40	157	5	valuable	valuable	JJ
cord-016197-y69wwy40	157	6	than	than	IN
cord-016197-y69wwy40	157	7	qualitative	qualitative	JJ
cord-016197-y69wwy40	157	8	data	datum	NNS
cord-016197-y69wwy40	157	9	and	and	CC
cord-016197-y69wwy40	157	10	all	all	DT
cord-016197-y69wwy40	157	11	testing	testing	NN
cord-016197-y69wwy40	157	12	must	must	MD
cord-016197-y69wwy40	157	13	be	be	VB
cord-016197-y69wwy40	157	14	shown	show	VBN
cord-016197-y69wwy40	157	15	to	to	TO
cord-016197-y69wwy40	157	16	yield	yield	VB
cord-016197-y69wwy40	157	17	results	result	NNS
cord-016197-y69wwy40	157	18	that	that	WDT
cord-016197-y69wwy40	157	19	are	be	VBP
cord-016197-y69wwy40	157	20	capable	capable	JJ
cord-016197-y69wwy40	157	21	of	of	IN
cord-016197-y69wwy40	157	22	valid	valid	JJ
cord-016197-y69wwy40	157	23	comparison	comparison	NN
cord-016197-y69wwy40	157	24	;	;	:
cord-016197-y69wwy40	157	25	3	3	CD
cord-016197-y69wwy40	157	26	.	.	.
cord-016197-y69wwy40	158	1	molecular	molecular	JJ
cord-016197-y69wwy40	158	2	techniques	technique	NNS
cord-016197-y69wwy40	158	3	should	should	MD
cord-016197-y69wwy40	158	4	be	be	VB
cord-016197-y69wwy40	158	5	used	use	VBN
cord-016197-y69wwy40	158	6	to	to	TO
cord-016197-y69wwy40	158	7	define	define	VB
cord-016197-y69wwy40	158	8	strains	strain	NNS
cord-016197-y69wwy40	158	9	and	and	CC
cord-016197-y69wwy40	158	10	detect	detect	VB
cord-016197-y69wwy40	158	11	mechanisms	mechanism	NNS
cord-016197-y69wwy40	158	12	of	of	IN
cord-016197-y69wwy40	158	13	resistance	resistance	NN
cord-016197-y69wwy40	158	14	(	(	-LRB-
cord-016197-y69wwy40	158	15	see	see	VB
cord-016197-y69wwy40	158	16	Poupard	Poupard	NNP
cord-016197-y69wwy40	158	17	,	,	,
cord-016197-y69wwy40	158	18	Chapter	chapter	NN
cord-016197-y69wwy40	158	19	23	23	CD
cord-016197-y69wwy40	158	20	)	)	-RRB-
cord-016197-y69wwy40	158	21	;	;	:
cord-016197-y69wwy40	158	22	4	4	CD
cord-016197-y69wwy40	158	23	.	.	.
cord-016197-y69wwy40	159	1	there	there	EX
cord-016197-y69wwy40	159	2	is	be	VBZ
cord-016197-y69wwy40	159	3	a	a	DT
cord-016197-y69wwy40	159	4	place	place	NN
cord-016197-y69wwy40	159	5	for	for	IN
cord-016197-y69wwy40	159	6	both	both	DT
cord-016197-y69wwy40	159	7	narrow	narrow	JJ
cord-016197-y69wwy40	159	8	focus	focus	NN
cord-016197-y69wwy40	159	9	and	and	CC
cord-016197-y69wwy40	159	10	broader	broad	JJR
cord-016197-y69wwy40	159	11	surveillance	surveillance	NN
cord-016197-y69wwy40	159	12	studies	study	NNS
cord-016197-y69wwy40	159	13	:	:	:
cord-016197-y69wwy40	159	14	both	both	DT
cord-016197-y69wwy40	159	15	require	require	VBP
cord-016197-y69wwy40	159	16	funding	funding	NN
cord-016197-y69wwy40	159	17	,	,	,
cord-016197-y69wwy40	159	18	but	but	CC
cord-016197-y69wwy40	159	19	broader	broad	JJR
cord-016197-y69wwy40	159	20	studies	study	NNS
cord-016197-y69wwy40	159	21	,	,	,
cord-016197-y69wwy40	159	22	including	include	VBG
cord-016197-y69wwy40	159	23	a	a	DT
cord-016197-y69wwy40	159	24	wide	wide	JJ
cord-016197-y69wwy40	159	25	range	range	NN
cord-016197-y69wwy40	159	26	of	of	IN
cord-016197-y69wwy40	159	27	organisms	organism	NNS
cord-016197-y69wwy40	159	28	and	and	CC
cord-016197-y69wwy40	159	29	compounds	compound	NNS
cord-016197-y69wwy40	159	30	,	,	,
cord-016197-y69wwy40	159	31	require	require	VBP
cord-016197-y69wwy40	159	32	consortium	consortium	NN
cord-016197-y69wwy40	159	33	funding	funding	NN
cord-016197-y69wwy40	159	34	.	.	.
cord-016197-y69wwy40	160	1	There	there	EX
cord-016197-y69wwy40	160	2	is	be	VBZ
cord-016197-y69wwy40	160	3	a	a	DT
cord-016197-y69wwy40	160	4	need	need	NN
cord-016197-y69wwy40	160	5	for	for	IN
cord-016197-y69wwy40	160	6	the	the	DT
cord-016197-y69wwy40	160	7	interested	interested	JJ
cord-016197-y69wwy40	160	8	parties	party	NNS
cord-016197-y69wwy40	160	9	such	such	JJ
cord-016197-y69wwy40	160	10	as	as	IN
cord-016197-y69wwy40	160	11	academia	academia	NN
cord-016197-y69wwy40	160	12	,	,	,
cord-016197-y69wwy40	160	13	policy	policy	NN
cord-016197-y69wwy40	160	14	-	-	HYPH
cord-016197-y69wwy40	160	15	makers	maker	NNS
cord-016197-y69wwy40	160	16	,	,	,
cord-016197-y69wwy40	160	17	regulators	regulator	NNS
cord-016197-y69wwy40	160	18	,	,	,
cord-016197-y69wwy40	160	19	and	and	CC
cord-016197-y69wwy40	160	20	Pharma	Pharma	NNP
cord-016197-y69wwy40	160	21	to	to	TO
cord-016197-y69wwy40	160	22	consider	consider	VB
cord-016197-y69wwy40	160	23	mutually	mutually	RB
cord-016197-y69wwy40	160	24	beneficial	beneficial	JJ
cord-016197-y69wwy40	160	25	surveillance	surveillance	NN
cord-016197-y69wwy40	160	26	programmes	programme	NNS
cord-016197-y69wwy40	160	27	,	,	,
cord-016197-y69wwy40	160	28	with	with	IN
cord-016197-y69wwy40	160	29	agreed	agree	VBN
cord-016197-y69wwy40	160	30	methodologies	methodology	NNS
cord-016197-y69wwy40	160	31	and	and	CC
cord-016197-y69wwy40	160	32	interpretations	interpretation	NNS
cord-016197-y69wwy40	160	33	persuant	persuant	JJ
cord-016197-y69wwy40	160	34	to	to	IN
cord-016197-y69wwy40	160	35	their	-PRON-	PRP$
cord-016197-y69wwy40	160	36	purpose	purpose	NN
cord-016197-y69wwy40	160	37	.	.	.
cord-016197-y69wwy40	161	1	This	this	DT
cord-016197-y69wwy40	161	2	approach	approach	NN
cord-016197-y69wwy40	161	3	may	may	MD
cord-016197-y69wwy40	161	4	not	not	RB
cord-016197-y69wwy40	161	5	only	only	RB
cord-016197-y69wwy40	161	6	provide	provide	VB
cord-016197-y69wwy40	161	7	efficiencies	efficiency	NNS
cord-016197-y69wwy40	161	8	in	in	IN
cord-016197-y69wwy40	161	9	utility	utility	NN
cord-016197-y69wwy40	161	10	,	,	,
cord-016197-y69wwy40	161	11	support	support	NN
cord-016197-y69wwy40	161	12	,	,	,
cord-016197-y69wwy40	161	13	and	and	CC
cord-016197-y69wwy40	161	14	sustainability	sustainability	NN
cord-016197-y69wwy40	161	15	but	but	CC
cord-016197-y69wwy40	161	16	also	also	RB
cord-016197-y69wwy40	161	17	a	a	DT
cord-016197-y69wwy40	161	18	better	well	JJR
cord-016197-y69wwy40	161	19	understanding	understanding	NN
cord-016197-y69wwy40	161	20	of	of	IN
cord-016197-y69wwy40	161	21	relationship	relationship	NN
cord-016197-y69wwy40	161	22	between	between	IN
cord-016197-y69wwy40	161	23	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	161	24	use	use	NN
cord-016197-y69wwy40	161	25	and	and	CC
cord-016197-y69wwy40	161	26	resistance	resistance	NN
cord-016197-y69wwy40	161	27	and	and	CC
cord-016197-y69wwy40	161	28	the	the	DT
cord-016197-y69wwy40	161	29	role	role	NN
cord-016197-y69wwy40	161	30	and	and	CC
cord-016197-y69wwy40	161	31	impact	impact	NN
cord-016197-y69wwy40	161	32	of	of	IN
cord-016197-y69wwy40	161	33	policies	policy	NNS
cord-016197-y69wwy40	161	34	and	and	CC
cord-016197-y69wwy40	161	35	interventions	intervention	NNS
cord-016197-y69wwy40	161	36	.	.	.
cord-016197-y69wwy40	162	1	In	in	IN
cord-016197-y69wwy40	162	2	addition	addition	NN
cord-016197-y69wwy40	162	3	to	to	IN
cord-016197-y69wwy40	162	4	the	the	DT
cord-016197-y69wwy40	162	5	key	key	JJ
cord-016197-y69wwy40	162	6	influential	influential	JJ
cord-016197-y69wwy40	162	7	recommendations	recommendation	NNS
cord-016197-y69wwy40	162	8	described	describe	VBN
cord-016197-y69wwy40	162	9	by	by	IN
cord-016197-y69wwy40	162	10	Carbon	Carbon	NNP
cord-016197-y69wwy40	162	11	et	et	NNP
cord-016197-y69wwy40	162	12	al	al	NNP
cord-016197-y69wwy40	162	13	.	.	.
cord-016197-y69wwy40	163	1	(	(	-LRB-
cord-016197-y69wwy40	163	2	2002	2002	CD
cord-016197-y69wwy40	163	3	)	)	-RRB-
cord-016197-y69wwy40	163	4	there	there	EX
cord-016197-y69wwy40	163	5	are	be	VBP
cord-016197-y69wwy40	163	6	many	many	JJ
cord-016197-y69wwy40	163	7	other	other	JJ
cord-016197-y69wwy40	163	8	national	national	JJ
cord-016197-y69wwy40	163	9	and	and	CC
cord-016197-y69wwy40	163	10	local	local	JJ
cord-016197-y69wwy40	163	11	guidelines	guideline	NNS
cord-016197-y69wwy40	163	12	,	,	,
cord-016197-y69wwy40	163	13	guidances	guidance	NNS
cord-016197-y69wwy40	163	14	,	,	,
cord-016197-y69wwy40	163	15	policies	policy	NNS
cord-016197-y69wwy40	163	16	,	,	,
cord-016197-y69wwy40	163	17	and	and	CC
cord-016197-y69wwy40	163	18	educational	educational	JJ
cord-016197-y69wwy40	163	19	campaigns	campaign	NNS
cord-016197-y69wwy40	163	20	which	which	WDT
cord-016197-y69wwy40	163	21	impact	impact	VBP
cord-016197-y69wwy40	163	22	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	163	23	use	use	NN
cord-016197-y69wwy40	163	24	.	.	.
cord-016197-y69wwy40	164	1	Most	Most	JJS
cord-016197-y69wwy40	164	2	such	such	JJ
cord-016197-y69wwy40	164	3	policies	policy	NNS
cord-016197-y69wwy40	164	4	either	either	CC
cord-016197-y69wwy40	164	5	describe	describe	VBP
cord-016197-y69wwy40	164	6	the	the	DT
cord-016197-y69wwy40	164	7	need	need	NN
cord-016197-y69wwy40	164	8	for	for	IN
cord-016197-y69wwy40	164	9	implementation	implementation	NN
cord-016197-y69wwy40	164	10	of	of	IN
cord-016197-y69wwy40	164	11	"	"	``
cord-016197-y69wwy40	164	12	judicious	judicious	JJ
cord-016197-y69wwy40	164	13	"	"	''
cord-016197-y69wwy40	164	14	or	or	CC
cord-016197-y69wwy40	164	15	"	"	``
cord-016197-y69wwy40	164	16	prudent	prudent	JJ
cord-016197-y69wwy40	164	17	"	"	''
cord-016197-y69wwy40	164	18	use	use	NN
cord-016197-y69wwy40	164	19	of	of	IN
cord-016197-y69wwy40	164	20	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	164	21	,	,	,
cord-016197-y69wwy40	164	22	or	or	CC
cord-016197-y69wwy40	164	23	use	use	VB
cord-016197-y69wwy40	164	24	terms	term	NNS
cord-016197-y69wwy40	164	25	such	such	JJ
cord-016197-y69wwy40	164	26	as	as	IN
cord-016197-y69wwy40	164	27	"	"	``
cord-016197-y69wwy40	164	28	misuse	misuse	NN
cord-016197-y69wwy40	164	29	"	"	''
cord-016197-y69wwy40	164	30	and	and	CC
cord-016197-y69wwy40	164	31	"	"	``
cord-016197-y69wwy40	164	32	overuse	overuse	NN
cord-016197-y69wwy40	164	33	"	"	''
cord-016197-y69wwy40	164	34	as	as	IN
cord-016197-y69wwy40	164	35	causes	cause	NNS
cord-016197-y69wwy40	164	36	of	of	IN
cord-016197-y69wwy40	164	37	resistance	resistance	NN
cord-016197-y69wwy40	164	38	and	and	CC
cord-016197-y69wwy40	164	39	imply	imply	VBP
cord-016197-y69wwy40	164	40	that	that	IN
cord-016197-y69wwy40	164	41	a	a	DT
cord-016197-y69wwy40	164	42	reduction	reduction	NN
cord-016197-y69wwy40	164	43	in	in	IN
cord-016197-y69wwy40	164	44	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	164	45	prescribing	prescribing	NN
cord-016197-y69wwy40	164	46	per	per	FW
cord-016197-y69wwy40	164	47	se	se	FW
cord-016197-y69wwy40	164	48	will	will	MD
cord-016197-y69wwy40	164	49	have	have	VB
cord-016197-y69wwy40	164	50	a	a	DT
cord-016197-y69wwy40	164	51	beneficial	beneficial	JJ
cord-016197-y69wwy40	164	52	and	and	CC
cord-016197-y69wwy40	164	53	sustainable	sustainable	JJ
cord-016197-y69wwy40	164	54	effect	effect	NN
cord-016197-y69wwy40	164	55	on	on	IN
cord-016197-y69wwy40	164	56	resistance	resistance	NN
cord-016197-y69wwy40	164	57	.	.	.
cord-016197-y69wwy40	165	1	There	there	EX
cord-016197-y69wwy40	165	2	is	be	VBZ
cord-016197-y69wwy40	165	3	a	a	DT
cord-016197-y69wwy40	165	4	recognition	recognition	NN
cord-016197-y69wwy40	165	5	that	that	IN
cord-016197-y69wwy40	165	6	while	while	IN
cord-016197-y69wwy40	165	7	prescribing	prescribe	VBG
cord-016197-y69wwy40	165	8	guidelines	guideline	NNS
cord-016197-y69wwy40	165	9	and	and	CC
cord-016197-y69wwy40	165	10	other	other	JJ
cord-016197-y69wwy40	165	11	prescribing	prescribe	VBG
cord-016197-y69wwy40	165	12	support	support	NN
cord-016197-y69wwy40	165	13	systems	system	NNS
cord-016197-y69wwy40	165	14	should	should	MD
cord-016197-y69wwy40	165	15	help	help	VB
cord-016197-y69wwy40	165	16	control	control	VB
cord-016197-y69wwy40	165	17	bacterial	bacterial	JJ
cord-016197-y69wwy40	165	18	resistance	resistance	NN
cord-016197-y69wwy40	165	19	in	in	IN
cord-016197-y69wwy40	165	20	the	the	DT
cord-016197-y69wwy40	165	21	community	community	NN
cord-016197-y69wwy40	165	22	,	,	,
cord-016197-y69wwy40	165	23	their	-PRON-	PRP$
cord-016197-y69wwy40	165	24	actual	actual	JJ
cord-016197-y69wwy40	165	25	effect	effect	NN
cord-016197-y69wwy40	165	26	on	on	IN
cord-016197-y69wwy40	165	27	resistance	resistance	NN
cord-016197-y69wwy40	165	28	patterns	pattern	NNS
cord-016197-y69wwy40	165	29	is	be	VBZ
cord-016197-y69wwy40	165	30	largely	largely	RB
cord-016197-y69wwy40	165	31	unknown	unknown	JJ
cord-016197-y69wwy40	165	32	(	(	-LRB-
cord-016197-y69wwy40	165	33	Finch	Finch	NNP
cord-016197-y69wwy40	165	34	and	and	CC
cord-016197-y69wwy40	165	35	Low	Low	NNP
cord-016197-y69wwy40	165	36	,	,	,
cord-016197-y69wwy40	165	37	2002	2002	CD
cord-016197-y69wwy40	165	38	)	)	-RRB-
cord-016197-y69wwy40	165	39	and	and	CC
cord-016197-y69wwy40	165	40	the	the	DT
cord-016197-y69wwy40	165	41	reversibility	reversibility	NN
cord-016197-y69wwy40	165	42	or	or	CC
cord-016197-y69wwy40	165	43	containment	containment	NN
cord-016197-y69wwy40	165	44	of	of	IN
cord-016197-y69wwy40	165	45	resistance	resistance	NN
cord-016197-y69wwy40	165	46	with	with	IN
cord-016197-y69wwy40	165	47	the	the	DT
cord-016197-y69wwy40	165	48	optimization	optimization	NN
cord-016197-y69wwy40	165	49	of	of	IN
cord-016197-y69wwy40	165	50	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	165	51	usage	usage	NN
cord-016197-y69wwy40	165	52	has	have	VBZ
cord-016197-y69wwy40	165	53	yet	yet	RB
cord-016197-y69wwy40	165	54	to	to	TO
cord-016197-y69wwy40	165	55	be	be	VB
cord-016197-y69wwy40	165	56	definitely	definitely	RB
cord-016197-y69wwy40	165	57	established	establish	VBN
cord-016197-y69wwy40	165	58	Davey	Davey	NNP
cord-016197-y69wwy40	165	59	et	et	NNP
cord-016197-y69wwy40	165	60	al	al	NNP
cord-016197-y69wwy40	165	61	.	.	NNP
cord-016197-y69wwy40	165	62	,	,	,
cord-016197-y69wwy40	165	63	2003	2003	CD
cord-016197-y69wwy40	165	64	)	)	-RRB-
cord-016197-y69wwy40	165	65	.	.	.
cord-016197-y69wwy40	166	1	Davey	Davey	NNP
cord-016197-y69wwy40	166	2	et	et	NNP
cord-016197-y69wwy40	166	3	al	al	NNP
cord-016197-y69wwy40	166	4	.	.	.
cord-016197-y69wwy40	167	1	(	(	-LRB-
cord-016197-y69wwy40	167	2	2003	2003	CD
cord-016197-y69wwy40	167	3	)	)	-RRB-
cord-016197-y69wwy40	167	4	described	describe	VBD
cord-016197-y69wwy40	167	5	the	the	DT
cord-016197-y69wwy40	167	6	control	control	NN
cord-016197-y69wwy40	167	7	of	of	IN
cord-016197-y69wwy40	167	8	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	167	9	prescribing	prescribing	NN
cord-016197-y69wwy40	167	10	as	as	IN
cord-016197-y69wwy40	167	11	a	a	DT
cord-016197-y69wwy40	167	12	crucial	crucial	JJ
cord-016197-y69wwy40	167	13	part	part	NN
cord-016197-y69wwy40	167	14	of	of	IN
cord-016197-y69wwy40	167	15	any	any	DT
cord-016197-y69wwy40	167	16	strategy	strategy	NN
cord-016197-y69wwy40	167	17	to	to	TO
cord-016197-y69wwy40	167	18	limit	limit	VB
cord-016197-y69wwy40	167	19	the	the	DT
cord-016197-y69wwy40	167	20	development	development	NN
cord-016197-y69wwy40	167	21	of	of	IN
cord-016197-y69wwy40	167	22	resistance	resistance	NN
cord-016197-y69wwy40	167	23	as	as	IN
cord-016197-y69wwy40	167	24	advocated	advocate	VBN
cord-016197-y69wwy40	167	25	by	by	IN
cord-016197-y69wwy40	167	26	the	the	DT
cord-016197-y69wwy40	167	27	UK	UK	NNP
cord-016197-y69wwy40	167	28	House	House	NNP
cord-016197-y69wwy40	167	29	of	of	IN
cord-016197-y69wwy40	167	30	Lords	Lords	NNP
cord-016197-y69wwy40	167	31	recommendations	recommendation	NNS
cord-016197-y69wwy40	167	32	and	and	CC
cord-016197-y69wwy40	167	33	the	the	DT
cord-016197-y69wwy40	167	34	Copenhagen	Copenhagen	NNP
cord-016197-y69wwy40	167	35	recommendations	recommendation	NNS
cord-016197-y69wwy40	167	36	.	.	.
cord-016197-y69wwy40	168	1	These	these	DT
cord-016197-y69wwy40	168	2	authors	author	NNS
cord-016197-y69wwy40	168	3	recognized	recognize	VBD
cord-016197-y69wwy40	168	4	the	the	DT
cord-016197-y69wwy40	168	5	difficulty	difficulty	NN
cord-016197-y69wwy40	168	6	in	in	IN
cord-016197-y69wwy40	168	7	proving	prove	VBG
cord-016197-y69wwy40	168	8	that	that	IN
cord-016197-y69wwy40	168	9	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	168	10	policies	policy	NNS
cord-016197-y69wwy40	168	11	help	help	VBP
cord-016197-y69wwy40	168	12	to	to	TO
cord-016197-y69wwy40	168	13	resolve	resolve	VB
cord-016197-y69wwy40	168	14	a	a	DT
cord-016197-y69wwy40	168	15	problem	problem	NN
cord-016197-y69wwy40	168	16	of	of	IN
cord-016197-y69wwy40	168	17	resistance	resistance	NN
cord-016197-y69wwy40	168	18	that	that	WDT
cord-016197-y69wwy40	168	19	has	have	VBZ
cord-016197-y69wwy40	168	20	already	already	RB
cord-016197-y69wwy40	168	21	developed	develop	VBN
cord-016197-y69wwy40	168	22	and	and	CC
cord-016197-y69wwy40	168	23	also	also	RB
cord-016197-y69wwy40	168	24	recognized	recognize	VBD
cord-016197-y69wwy40	168	25	the	the	DT
cord-016197-y69wwy40	168	26	greater	great	JJR
cord-016197-y69wwy40	168	27	difficulty	difficulty	NN
cord-016197-y69wwy40	168	28	in	in	IN
cord-016197-y69wwy40	168	29	proving	prove	VBG
cord-016197-y69wwy40	168	30	that	that	IN
cord-016197-y69wwy40	168	31	policies	policy	NNS
cord-016197-y69wwy40	168	32	prevent	prevent	VBP
cord-016197-y69wwy40	168	33	the	the	DT
cord-016197-y69wwy40	168	34	development	development	NN
cord-016197-y69wwy40	168	35	of	of	IN
cord-016197-y69wwy40	168	36	resistance	resistance	NN
cord-016197-y69wwy40	168	37	.	.	.
cord-016197-y69wwy40	169	1	Most	Most	JJS
cord-016197-y69wwy40	169	2	policies	policy	NNS
cord-016197-y69wwy40	169	3	(	(	-LRB-
cord-016197-y69wwy40	169	4	and	and	CC
cord-016197-y69wwy40	169	5	guidelines	guideline	NNS
cord-016197-y69wwy40	169	6	)	)	-RRB-
cord-016197-y69wwy40	169	7	are	be	VBP
cord-016197-y69wwy40	169	8	concerned	concern	VBN
cord-016197-y69wwy40	169	9	with	with	IN
cord-016197-y69wwy40	169	10	which	which	WDT
cord-016197-y69wwy40	169	11	antibiotic	antibiotic	NN
cord-016197-y69wwy40	169	12	is	be	VBZ
cord-016197-y69wwy40	169	13	prescribed	prescribe	VBN
cord-016197-y69wwy40	169	14	and	and	CC
cord-016197-y69wwy40	169	15	Davey	Davey	NNP
cord-016197-y69wwy40	169	16	et	et	NNP
cord-016197-y69wwy40	169	17	al	al	NNP
cord-016197-y69wwy40	169	18	.	.	.
cord-016197-y69wwy40	170	1	(	(	-LRB-
cord-016197-y69wwy40	170	2	2003	2003	CD
cord-016197-y69wwy40	170	3	)	)	-RRB-
cord-016197-y69wwy40	170	4	state	state	NN
cord-016197-y69wwy40	170	5	that	that	IN
cord-016197-y69wwy40	170	6	it	-PRON-	PRP
cord-016197-y69wwy40	170	7	is	be	VBZ
cord-016197-y69wwy40	170	8	more	more	RBR
cord-016197-y69wwy40	170	9	likely	likely	JJ
cord-016197-y69wwy40	170	10	that	that	IN
cord-016197-y69wwy40	170	11	development	development	NN
cord-016197-y69wwy40	170	12	of	of	IN
cord-016197-y69wwy40	170	13	resistance	resistance	NN
cord-016197-y69wwy40	170	14	will	will	MD
cord-016197-y69wwy40	170	15	be	be	VB
cord-016197-y69wwy40	170	16	contained	contain	VBN
cord-016197-y69wwy40	170	17	by	by	IN
cord-016197-y69wwy40	170	18	policies	policy	NNS
cord-016197-y69wwy40	170	19	which	which	WDT
cord-016197-y69wwy40	170	20	also	also	RB
cord-016197-y69wwy40	170	21	try	try	VBP
cord-016197-y69wwy40	170	22	to	to	TO
cord-016197-y69wwy40	170	23	limit	limit	VB
cord-016197-y69wwy40	170	24	unnecessary	unnecessary	JJ
cord-016197-y69wwy40	170	25	prescribing	prescribing	NN
cord-016197-y69wwy40	170	26	of	of	IN
cord-016197-y69wwy40	170	27	antibiotics	antibiotic	NNS
cord-016197-y69wwy40	171	1	(	(	-LRB-
cord-016197-y69wwy40	171	2	i.e.	i.e.	FW
cord-016197-y69wwy40	171	3	,	,	,
cord-016197-y69wwy40	171	4	prescribing	prescribe	VBG
cord-016197-y69wwy40	171	5	for	for	IN
cord-016197-y69wwy40	171	6	non	non	JJ
cord-016197-y69wwy40	171	7	-	-	JJ
cord-016197-y69wwy40	171	8	bacterial	bacterial	JJ
cord-016197-y69wwy40	171	9	or	or	CC
cord-016197-y69wwy40	171	10	self	self	NN
cord-016197-y69wwy40	171	11	-	-	HYPH
cord-016197-y69wwy40	171	12	limiting	limit	VBG
cord-016197-y69wwy40	171	13	illness	illness	NN
cord-016197-y69wwy40	171	14	)	)	-RRB-
cord-016197-y69wwy40	171	15	.	.	.
cord-016197-y69wwy40	172	1	The	the	DT
cord-016197-y69wwy40	172	2	general	general	JJ
cord-016197-y69wwy40	172	3	advantages	advantage	NNS
cord-016197-y69wwy40	172	4	of	of	IN
cord-016197-y69wwy40	172	5	an	an	DT
cord-016197-y69wwy40	172	6	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	172	7	policy	policy	NN
cord-016197-y69wwy40	172	8	are	be	VBP
cord-016197-y69wwy40	172	9	described	describe	VBN
cord-016197-y69wwy40	172	10	by	by	IN
cord-016197-y69wwy40	172	11	Davey	Davey	NNP
cord-016197-y69wwy40	172	12	et	et	NNP
cord-016197-y69wwy40	172	13	al	al	NNP
cord-016197-y69wwy40	172	14	.	.	.
cord-016197-y69wwy40	173	1	(	(	-LRB-
cord-016197-y69wwy40	173	2	2003	2003	CD
cord-016197-y69wwy40	173	3	)	)	-RRB-
cord-016197-y69wwy40	173	4	as	as	IN
cord-016197-y69wwy40	173	5	:	:	:
cord-016197-y69wwy40	173	6	•	•	NN
cord-016197-y69wwy40	173	7	promotion	promotion	NN
cord-016197-y69wwy40	173	8	of	of	IN
cord-016197-y69wwy40	173	9	awareness	awareness	NN
cord-016197-y69wwy40	173	10	of	of	IN
cord-016197-y69wwy40	173	11	benefits	benefit	NNS
cord-016197-y69wwy40	173	12	,	,	,
cord-016197-y69wwy40	173	13	risks	risk	NNS
cord-016197-y69wwy40	173	14	,	,	,
cord-016197-y69wwy40	173	15	and	and	CC
cord-016197-y69wwy40	173	16	cost	cost	NN
cord-016197-y69wwy40	173	17	of	of	IN
cord-016197-y69wwy40	173	18	prescribing	prescribe	VBG
cord-016197-y69wwy40	173	19	•	•	NNP
cord-016197-y69wwy40	173	20	facilitation	facilitation	NN
cord-016197-y69wwy40	173	21	of	of	IN
cord-016197-y69wwy40	173	22	educational	educational	JJ
cord-016197-y69wwy40	173	23	and	and	CC
cord-016197-y69wwy40	173	24	training	training	NN
cord-016197-y69wwy40	173	25	programmes	programme	NNS
cord-016197-y69wwy40	173	26	•	•	NNP
cord-016197-y69wwy40	173	27	reduction	reduction	NN
cord-016197-y69wwy40	173	28	of	of	IN
cord-016197-y69wwy40	173	29	aggressive	aggressive	JJ
cord-016197-y69wwy40	173	30	marketing	marketing	NN
cord-016197-y69wwy40	173	31	by	by	IN
cord-016197-y69wwy40	174	1	Pharma	Pharma	NNS
cord-016197-y69wwy40	174	2	•	•	NNP
cord-016197-y69wwy40	174	3	encouragement	encouragement	NN
cord-016197-y69wwy40	174	4	of	of	IN
cord-016197-y69wwy40	174	5	rational	rational	JJ
cord-016197-y69wwy40	174	6	choice	choice	NN
cord-016197-y69wwy40	174	7	between	between	IN
cord-016197-y69wwy40	174	8	drugs	drug	NNS
cord-016197-y69wwy40	174	9	based	base	VBN
cord-016197-y69wwy40	174	10	on	on	IN
cord-016197-y69wwy40	174	11	analysis	analysis	NN
cord-016197-y69wwy40	174	12	of	of	IN
cord-016197-y69wwy40	174	13	pharmacology	pharmacology	NN
cord-016197-y69wwy40	174	14	,	,	,
cord-016197-y69wwy40	174	15	clinical	clinical	JJ
cord-016197-y69wwy40	174	16	effectiveness	effectiveness	NN
cord-016197-y69wwy40	174	17	,	,	,
cord-016197-y69wwy40	174	18	safety	safety	NN
cord-016197-y69wwy40	174	19	,	,	,
cord-016197-y69wwy40	174	20	and	and	CC
cord-016197-y69wwy40	174	21	cost	cost	NN
cord-016197-y69wwy40	174	22	;	;	:
cord-016197-y69wwy40	174	23	and	and	CC
cord-016197-y69wwy40	174	24	specifically	specifically	RB
cord-016197-y69wwy40	174	25	to	to	IN
cord-016197-y69wwy40	174	26	antimicrobials	antimicrobial	NNS
cord-016197-y69wwy40	174	27	as	as	IN
cord-016197-y69wwy40	174	28	:	:	:
cord-016197-y69wwy40	174	29	•	•	NNP
cord-016197-y69wwy40	174	30	the	the	DT
cord-016197-y69wwy40	174	31	promotion	promotion	NN
cord-016197-y69wwy40	174	32	of	of	IN
cord-016197-y69wwy40	174	33	education	education	NN
cord-016197-y69wwy40	174	34	on	on	IN
cord-016197-y69wwy40	174	35	local	local	JJ
cord-016197-y69wwy40	174	36	pathogen	pathogen	NN
cord-016197-y69wwy40	174	37	epidemiology	epidemiology	NN
cord-016197-y69wwy40	174	38	and	and	CC
cord-016197-y69wwy40	174	39	susceptibility	susceptibility	NN
cord-016197-y69wwy40	174	40	along	along	IN
cord-016197-y69wwy40	174	41	with	with	IN
cord-016197-y69wwy40	174	42	awareness	awareness	NN
cord-016197-y69wwy40	174	43	of	of	IN
cord-016197-y69wwy40	174	44	infection	infection	NN
cord-016197-y69wwy40	174	45	control	control	NN
cord-016197-y69wwy40	174	46	.	.	.
cord-016197-y69wwy40	175	1	The	the	DT
cord-016197-y69wwy40	175	2	general	general	JJ
cord-016197-y69wwy40	175	3	benefits	benefit	NNS
cord-016197-y69wwy40	175	4	are	be	VBP
cord-016197-y69wwy40	175	5	described	describe	VBN
cord-016197-y69wwy40	175	6	as	as	IN
cord-016197-y69wwy40	175	7	:	:	:
cord-016197-y69wwy40	175	8	•	•	NNP
cord-016197-y69wwy40	175	9	improved	improve	VBD
cord-016197-y69wwy40	175	10	efficacy	efficacy	NN
cord-016197-y69wwy40	175	11	of	of	IN
cord-016197-y69wwy40	175	12	prescribing	prescribe	VBG
cord-016197-y69wwy40	175	13	(	(	-LRB-
cord-016197-y69wwy40	175	14	sensitivity	sensitivity	NN
cord-016197-y69wwy40	175	15	and	and	CC
cord-016197-y69wwy40	175	16	specificity	specificity	NN
cord-016197-y69wwy40	175	17	)	)	-RRB-
cord-016197-y69wwy40	176	1	•	•	NNP
cord-016197-y69wwy40	176	2	improved	improve	VBD
cord-016197-y69wwy40	176	3	clinical	clinical	JJ
cord-016197-y69wwy40	176	4	outcome	outcome	NN
cord-016197-y69wwy40	176	5	•	•	NNP
cord-016197-y69wwy40	176	6	reduced	reduce	VBD
cord-016197-y69wwy40	176	7	medical	medical	JJ
cord-016197-y69wwy40	176	8	liability	liability	NN
cord-016197-y69wwy40	176	9	;	;	:
cord-016197-y69wwy40	176	10	and	and	CC
cord-016197-y69wwy40	176	11	specifically	specifically	RB
cord-016197-y69wwy40	176	12	to	to	IN
cord-016197-y69wwy40	176	13	antimicrobials	antimicrobial	NNS
cord-016197-y69wwy40	176	14	as	as	IN
cord-016197-y69wwy40	176	15	:	:	:
cord-016197-y69wwy40	176	16	•	•	NNP
cord-016197-y69wwy40	176	17	limited	limit	VBD
cord-016197-y69wwy40	176	18	emergence	emergence	NN
cord-016197-y69wwy40	176	19	and	and	CC
cord-016197-y69wwy40	176	20	spread	spread	NN
cord-016197-y69wwy40	176	21	of	of	IN
cord-016197-y69wwy40	176	22	resistance	resistance	NN
cord-016197-y69wwy40	176	23	.	.	.
cord-016197-y69wwy40	177	1	Davey	Davey	NNP
cord-016197-y69wwy40	177	2	et	et	NNP
cord-016197-y69wwy40	177	3	al	al	NNP
cord-016197-y69wwy40	177	4	.	.	.
cord-016197-y69wwy40	178	1	(	(	-LRB-
cord-016197-y69wwy40	178	2	2003	2003	CD
cord-016197-y69wwy40	178	3	)	)	-RRB-
cord-016197-y69wwy40	178	4	suggest	suggest	VBP
cord-016197-y69wwy40	178	5	that	that	IN
cord-016197-y69wwy40	178	6	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	178	7	policies	policy	NNS
cord-016197-y69wwy40	178	8	can	can	MD
cord-016197-y69wwy40	178	9	definitely	definitely	RB
cord-016197-y69wwy40	178	10	improve	improve	VB
cord-016197-y69wwy40	178	11	the	the	DT
cord-016197-y69wwy40	178	12	quality	quality	NN
cord-016197-y69wwy40	178	13	of	of	IN
cord-016197-y69wwy40	178	14	prescribing	prescribing	NN
cord-016197-y69wwy40	178	15	and	and	CC
cord-016197-y69wwy40	178	16	may	may	MD
cord-016197-y69wwy40	178	17	be	be	VB
cord-016197-y69wwy40	178	18	used	use	VBN
cord-016197-y69wwy40	178	19	to	to	TO
cord-016197-y69wwy40	178	20	limit	limit	VB
cord-016197-y69wwy40	178	21	cost	cost	NN
cord-016197-y69wwy40	178	22	and	and	CC
cord-016197-y69wwy40	178	23	that	that	IN
cord-016197-y69wwy40	178	24	limiting	limit	VBG
cord-016197-y69wwy40	178	25	superinfections	superinfection	NNS
cord-016197-y69wwy40	178	26	and	and	CC
cord-016197-y69wwy40	178	27	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	178	28	resistance	resistance	NN
cord-016197-y69wwy40	178	29	should	should	MD
cord-016197-y69wwy40	178	30	be	be	VB
cord-016197-y69wwy40	178	31	viewed	view	VBN
cord-016197-y69wwy40	178	32	as	as	IN
cord-016197-y69wwy40	178	33	additional	additional	JJ
cord-016197-y69wwy40	178	34	benefit	benefit	NN
cord-016197-y69wwy40	178	35	(	(	-LRB-
cord-016197-y69wwy40	178	36	and	and	CC
cord-016197-y69wwy40	178	37	probably	probably	RB
cord-016197-y69wwy40	178	38	not	not	RB
cord-016197-y69wwy40	178	39	a	a	DT
cord-016197-y69wwy40	178	40	realistic	realistic	JJ
cord-016197-y69wwy40	178	41	primary	primary	JJ
cord-016197-y69wwy40	178	42	aim	aim	NN
cord-016197-y69wwy40	178	43	)	)	-RRB-
cord-016197-y69wwy40	178	44	.	.	.
cord-016197-y69wwy40	179	1	Similarly	similarly	RB
cord-016197-y69wwy40	179	2	,	,	,
cord-016197-y69wwy40	179	3	Ball	Ball	NNP
cord-016197-y69wwy40	179	4	et	et	FW
cord-016197-y69wwy40	179	5	al	al	NNP
cord-016197-y69wwy40	179	6	.	.	.
cord-016197-y69wwy40	180	1	(	(	-LRB-
cord-016197-y69wwy40	180	2	2002	2002	CD
cord-016197-y69wwy40	180	3	)	)	-RRB-
cord-016197-y69wwy40	180	4	stated	state	VBD
cord-016197-y69wwy40	180	5	that	that	IN
cord-016197-y69wwy40	180	6	when	when	WRB
cord-016197-y69wwy40	180	7	prescribing	prescribe	VBG
cord-016197-y69wwy40	180	8	is	be	VBZ
cord-016197-y69wwy40	180	9	necessary	necessary	JJ
cord-016197-y69wwy40	180	10	,	,	,
cord-016197-y69wwy40	180	11	quality	quality	NN
cord-016197-y69wwy40	180	12	prescribing	prescribing	NN
cord-016197-y69wwy40	180	13	may	may	MD
cord-016197-y69wwy40	180	14	not	not	RB
cord-016197-y69wwy40	180	15	only	only	RB
cord-016197-y69wwy40	180	16	combat	combat	NN
cord-016197-y69wwy40	180	17	resistance	resistance	NN
cord-016197-y69wwy40	180	18	and	and	CC
cord-016197-y69wwy40	180	19	optimize	optimize	VB
cord-016197-y69wwy40	180	20	patient	patient	JJ
cord-016197-y69wwy40	180	21	outcomes	outcome	NNS
cord-016197-y69wwy40	180	22	but	but	CC
cord-016197-y69wwy40	180	23	also	also	RB
cord-016197-y69wwy40	180	24	provide	provide	VB
cord-016197-y69wwy40	180	25	cost	cost	NN
cord-016197-y69wwy40	180	26	benefits	benefit	NNS
cord-016197-y69wwy40	180	27	.	.	.
cord-016197-y69wwy40	181	1	In	in	IN
cord-016197-y69wwy40	181	2	a	a	DT
cord-016197-y69wwy40	181	3	review	review	NN
cord-016197-y69wwy40	181	4	of	of	IN
cord-016197-y69wwy40	181	5	the	the	DT
cord-016197-y69wwy40	181	6	impact	impact	NN
cord-016197-y69wwy40	181	7	of	of	IN
cord-016197-y69wwy40	181	8	guidelines	guideline	NNS
cord-016197-y69wwy40	181	9	in	in	IN
cord-016197-y69wwy40	181	10	the	the	DT
cord-016197-y69wwy40	181	11	management	management	NN
cord-016197-y69wwy40	181	12	of	of	IN
cord-016197-y69wwy40	181	13	communityacquired	communityacquired	JJ
cord-016197-y69wwy40	181	14	pneumonia	pneumonia	NN
cord-016197-y69wwy40	181	15	,	,	,
cord-016197-y69wwy40	181	16	several	several	JJ
cord-016197-y69wwy40	181	17	studies	study	NNS
cord-016197-y69wwy40	181	18	were	be	VBD
cord-016197-y69wwy40	181	19	identified	identify	VBN
cord-016197-y69wwy40	181	20	which	which	WDT
cord-016197-y69wwy40	181	21	showed	show	VBD
cord-016197-y69wwy40	181	22	that	that	IN
cord-016197-y69wwy40	181	23	an	an	DT
cord-016197-y69wwy40	181	24	increase	increase	NN
cord-016197-y69wwy40	181	25	in	in	IN
cord-016197-y69wwy40	181	26	the	the	DT
cord-016197-y69wwy40	181	27	proportion	proportion	NN
cord-016197-y69wwy40	181	28	of	of	IN
cord-016197-y69wwy40	181	29	patients	patient	NNS
cord-016197-y69wwy40	181	30	who	who	WP
cord-016197-y69wwy40	181	31	receive	receive	VBP
cord-016197-y69wwy40	181	32	prompt	prompt	JJ
cord-016197-y69wwy40	181	33	,	,	,
cord-016197-y69wwy40	181	34	appropriate	appropriate	JJ
cord-016197-y69wwy40	181	35	therapy	therapy	NN
cord-016197-y69wwy40	181	36	was	be	VBD
cord-016197-y69wwy40	181	37	associated	associate	VBN
cord-016197-y69wwy40	181	38	with	with	IN
cord-016197-y69wwy40	181	39	improvements	improvement	NNS
cord-016197-y69wwy40	181	40	in	in	IN
cord-016197-y69wwy40	181	41	outcome	outcome	NN
cord-016197-y69wwy40	181	42	measurements	measurement	NNS
cord-016197-y69wwy40	181	43	such	such	JJ
cord-016197-y69wwy40	181	44	as	as	IN
cord-016197-y69wwy40	181	45	mortality	mortality	NN
cord-016197-y69wwy40	181	46	and	and	CC
cord-016197-y69wwy40	181	47	length	length	NN
cord-016197-y69wwy40	181	48	of	of	IN
cord-016197-y69wwy40	181	49	hospital	hospital	NN
cord-016197-y69wwy40	181	50	stay	stay	NN
cord-016197-y69wwy40	181	51	(	(	-LRB-
cord-016197-y69wwy40	182	1	Nathwani	Nathwani	NNP
cord-016197-y69wwy40	182	2	et	et	NNP
cord-016197-y69wwy40	182	3	al	al	NNP
cord-016197-y69wwy40	182	4	.	.	NNP
cord-016197-y69wwy40	182	5	,	,	,
cord-016197-y69wwy40	182	6	2001	2001	CD
cord-016197-y69wwy40	182	7	)	)	-RRB-
cord-016197-y69wwy40	182	8	.	.	.
cord-016197-y69wwy40	183	1	Gould	Gould	NNP
cord-016197-y69wwy40	183	2	undertook	undertake	VBD
cord-016197-y69wwy40	183	3	a	a	DT
cord-016197-y69wwy40	183	4	review	review	NN
cord-016197-y69wwy40	183	5	of	of	IN
cord-016197-y69wwy40	183	6	the	the	DT
cord-016197-y69wwy40	183	7	role	role	NN
cord-016197-y69wwy40	183	8	of	of	IN
cord-016197-y69wwy40	183	9	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	183	10	policies	policy	NNS
cord-016197-y69wwy40	183	11	in	in	IN
cord-016197-y69wwy40	183	12	the	the	DT
cord-016197-y69wwy40	183	13	control	control	NN
cord-016197-y69wwy40	183	14	of	of	IN
cord-016197-y69wwy40	183	15	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	183	16	resistance	resistance	NN
cord-016197-y69wwy40	183	17	,	,	,
cord-016197-y69wwy40	183	18	noting	note	VBG
cord-016197-y69wwy40	183	19	that	that	IN
cord-016197-y69wwy40	183	20	the	the	DT
cord-016197-y69wwy40	183	21	pragmatic	pragmatic	JJ
cord-016197-y69wwy40	183	22	and	and	CC
cord-016197-y69wwy40	183	23	essential	essential	JJ
cord-016197-y69wwy40	183	24	approach	approach	NN
cord-016197-y69wwy40	183	25	to	to	IN
cord-016197-y69wwy40	183	26	the	the	DT
cord-016197-y69wwy40	183	27	control	control	NN
cord-016197-y69wwy40	183	28	of	of	IN
cord-016197-y69wwy40	183	29	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	183	30	resistance	resistance	NN
cord-016197-y69wwy40	183	31	is	be	VBZ
cord-016197-y69wwy40	183	32	to	to	TO
cord-016197-y69wwy40	183	33	control	control	VB
cord-016197-y69wwy40	183	34	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	183	35	use	use	NN
cord-016197-y69wwy40	183	36	(	(	-LRB-
cord-016197-y69wwy40	183	37	Gould	Gould	NNP
cord-016197-y69wwy40	183	38	,	,	,
cord-016197-y69wwy40	183	39	1999	1999	CD
cord-016197-y69wwy40	183	40	)	)	-RRB-
cord-016197-y69wwy40	183	41	.	.	.
cord-016197-y69wwy40	184	1	He	-PRON-	PRP
cord-016197-y69wwy40	184	2	also	also	RB
cord-016197-y69wwy40	184	3	noted	note	VBD
cord-016197-y69wwy40	184	4	that	that	IN
cord-016197-y69wwy40	184	5	policies	policy	NNS
cord-016197-y69wwy40	184	6	can	can	MD
cord-016197-y69wwy40	184	7	be	be	VB
cord-016197-y69wwy40	184	8	efficacious	efficacious	JJ
cord-016197-y69wwy40	184	9	in	in	IN
cord-016197-y69wwy40	184	10	reducing	reduce	VBG
cord-016197-y69wwy40	184	11	costs	cost	NNS
cord-016197-y69wwy40	184	12	and	and	CC
cord-016197-y69wwy40	184	13	levels	level	NNS
cord-016197-y69wwy40	184	14	of	of	IN
cord-016197-y69wwy40	184	15	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	184	16	use	use	NN
cord-016197-y69wwy40	184	17	,	,	,
cord-016197-y69wwy40	184	18	but	but	CC
cord-016197-y69wwy40	184	19	the	the	DT
cord-016197-y69wwy40	184	20	subject	subject	NN
cord-016197-y69wwy40	184	21	of	of	IN
cord-016197-y69wwy40	184	22	debate	debate	NN
cord-016197-y69wwy40	184	23	is	be	VBZ
cord-016197-y69wwy40	184	24	whether	whether	IN
cord-016197-y69wwy40	184	25	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	184	26	control	control	NN
cord-016197-y69wwy40	184	27	measures	measure	NNS
cord-016197-y69wwy40	184	28	can	can	MD
cord-016197-y69wwy40	184	29	reduce	reduce	VB
cord-016197-y69wwy40	184	30	current	current	JJ
cord-016197-y69wwy40	184	31	levels	level	NNS
cord-016197-y69wwy40	184	32	of	of	IN
cord-016197-y69wwy40	184	33	resistance	resistance	NN
cord-016197-y69wwy40	184	34	rather	rather	RB
cord-016197-y69wwy40	184	35	than	than	IN
cord-016197-y69wwy40	184	36	just	just	RB
cord-016197-y69wwy40	184	37	halting	halt	VBG
cord-016197-y69wwy40	184	38	it	-PRON-	PRP
cord-016197-y69wwy40	184	39	.	.	.
cord-016197-y69wwy40	185	1	There	there	EX
cord-016197-y69wwy40	185	2	are	be	VBP
cord-016197-y69wwy40	185	3	examples	example	NNS
cord-016197-y69wwy40	185	4	where	where	WRB
cord-016197-y69wwy40	185	5	control	control	NN
cord-016197-y69wwy40	185	6	of	of	IN
cord-016197-y69wwy40	185	7	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	185	8	use	use	NN
cord-016197-y69wwy40	185	9	has	have	VBZ
cord-016197-y69wwy40	185	10	reduced	reduce	VBN
cord-016197-y69wwy40	185	11	the	the	DT
cord-016197-y69wwy40	185	12	incidence	incidence	NN
cord-016197-y69wwy40	185	13	of	of	IN
cord-016197-y69wwy40	185	14	outbreak	outbreak	NN
cord-016197-y69wwy40	185	15	and	and	CC
cord-016197-y69wwy40	185	16	resistant	resistant	JJ
cord-016197-y69wwy40	185	17	organisms	organism	NNS
cord-016197-y69wwy40	185	18	in	in	IN
cord-016197-y69wwy40	185	19	hospitals	hospital	NNS
cord-016197-y69wwy40	185	20	and	and	CC
cord-016197-y69wwy40	185	21	similar	similar	JJ
cord-016197-y69wwy40	185	22	examples	example	NNS
cord-016197-y69wwy40	185	23	where	where	WRB
cord-016197-y69wwy40	185	24	reduction	reduction	NN
cord-016197-y69wwy40	185	25	of	of	IN
cord-016197-y69wwy40	185	26	prescribing	prescribing	NN
cord-016197-y69wwy40	185	27	in	in	IN
cord-016197-y69wwy40	185	28	the	the	DT
cord-016197-y69wwy40	185	29	community	community	NN
cord-016197-y69wwy40	185	30	has	have	VBZ
cord-016197-y69wwy40	185	31	led	lead	VBN
cord-016197-y69wwy40	185	32	to	to	IN
cord-016197-y69wwy40	185	33	a	a	DT
cord-016197-y69wwy40	185	34	degree	degree	NN
cord-016197-y69wwy40	185	35	of	of	IN
cord-016197-y69wwy40	185	36	control	control	NN
cord-016197-y69wwy40	185	37	of	of	IN
cord-016197-y69wwy40	185	38	resistance	resistance	NN
cord-016197-y69wwy40	185	39	.	.	.
cord-016197-y69wwy40	186	1	There	there	EX
cord-016197-y69wwy40	186	2	are	be	VBP
cord-016197-y69wwy40	186	3	a	a	DT
cord-016197-y69wwy40	186	4	number	number	NN
cord-016197-y69wwy40	186	5	of	of	IN
cord-016197-y69wwy40	186	6	confounding	confounding	JJ
cord-016197-y69wwy40	186	7	factors	factor	NNS
cord-016197-y69wwy40	186	8	which	which	WDT
cord-016197-y69wwy40	186	9	make	make	VBP
cord-016197-y69wwy40	186	10	it	-PRON-	PRP
cord-016197-y69wwy40	186	11	difficult	difficult	JJ
cord-016197-y69wwy40	186	12	to	to	TO
cord-016197-y69wwy40	186	13	attribute	attribute	VB
cord-016197-y69wwy40	186	14	cause	cause	NN
cord-016197-y69wwy40	186	15	and	and	CC
cord-016197-y69wwy40	186	16	effect	effect	NN
cord-016197-y69wwy40	186	17	entirely	entirely	RB
cord-016197-y69wwy40	186	18	to	to	IN
cord-016197-y69wwy40	186	19	reduction	reduction	VB
cord-016197-y69wwy40	186	20	in	in	IN
cord-016197-y69wwy40	186	21	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	186	22	prescribing	prescribing	NN
cord-016197-y69wwy40	187	1	(	(	-LRB-
cord-016197-y69wwy40	187	2	Davey	Davey	NNP
cord-016197-y69wwy40	187	3	et	et	NNP
cord-016197-y69wwy40	187	4	al	al	NNP
cord-016197-y69wwy40	187	5	.	.	NNP
cord-016197-y69wwy40	187	6	,	,	,
cord-016197-y69wwy40	187	7	2003	2003	CD
cord-016197-y69wwy40	187	8	;	;	:
cord-016197-y69wwy40	187	9	Gould	Gould	NNP
cord-016197-y69wwy40	187	10	,	,	,
cord-016197-y69wwy40	187	11	1999	1999	CD
cord-016197-y69wwy40	187	12	)	)	-RRB-
cord-016197-y69wwy40	187	13	.	.	.
cord-016197-y69wwy40	188	1	Mathematical	mathematical	JJ
cord-016197-y69wwy40	188	2	modelling	modelling	NN
cord-016197-y69wwy40	188	3	seeks	seek	VBZ
cord-016197-y69wwy40	188	4	to	to	TO
cord-016197-y69wwy40	188	5	take	take	VB
cord-016197-y69wwy40	188	6	these	these	DT
cord-016197-y69wwy40	188	7	factors	factor	NNS
cord-016197-y69wwy40	188	8	into	into	IN
cord-016197-y69wwy40	188	9	account	account	NN
cord-016197-y69wwy40	188	10	and	and	CC
cord-016197-y69wwy40	188	11	,	,	,
cord-016197-y69wwy40	188	12	while	while	IN
cord-016197-y69wwy40	188	13	also	also	RB
cord-016197-y69wwy40	188	14	casting	cast	VBG
cord-016197-y69wwy40	188	15	doubts	doubt	NNS
cord-016197-y69wwy40	188	16	on	on	IN
cord-016197-y69wwy40	188	17	whether	whether	IN
cord-016197-y69wwy40	188	18	reduction	reduction	NN
cord-016197-y69wwy40	188	19	alone	alone	RB
cord-016197-y69wwy40	188	20	will	will	MD
cord-016197-y69wwy40	188	21	prevent	prevent	VB
cord-016197-y69wwy40	188	22	or	or	CC
cord-016197-y69wwy40	188	23	reduce	reduce	VB
cord-016197-y69wwy40	188	24	resistance	resistance	NN
cord-016197-y69wwy40	188	25	(	(	-LRB-
cord-016197-y69wwy40	188	26	Austin	Austin	NNP
cord-016197-y69wwy40	188	27	et	et	NNP
cord-016197-y69wwy40	188	28	al	al	NNP
cord-016197-y69wwy40	188	29	.	.	NNP
cord-016197-y69wwy40	188	30	,	,	,
cord-016197-y69wwy40	188	31	1999	1999	CD
cord-016197-y69wwy40	188	32	;	;	:
cord-016197-y69wwy40	188	33	Gould	Gould	NNP
cord-016197-y69wwy40	188	34	,	,	,
cord-016197-y69wwy40	188	35	1999	1999	CD
cord-016197-y69wwy40	188	36	)	)	-RRB-
cord-016197-y69wwy40	188	37	,	,	,
cord-016197-y69wwy40	188	38	may	may	MD
cord-016197-y69wwy40	188	39	help	help	VB
cord-016197-y69wwy40	188	40	with	with	IN
cord-016197-y69wwy40	188	41	future	future	JJ
cord-016197-y69wwy40	188	42	understanding	understanding	NN
cord-016197-y69wwy40	188	43	of	of	IN
cord-016197-y69wwy40	188	44	measures	measure	NNS
cord-016197-y69wwy40	188	45	which	which	WDT
cord-016197-y69wwy40	188	46	contribute	contribute	VBP
cord-016197-y69wwy40	188	47	to	to	IN
cord-016197-y69wwy40	188	48	or	or	CC
cord-016197-y69wwy40	188	49	reduce	reduce	VB
cord-016197-y69wwy40	188	50	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	188	51	resistance	resistance	NN
cord-016197-y69wwy40	188	52	,	,	,
cord-016197-y69wwy40	188	53	and	and	CC
cord-016197-y69wwy40	188	54	as	as	IN
cord-016197-y69wwy40	188	55	such	such	JJ
cord-016197-y69wwy40	188	56	should	should	MD
cord-016197-y69wwy40	188	57	be	be	VB
cord-016197-y69wwy40	188	58	encouraged	encourage	VBN
cord-016197-y69wwy40	188	59	.	.	.
cord-016197-y69wwy40	189	1	Use	use	NN
cord-016197-y69wwy40	189	2	of	of	IN
cord-016197-y69wwy40	189	3	this	this	DT
cord-016197-y69wwy40	189	4	approach	approach	NN
cord-016197-y69wwy40	189	5	to	to	TO
cord-016197-y69wwy40	189	6	define	define	VB
cord-016197-y69wwy40	189	7	policies	policy	NNS
cord-016197-y69wwy40	189	8	has	have	VBZ
cord-016197-y69wwy40	189	9	been	be	VBN
cord-016197-y69wwy40	189	10	limited	limit	VBN
cord-016197-y69wwy40	189	11	(	(	-LRB-
cord-016197-y69wwy40	189	12	if	if	IN
cord-016197-y69wwy40	189	13	used	use	VBN
cord-016197-y69wwy40	189	14	at	at	RB
cord-016197-y69wwy40	189	15	all	all	RB
cord-016197-y69wwy40	189	16	)	)	-RRB-
cord-016197-y69wwy40	190	1	(	(	-LRB-
cord-016197-y69wwy40	190	2	Davey	Davey	NNP
cord-016197-y69wwy40	190	3	et	et	NNP
cord-016197-y69wwy40	190	4	al	al	NNP
cord-016197-y69wwy40	190	5	.	.	NNP
cord-016197-y69wwy40	190	6	,	,	,
cord-016197-y69wwy40	190	7	2003	2003	CD
cord-016197-y69wwy40	190	8	)	)	-RRB-
cord-016197-y69wwy40	190	9	.	.	.
cord-016197-y69wwy40	191	1	Nevertheless	nevertheless	RB
cord-016197-y69wwy40	191	2	,	,	,
cord-016197-y69wwy40	191	3	policy	policy	NN
cord-016197-y69wwy40	191	4	decisions	decision	NNS
cord-016197-y69wwy40	191	5	should	should	MD
cord-016197-y69wwy40	191	6	be	be	VB
cord-016197-y69wwy40	191	7	supported	support	VBN
cord-016197-y69wwy40	191	8	by	by	IN
cord-016197-y69wwy40	191	9	evidence	evidence	NN
cord-016197-y69wwy40	191	10	,	,	,
cord-016197-y69wwy40	191	11	and	and	CC
cord-016197-y69wwy40	191	12	not	not	RB
cord-016197-y69wwy40	191	13	just	just	RB
cord-016197-y69wwy40	191	14	by	by	IN
cord-016197-y69wwy40	191	15	concerns	concern	NNS
cord-016197-y69wwy40	191	16	about	about	IN
cord-016197-y69wwy40	191	17	future	future	JJ
cord-016197-y69wwy40	191	18	development	development	NN
cord-016197-y69wwy40	191	19	of	of	IN
cord-016197-y69wwy40	191	20	resistance	resistance	NN
cord-016197-y69wwy40	191	21	or	or	CC
cord-016197-y69wwy40	191	22	the	the	DT
cord-016197-y69wwy40	191	23	desire	desire	NN
cord-016197-y69wwy40	191	24	to	to	TO
cord-016197-y69wwy40	191	25	reduce	reduce	VB
cord-016197-y69wwy40	191	26	costs	cost	NNS
cord-016197-y69wwy40	192	1	(	(	-LRB-
cord-016197-y69wwy40	192	2	Davey	Davey	NNP
cord-016197-y69wwy40	192	3	et	et	NNP
cord-016197-y69wwy40	192	4	al	al	NNP
cord-016197-y69wwy40	192	5	.	.	NNP
cord-016197-y69wwy40	192	6	,	,	,
cord-016197-y69wwy40	192	7	2003	2003	CD
cord-016197-y69wwy40	192	8	)	)	-RRB-
cord-016197-y69wwy40	192	9	.	.	.
cord-016197-y69wwy40	193	1	Importantly	importantly	RB
cord-016197-y69wwy40	193	2	,	,	,
cord-016197-y69wwy40	193	3	appropriate	appropriate	JJ
cord-016197-y69wwy40	193	4	use	use	NN
cord-016197-y69wwy40	193	5	of	of	IN
cord-016197-y69wwy40	193	6	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	193	7	needs	need	VBZ
cord-016197-y69wwy40	193	8	a	a	DT
cord-016197-y69wwy40	193	9	clear	clear	JJ
cord-016197-y69wwy40	193	10	definition	definition	NN
cord-016197-y69wwy40	193	11	.	.	.
cord-016197-y69wwy40	194	1	It	-PRON-	PRP
cord-016197-y69wwy40	194	2	is	be	VBZ
cord-016197-y69wwy40	194	3	recognized	recognize	VBN
cord-016197-y69wwy40	194	4	that	that	IN
cord-016197-y69wwy40	194	5	recommendations	recommendation	NNS
cord-016197-y69wwy40	194	6	and	and	CC
cord-016197-y69wwy40	194	7	guidelines	guideline	NNS
cord-016197-y69wwy40	194	8	should	should	MD
cord-016197-y69wwy40	194	9	emphasize	emphasize	VB
cord-016197-y69wwy40	194	10	that	that	IN
cord-016197-y69wwy40	194	11	the	the	DT
cord-016197-y69wwy40	194	12	role	role	NN
cord-016197-y69wwy40	194	13	of	of	IN
cord-016197-y69wwy40	194	14	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	194	15	is	be	VBZ
cord-016197-y69wwy40	194	16	for	for	IN
cord-016197-y69wwy40	194	17	treating	treat	VBG
cord-016197-y69wwy40	194	18	bacterial	bacterial	JJ
cord-016197-y69wwy40	194	19	infection	infection	NN
cord-016197-y69wwy40	194	20	,	,	,
cord-016197-y69wwy40	194	21	when	when	WRB
cord-016197-y69wwy40	194	22	known	know	VBN
cord-016197-y69wwy40	194	23	or	or	CC
cord-016197-y69wwy40	194	24	suspected	suspect	VBN
cord-016197-y69wwy40	194	25	(	(	-LRB-
cord-016197-y69wwy40	194	26	Ball	ball	NN
cord-016197-y69wwy40	194	27	et	et	FW
cord-016197-y69wwy40	194	28	al	al	NNP
cord-016197-y69wwy40	194	29	.	.	NNP
cord-016197-y69wwy40	194	30	,	,	,
cord-016197-y69wwy40	194	31	2002	2002	CD
cord-016197-y69wwy40	194	32	;	;	:
cord-016197-y69wwy40	195	1	Davey	Davey	NNP
cord-016197-y69wwy40	195	2	et	et	NNP
cord-016197-y69wwy40	195	3	al	al	NNP
cord-016197-y69wwy40	195	4	.	.	NNP
cord-016197-y69wwy40	195	5	,	,	,
cord-016197-y69wwy40	195	6	2003	2003	CD
cord-016197-y69wwy40	195	7	)	)	-RRB-
cord-016197-y69wwy40	195	8	.	.	.
cord-016197-y69wwy40	196	1	Use	use	NN
cord-016197-y69wwy40	196	2	of	of	IN
cord-016197-y69wwy40	196	3	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	196	4	outside	outside	RB
cord-016197-y69wwy40	196	5	of	of	IN
cord-016197-y69wwy40	196	6	this	this	DT
cord-016197-y69wwy40	196	7	scenario	scenario	NN
cord-016197-y69wwy40	196	8	is	be	VBZ
cord-016197-y69wwy40	196	9	unnecessary	unnecessary	JJ
cord-016197-y69wwy40	196	10	,	,	,
cord-016197-y69wwy40	196	11	contributes	contribute	VBZ
cord-016197-y69wwy40	196	12	to	to	IN
cord-016197-y69wwy40	196	13	overuse	overuse	NN
cord-016197-y69wwy40	196	14	and	and	CC
cord-016197-y69wwy40	196	15	is	be	VBZ
cord-016197-y69wwy40	196	16	an	an	DT
cord-016197-y69wwy40	196	17	avoidable	avoidable	JJ
cord-016197-y69wwy40	196	18	risk	risk	NN
cord-016197-y69wwy40	196	19	factor	factor	NN
cord-016197-y69wwy40	196	20	in	in	IN
cord-016197-y69wwy40	196	21	the	the	DT
cord-016197-y69wwy40	196	22	development	development	NN
cord-016197-y69wwy40	196	23	of	of	IN
cord-016197-y69wwy40	196	24	resistance	resistance	NN
cord-016197-y69wwy40	196	25	(	(	-LRB-
cord-016197-y69wwy40	196	26	Ball	Ball	NNP
cord-016197-y69wwy40	196	27	et	et	FW
cord-016197-y69wwy40	196	28	al	al	NNP
cord-016197-y69wwy40	196	29	.	.	NNP
cord-016197-y69wwy40	196	30	,	,	,
cord-016197-y69wwy40	196	31	2002	2002	CD
cord-016197-y69wwy40	196	32	;	;	:
cord-016197-y69wwy40	196	33	Davey	Davey	NNP
cord-016197-y69wwy40	196	34	et	et	NNP
cord-016197-y69wwy40	196	35	al	al	NNP
cord-016197-y69wwy40	196	36	.	.	NNP
cord-016197-y69wwy40	196	37	,	,	,
cord-016197-y69wwy40	196	38	2003	2003	CD
cord-016197-y69wwy40	196	39	)	)	-RRB-
cord-016197-y69wwy40	196	40	.	.	.
cord-016197-y69wwy40	197	1	However	however	RB
cord-016197-y69wwy40	197	2	,	,	,
cord-016197-y69wwy40	197	3	when	when	WRB
cord-016197-y69wwy40	197	4	use	use	NN
cord-016197-y69wwy40	197	5	of	of	IN
cord-016197-y69wwy40	197	6	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	197	7	is	be	VBZ
cord-016197-y69wwy40	197	8	warranted	warrant	VBN
cord-016197-y69wwy40	197	9	(	(	-LRB-
cord-016197-y69wwy40	197	10	necessary	necessary	JJ
cord-016197-y69wwy40	197	11	)	)	-RRB-
cord-016197-y69wwy40	197	12	to	to	TO
cord-016197-y69wwy40	197	13	treat	treat	VB
cord-016197-y69wwy40	197	14	bacterial	bacterial	JJ
cord-016197-y69wwy40	197	15	infection	infection	NN
cord-016197-y69wwy40	197	16	,	,	,
cord-016197-y69wwy40	197	17	such	such	JJ
cord-016197-y69wwy40	197	18	use	use	NN
cord-016197-y69wwy40	197	19	may	may	MD
cord-016197-y69wwy40	197	20	also	also	RB
cord-016197-y69wwy40	197	21	be	be	VB
cord-016197-y69wwy40	197	22	inappropriate	inappropriate	JJ
cord-016197-y69wwy40	197	23	or	or	CC
cord-016197-y69wwy40	197	24	suboptimal	suboptimal	JJ
cord-016197-y69wwy40	197	25	in	in	IN
cord-016197-y69wwy40	197	26	terms	term	NNS
cord-016197-y69wwy40	197	27	of	of	IN
cord-016197-y69wwy40	197	28	choice	choice	NN
cord-016197-y69wwy40	197	29	of	of	IN
cord-016197-y69wwy40	197	30	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	197	31	,	,	,
cord-016197-y69wwy40	197	32	dose	dose	NN
cord-016197-y69wwy40	197	33	,	,	,
cord-016197-y69wwy40	197	34	or	or	CC
cord-016197-y69wwy40	197	35	duration	duration	NN
cord-016197-y69wwy40	197	36	.	.	.
cord-016197-y69wwy40	198	1	For	for	IN
cord-016197-y69wwy40	198	2	example	example	NN
cord-016197-y69wwy40	198	3	,	,	,
cord-016197-y69wwy40	198	4	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	198	5	(	(	-LRB-
cord-016197-y69wwy40	198	6	2001	2001	CD
cord-016197-y69wwy40	198	7	)	)	-RRB-
cord-016197-y69wwy40	198	8	concluded	conclude	VBD
cord-016197-y69wwy40	198	9	that	that	IN
cord-016197-y69wwy40	198	10	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	198	11	misuse	misuse	NN
cord-016197-y69wwy40	198	12	does	do	VBZ
cord-016197-y69wwy40	198	13	have	have	VB
cord-016197-y69wwy40	198	14	an	an	DT
cord-016197-y69wwy40	198	15	impact	impact	NN
cord-016197-y69wwy40	198	16	on	on	IN
cord-016197-y69wwy40	198	17	promoting	promote	VBG
cord-016197-y69wwy40	198	18	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	198	19	resistance	resistance	NN
cord-016197-y69wwy40	198	20	,	,	,
cord-016197-y69wwy40	198	21	and	and	CC
cord-016197-y69wwy40	198	22	that	that	IN
cord-016197-y69wwy40	198	23	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	198	24	choice	choice	NN
cord-016197-y69wwy40	198	25	,	,	,
cord-016197-y69wwy40	198	26	dosage	dosage	NN
cord-016197-y69wwy40	198	27	,	,	,
cord-016197-y69wwy40	198	28	dosing	dose	VBG
cord-016197-y69wwy40	198	29	regimen	regimen	NN
cord-016197-y69wwy40	198	30	,	,	,
cord-016197-y69wwy40	198	31	or	or	CC
cord-016197-y69wwy40	198	32	duration	duration	NN
cord-016197-y69wwy40	198	33	of	of	IN
cord-016197-y69wwy40	198	34	therapy	therapy	NN
cord-016197-y69wwy40	198	35	must	must	MD
cord-016197-y69wwy40	198	36	also	also	RB
cord-016197-y69wwy40	198	37	,	,	,
cord-016197-y69wwy40	198	38	therefore	therefore	RB
cord-016197-y69wwy40	198	39	,	,	,
cord-016197-y69wwy40	198	40	be	be	VB
cord-016197-y69wwy40	198	41	considered	consider	VBN
cord-016197-y69wwy40	198	42	.	.	.
cord-016197-y69wwy40	199	1	Carbon	carbon	NN
cord-016197-y69wwy40	199	2	et	et	NNP
cord-016197-y69wwy40	199	3	al	al	NNP
cord-016197-y69wwy40	199	4	.	.	.
cord-016197-y69wwy40	200	1	(	(	-LRB-
cord-016197-y69wwy40	200	2	2002	2002	CD
cord-016197-y69wwy40	200	3	)	)	-RRB-
cord-016197-y69wwy40	200	4	suggested	suggest	VBD
cord-016197-y69wwy40	200	5	that	that	IN
cord-016197-y69wwy40	200	6	,	,	,
cord-016197-y69wwy40	200	7	for	for	IN
cord-016197-y69wwy40	200	8	now	now	RB
cord-016197-y69wwy40	200	9	,	,	,
cord-016197-y69wwy40	200	10	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	200	11	management	management	NN
cord-016197-y69wwy40	200	12	programmes	programme	NNS
cord-016197-y69wwy40	200	13	should	should	MD
cord-016197-y69wwy40	200	14	focus	focus	VB
cord-016197-y69wwy40	200	15	on	on	IN
cord-016197-y69wwy40	200	16	ensuring	ensure	VBG
cord-016197-y69wwy40	200	17	the	the	DT
cord-016197-y69wwy40	200	18	most	most	RBS
cord-016197-y69wwy40	200	19	appropriate	appropriate	JJ
cord-016197-y69wwy40	200	20	use	use	NN
cord-016197-y69wwy40	200	21	of	of	IN
cord-016197-y69wwy40	200	22	antimicrobials	antimicrobial	NNS
cord-016197-y69wwy40	200	23	rather	rather	RB
cord-016197-y69wwy40	200	24	than	than	IN
cord-016197-y69wwy40	200	25	simply	simply	RB
cord-016197-y69wwy40	200	26	on	on	IN
cord-016197-y69wwy40	200	27	limiting	limit	VBG
cord-016197-y69wwy40	200	28	use	use	NN
cord-016197-y69wwy40	200	29	or	or	CC
cord-016197-y69wwy40	200	30	choices	choice	NNS
cord-016197-y69wwy40	200	31	.	.	.
cord-016197-y69wwy40	201	1	A	a	DT
cord-016197-y69wwy40	201	2	Consensus	Consensus	NNP
cord-016197-y69wwy40	201	3	Group	Group	NNP
cord-016197-y69wwy40	201	4	(	(	-LRB-
cord-016197-y69wwy40	201	5	Ball	Ball	NNP
cord-016197-y69wwy40	201	6	et	et	FW
cord-016197-y69wwy40	201	7	al	al	NNP
cord-016197-y69wwy40	201	8	.	.	NNP
cord-016197-y69wwy40	201	9	,	,	,
cord-016197-y69wwy40	201	10	2002	2002	CD
cord-016197-y69wwy40	201	11	)	)	-RRB-
cord-016197-y69wwy40	201	12	has	have	VBZ
cord-016197-y69wwy40	201	13	recently	recently	RB
cord-016197-y69wwy40	201	14	identified	identify	VBN
cord-016197-y69wwy40	201	15	principles	principle	NNS
cord-016197-y69wwy40	201	16	for	for	IN
cord-016197-y69wwy40	201	17	appropriate	appropriate	JJ
cord-016197-y69wwy40	201	18	prescribing	prescribing	NN
cord-016197-y69wwy40	201	19	of	of	IN
cord-016197-y69wwy40	201	20	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	201	21	in	in	IN
cord-016197-y69wwy40	201	22	lower	low	JJR
cord-016197-y69wwy40	201	23	respiratory	respiratory	JJ
cord-016197-y69wwy40	201	24	tract	tract	NN
cord-016197-y69wwy40	201	25	infection	infection	NN
cord-016197-y69wwy40	201	26	with	with	IN
cord-016197-y69wwy40	201	27	which	which	WDT
cord-016197-y69wwy40	201	28	to	to	TO
cord-016197-y69wwy40	201	29	underlay	underlay	VB
cord-016197-y69wwy40	201	30	prescribing	prescribing	NN
cord-016197-y69wwy40	201	31	and	and	CC
cord-016197-y69wwy40	201	32	guideline	guideline	NN
cord-016197-y69wwy40	201	33	formulation	formulation	NN
cord-016197-y69wwy40	201	34	.	.	.
cord-016197-y69wwy40	202	1	These	these	DT
cord-016197-y69wwy40	202	2	principles	principle	NNS
cord-016197-y69wwy40	202	3	include	include	VBP
cord-016197-y69wwy40	202	4	:	:	:
cord-016197-y69wwy40	202	5	•	•	NN
cord-016197-y69wwy40	202	6	identification	identification	NN
cord-016197-y69wwy40	202	7	of	of	IN
cord-016197-y69wwy40	202	8	bacterial	bacterial	JJ
cord-016197-y69wwy40	202	9	infection	infection	NN
cord-016197-y69wwy40	202	10	by	by	IN
cord-016197-y69wwy40	202	11	optimized	optimize	VBN
cord-016197-y69wwy40	202	12	diagnosis	diagnosis	NN
cord-016197-y69wwy40	202	13	•	•	NN
cord-016197-y69wwy40	202	14	severity	severity	NN
cord-016197-y69wwy40	202	15	assessment	assessment	NN
cord-016197-y69wwy40	202	16	where	where	WRB
cord-016197-y69wwy40	202	17	relevant	relevant	JJ
cord-016197-y69wwy40	202	18	•	•	NN
cord-016197-y69wwy40	202	19	recognition	recognition	NN
cord-016197-y69wwy40	202	20	and	and	CC
cord-016197-y69wwy40	202	21	incorporation	incorporation	NN
cord-016197-y69wwy40	202	22	of	of	IN
cord-016197-y69wwy40	202	23	ambient	ambient	JJ
cord-016197-y69wwy40	202	24	resistance	resistance	NN
cord-016197-y69wwy40	202	25	data	datum	NNS
cord-016197-y69wwy40	203	1	•	•	NNP
cord-016197-y69wwy40	203	2	targeting	target	VBG
cord-016197-y69wwy40	203	3	bacterial	bacterial	JJ
cord-016197-y69wwy40	203	4	eradication	eradication	NN
cord-016197-y69wwy40	203	5	(	(	-LRB-
cord-016197-y69wwy40	203	6	or	or	CC
cord-016197-y69wwy40	203	7	maximal	maximal	JJ
cord-016197-y69wwy40	203	8	reduction	reduction	NN
cord-016197-y69wwy40	203	9	in	in	IN
cord-016197-y69wwy40	203	10	bacterial	bacterial	JJ
cord-016197-y69wwy40	203	11	load	load	NN
cord-016197-y69wwy40	203	12	)	)	-RRB-
cord-016197-y69wwy40	204	1	•	•	NNP
cord-016197-y69wwy40	204	2	use	use	NN
cord-016197-y69wwy40	204	3	of	of	IN
cord-016197-y69wwy40	204	4	pharmacodynamic	pharmacodynamic	JJ
cord-016197-y69wwy40	204	5	(	(	-LRB-
cord-016197-y69wwy40	204	6	PD	PD	NNP
cord-016197-y69wwy40	204	7	)	)	-RRB-
cord-016197-y69wwy40	204	8	indices	index	NNS
cord-016197-y69wwy40	204	9	to	to	TO
cord-016197-y69wwy40	204	10	optimize	optimize	VB
cord-016197-y69wwy40	204	11	choice	choice	NN
cord-016197-y69wwy40	204	12	and	and	CC
cord-016197-y69wwy40	204	13	dosage	dosage	VB
cord-016197-y69wwy40	204	14	•	•	NNP
cord-016197-y69wwy40	204	15	objective	objective	JJ
cord-016197-y69wwy40	204	16	assessment	assessment	NN
cord-016197-y69wwy40	204	17	of	of	IN
cord-016197-y69wwy40	204	18	true	true	JJ
cord-016197-y69wwy40	204	19	(	(	-LRB-
cord-016197-y69wwy40	204	20	overall	overall	JJ
cord-016197-y69wwy40	204	21	)	)	-RRB-
cord-016197-y69wwy40	204	22	costs	cost	NNS
cord-016197-y69wwy40	204	23	of	of	IN
cord-016197-y69wwy40	204	24	resistance	resistance	NN
cord-016197-y69wwy40	204	25	and	and	CC
cord-016197-y69wwy40	204	26	related	related	JJ
cord-016197-y69wwy40	204	27	treatment	treatment	NN
cord-016197-y69wwy40	204	28	failure	failure	NN
cord-016197-y69wwy40	204	29	.	.	.
cord-016197-y69wwy40	205	1	Guidelines	guideline	NNS
cord-016197-y69wwy40	205	2	,	,	,
cord-016197-y69wwy40	205	3	policies	policy	NNS
cord-016197-y69wwy40	205	4	,	,	,
cord-016197-y69wwy40	205	5	and	and	CC
cord-016197-y69wwy40	205	6	educational	educational	JJ
cord-016197-y69wwy40	205	7	campaigns	campaign	NNS
cord-016197-y69wwy40	205	8	should	should	MD
cord-016197-y69wwy40	205	9	seek	seek	VB
cord-016197-y69wwy40	205	10	to	to	TO
cord-016197-y69wwy40	205	11	better	better	RB
cord-016197-y69wwy40	205	12	define	define	VB
cord-016197-y69wwy40	205	13	,	,	,
cord-016197-y69wwy40	205	14	support	support	VB
cord-016197-y69wwy40	205	15	,	,	,
cord-016197-y69wwy40	205	16	and	and	CC
cord-016197-y69wwy40	205	17	implement	implement	VB
cord-016197-y69wwy40	205	18	appropriate	appropriate	JJ
cord-016197-y69wwy40	205	19	use	use	NN
cord-016197-y69wwy40	205	20	based	base	VBN
cord-016197-y69wwy40	205	21	on	on	IN
cord-016197-y69wwy40	205	22	principles	principle	NNS
cord-016197-y69wwy40	205	23	such	such	JJ
cord-016197-y69wwy40	205	24	as	as	IN
cord-016197-y69wwy40	205	25	those	those	DT
cord-016197-y69wwy40	205	26	from	from	IN
cord-016197-y69wwy40	205	27	the	the	DT
cord-016197-y69wwy40	205	28	Consensus	Consensus	NNP
cord-016197-y69wwy40	205	29	Group	Group	NNP
cord-016197-y69wwy40	205	30	(	(	-LRB-
cord-016197-y69wwy40	205	31	Ball	Ball	NNP
cord-016197-y69wwy40	205	32	et	et	FW
cord-016197-y69wwy40	205	33	al	al	NNP
cord-016197-y69wwy40	205	34	.	.	NNP
cord-016197-y69wwy40	205	35	,	,	,
cord-016197-y69wwy40	205	36	2002	2002	CD
cord-016197-y69wwy40	205	37	)	)	-RRB-
cord-016197-y69wwy40	205	38	.	.	.
cord-016197-y69wwy40	206	1	"	"	``
cord-016197-y69wwy40	206	2	Prudent	prudent	JJ
cord-016197-y69wwy40	206	3	"	"	''
cord-016197-y69wwy40	206	4	use	use	NN
cord-016197-y69wwy40	206	5	or	or	CC
cord-016197-y69wwy40	206	6	reduction	reduction	NN
cord-016197-y69wwy40	206	7	in	in	IN
cord-016197-y69wwy40	206	8	use	use	NN
cord-016197-y69wwy40	206	9	alone	alone	RB
cord-016197-y69wwy40	206	10	will	will	MD
cord-016197-y69wwy40	206	11	not	not	RB
cord-016197-y69wwy40	206	12	adequately	adequately	RB
cord-016197-y69wwy40	206	13	define	define	VB
cord-016197-y69wwy40	206	14	or	or	CC
cord-016197-y69wwy40	206	15	ensure	ensure	VB
cord-016197-y69wwy40	206	16	optimum	optimum	JJ
cord-016197-y69wwy40	206	17	or	or	CC
cord-016197-y69wwy40	206	18	appropriate	appropriate	JJ
cord-016197-y69wwy40	206	19	use	use	NN
cord-016197-y69wwy40	206	20	of	of	IN
cord-016197-y69wwy40	206	21	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	206	22	.	.	.
cord-016197-y69wwy40	207	1	The	the	DT
cord-016197-y69wwy40	207	2	definition	definition	NN
cord-016197-y69wwy40	207	3	and	and	CC
cord-016197-y69wwy40	207	4	implementation	implementation	NN
cord-016197-y69wwy40	207	5	of	of	IN
cord-016197-y69wwy40	207	6	appropriate	appropriate	JJ
cord-016197-y69wwy40	207	7	prescribing	prescribing	NN
cord-016197-y69wwy40	207	8	based	base	VBN
cord-016197-y69wwy40	207	9	on	on	IN
cord-016197-y69wwy40	207	10	evidence	evidence	NN
cord-016197-y69wwy40	207	11	-	-	HYPH
cord-016197-y69wwy40	207	12	based	base	VBN
cord-016197-y69wwy40	207	13	optimization	optimization	NN
cord-016197-y69wwy40	207	14	of	of	IN
cord-016197-y69wwy40	207	15	quality	quality	NN
cord-016197-y69wwy40	207	16	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	207	17	use	use	NN
cord-016197-y69wwy40	207	18	(	(	-LRB-
cord-016197-y69wwy40	207	19	right	right	JJ
cord-016197-y69wwy40	207	20	drug	drug	NN
cord-016197-y69wwy40	207	21	/	/	SYM
cord-016197-y69wwy40	207	22	dose	dose	NN
cord-016197-y69wwy40	207	23	/	/	SYM
cord-016197-y69wwy40	207	24	duration	duration	NN
cord-016197-y69wwy40	207	25	based	base	VBN
cord-016197-y69wwy40	207	26	on	on	IN
cord-016197-y69wwy40	207	27	PD	PD	NNP
cord-016197-y69wwy40	207	28	indices	index	NNS
cord-016197-y69wwy40	207	29	and	and	CC
cord-016197-y69wwy40	207	30	local	local	JJ
cord-016197-y69wwy40	207	31	resistance	resistance	NN
cord-016197-y69wwy40	207	32	patterns	pattern	NNS
cord-016197-y69wwy40	207	33	)	)	-RRB-
cord-016197-y69wwy40	207	34	,	,	,
cord-016197-y69wwy40	207	35	rather	rather	RB
cord-016197-y69wwy40	207	36	than	than	IN
cord-016197-y69wwy40	207	37	reduction	reduction	NN
cord-016197-y69wwy40	207	38	in	in	IN
cord-016197-y69wwy40	207	39	quantity	quantity	NN
cord-016197-y69wwy40	207	40	alone	alone	RB
cord-016197-y69wwy40	207	41	may	may	MD
cord-016197-y69wwy40	207	42	contribute	contribute	VB
cord-016197-y69wwy40	207	43	towards	towards	IN
cord-016197-y69wwy40	207	44	the	the	DT
cord-016197-y69wwy40	207	45	aim	aim	NN
cord-016197-y69wwy40	207	46	of	of	IN
cord-016197-y69wwy40	207	47	slowing	slow	VBG
cord-016197-y69wwy40	207	48	or	or	CC
cord-016197-y69wwy40	207	49	preventing	prevent	VBG
cord-016197-y69wwy40	207	50	the	the	DT
cord-016197-y69wwy40	207	51	emergence	emergence	NN
cord-016197-y69wwy40	207	52	of	of	IN
cord-016197-y69wwy40	207	53	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	207	54	resistance	resistance	NN
cord-016197-y69wwy40	207	55	,	,	,
cord-016197-y69wwy40	207	56	and	and	CC
cord-016197-y69wwy40	207	57	also	also	RB
cord-016197-y69wwy40	207	58	offer	offer	VB
cord-016197-y69wwy40	207	59	associated	associate	VBN
cord-016197-y69wwy40	207	60	cost	cost	NN
cord-016197-y69wwy40	207	61	and	and	CC
cord-016197-y69wwy40	207	62	efficiency	efficiency	NN
cord-016197-y69wwy40	207	63	benefits	benefit	NNS
cord-016197-y69wwy40	207	64	.	.	.
cord-016197-y69wwy40	208	1	Importantly	importantly	RB
cord-016197-y69wwy40	208	2	,	,	,
cord-016197-y69wwy40	208	3	this	this	DT
cord-016197-y69wwy40	208	4	approach	approach	NN
cord-016197-y69wwy40	208	5	may	may	MD
cord-016197-y69wwy40	208	6	also	also	RB
cord-016197-y69wwy40	208	7	maintain	maintain	VB
cord-016197-y69wwy40	208	8	an	an	DT
cord-016197-y69wwy40	208	9	environment	environment	NN
cord-016197-y69wwy40	208	10	that	that	WDT
cord-016197-y69wwy40	208	11	supports	support	VBZ
cord-016197-y69wwy40	208	12	the	the	DT
cord-016197-y69wwy40	208	13	use	use	NN
cord-016197-y69wwy40	208	14	of	of	IN
cord-016197-y69wwy40	208	15	new	new	JJ
cord-016197-y69wwy40	208	16	effective	effective	JJ
cord-016197-y69wwy40	208	17	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	208	18	and	and	CC
cord-016197-y69wwy40	208	19	a	a	DT
cord-016197-y69wwy40	208	20	commercial	commercial	JJ
cord-016197-y69wwy40	208	21	rationale	rationale	NN
cord-016197-y69wwy40	208	22	for	for	IN
cord-016197-y69wwy40	208	23	investment	investment	NN
cord-016197-y69wwy40	208	24	and	and	CC
cord-016197-y69wwy40	208	25	development	development	NN
cord-016197-y69wwy40	208	26	by	by	IN
cord-016197-y69wwy40	208	27	Pharma	Pharma	NNP
cord-016197-y69wwy40	208	28	.	.	.
cord-016197-y69wwy40	209	1	An	an	DT
cord-016197-y69wwy40	209	2	ill	ill	RB
cord-016197-y69wwy40	209	3	-	-	HYPH
cord-016197-y69wwy40	209	4	defined	define	VBN
cord-016197-y69wwy40	209	5	environment	environment	NN
cord-016197-y69wwy40	209	6	,	,	,
cord-016197-y69wwy40	209	7	focusing	focus	VBG
cord-016197-y69wwy40	209	8	on	on	IN
cord-016197-y69wwy40	209	9	the	the	DT
cord-016197-y69wwy40	209	10	need	need	NN
cord-016197-y69wwy40	209	11	to	to	TO
cord-016197-y69wwy40	209	12	reduce	reduce	VB
cord-016197-y69wwy40	209	13	quantity	quantity	NN
cord-016197-y69wwy40	209	14	with	with	IN
cord-016197-y69wwy40	209	15	little	little	JJ
cord-016197-y69wwy40	209	16	differentiation	differentiation	NN
cord-016197-y69wwy40	209	17	between	between	IN
cord-016197-y69wwy40	209	18	optimal	optimal	JJ
cord-016197-y69wwy40	209	19	and	and	CC
cord-016197-y69wwy40	209	20	suboptimal	suboptimal	JJ
cord-016197-y69wwy40	209	21	agents	agent	NNS
cord-016197-y69wwy40	209	22	is	be	VBZ
cord-016197-y69wwy40	209	23	not	not	RB
cord-016197-y69wwy40	209	24	conducive	conducive	JJ
cord-016197-y69wwy40	209	25	to	to	IN
cord-016197-y69wwy40	209	26	the	the	DT
cord-016197-y69wwy40	209	27	development	development	NN
cord-016197-y69wwy40	209	28	and	and	CC
cord-016197-y69wwy40	209	29	marketing	marketing	NN
cord-016197-y69wwy40	209	30	of	of	IN
cord-016197-y69wwy40	209	31	agents	agent	NNS
cord-016197-y69wwy40	209	32	with	with	IN
cord-016197-y69wwy40	209	33	improved	improved	JJ
cord-016197-y69wwy40	209	34	activity	activity	NN
cord-016197-y69wwy40	209	35	and	and	CC
cord-016197-y69wwy40	209	36	efficacy	efficacy	NN
cord-016197-y69wwy40	209	37	benefits	benefit	NNS
cord-016197-y69wwy40	209	38	.	.	.
cord-016197-y69wwy40	210	1	Increasing	increase	VBG
cord-016197-y69wwy40	210	2	development	development	NN
cord-016197-y69wwy40	210	3	costs	cost	NNS
cord-016197-y69wwy40	210	4	and	and	CC
cord-016197-y69wwy40	210	5	hurdles	hurdle	NNS
cord-016197-y69wwy40	210	6	and	and	CC
cord-016197-y69wwy40	210	7	shrinking	shrink	VBG
cord-016197-y69wwy40	210	8	market	market	NN
cord-016197-y69wwy40	210	9	sizes	size	NNS
cord-016197-y69wwy40	210	10	,	,	,
cord-016197-y69wwy40	210	11	means	mean	VBZ
cord-016197-y69wwy40	210	12	that	that	IN
cord-016197-y69wwy40	210	13	Pharma	Pharma	NNP
cord-016197-y69wwy40	210	14	has	have	VBZ
cord-016197-y69wwy40	210	15	to	to	TO
cord-016197-y69wwy40	210	16	get	get	VB
cord-016197-y69wwy40	210	17	more	more	JJR
cord-016197-y69wwy40	210	18	value	value	NN
cord-016197-y69wwy40	210	19	out	out	IN
cord-016197-y69wwy40	210	20	of	of	IN
cord-016197-y69wwy40	210	21	the	the	DT
cord-016197-y69wwy40	210	22	R&D	r&d	NN
cord-016197-y69wwy40	210	23	investment	investment	NN
cord-016197-y69wwy40	210	24	by	by	IN
cord-016197-y69wwy40	210	25	improving	improve	VBG
cord-016197-y69wwy40	210	26	productivity	productivity	NN
cord-016197-y69wwy40	210	27	,	,	,
cord-016197-y69wwy40	210	28	reducing	reduce	VBG
cord-016197-y69wwy40	210	29	development	development	NN
cord-016197-y69wwy40	210	30	timelines	timeline	NNS
cord-016197-y69wwy40	210	31	,	,	,
cord-016197-y69wwy40	210	32	reducing	reduce	VBG
cord-016197-y69wwy40	210	33	risk	risk	NN
cord-016197-y69wwy40	210	34	,	,	,
cord-016197-y69wwy40	210	35	and	and	CC
cord-016197-y69wwy40	210	36	increasing	increase	VBG
cord-016197-y69wwy40	210	37	the	the	DT
cord-016197-y69wwy40	210	38	value	value	NN
cord-016197-y69wwy40	210	39	of	of	IN
cord-016197-y69wwy40	210	40	agents	agent	NNS
cord-016197-y69wwy40	210	41	progressed	progress	VBD
cord-016197-y69wwy40	210	42	to	to	IN
cord-016197-y69wwy40	210	43	market	market	NN
cord-016197-y69wwy40	210	44	.	.	.
cord-016197-y69wwy40	211	1	In	in	IN
cord-016197-y69wwy40	211	2	the	the	DT
cord-016197-y69wwy40	211	3	case	case	NN
cord-016197-y69wwy40	211	4	of	of	IN
cord-016197-y69wwy40	211	5	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	211	6	,	,	,
cord-016197-y69wwy40	211	7	the	the	DT
cord-016197-y69wwy40	211	8	situation	situation	NN
cord-016197-y69wwy40	211	9	is	be	VBZ
cord-016197-y69wwy40	211	10	compounded	compound	VBN
cord-016197-y69wwy40	211	11	by	by	IN
cord-016197-y69wwy40	211	12	increasingly	increasingly	RB
cord-016197-y69wwy40	211	13	demanding	demand	VBG
cord-016197-y69wwy40	211	14	regulatory	regulatory	JJ
cord-016197-y69wwy40	211	15	policies	policy	NNS
cord-016197-y69wwy40	211	16	affecting	affect	VBG
cord-016197-y69wwy40	211	17	the	the	DT
cord-016197-y69wwy40	211	18	activities	activity	NNS
cord-016197-y69wwy40	211	19	required	require	VBN
cord-016197-y69wwy40	211	20	to	to	TO
cord-016197-y69wwy40	211	21	secure	secure	VB
cord-016197-y69wwy40	211	22	product	product	NN
cord-016197-y69wwy40	211	23	registration	registration	NN
cord-016197-y69wwy40	211	24	,	,	,
cord-016197-y69wwy40	211	25	the	the	DT
cord-016197-y69wwy40	211	26	product	product	NN
cord-016197-y69wwy40	211	27	label	label	NN
cord-016197-y69wwy40	211	28	and	and	CC
cord-016197-y69wwy40	211	29	clinical	clinical	JJ
cord-016197-y69wwy40	211	30	use	use	NN
cord-016197-y69wwy40	211	31	(	(	-LRB-
cord-016197-y69wwy40	211	32	Shlaes	Shlaes	NNP
cord-016197-y69wwy40	211	33	and	and	CC
cord-016197-y69wwy40	211	34	Ryan	Ryan	NNP
cord-016197-y69wwy40	211	35	,	,	,
cord-016197-y69wwy40	211	36	2003	2003	CD
cord-016197-y69wwy40	211	37	)	)	-RRB-
cord-016197-y69wwy40	211	38	.	.	.
cord-016197-y69wwy40	212	1	The	the	DT
cord-016197-y69wwy40	212	2	extent	extent	NN
cord-016197-y69wwy40	212	3	and	and	CC
cord-016197-y69wwy40	212	4	success	success	NN
cord-016197-y69wwy40	212	5	of	of	IN
cord-016197-y69wwy40	212	6	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	212	7	research	research	NN
cord-016197-y69wwy40	212	8	has	have	VBZ
cord-016197-y69wwy40	212	9	declined	decline	VBN
cord-016197-y69wwy40	212	10	(	(	-LRB-
cord-016197-y69wwy40	212	11	IDSA	IDSA	NNP
cord-016197-y69wwy40	212	12	,	,	,
cord-016197-y69wwy40	212	13	2003	2003	CD
cord-016197-y69wwy40	212	14	)	)	-RRB-
cord-016197-y69wwy40	212	15	and	and	CC
cord-016197-y69wwy40	212	16	is	be	VBZ
cord-016197-y69wwy40	212	17	partly	partly	RB
cord-016197-y69wwy40	212	18	a	a	DT
cord-016197-y69wwy40	212	19	reflection	reflection	NN
cord-016197-y69wwy40	212	20	of	of	IN
cord-016197-y69wwy40	212	21	its	-PRON-	PRP$
cord-016197-y69wwy40	212	22	relatively	relatively	RB
cord-016197-y69wwy40	212	23	low	low	JJ
cord-016197-y69wwy40	212	24	commercial	commercial	JJ
cord-016197-y69wwy40	212	25	attractiveness	attractiveness	NN
cord-016197-y69wwy40	212	26	compared	compare	VBN
cord-016197-y69wwy40	212	27	to	to	IN
cord-016197-y69wwy40	212	28	other	other	JJ
cord-016197-y69wwy40	212	29	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	212	30	areas	area	NNS
cord-016197-y69wwy40	212	31	.	.	.
cord-016197-y69wwy40	213	1	The	the	DT
cord-016197-y69wwy40	213	2	relative	relative	JJ
cord-016197-y69wwy40	213	3	return	return	NN
cord-016197-y69wwy40	213	4	on	on	IN
cord-016197-y69wwy40	213	5	investment	investment	NN
cord-016197-y69wwy40	213	6	(	(	-LRB-
cord-016197-y69wwy40	213	7	ROI	ROI	NNP
cord-016197-y69wwy40	213	8	)	)	-RRB-
cord-016197-y69wwy40	213	9	or	or	CC
cord-016197-y69wwy40	213	10	net	net	JJ
cord-016197-y69wwy40	213	11	present	present	JJ
cord-016197-y69wwy40	213	12	value	value	NN
cord-016197-y69wwy40	213	13	(	(	-LRB-
cord-016197-y69wwy40	213	14	NPV	NPV	NNP
cord-016197-y69wwy40	213	15	)	)	-RRB-
cord-016197-y69wwy40	213	16	of	of	IN
cord-016197-y69wwy40	213	17	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	213	18	is	be	VBZ
cord-016197-y69wwy40	213	19	a	a	DT
cord-016197-y69wwy40	213	20	reflection	reflection	NN
cord-016197-y69wwy40	213	21	of	of	IN
cord-016197-y69wwy40	213	22	the	the	DT
cord-016197-y69wwy40	213	23	market	market	NN
cord-016197-y69wwy40	213	24	size	size	NN
cord-016197-y69wwy40	213	25	and	and	CC
cord-016197-y69wwy40	213	26	chance	chance	NN
cord-016197-y69wwy40	213	27	of	of	IN
cord-016197-y69wwy40	213	28	success	success	NN
cord-016197-y69wwy40	213	29	in	in	IN
cord-016197-y69wwy40	213	30	capturing	capture	VBG
cord-016197-y69wwy40	213	31	a	a	DT
cord-016197-y69wwy40	213	32	commercially	commercially	RB
cord-016197-y69wwy40	213	33	acceptable	acceptable	JJ
cord-016197-y69wwy40	213	34	part	part	NN
cord-016197-y69wwy40	213	35	of	of	IN
cord-016197-y69wwy40	213	36	that	that	DT
cord-016197-y69wwy40	213	37	market	market	NN
cord-016197-y69wwy40	213	38	.	.	.
cord-016197-y69wwy40	214	1	This	this	DT
cord-016197-y69wwy40	214	2	important	important	JJ
cord-016197-y69wwy40	214	3	"	"	``
cord-016197-y69wwy40	214	4	market	market	NN
cord-016197-y69wwy40	214	5	share	share	NN
cord-016197-y69wwy40	214	6	"	"	''
cord-016197-y69wwy40	214	7	will	will	MD
cord-016197-y69wwy40	214	8	be	be	VB
cord-016197-y69wwy40	214	9	a	a	DT
cord-016197-y69wwy40	214	10	reflection	reflection	NN
cord-016197-y69wwy40	214	11	of	of	IN
cord-016197-y69wwy40	214	12	the	the	DT
cord-016197-y69wwy40	214	13	properties	property	NNS
cord-016197-y69wwy40	214	14	and	and	CC
cord-016197-y69wwy40	214	15	utility	utility	NN
cord-016197-y69wwy40	214	16	of	of	IN
cord-016197-y69wwy40	214	17	the	the	DT
cord-016197-y69wwy40	214	18	agents	agent	NNS
cord-016197-y69wwy40	214	19	along	along	IN
cord-016197-y69wwy40	214	20	with	with	IN
cord-016197-y69wwy40	214	21	the	the	DT
cord-016197-y69wwy40	214	22	success	success	NN
cord-016197-y69wwy40	214	23	of	of	IN
cord-016197-y69wwy40	214	24	marketing	marketing	NN
cord-016197-y69wwy40	214	25	activities	activity	NNS
cord-016197-y69wwy40	214	26	.	.	.
cord-016197-y69wwy40	215	1	Differentiation	differentiation	NN
cord-016197-y69wwy40	215	2	of	of	IN
cord-016197-y69wwy40	215	3	comparative	comparative	JJ
cord-016197-y69wwy40	215	4	benefits	benefit	NNS
cord-016197-y69wwy40	215	5	,	,	,
cord-016197-y69wwy40	215	6	such	such	JJ
cord-016197-y69wwy40	215	7	as	as	IN
cord-016197-y69wwy40	215	8	efficacy	efficacy	NN
cord-016197-y69wwy40	215	9	against	against	IN
cord-016197-y69wwy40	215	10	resistant	resistant	JJ
cord-016197-y69wwy40	215	11	organisms	organism	NNS
cord-016197-y69wwy40	215	12	,	,	,
cord-016197-y69wwy40	215	13	broader	broad	JJR
cord-016197-y69wwy40	215	14	spectrum	spectrum	NN
cord-016197-y69wwy40	215	15	of	of	IN
cord-016197-y69wwy40	215	16	pathogens	pathogen	NNS
cord-016197-y69wwy40	215	17	for	for	IN
cord-016197-y69wwy40	215	18	a	a	DT
cord-016197-y69wwy40	215	19	given	give	VBN
cord-016197-y69wwy40	215	20	indication	indication	NN
cord-016197-y69wwy40	215	21	,	,	,
cord-016197-y69wwy40	215	22	superior	superior	JJ
cord-016197-y69wwy40	215	23	efficacy	efficacy	NN
cord-016197-y69wwy40	215	24	over	over	IN
cord-016197-y69wwy40	215	25	commonly	commonly	RB
cord-016197-y69wwy40	215	26	used	use	VBN
cord-016197-y69wwy40	215	27	treatments	treatment	NNS
cord-016197-y69wwy40	215	28	,	,	,
cord-016197-y69wwy40	215	29	improved	improve	VBN
cord-016197-y69wwy40	215	30	dosage	dosage	NN
cord-016197-y69wwy40	215	31	regimens	regimen	NNS
cord-016197-y69wwy40	215	32	and	and	CC
cord-016197-y69wwy40	215	33	compliance	compliance	NN
cord-016197-y69wwy40	215	34	,	,	,
cord-016197-y69wwy40	215	35	or	or	CC
cord-016197-y69wwy40	215	36	better	well	JJR
cord-016197-y69wwy40	215	37	safety	safety	NN
cord-016197-y69wwy40	215	38	characteristics	characteristic	NNS
cord-016197-y69wwy40	215	39	are	be	VBP
cord-016197-y69wwy40	215	40	important	important	JJ
cord-016197-y69wwy40	215	41	features	feature	NNS
cord-016197-y69wwy40	215	42	in	in	IN
cord-016197-y69wwy40	215	43	marketing	market	VBG
cord-016197-y69wwy40	215	44	an	an	DT
cord-016197-y69wwy40	215	45	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	215	46	and	and	CC
cord-016197-y69wwy40	215	47	in	in	IN
cord-016197-y69wwy40	215	48	the	the	DT
cord-016197-y69wwy40	215	49	acceptance	acceptance	NN
cord-016197-y69wwy40	215	50	and	and	CC
cord-016197-y69wwy40	215	51	uptake	uptake	NN
cord-016197-y69wwy40	215	52	by	by	IN
cord-016197-y69wwy40	215	53	policy	policy	NN
cord-016197-y69wwy40	215	54	-	-	HYPH
cord-016197-y69wwy40	215	55	makers	maker	NNS
cord-016197-y69wwy40	215	56	and	and	CC
cord-016197-y69wwy40	215	57	in	in	IN
cord-016197-y69wwy40	215	58	the	the	DT
cord-016197-y69wwy40	215	59	demonstration	demonstration	NN
cord-016197-y69wwy40	215	60	of	of	IN
cord-016197-y69wwy40	215	61	cost	cost	NN
cord-016197-y69wwy40	215	62	-	-	HYPH
cord-016197-y69wwy40	215	63	benefits	benefit	NNS
cord-016197-y69wwy40	215	64	to	to	IN
cord-016197-y69wwy40	215	65	formularies	formulary	NNS
cord-016197-y69wwy40	215	66	.	.	.
cord-016197-y69wwy40	216	1	Policies	policy	NNS
cord-016197-y69wwy40	216	2	or	or	CC
cord-016197-y69wwy40	216	3	guidelines	guideline	NNS
cord-016197-y69wwy40	216	4	which	which	WDT
cord-016197-y69wwy40	216	5	decrease	decrease	VBP
cord-016197-y69wwy40	216	6	the	the	DT
cord-016197-y69wwy40	216	7	ability	ability	NN
cord-016197-y69wwy40	216	8	of	of	IN
cord-016197-y69wwy40	216	9	Pharma	Pharma	NNPS
cord-016197-y69wwy40	216	10	to	to	TO
cord-016197-y69wwy40	216	11	demonstrate	demonstrate	VB
cord-016197-y69wwy40	216	12	these	these	DT
cord-016197-y69wwy40	216	13	benefits	benefit	NNS
cord-016197-y69wwy40	216	14	,	,	,
cord-016197-y69wwy40	216	15	reduce	reduce	VB
cord-016197-y69wwy40	216	16	the	the	DT
cord-016197-y69wwy40	216	17	chance	chance	NN
cord-016197-y69wwy40	216	18	of	of	IN
cord-016197-y69wwy40	216	19	gaining	gain	VBG
cord-016197-y69wwy40	216	20	differentiated	differentiated	JJ
cord-016197-y69wwy40	216	21	label	label	NN
cord-016197-y69wwy40	216	22	indications	indication	NNS
cord-016197-y69wwy40	216	23	(	(	-LRB-
cord-016197-y69wwy40	216	24	such	such	JJ
cord-016197-y69wwy40	216	25	as	as	IN
cord-016197-y69wwy40	216	26	the	the	DT
cord-016197-y69wwy40	216	27	inclusion	inclusion	NN
cord-016197-y69wwy40	216	28	of	of	IN
cord-016197-y69wwy40	216	29	resistant	resistant	JJ
cord-016197-y69wwy40	216	30	organisms	organism	NNS
cord-016197-y69wwy40	216	31	)	)	-RRB-
cord-016197-y69wwy40	216	32	,	,	,
cord-016197-y69wwy40	216	33	or	or	CC
cord-016197-y69wwy40	216	34	restrict	restrict	VB
cord-016197-y69wwy40	216	35	usage	usage	NN
cord-016197-y69wwy40	216	36	to	to	IN
cord-016197-y69wwy40	216	37	limited	limited	JJ
cord-016197-y69wwy40	216	38	indications	indication	NNS
cord-016197-y69wwy40	216	39	(	(	-LRB-
cord-016197-y69wwy40	216	40	such	such	JJ
cord-016197-y69wwy40	216	41	as	as	IN
cord-016197-y69wwy40	216	42	only	only	RB
cord-016197-y69wwy40	216	43	to	to	IN
cord-016197-y69wwy40	216	44	resistant	resistant	JJ
cord-016197-y69wwy40	216	45	organisms	organism	NNS
cord-016197-y69wwy40	216	46	)	)	-RRB-
cord-016197-y69wwy40	216	47	will	will	MD
cord-016197-y69wwy40	216	48	negatively	negatively	RB
cord-016197-y69wwy40	216	49	impact	impact	VB
cord-016197-y69wwy40	216	50	NPVs	npv	NNS
cord-016197-y69wwy40	216	51	and	and	CC
cord-016197-y69wwy40	216	52	ROIs	roi	NNS
cord-016197-y69wwy40	216	53	for	for	IN
cord-016197-y69wwy40	216	54	new	new	JJ
cord-016197-y69wwy40	216	55	agents	agent	NNS
cord-016197-y69wwy40	216	56	.	.	.
cord-016197-y69wwy40	217	1	Development	development	NN
cord-016197-y69wwy40	217	2	of	of	IN
cord-016197-y69wwy40	217	3	an	an	DT
cord-016197-y69wwy40	217	4	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	217	5	agent	agent	NN
cord-016197-y69wwy40	217	6	for	for	IN
cord-016197-y69wwy40	217	7	restricted	restricted	JJ
cord-016197-y69wwy40	217	8	use	use	NN
cord-016197-y69wwy40	217	9	only	only	RB
cord-016197-y69wwy40	217	10	may	may	MD
cord-016197-y69wwy40	217	11	not	not	RB
cord-016197-y69wwy40	217	12	be	be	VB
cord-016197-y69wwy40	217	13	a	a	DT
cord-016197-y69wwy40	217	14	commercially	commercially	RB
cord-016197-y69wwy40	217	15	attractive	attractive	JJ
cord-016197-y69wwy40	217	16	proposition	proposition	NN
cord-016197-y69wwy40	217	17	for	for	IN
cord-016197-y69wwy40	217	18	Pharma	Pharma	NNP
cord-016197-y69wwy40	217	19	companies	company	NNS
cord-016197-y69wwy40	217	20	with	with	IN
cord-016197-y69wwy40	217	21	interests	interest	NNS
cord-016197-y69wwy40	217	22	in	in	IN
cord-016197-y69wwy40	217	23	other	other	JJ
cord-016197-y69wwy40	217	24	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	217	25	areas	area	NNS
cord-016197-y69wwy40	217	26	.	.	.
cord-016197-y69wwy40	218	1	In	in	IN
cord-016197-y69wwy40	218	2	order	order	NN
cord-016197-y69wwy40	218	3	for	for	IN
cord-016197-y69wwy40	218	4	Pharma	Pharma	NNP
cord-016197-y69wwy40	218	5	to	to	TO
cord-016197-y69wwy40	218	6	succeed	succeed	VB
cord-016197-y69wwy40	218	7	and	and	CC
cord-016197-y69wwy40	218	8	maintain	maintain	VB
cord-016197-y69wwy40	218	9	investment	investment	NN
cord-016197-y69wwy40	218	10	,	,	,
cord-016197-y69wwy40	218	11	hurdles	hurdle	NNS
cord-016197-y69wwy40	218	12	in	in	IN
cord-016197-y69wwy40	218	13	productivity	productivity	NN
cord-016197-y69wwy40	218	14	in	in	IN
cord-016197-y69wwy40	218	15	discovery	discovery	NN
cord-016197-y69wwy40	218	16	and	and	CC
cord-016197-y69wwy40	218	17	development	development	NN
cord-016197-y69wwy40	218	18	need	need	VBP
cord-016197-y69wwy40	218	19	to	to	TO
cord-016197-y69wwy40	218	20	be	be	VB
cord-016197-y69wwy40	218	21	overcome	overcome	VBN
cord-016197-y69wwy40	218	22	and	and	CC
cord-016197-y69wwy40	218	23	the	the	DT
cord-016197-y69wwy40	218	24	key	key	JJ
cord-016197-y69wwy40	218	25	issue	issue	NN
cord-016197-y69wwy40	218	26	of	of	IN
cord-016197-y69wwy40	218	27	ROI	ROI	NNP
cord-016197-y69wwy40	218	28	based	base	VBN
cord-016197-y69wwy40	218	29	on	on	IN
cord-016197-y69wwy40	218	30	product	product	NN
cord-016197-y69wwy40	218	31	benefits	benefit	NNS
cord-016197-y69wwy40	218	32	and	and	CC
cord-016197-y69wwy40	218	33	use	use	VB
cord-016197-y69wwy40	218	34	needs	need	NNS
cord-016197-y69wwy40	218	35	to	to	TO
cord-016197-y69wwy40	218	36	be	be	VB
cord-016197-y69wwy40	218	37	addressed	address	VBN
cord-016197-y69wwy40	218	38	.	.	.
cord-016197-y69wwy40	219	1	Although	although	IN
cord-016197-y69wwy40	219	2	policies	policy	NNS
cord-016197-y69wwy40	219	3	themselves	-PRON-	PRP
cord-016197-y69wwy40	219	4	do	do	VBP
cord-016197-y69wwy40	219	5	not	not	RB
cord-016197-y69wwy40	219	6	directly	directly	RB
cord-016197-y69wwy40	219	7	impact	impact	VB
cord-016197-y69wwy40	219	8	upon	upon	IN
cord-016197-y69wwy40	219	9	the	the	DT
cord-016197-y69wwy40	219	10	process	process	NN
cord-016197-y69wwy40	219	11	of	of	IN
cord-016197-y69wwy40	219	12	discovery	discovery	NN
cord-016197-y69wwy40	219	13	of	of	IN
cord-016197-y69wwy40	219	14	new	new	JJ
cord-016197-y69wwy40	219	15	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	219	16	,	,	,
cord-016197-y69wwy40	219	17	they	-PRON-	PRP
cord-016197-y69wwy40	219	18	do	do	VBP
cord-016197-y69wwy40	219	19	have	have	VB
cord-016197-y69wwy40	219	20	a	a	DT
cord-016197-y69wwy40	219	21	cumulative	cumulative	JJ
cord-016197-y69wwy40	219	22	negative	negative	JJ
cord-016197-y69wwy40	219	23	impact	impact	NN
cord-016197-y69wwy40	219	24	on	on	IN
cord-016197-y69wwy40	219	25	the	the	DT
cord-016197-y69wwy40	219	26	chance	chance	NN
cord-016197-y69wwy40	219	27	of	of	IN
cord-016197-y69wwy40	219	28	success	success	NN
cord-016197-y69wwy40	219	29	of	of	IN
cord-016197-y69wwy40	219	30	developing	develop	VBG
cord-016197-y69wwy40	219	31	and	and	CC
cord-016197-y69wwy40	219	32	marketing	market	VBG
cord-016197-y69wwy40	219	33	new	new	JJ
cord-016197-y69wwy40	219	34	differentiated	differentiated	JJ
cord-016197-y69wwy40	219	35	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	219	36	and	and	CC
cord-016197-y69wwy40	219	37	consequently	consequently	RB
cord-016197-y69wwy40	219	38	,	,	,
cord-016197-y69wwy40	219	39	the	the	DT
cord-016197-y69wwy40	219	40	willingness	willingness	NN
cord-016197-y69wwy40	219	41	of	of	IN
cord-016197-y69wwy40	219	42	companies	company	NNS
cord-016197-y69wwy40	219	43	to	to	TO
cord-016197-y69wwy40	219	44	initiate	initiate	VB
cord-016197-y69wwy40	219	45	or	or	CC
cord-016197-y69wwy40	219	46	continue	continue	VB
cord-016197-y69wwy40	219	47	investing	invest	VBG
cord-016197-y69wwy40	219	48	in	in	IN
cord-016197-y69wwy40	219	49	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	219	50	discovery	discovery	NN
cord-016197-y69wwy40	219	51	research	research	NN
cord-016197-y69wwy40	219	52	.	.	.
cord-016197-y69wwy40	220	1	The	the	DT
cord-016197-y69wwy40	220	2	urgent	urgent	JJ
cord-016197-y69wwy40	220	3	need	need	NN
cord-016197-y69wwy40	220	4	for	for	IN
cord-016197-y69wwy40	220	5	new	new	JJ
cord-016197-y69wwy40	220	6	classes	class	NNS
cord-016197-y69wwy40	220	7	of	of	IN
cord-016197-y69wwy40	220	8	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	220	9	has	have	VBZ
cord-016197-y69wwy40	220	10	,	,	,
cord-016197-y69wwy40	220	11	however	however	RB
cord-016197-y69wwy40	220	12	,	,	,
cord-016197-y69wwy40	220	13	increased	increase	VBD
cord-016197-y69wwy40	220	14	the	the	DT
cord-016197-y69wwy40	220	15	pressure	pressure	NN
cord-016197-y69wwy40	220	16	in	in	IN
cord-016197-y69wwy40	220	17	Pharma	Pharma	NNP
cord-016197-y69wwy40	220	18	to	to	TO
cord-016197-y69wwy40	220	19	maximize	maximize	VB
cord-016197-y69wwy40	220	20	efficiencies	efficiency	NNS
cord-016197-y69wwy40	220	21	in	in	IN
cord-016197-y69wwy40	220	22	identifying	identify	VBG
cord-016197-y69wwy40	220	23	new	new	JJ
cord-016197-y69wwy40	220	24	molecular	molecular	JJ
cord-016197-y69wwy40	220	25	targets	target	NNS
cord-016197-y69wwy40	220	26	for	for	IN
cord-016197-y69wwy40	220	27	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	220	28	and	and	CC
cord-016197-y69wwy40	220	29	compounds	compound	NNS
cord-016197-y69wwy40	220	30	active	active	JJ
cord-016197-y69wwy40	220	31	against	against	IN
cord-016197-y69wwy40	220	32	those	those	DT
cord-016197-y69wwy40	220	33	targets	target	NNS
cord-016197-y69wwy40	220	34	.	.	.
cord-016197-y69wwy40	221	1	Genomics	genomic	NNS
cord-016197-y69wwy40	221	2	and	and	CC
cord-016197-y69wwy40	221	3	high	high	JJ
cord-016197-y69wwy40	221	4	-	-	HYPH
cord-016197-y69wwy40	221	5	throughput	throughput	NN
cord-016197-y69wwy40	221	6	screening	screening	NN
cord-016197-y69wwy40	221	7	(	(	-LRB-
cord-016197-y69wwy40	221	8	HTS	HTS	NNP
cord-016197-y69wwy40	221	9	)	)	-RRB-
cord-016197-y69wwy40	221	10	offer	offer	VBP
cord-016197-y69wwy40	221	11	important	important	JJ
cord-016197-y69wwy40	221	12	potential	potential	JJ
cord-016197-y69wwy40	221	13	advances	advance	NNS
cord-016197-y69wwy40	221	14	in	in	IN
cord-016197-y69wwy40	221	15	this	this	DT
cord-016197-y69wwy40	221	16	area	area	NN
cord-016197-y69wwy40	221	17	.	.	.
cord-016197-y69wwy40	222	1	On	on	IN
cord-016197-y69wwy40	222	2	25	25	CD
cord-016197-y69wwy40	222	3	April	April	NNP
cord-016197-y69wwy40	222	4	1953	1953	CD
cord-016197-y69wwy40	222	5	Francis	Francis	NNP
cord-016197-y69wwy40	222	6	Crick	Crick	NNP
cord-016197-y69wwy40	222	7	and	and	CC
cord-016197-y69wwy40	222	8	James	James	NNP
cord-016197-y69wwy40	222	9	D.	D.	NNP
cord-016197-y69wwy40	222	10	Watson	Watson	NNP
cord-016197-y69wwy40	222	11	published	publish	VBD
cord-016197-y69wwy40	222	12	their	-PRON-	PRP$
cord-016197-y69wwy40	222	13	paper	paper	NN
cord-016197-y69wwy40	222	14	"	"	``
cord-016197-y69wwy40	222	15	Molecular	molecular	JJ
cord-016197-y69wwy40	222	16	structure	structure	NN
cord-016197-y69wwy40	222	17	of	of	IN
cord-016197-y69wwy40	222	18	nucleic	nucleic	JJ
cord-016197-y69wwy40	222	19	acids	acid	NNS
cord-016197-y69wwy40	222	20	"	"	''
cord-016197-y69wwy40	222	21	in	in	IN
cord-016197-y69wwy40	222	22	Nature	Nature	NNP
cord-016197-y69wwy40	222	23	(	(	-LRB-
cord-016197-y69wwy40	222	24	Watson	Watson	NNP
cord-016197-y69wwy40	222	25	and	and	CC
cord-016197-y69wwy40	222	26	Crick	Crick	NNP
cord-016197-y69wwy40	222	27	,	,	,
cord-016197-y69wwy40	222	28	1953	1953	CD
cord-016197-y69wwy40	222	29	)	)	-RRB-
cord-016197-y69wwy40	223	1	The	the	DT
cord-016197-y69wwy40	223	2	role	role	NN
cord-016197-y69wwy40	223	3	of	of	IN
cord-016197-y69wwy40	223	4	genomics	genomic	NNS
cord-016197-y69wwy40	223	5	in	in	IN
cord-016197-y69wwy40	223	6	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	223	7	discovery	discovery	NN
cord-016197-y69wwy40	223	8	should	should	MD
cord-016197-y69wwy40	223	9	be	be	VB
cord-016197-y69wwy40	223	10	considered	consider	VBN
cord-016197-y69wwy40	223	11	against	against	IN
cord-016197-y69wwy40	223	12	the	the	DT
cord-016197-y69wwy40	223	13	background	background	NN
cord-016197-y69wwy40	223	14	of	of	IN
cord-016197-y69wwy40	223	15	Pharma	Pharma	NNP
cord-016197-y69wwy40	223	16	's	's	POS
cord-016197-y69wwy40	223	17	efforts	effort	NNS
cord-016197-y69wwy40	223	18	over	over	IN
cord-016197-y69wwy40	223	19	many	many	JJ
cord-016197-y69wwy40	223	20	years	year	NNS
cord-016197-y69wwy40	223	21	in	in	IN
cord-016197-y69wwy40	223	22	fine	fine	RB
cord-016197-y69wwy40	223	23	-	-	HYPH
cord-016197-y69wwy40	223	24	tuning	tuning	VB
cord-016197-y69wwy40	223	25	the	the	DT
cord-016197-y69wwy40	223	26	existing	exist	VBG
cord-016197-y69wwy40	223	27	classes	class	NNS
cord-016197-y69wwy40	223	28	of	of	IN
cord-016197-y69wwy40	223	29	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	223	30	to	to	TO
cord-016197-y69wwy40	223	31	improve	improve	VB
cord-016197-y69wwy40	223	32	their	-PRON-	PRP$
cord-016197-y69wwy40	223	33	spectra	spectrum	NNS
cord-016197-y69wwy40	223	34	,	,	,
cord-016197-y69wwy40	223	35	efficacy	efficacy	NN
cord-016197-y69wwy40	223	36	,	,	,
cord-016197-y69wwy40	223	37	and	and	CC
cord-016197-y69wwy40	223	38	safety	safety	NN
cord-016197-y69wwy40	223	39	through	through	IN
cord-016197-y69wwy40	223	40	semisynthetic	semisynthetic	JJ
cord-016197-y69wwy40	223	41	and	and	CC
cord-016197-y69wwy40	223	42	wholly	wholly	RB
cord-016197-y69wwy40	223	43	synthetic	synthetic	JJ
cord-016197-y69wwy40	223	44	chemistry	chemistry	NN
cord-016197-y69wwy40	223	45	approaches	approach	NNS
cord-016197-y69wwy40	223	46	.	.	.
cord-016197-y69wwy40	224	1	Linezolid	Linezolid	NNP
cord-016197-y69wwy40	224	2	,	,	,
cord-016197-y69wwy40	224	3	an	an	DT
cord-016197-y69wwy40	224	4	oxazolidinone	oxazolidinone	NN
cord-016197-y69wwy40	224	5	,	,	,
cord-016197-y69wwy40	224	6	represented	represent	VBD
cord-016197-y69wwy40	224	7	the	the	DT
cord-016197-y69wwy40	224	8	first	first	JJ
cord-016197-y69wwy40	224	9	novel	novel	JJ
cord-016197-y69wwy40	224	10	compound	compound	NN
cord-016197-y69wwy40	224	11	class	class	NN
cord-016197-y69wwy40	224	12	introduced	introduce	VBN
cord-016197-y69wwy40	224	13	to	to	IN
cord-016197-y69wwy40	224	14	the	the	DT
cord-016197-y69wwy40	224	15	market	market	NN
cord-016197-y69wwy40	224	16	in	in	IN
cord-016197-y69wwy40	224	17	more	more	JJR
cord-016197-y69wwy40	224	18	than	than	IN
cord-016197-y69wwy40	224	19	25	25	CD
cord-016197-y69wwy40	224	20	years	year	NNS
cord-016197-y69wwy40	224	21	(	(	-LRB-
cord-016197-y69wwy40	224	22	Diekema	Diekema	NNP
cord-016197-y69wwy40	224	23	and	and	CC
cord-016197-y69wwy40	224	24	Jones	Jones	NNP
cord-016197-y69wwy40	224	25	,	,	,
cord-016197-y69wwy40	224	26	2000	2000	CD
cord-016197-y69wwy40	224	27	)	)	-RRB-
cord-016197-y69wwy40	224	28	.	.	.
cord-016197-y69wwy40	225	1	Traditional	traditional	JJ
cord-016197-y69wwy40	225	2	chemical	chemical	NN
cord-016197-y69wwy40	225	3	modification	modification	NN
cord-016197-y69wwy40	225	4	to	to	TO
cord-016197-y69wwy40	225	5	produce	produce	VB
cord-016197-y69wwy40	225	6	new	new	JJ
cord-016197-y69wwy40	225	7	members	member	NNS
cord-016197-y69wwy40	225	8	of	of	IN
cord-016197-y69wwy40	225	9	existing	exist	VBG
cord-016197-y69wwy40	225	10	classes	class	NNS
cord-016197-y69wwy40	225	11	has	have	VBZ
cord-016197-y69wwy40	225	12	resulted	result	VBN
cord-016197-y69wwy40	225	13	in	in	IN
cord-016197-y69wwy40	225	14	significant	significant	JJ
cord-016197-y69wwy40	225	15	improvements	improvement	NNS
cord-016197-y69wwy40	225	16	in	in	IN
cord-016197-y69wwy40	225	17	␤	␤	NNP
cord-016197-y69wwy40	225	18	-lactams	-lactam	NNS
cord-016197-y69wwy40	225	19	,	,	,
cord-016197-y69wwy40	225	20	macrolides	macrolide	NNS
cord-016197-y69wwy40	225	21	,	,	,
cord-016197-y69wwy40	225	22	and	and	CC
cord-016197-y69wwy40	225	23	fluoroquinolones	fluoroquinolone	NNS
cord-016197-y69wwy40	225	24	(	(	-LRB-
cord-016197-y69wwy40	225	25	e.g.	e.g.	RB
cord-016197-y69wwy40	225	26	,	,	,
cord-016197-y69wwy40	225	27	Rasmussen	Rasmussen	NNP
cord-016197-y69wwy40	225	28	and	and	CC
cord-016197-y69wwy40	225	29	Projan	Projan	NNP
cord-016197-y69wwy40	225	30	,	,	,
cord-016197-y69wwy40	225	31	2003	2003	CD
cord-016197-y69wwy40	225	32	)	)	-RRB-
cord-016197-y69wwy40	225	33	,	,	,
cord-016197-y69wwy40	225	34	but	but	CC
cord-016197-y69wwy40	225	35	has	have	VBZ
cord-016197-y69wwy40	225	36	been	be	VBN
cord-016197-y69wwy40	225	37	a	a	DT
cord-016197-y69wwy40	225	38	relatively	relatively	RB
cord-016197-y69wwy40	225	39	slow	slow	JJ
cord-016197-y69wwy40	225	40	and	and	CC
cord-016197-y69wwy40	225	41	labourintensive	labourintensive	NN
cord-016197-y69wwy40	225	42	process	process	NN
cord-016197-y69wwy40	225	43	with	with	IN
cord-016197-y69wwy40	225	44	limited	limited	JJ
cord-016197-y69wwy40	225	45	additional	additional	JJ
cord-016197-y69wwy40	225	46	success	success	NN
cord-016197-y69wwy40	225	47	in	in	IN
cord-016197-y69wwy40	225	48	recent	recent	JJ
cord-016197-y69wwy40	225	49	years	year	NNS
cord-016197-y69wwy40	225	50	.	.	.
cord-016197-y69wwy40	226	1	A	a	DT
cord-016197-y69wwy40	226	2	team	team	NN
cord-016197-y69wwy40	226	3	of	of	IN
cord-016197-y69wwy40	226	4	bench	bench	NN
cord-016197-y69wwy40	226	5	chemists	chemist	NNS
cord-016197-y69wwy40	226	6	in	in	IN
cord-016197-y69wwy40	226	7	the	the	DT
cord-016197-y69wwy40	226	8	1970s	1970	NNS
cord-016197-y69wwy40	226	9	might	may	MD
cord-016197-y69wwy40	226	10	produce	produce	VB
cord-016197-y69wwy40	226	11	up	up	IN
cord-016197-y69wwy40	226	12	to	to	TO
cord-016197-y69wwy40	226	13	30	30	CD
cord-016197-y69wwy40	226	14	novel	novel	NN
cord-016197-y69wwy40	226	15	compounds	compound	NNS
cord-016197-y69wwy40	226	16	each	each	DT
cord-016197-y69wwy40	226	17	per	per	IN
cord-016197-y69wwy40	226	18	annum	annum	NN
cord-016197-y69wwy40	226	19	for	for	IN
cord-016197-y69wwy40	226	20	biological	biological	JJ
cord-016197-y69wwy40	226	21	screening	screening	NN
cord-016197-y69wwy40	226	22	against	against	IN
cord-016197-y69wwy40	226	23	a	a	DT
cord-016197-y69wwy40	226	24	panel	panel	NN
cord-016197-y69wwy40	226	25	of	of	IN
cord-016197-y69wwy40	226	26	target	target	NN
cord-016197-y69wwy40	226	27	organisms	organism	NNS
cord-016197-y69wwy40	226	28	,	,	,
cord-016197-y69wwy40	226	29	resulting	result	VBG
cord-016197-y69wwy40	226	30	in	in	IN
cord-016197-y69wwy40	226	31	a	a	DT
cord-016197-y69wwy40	226	32	total	total	NN
cord-016197-y69wwy40	226	33	,	,	,
cord-016197-y69wwy40	226	34	perhaps	perhaps	RB
cord-016197-y69wwy40	226	35	of	of	IN
cord-016197-y69wwy40	226	36	hundreds	hundred	NNS
cord-016197-y69wwy40	226	37	of	of	IN
cord-016197-y69wwy40	226	38	compounds	compound	NNS
cord-016197-y69wwy40	226	39	being	be	VBG
cord-016197-y69wwy40	226	40	screened	screen	VBN
cord-016197-y69wwy40	226	41	.	.	.
cord-016197-y69wwy40	227	1	For	for	IN
cord-016197-y69wwy40	227	2	example	example	NN
cord-016197-y69wwy40	227	3	,	,	,
cord-016197-y69wwy40	227	4	methicillin	methicillin	NN
cord-016197-y69wwy40	227	5	,	,	,
cord-016197-y69wwy40	227	6	discovered	discover	VBN
cord-016197-y69wwy40	227	7	in	in	IN
cord-016197-y69wwy40	227	8	1960	1960	CD
cord-016197-y69wwy40	227	9	had	have	VBD
cord-016197-y69wwy40	227	10	a	a	DT
cord-016197-y69wwy40	227	11	Beecham	Beecham	NNP
cord-016197-y69wwy40	227	12	Research	Research	NNP
cord-016197-y69wwy40	227	13	number	number	NN
cord-016197-y69wwy40	227	14	of	of	IN
cord-016197-y69wwy40	227	15	BRL	BRL	NNP
cord-016197-y69wwy40	227	16	1241	1241	CD
cord-016197-y69wwy40	227	17	,	,	,
cord-016197-y69wwy40	227	18	and	and	CC
cord-016197-y69wwy40	227	19	was	be	VBD
cord-016197-y69wwy40	227	20	followed	follow	VBN
cord-016197-y69wwy40	227	21	by	by	IN
cord-016197-y69wwy40	227	22	many	many	JJ
cord-016197-y69wwy40	227	23	valuable	valuable	JJ
cord-016197-y69wwy40	227	24	semisynthetic	semisynthetic	JJ
cord-016197-y69wwy40	227	25	penicillins	penicillin	NNS
cord-016197-y69wwy40	227	26	over	over	IN
cord-016197-y69wwy40	227	27	the	the	DT
cord-016197-y69wwy40	227	28	next	next	JJ
cord-016197-y69wwy40	227	29	decade	decade	NN
cord-016197-y69wwy40	227	30	,	,	,
cord-016197-y69wwy40	227	31	notably	notably	RB
cord-016197-y69wwy40	227	32	ampicillin	ampicillin	NN
cord-016197-y69wwy40	227	33	(	(	-LRB-
cord-016197-y69wwy40	227	34	in	in	IN
cord-016197-y69wwy40	227	35	1961	1961	CD
cord-016197-y69wwy40	227	36	(	(	-LRB-
cord-016197-y69wwy40	227	37	in	in	IN
cord-016197-y69wwy40	227	38	)	)	-RRB-
cord-016197-y69wwy40	227	39	,	,	,
cord-016197-y69wwy40	227	40	carbenicillin	carbenicillin	NNP
cord-016197-y69wwy40	227	41	(	(	-LRB-
cord-016197-y69wwy40	227	42	1967	1967	CD
cord-016197-y69wwy40	227	43	(	(	-LRB-
cord-016197-y69wwy40	227	44	in	in	IN
cord-016197-y69wwy40	227	45	)	)	-RRB-
cord-016197-y69wwy40	227	46	,	,	,
cord-016197-y69wwy40	227	47	and	and	CC
cord-016197-y69wwy40	227	48	amoxicillin	amoxicillin	NNP
cord-016197-y69wwy40	227	49	,	,	,
cord-016197-y69wwy40	227	50	designated	designate	VBN
cord-016197-y69wwy40	227	51	BRL	BRL	NNP
cord-016197-y69wwy40	227	52	2333	2333	CD
cord-016197-y69wwy40	227	53	(	(	-LRB-
cord-016197-y69wwy40	227	54	in	in	IN
cord-016197-y69wwy40	227	55	(	(	-LRB-
cord-016197-y69wwy40	227	56	1972	1972	CD
cord-016197-y69wwy40	227	57	,	,	,
cord-016197-y69wwy40	227	58	indicating	indicate	VBG
cord-016197-y69wwy40	227	59	the	the	DT
cord-016197-y69wwy40	227	60	extent	extent	NN
cord-016197-y69wwy40	227	61	of	of	IN
cord-016197-y69wwy40	227	62	synthesis	synthesis	NN
cord-016197-y69wwy40	227	63	and	and	CC
cord-016197-y69wwy40	227	64	screening	screening	NN
cord-016197-y69wwy40	227	65	of	of	IN
cord-016197-y69wwy40	227	66	this	this	DT
cord-016197-y69wwy40	227	67	highly	highly	RB
cord-016197-y69wwy40	227	68	successful	successful	JJ
cord-016197-y69wwy40	227	69	semisynthetic	semisynthetic	JJ
cord-016197-y69wwy40	227	70	range	range	NN
cord-016197-y69wwy40	227	71	of	of	IN
cord-016197-y69wwy40	227	72	compounds	compound	NNS
cord-016197-y69wwy40	227	73	,	,	,
cord-016197-y69wwy40	227	74	at	at	IN
cord-016197-y69wwy40	227	75	approximately	approximately	RB
cord-016197-y69wwy40	227	76	100	100	CD
cord-016197-y69wwy40	227	77	per	per	IN
cord-016197-y69wwy40	227	78	year	year	NN
cord-016197-y69wwy40	227	79	.	.	.
cord-016197-y69wwy40	228	1	Unfortunately	unfortunately	RB
cord-016197-y69wwy40	228	2	,	,	,
cord-016197-y69wwy40	228	3	this	this	DT
cord-016197-y69wwy40	228	4	approach	approach	NN
cord-016197-y69wwy40	228	5	of	of	IN
cord-016197-y69wwy40	228	6	chemical	chemical	JJ
cord-016197-y69wwy40	228	7	modification	modification	NN
cord-016197-y69wwy40	228	8	based	base	VBN
cord-016197-y69wwy40	228	9	on	on	IN
cord-016197-y69wwy40	228	10	knowledge	knowledge	NN
cord-016197-y69wwy40	228	11	of	of	IN
cord-016197-y69wwy40	228	12	structure	structure	NN
cord-016197-y69wwy40	228	13	-	-	HYPH
cord-016197-y69wwy40	228	14	activity	activity	NN
cord-016197-y69wwy40	228	15	relationships	relationship	NNS
cord-016197-y69wwy40	228	16	combined	combine	VBN
cord-016197-y69wwy40	228	17	with	with	IN
cord-016197-y69wwy40	228	18	improvements	improvement	NNS
cord-016197-y69wwy40	228	19	in	in	IN
cord-016197-y69wwy40	228	20	throughputs	throughput	NNS
cord-016197-y69wwy40	228	21	of	of	IN
cord-016197-y69wwy40	228	22	screening	screening	NN
cord-016197-y69wwy40	228	23	has	have	VBZ
cord-016197-y69wwy40	228	24	failed	fail	VBN
cord-016197-y69wwy40	228	25	to	to	TO
cord-016197-y69wwy40	228	26	increase	increase	VB
cord-016197-y69wwy40	228	27	the	the	DT
cord-016197-y69wwy40	228	28	number	number	NN
cord-016197-y69wwy40	228	29	and	and	CC
cord-016197-y69wwy40	228	30	diversity	diversity	NN
cord-016197-y69wwy40	228	31	of	of	IN
cord-016197-y69wwy40	228	32	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	228	33	in	in	IN
cord-016197-y69wwy40	228	34	recent	recent	JJ
cord-016197-y69wwy40	228	35	times	time	NNS
cord-016197-y69wwy40	228	36	.	.	.
cord-016197-y69wwy40	229	1	Mills	Mills	NNP
cord-016197-y69wwy40	229	2	(	(	-LRB-
cord-016197-y69wwy40	229	3	2003	2003	CD
cord-016197-y69wwy40	229	4	)	)	-RRB-
cord-016197-y69wwy40	229	5	describes	describe	VBZ
cord-016197-y69wwy40	229	6	genomics	genomics	NN
cord-016197-y69wwy40	229	7	-	-	HYPH
cord-016197-y69wwy40	229	8	related	relate	VBN
cord-016197-y69wwy40	229	9	technologies	technology	NNS
cord-016197-y69wwy40	229	10	as	as	IN
cord-016197-y69wwy40	229	11	they	-PRON-	PRP
cord-016197-y69wwy40	229	12	are	be	VBP
cord-016197-y69wwy40	229	13	currently	currently	RB
cord-016197-y69wwy40	229	14	applied	apply	VBN
cord-016197-y69wwy40	229	15	to	to	IN
cord-016197-y69wwy40	229	16	the	the	DT
cord-016197-y69wwy40	229	17	discovery	discovery	NN
cord-016197-y69wwy40	229	18	of	of	IN
cord-016197-y69wwy40	229	19	small	small	JJ
cord-016197-y69wwy40	229	20	molecule	molecule	NN
cord-016197-y69wwy40	229	21	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	229	22	therapies	therapy	NNS
cord-016197-y69wwy40	229	23	.	.	.
cord-016197-y69wwy40	230	1	With	with	IN
cord-016197-y69wwy40	230	2	respect	respect	NN
cord-016197-y69wwy40	230	3	to	to	IN
cord-016197-y69wwy40	230	4	microbial	microbial	JJ
cord-016197-y69wwy40	230	5	genomics	genomic	NNS
cord-016197-y69wwy40	230	6	,	,	,
cord-016197-y69wwy40	230	7	the	the	DT
cord-016197-y69wwy40	230	8	DNA	dna	NN
cord-016197-y69wwy40	230	9	sequence	sequence	NN
cord-016197-y69wwy40	230	10	of	of	IN
cord-016197-y69wwy40	230	11	Haemophilus	haemophilus	JJ
cord-016197-y69wwy40	230	12	influenzae	influenzae	NN
cord-016197-y69wwy40	230	13	was	be	VBD
cord-016197-y69wwy40	230	14	published	publish	VBN
cord-016197-y69wwy40	230	15	in	in	IN
cord-016197-y69wwy40	230	16	1995	1995	CD
cord-016197-y69wwy40	230	17	(	(	-LRB-
cord-016197-y69wwy40	230	18	the	the	DT
cord-016197-y69wwy40	230	19	first	first	JJ
cord-016197-y69wwy40	230	20	free	free	RB
cord-016197-y69wwy40	230	21	-	-	HYPH
cord-016197-y69wwy40	230	22	living	live	VBG
cord-016197-y69wwy40	230	23	whole	whole	JJ
cord-016197-y69wwy40	230	24	-	-	HYPH
cord-016197-y69wwy40	230	25	organism	organism	NN
cord-016197-y69wwy40	230	26	sequence	sequence	NN
cord-016197-y69wwy40	230	27	)	)	-RRB-
cord-016197-y69wwy40	230	28	,	,	,
cord-016197-y69wwy40	230	29	followed	follow	VBN
cord-016197-y69wwy40	230	30	by	by	IN
cord-016197-y69wwy40	230	31	Mycoplasma	Mycoplasma	NNP
cord-016197-y69wwy40	230	32	genitalium	genitalium	NN
cord-016197-y69wwy40	230	33	and	and	CC
cord-016197-y69wwy40	230	34	many	many	JJ
cord-016197-y69wwy40	230	35	other	other	JJ
cord-016197-y69wwy40	230	36	sequenced	sequence	VBN
cord-016197-y69wwy40	230	37	complete	complete	JJ
cord-016197-y69wwy40	230	38	bacterial	bacterial	JJ
cord-016197-y69wwy40	230	39	genomes	genome	NNS
cord-016197-y69wwy40	230	40	,	,	,
cord-016197-y69wwy40	230	41	of	of	IN
cord-016197-y69wwy40	230	42	which	which	WDT
cord-016197-y69wwy40	230	43	79	79	CD
cord-016197-y69wwy40	230	44	are	be	VBP
cord-016197-y69wwy40	230	45	publicly	publicly	RB
cord-016197-y69wwy40	230	46	available	available	JJ
cord-016197-y69wwy40	230	47	,	,	,
cord-016197-y69wwy40	230	48	including	include	VBG
cord-016197-y69wwy40	230	49	those	those	DT
cord-016197-y69wwy40	230	50	of	of	IN
cord-016197-y69wwy40	230	51	more	more	JJR
cord-016197-y69wwy40	230	52	than	than	IN
cord-016197-y69wwy40	230	53	40	40	CD
cord-016197-y69wwy40	230	54	human	human	JJ
cord-016197-y69wwy40	230	55	pathogens	pathogen	NNS
cord-016197-y69wwy40	230	56	.	.	.
cord-016197-y69wwy40	231	1	The	the	DT
cord-016197-y69wwy40	231	2	process	process	NN
cord-016197-y69wwy40	231	3	of	of	IN
cord-016197-y69wwy40	231	4	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	231	5	discovery	discovery	NN
cord-016197-y69wwy40	231	6	through	through	IN
cord-016197-y69wwy40	231	7	genomics	genomic	NNS
cord-016197-y69wwy40	231	8	revolves	revolve	VBZ
cord-016197-y69wwy40	231	9	around	around	IN
cord-016197-y69wwy40	231	10	the	the	DT
cord-016197-y69wwy40	231	11	"	"	``
cord-016197-y69wwy40	231	12	minimum	minimum	JJ
cord-016197-y69wwy40	231	13	gene	gene	NN
cord-016197-y69wwy40	231	14	set	set	VBN
cord-016197-y69wwy40	231	15	for	for	IN
cord-016197-y69wwy40	231	16	cellular	cellular	JJ
cord-016197-y69wwy40	231	17	life	life	NN
cord-016197-y69wwy40	231	18	hypothesis	hypothesis	NN
cord-016197-y69wwy40	231	19	"	"	''
cord-016197-y69wwy40	231	20	(	(	-LRB-
cord-016197-y69wwy40	231	21	Koonin	Koonin	NNP
cord-016197-y69wwy40	231	22	,	,	,
cord-016197-y69wwy40	231	23	2000	2000	CD
cord-016197-y69wwy40	231	24	;	;	:
cord-016197-y69wwy40	231	25	Mills	Mills	NNPS
cord-016197-y69wwy40	231	26	,	,	,
cord-016197-y69wwy40	231	27	2003	2003	CD
cord-016197-y69wwy40	231	28	)	)	-RRB-
cord-016197-y69wwy40	231	29	and	and	CC
cord-016197-y69wwy40	231	30	a	a	DT
cord-016197-y69wwy40	231	31	number	number	NN
cord-016197-y69wwy40	231	32	of	of	IN
cord-016197-y69wwy40	231	33	defined	define	VBN
cord-016197-y69wwy40	231	34	stages	stage	NNS
cord-016197-y69wwy40	231	35	in	in	IN
cord-016197-y69wwy40	231	36	the	the	DT
cord-016197-y69wwy40	231	37	process	process	NN
cord-016197-y69wwy40	231	38	.	.	.
cord-016197-y69wwy40	232	1	(	(	-LRB-
cord-016197-y69wwy40	232	2	a	a	LS
cord-016197-y69wwy40	232	3	)	)	-RRB-
cord-016197-y69wwy40	232	4	genome	genome	NN
cord-016197-y69wwy40	232	5	-	-	HYPH
cord-016197-y69wwy40	232	6	scale	scale	NN
cord-016197-y69wwy40	232	7	transposon	transposon	NN
cord-016197-y69wwy40	232	8	mutagenesis	mutagenesis	NN
cord-016197-y69wwy40	232	9	to	to	TO
cord-016197-y69wwy40	232	10	identify	identify	VB
cord-016197-y69wwy40	232	11	all	all	DT
cord-016197-y69wwy40	232	12	non	non	JJ
cord-016197-y69wwy40	232	13	-	-	JJ
cord-016197-y69wwy40	232	14	essential	essential	JJ
cord-016197-y69wwy40	232	15	genes	gene	NNS
cord-016197-y69wwy40	233	1	(	(	-LRB-
cord-016197-y69wwy40	233	2	inferring	infer	VBG
cord-016197-y69wwy40	233	3	essential	essential	JJ
cord-016197-y69wwy40	233	4	genes	gene	NNS
cord-016197-y69wwy40	233	5	)	)	-RRB-
cord-016197-y69wwy40	233	6	;	;	:
cord-016197-y69wwy40	233	7	(	(	-LRB-
cord-016197-y69wwy40	233	8	b	b	NN
cord-016197-y69wwy40	233	9	)	)	-RRB-
cord-016197-y69wwy40	233	10	expression	expression	NN
cord-016197-y69wwy40	233	11	of	of	IN
cord-016197-y69wwy40	233	12	anti	anti	JJ
cord-016197-y69wwy40	233	13	-	-	JJ
cord-016197-y69wwy40	233	14	sense	sense	JJ
cord-016197-y69wwy40	233	15	RNA	RNA	NNP
cord-016197-y69wwy40	233	16	to	to	TO
cord-016197-y69wwy40	233	17	probe	probe	VB
cord-016197-y69wwy40	233	18	suspected	suspect	VBN
cord-016197-y69wwy40	233	19	essential	essential	JJ
cord-016197-y69wwy40	233	20	genes	gene	NNS
cord-016197-y69wwy40	233	21	,	,	,
cord-016197-y69wwy40	233	22	and	and	CC
cord-016197-y69wwy40	233	23	knocking	knock	VBG
cord-016197-y69wwy40	233	24	out	out	RP
cord-016197-y69wwy40	233	25	conserved	conserve	VBN
cord-016197-y69wwy40	233	26	genes	gene	NNS
cord-016197-y69wwy40	233	27	of	of	IN
cord-016197-y69wwy40	233	28	unknown	unknown	JJ
cord-016197-y69wwy40	233	29	function	function	NN
cord-016197-y69wwy40	233	30	to	to	TO
cord-016197-y69wwy40	233	31	identify	identify	VB
cord-016197-y69wwy40	233	32	novel	novel	JJ
cord-016197-y69wwy40	233	33	"	"	``
cord-016197-y69wwy40	233	34	broad	broad	JJ
cord-016197-y69wwy40	233	35	-	-	HYPH
cord-016197-y69wwy40	233	36	spectrum	spectrum	NN
cord-016197-y69wwy40	233	37	"	"	``
cord-016197-y69wwy40	233	38	essential	essential	JJ
cord-016197-y69wwy40	233	39	genes	gene	NNS
cord-016197-y69wwy40	233	40	.	.	.
cord-016197-y69wwy40	234	1	2	2	LS
cord-016197-y69wwy40	234	2	.	.	.
cord-016197-y69wwy40	235	1	Identification	identification	NN
cord-016197-y69wwy40	235	2	of	of	IN
cord-016197-y69wwy40	235	3	target	target	NN
cord-016197-y69wwy40	235	4	genes	gene	NNS
cord-016197-y69wwy40	235	5	:	:	:
cord-016197-y69wwy40	235	6	(	(	-LRB-
cord-016197-y69wwy40	235	7	a	a	LS
cord-016197-y69wwy40	235	8	)	)	-RRB-
cord-016197-y69wwy40	235	9	select	select	JJ
cord-016197-y69wwy40	235	10	target	target	NN
cord-016197-y69wwy40	235	11	gene	gene	NN
cord-016197-y69wwy40	235	12	either	either	CC
cord-016197-y69wwy40	235	13	as	as	IN
cord-016197-y69wwy40	235	14	narrow	narrow	JJ
cord-016197-y69wwy40	235	15	-	-	HYPH
cord-016197-y69wwy40	235	16	or	or	CC
cord-016197-y69wwy40	235	17	broad	broad	JJ
cord-016197-y69wwy40	235	18	-	-	HYPH
cord-016197-y69wwy40	235	19	spectrum	spectrum	NN
cord-016197-y69wwy40	235	20	by	by	IN
cord-016197-y69wwy40	235	21	specific	specific	JJ
cord-016197-y69wwy40	235	22	conservation	conservation	NN
cord-016197-y69wwy40	235	23	profile	profile	NN
cord-016197-y69wwy40	235	24	based	base	VBN
cord-016197-y69wwy40	235	25	on	on	IN
cord-016197-y69wwy40	235	26	comparative	comparative	JJ
cord-016197-y69wwy40	235	27	genomic	genomic	JJ
cord-016197-y69wwy40	235	28	analysis	analysis	NN
cord-016197-y69wwy40	235	29	;	;	:
cord-016197-y69wwy40	235	30	(	(	-LRB-
cord-016197-y69wwy40	235	31	b	b	LS
cord-016197-y69wwy40	235	32	)	)	-RRB-
cord-016197-y69wwy40	235	33	prove	prove	VB
cord-016197-y69wwy40	235	34	essential	essential	JJ
cord-016197-y69wwy40	235	35	for	for	IN
cord-016197-y69wwy40	235	36	in	in	FW
cord-016197-y69wwy40	235	37	vitro	vitro	FW
cord-016197-y69wwy40	235	38	growth	growth	NN
cord-016197-y69wwy40	235	39	,	,	,
cord-016197-y69wwy40	235	40	for	for	IN
cord-016197-y69wwy40	235	41	example	example	NN
cord-016197-y69wwy40	235	42	,	,	,
cord-016197-y69wwy40	235	43	by	by	IN
cord-016197-y69wwy40	235	44	gene	gene	NN
cord-016197-y69wwy40	235	45	knockout	knockout	NN
cord-016197-y69wwy40	235	46	in	in	IN
cord-016197-y69wwy40	235	47	relevant	relevant	JJ
cord-016197-y69wwy40	235	48	bacteria	bacteria	NNS
cord-016197-y69wwy40	235	49	;	;	,
cord-016197-y69wwy40	235	50	(	(	-LRB-
cord-016197-y69wwy40	235	51	c	c	NN
cord-016197-y69wwy40	235	52	)	)	-RRB-
cord-016197-y69wwy40	235	53	clone	clone	NN
cord-016197-y69wwy40	235	54	and	and	CC
cord-016197-y69wwy40	235	55	sequence	sequence	NN
cord-016197-y69wwy40	235	56	gene	gene	NN
cord-016197-y69wwy40	235	57	and	and	CC
cord-016197-y69wwy40	235	58	optimally	optimally	RB
cord-016197-y69wwy40	235	59	express	express	VB
cord-016197-y69wwy40	235	60	protein	protein	NN
cord-016197-y69wwy40	235	61	product	product	NN
cord-016197-y69wwy40	235	62	;	;	,
cord-016197-y69wwy40	235	63	(	(	-LRB-
cord-016197-y69wwy40	235	64	d	d	LS
cord-016197-y69wwy40	235	65	)	)	-RRB-
cord-016197-y69wwy40	235	66	purify	purify	VB
cord-016197-y69wwy40	235	67	and	and	CC
cord-016197-y69wwy40	235	68	develop	develop	VB
cord-016197-y69wwy40	235	69	assay	assay	NN
cord-016197-y69wwy40	235	70	,	,	,
cord-016197-y69wwy40	235	71	and	and	CC
cord-016197-y69wwy40	235	72	screen	screen	NN
cord-016197-y69wwy40	235	73	and	and	CC
cord-016197-y69wwy40	235	74	identify	identify	VB
cord-016197-y69wwy40	235	75	target	target	NN
cord-016197-y69wwy40	235	76	inhibitors	inhibitor	NNS
cord-016197-y69wwy40	235	77	"	"	``
cord-016197-y69wwy40	235	78	hits	hit	NNS
cord-016197-y69wwy40	235	79	"	"	''
cord-016197-y69wwy40	235	80	;	;	,
cord-016197-y69wwy40	235	81	(	(	-LRB-
cord-016197-y69wwy40	235	82	e	e	LS
cord-016197-y69wwy40	235	83	)	)	-RRB-
cord-016197-y69wwy40	235	84	characterize	characterize	VB
cord-016197-y69wwy40	235	85	hits	hit	NNS
cord-016197-y69wwy40	235	86	in	in	IN
cord-016197-y69wwy40	235	87	terms	term	NNS
cord-016197-y69wwy40	235	88	of	of	IN
cord-016197-y69wwy40	235	89	potency	potency	NN
cord-016197-y69wwy40	235	90	,	,	,
cord-016197-y69wwy40	235	91	mechanism	mechanism	NN
cord-016197-y69wwy40	235	92	of	of	IN
cord-016197-y69wwy40	235	93	action	action	NN
cord-016197-y69wwy40	235	94	,	,	,
cord-016197-y69wwy40	235	95	spectrum	spectrum	NN
cord-016197-y69wwy40	235	96	,	,	,
cord-016197-y69wwy40	235	97	and	and	CC
cord-016197-y69wwy40	235	98	selectivity	selectivity	NN
cord-016197-y69wwy40	235	99	.	.	.
cord-016197-y69wwy40	236	1	For	for	IN
cord-016197-y69wwy40	236	2	broad	broad	JJ
cord-016197-y69wwy40	236	3	-	-	HYPH
cord-016197-y69wwy40	236	4	spectrum	spectrum	NN
cord-016197-y69wwy40	236	5	targets	target	NNS
cord-016197-y69wwy40	236	6	a	a	DT
cord-016197-y69wwy40	236	7	key	key	JJ
cord-016197-y69wwy40	236	8	issue	issue	NN
cord-016197-y69wwy40	236	9	is	be	VBZ
cord-016197-y69wwy40	236	10	to	to	TO
cord-016197-y69wwy40	236	11	study	study	VB
cord-016197-y69wwy40	236	12	isozymes	isozyme	NNS
cord-016197-y69wwy40	236	13	from	from	IN
cord-016197-y69wwy40	236	14	several	several	JJ
cord-016197-y69wwy40	236	15	genetically	genetically	RB
cord-016197-y69wwy40	236	16	diverse	diverse	JJ
cord-016197-y69wwy40	236	17	bacterial	bacterial	JJ
cord-016197-y69wwy40	236	18	species	specie	NNS
cord-016197-y69wwy40	236	19	along	along	IN
cord-016197-y69wwy40	236	20	with	with	IN
cord-016197-y69wwy40	236	21	further	further	JJ
cord-016197-y69wwy40	236	22	screening	screening	NN
cord-016197-y69wwy40	236	23	against	against	IN
cord-016197-y69wwy40	236	24	a	a	DT
cord-016197-y69wwy40	236	25	panel	panel	NN
cord-016197-y69wwy40	236	26	of	of	IN
cord-016197-y69wwy40	236	27	microbes	microbe	NNS
cord-016197-y69wwy40	236	28	for	for	IN
cord-016197-y69wwy40	236	29	cellular	cellular	JJ
cord-016197-y69wwy40	236	30	activity	activity	NN
cord-016197-y69wwy40	236	31	,	,	,
cord-016197-y69wwy40	236	32	particularly	particularly	RB
cord-016197-y69wwy40	236	33	to	to	TO
cord-016197-y69wwy40	236	34	address	address	VB
cord-016197-y69wwy40	236	35	the	the	DT
cord-016197-y69wwy40	236	36	potential	potential	JJ
cord-016197-y69wwy40	236	37	role	role	NN
cord-016197-y69wwy40	236	38	of	of	IN
cord-016197-y69wwy40	236	39	intake	intake	NN
cord-016197-y69wwy40	236	40	cell	cell	NN
cord-016197-y69wwy40	236	41	membrane	membrane	NN
cord-016197-y69wwy40	236	42	barriers	barrier	NNS
cord-016197-y69wwy40	236	43	or	or	CC
cord-016197-y69wwy40	236	44	efflux	efflux	NN
cord-016197-y69wwy40	236	45	mechanisms	mechanism	NNS
cord-016197-y69wwy40	236	46	(	(	-LRB-
cord-016197-y69wwy40	236	47	MDRs	mdr	NNS
cord-016197-y69wwy40	236	48	)	)	-RRB-
cord-016197-y69wwy40	236	49	on	on	IN
cord-016197-y69wwy40	236	50	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	236	51	activity	activity	NN
cord-016197-y69wwy40	236	52	.	.	.
cord-016197-y69wwy40	237	1	Lead	lead	NN
cord-016197-y69wwy40	237	2	compounds	compound	NNS
cord-016197-y69wwy40	237	3	can	can	MD
cord-016197-y69wwy40	237	4	be	be	VB
cord-016197-y69wwy40	237	5	further	further	RB
cord-016197-y69wwy40	237	6	optimized	optimize	VBN
cord-016197-y69wwy40	237	7	in	in	IN
cord-016197-y69wwy40	237	8	terms	term	NNS
cord-016197-y69wwy40	237	9	of	of	IN
cord-016197-y69wwy40	237	10	potency	potency	NN
cord-016197-y69wwy40	237	11	,	,	,
cord-016197-y69wwy40	237	12	spectrum	spectrum	NN
cord-016197-y69wwy40	237	13	,	,	,
cord-016197-y69wwy40	237	14	and	and	CC
cord-016197-y69wwy40	237	15	selectivity	selectivity	NN
cord-016197-y69wwy40	237	16	through	through	IN
cord-016197-y69wwy40	237	17	studies	study	NNS
cord-016197-y69wwy40	237	18	on	on	IN
cord-016197-y69wwy40	237	19	the	the	DT
cord-016197-y69wwy40	237	20	mode	mode	NN
cord-016197-y69wwy40	237	21	of	of	IN
cord-016197-y69wwy40	237	22	action	action	NN
cord-016197-y69wwy40	237	23	(	(	-LRB-
cord-016197-y69wwy40	237	24	MOA	MOA	NNP
cord-016197-y69wwy40	237	25	)	)	-RRB-
cord-016197-y69wwy40	237	26	.	.	.
cord-016197-y69wwy40	238	1	Optimization	optimization	NN
cord-016197-y69wwy40	238	2	of	of	IN
cord-016197-y69wwy40	238	3	pharmacokinetic	pharmacokinetic	JJ
cord-016197-y69wwy40	238	4	(	(	-LRB-
cord-016197-y69wwy40	238	5	PK	PK	NNP
cord-016197-y69wwy40	238	6	)	)	-RRB-
cord-016197-y69wwy40	238	7	and	and	CC
cord-016197-y69wwy40	238	8	PD	PD	NNP
cord-016197-y69wwy40	238	9	properties	property	NNS
cord-016197-y69wwy40	238	10	through	through	IN
cord-016197-y69wwy40	238	11	distribution	distribution	NN
cord-016197-y69wwy40	238	12	,	,	,
cord-016197-y69wwy40	238	13	metabolism	metabolism	NN
cord-016197-y69wwy40	238	14	,	,	,
cord-016197-y69wwy40	238	15	and	and	CC
cord-016197-y69wwy40	238	16	PK	PK	NNP
cord-016197-y69wwy40	238	17	(	(	-LRB-
cord-016197-y69wwy40	238	18	DMPK	DMPK	NNP
cord-016197-y69wwy40	238	19	)	)	-RRB-
cord-016197-y69wwy40	238	20	studies	study	NNS
cord-016197-y69wwy40	238	21	and	and	CC
cord-016197-y69wwy40	238	22	drug	drug	NN
cord-016197-y69wwy40	238	23	delivery	delivery	NN
cord-016197-y69wwy40	238	24	/	/	SYM
cord-016197-y69wwy40	238	25	formulation	formulation	NN
cord-016197-y69wwy40	238	26	are	be	VBP
cord-016197-y69wwy40	238	27	increasingly	increasingly	RB
cord-016197-y69wwy40	238	28	important	important	JJ
cord-016197-y69wwy40	238	29	areas	area	NNS
cord-016197-y69wwy40	238	30	in	in	IN
cord-016197-y69wwy40	238	31	the	the	DT
cord-016197-y69wwy40	238	32	development	development	NN
cord-016197-y69wwy40	238	33	process	process	NN
cord-016197-y69wwy40	238	34	.	.	.
cord-016197-y69wwy40	239	1	In	in	IN
cord-016197-y69wwy40	239	2	particular	particular	JJ
cord-016197-y69wwy40	239	3	,	,	,
cord-016197-y69wwy40	239	4	knowledge	knowledge	NN
cord-016197-y69wwy40	239	5	of	of	IN
cord-016197-y69wwy40	239	6	the	the	DT
cord-016197-y69wwy40	239	7	role	role	NN
cord-016197-y69wwy40	239	8	of	of	IN
cord-016197-y69wwy40	239	9	PK	PK	NNP
cord-016197-y69wwy40	239	10	/	/	SYM
cord-016197-y69wwy40	239	11	PD	PD	NNP
cord-016197-y69wwy40	239	12	in	in	IN
cord-016197-y69wwy40	239	13	relation	relation	NN
cord-016197-y69wwy40	239	14	to	to	IN
cord-016197-y69wwy40	239	15	appropriate	appropriate	JJ
cord-016197-y69wwy40	239	16	dosing	dosing	NN
cord-016197-y69wwy40	239	17	and	and	CC
cord-016197-y69wwy40	239	18	the	the	DT
cord-016197-y69wwy40	239	19	potential	potential	NN
cord-016197-y69wwy40	239	20	for	for	IN
cord-016197-y69wwy40	239	21	resistance	resistance	NN
cord-016197-y69wwy40	239	22	development	development	NN
cord-016197-y69wwy40	239	23	is	be	VBZ
cord-016197-y69wwy40	239	24	evolving	evolve	VBG
cord-016197-y69wwy40	239	25	and	and	CC
cord-016197-y69wwy40	239	26	is	be	VBZ
cord-016197-y69wwy40	239	27	being	be	VBG
cord-016197-y69wwy40	239	28	used	use	VBN
cord-016197-y69wwy40	239	29	increasingly	increasingly	RB
cord-016197-y69wwy40	239	30	by	by	IN
cord-016197-y69wwy40	239	31	Pharma	Pharma	NNS
cord-016197-y69wwy40	239	32	.	.	.
cord-016197-y69wwy40	240	1	The	the	DT
cord-016197-y69wwy40	240	2	proof	proof	NN
cord-016197-y69wwy40	240	3	of	of	IN
cord-016197-y69wwy40	240	4	principle	principle	NN
cord-016197-y69wwy40	240	5	of	of	IN
cord-016197-y69wwy40	240	6	this	this	DT
cord-016197-y69wwy40	240	7	genomics	genomics	NN
cord-016197-y69wwy40	240	8	-	-	HYPH
cord-016197-y69wwy40	240	9	driven	drive	VBN
cord-016197-y69wwy40	240	10	,	,	,
cord-016197-y69wwy40	240	11	target	target	NN
cord-016197-y69wwy40	240	12	-	-	HYPH
cord-016197-y69wwy40	240	13	based	base	VBN
cord-016197-y69wwy40	240	14	approach	approach	NN
cord-016197-y69wwy40	240	15	,	,	,
cord-016197-y69wwy40	240	16	starting	start	VBG
cord-016197-y69wwy40	240	17	with	with	IN
cord-016197-y69wwy40	240	18	a	a	DT
cord-016197-y69wwy40	240	19	conserved	conserve	VBN
cord-016197-y69wwy40	240	20	gene	gene	NN
cord-016197-y69wwy40	240	21	and	and	CC
cord-016197-y69wwy40	240	22	leading	lead	VBG
cord-016197-y69wwy40	240	23	to	to	IN
cord-016197-y69wwy40	240	24	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	240	25	compound	compound	NN
cord-016197-y69wwy40	240	26	is	be	VBZ
cord-016197-y69wwy40	240	27	the	the	DT
cord-016197-y69wwy40	240	28	discovery	discovery	NN
cord-016197-y69wwy40	240	29	of	of	IN
cord-016197-y69wwy40	240	30	BB-3497	BB-3497	NNP
cord-016197-y69wwy40	240	31	,	,	,
cord-016197-y69wwy40	240	32	a	a	DT
cord-016197-y69wwy40	240	33	peptide	peptide	NN
cord-016197-y69wwy40	240	34	deformylase	deformylase	NN
cord-016197-y69wwy40	240	35	inhibitor	inhibitor	NN
cord-016197-y69wwy40	240	36	with	with	IN
cord-016197-y69wwy40	240	37	Gram	gram	NN
cord-016197-y69wwy40	240	38	-	-	HYPH
cord-016197-y69wwy40	240	39	positive	positive	JJ
cord-016197-y69wwy40	240	40	and	and	CC
cord-016197-y69wwy40	240	41	Gram	gram	NN
cord-016197-y69wwy40	240	42	-	-	HYPH
cord-016197-y69wwy40	240	43	negative	negative	JJ
cord-016197-y69wwy40	240	44	activity	activity	NN
cord-016197-y69wwy40	240	45	.	.	.
cord-016197-y69wwy40	241	1	Optimization	optimization	NN
cord-016197-y69wwy40	241	2	by	by	IN
cord-016197-y69wwy40	241	3	HTS	HTS	NNP
cord-016197-y69wwy40	241	4	is	be	VBZ
cord-016197-y69wwy40	241	5	exemplified	exemplify	VBN
cord-016197-y69wwy40	241	6	by	by	IN
cord-016197-y69wwy40	241	7	methionyl	methionyl	NNP
cord-016197-y69wwy40	241	8	tRNA	tRNA	NNP
cord-016197-y69wwy40	241	9	synthetase	synthetase	NNP
cord-016197-y69wwy40	241	10	.	.	.
cord-016197-y69wwy40	242	1	A	a	DT
cord-016197-y69wwy40	242	2	target	target	NN
cord-016197-y69wwy40	242	3	identified	identify	VBN
cord-016197-y69wwy40	242	4	through	through	IN
cord-016197-y69wwy40	242	5	genomics	genomic	NNS
cord-016197-y69wwy40	242	6	and	and	CC
cord-016197-y69wwy40	242	7	genetics	genetic	NNS
cord-016197-y69wwy40	242	8	and	and	CC
cord-016197-y69wwy40	242	9	to	to	IN
cord-016197-y69wwy40	242	10	which	which	WDT
cord-016197-y69wwy40	242	11	whole	whole	JJ
cord-016197-y69wwy40	242	12	-	-	HYPH
cord-016197-y69wwy40	242	13	cell	cell	NN
cord-016197-y69wwy40	242	14	screening	screening	NN
cord-016197-y69wwy40	242	15	of	of	IN
cord-016197-y69wwy40	242	16	target	target	NN
cord-016197-y69wwy40	242	17	-	-	HYPH
cord-016197-y69wwy40	242	18	specific	specific	JJ
cord-016197-y69wwy40	242	19	inhibitors	inhibitor	NNS
cord-016197-y69wwy40	242	20	has	have	VBZ
cord-016197-y69wwy40	242	21	been	be	VBN
cord-016197-y69wwy40	242	22	undertaken	undertake	VBN
cord-016197-y69wwy40	242	23	is	be	VBZ
cord-016197-y69wwy40	242	24	LpxC	LpxC	NNP
cord-016197-y69wwy40	242	25	,	,	,
cord-016197-y69wwy40	242	26	a	a	DT
cord-016197-y69wwy40	242	27	metallo	metallo	NN
cord-016197-y69wwy40	242	28	-	-	HYPH
cord-016197-y69wwy40	242	29	enzyme	enzyme	NN
cord-016197-y69wwy40	242	30	essential	essential	NN
cord-016197-y69wwy40	242	31	for	for	IN
cord-016197-y69wwy40	242	32	growth	growth	NN
cord-016197-y69wwy40	242	33	of	of	IN
cord-016197-y69wwy40	242	34	Gram	gram	NN
cord-016197-y69wwy40	242	35	-	-	HYPH
cord-016197-y69wwy40	242	36	negative	negative	JJ
cord-016197-y69wwy40	242	37	bacteria	bacteria	NNS
cord-016197-y69wwy40	242	38	.	.	.
cord-016197-y69wwy40	243	1	High	high	JJ
cord-016197-y69wwy40	243	2	-	-	HYPH
cord-016197-y69wwy40	243	3	density	density	NN
cord-016197-y69wwy40	243	4	DNA	dna	NN
cord-016197-y69wwy40	243	5	microarrays	microarray	NNS
cord-016197-y69wwy40	243	6	is	be	VBZ
cord-016197-y69wwy40	243	7	a	a	DT
cord-016197-y69wwy40	243	8	technology	technology	NN
cord-016197-y69wwy40	243	9	undergoing	undergo	VBG
cord-016197-y69wwy40	243	10	validation	validation	NN
cord-016197-y69wwy40	243	11	which	which	WDT
cord-016197-y69wwy40	243	12	has	have	VBZ
cord-016197-y69wwy40	243	13	the	the	DT
cord-016197-y69wwy40	243	14	potential	potential	NN
cord-016197-y69wwy40	243	15	to	to	TO
cord-016197-y69wwy40	243	16	generate	generate	VB
cord-016197-y69wwy40	243	17	a	a	DT
cord-016197-y69wwy40	243	18	vast	vast	JJ
cord-016197-y69wwy40	243	19	amount	amount	NN
cord-016197-y69wwy40	243	20	of	of	IN
cord-016197-y69wwy40	243	21	functional	functional	JJ
cord-016197-y69wwy40	243	22	information	information	NN
cord-016197-y69wwy40	243	23	on	on	IN
cord-016197-y69wwy40	243	24	coordinated	coordinated	JJ
cord-016197-y69wwy40	243	25	gene	gene	NN
cord-016197-y69wwy40	243	26	expression	expression	NN
cord-016197-y69wwy40	243	27	under	under	IN
cord-016197-y69wwy40	243	28	various	various	JJ
cord-016197-y69wwy40	243	29	growth	growth	NN
cord-016197-y69wwy40	243	30	conditions	condition	NNS
cord-016197-y69wwy40	243	31	.	.	.
cord-016197-y69wwy40	244	1	There	there	EX
cord-016197-y69wwy40	244	2	are	be	VBP
cord-016197-y69wwy40	244	3	a	a	DT
cord-016197-y69wwy40	244	4	number	number	NN
cord-016197-y69wwy40	244	5	of	of	IN
cord-016197-y69wwy40	244	6	new	new	JJ
cord-016197-y69wwy40	244	7	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	244	8	currently	currently	RB
cord-016197-y69wwy40	244	9	in	in	IN
cord-016197-y69wwy40	244	10	late	late	JJ
cord-016197-y69wwy40	244	11	-	-	HYPH
cord-016197-y69wwy40	244	12	stage	stage	NN
cord-016197-y69wwy40	244	13	development	development	NN
cord-016197-y69wwy40	244	14	,	,	,
cord-016197-y69wwy40	244	15	although	although	IN
cord-016197-y69wwy40	244	16	all	all	DT
cord-016197-y69wwy40	244	17	of	of	IN
cord-016197-y69wwy40	244	18	these	these	DT
cord-016197-y69wwy40	244	19	are	be	VBP
cord-016197-y69wwy40	244	20	from	from	IN
cord-016197-y69wwy40	244	21	existing	exist	VBG
cord-016197-y69wwy40	244	22	established	establish	VBN
cord-016197-y69wwy40	244	23	classes	class	NNS
cord-016197-y69wwy40	244	24	(	(	-LRB-
cord-016197-y69wwy40	244	25	e.g.	e.g.	RB
cord-016197-y69wwy40	244	26	,	,	,
cord-016197-y69wwy40	244	27	penem	penem	NNP
cord-016197-y69wwy40	244	28	,	,	,
cord-016197-y69wwy40	244	29	fluoroquinolone	fluoroquinolone	NN
cord-016197-y69wwy40	244	30	,	,	,
cord-016197-y69wwy40	244	31	glycopeptide	glycopeptide	NNP
cord-016197-y69wwy40	244	32	,	,	,
cord-016197-y69wwy40	244	33	lipopeptide	lipopeptide	NNP
cord-016197-y69wwy40	244	34	,	,	,
cord-016197-y69wwy40	244	35	glycylcycline	glycylcycline	NNP
cord-016197-y69wwy40	244	36	)	)	-RRB-
cord-016197-y69wwy40	244	37	(	(	-LRB-
cord-016197-y69wwy40	244	38	Rasmussen	Rasmussen	NNP
cord-016197-y69wwy40	244	39	and	and	CC
cord-016197-y69wwy40	244	40	Projan	Projan	NNP
cord-016197-y69wwy40	244	41	,	,	,
cord-016197-y69wwy40	244	42	2003	2003	CD
cord-016197-y69wwy40	244	43	)	)	-RRB-
cord-016197-y69wwy40	244	44	.	.	.
cord-016197-y69wwy40	245	1	It	-PRON-	PRP
cord-016197-y69wwy40	245	2	is	be	VBZ
cord-016197-y69wwy40	245	3	hoped	hope	VBN
cord-016197-y69wwy40	245	4	that	that	IN
cord-016197-y69wwy40	245	5	use	use	NN
cord-016197-y69wwy40	245	6	of	of	IN
cord-016197-y69wwy40	245	7	genomics	genomic	NNS
cord-016197-y69wwy40	245	8	to	to	TO
cord-016197-y69wwy40	245	9	identify	identify	VB
cord-016197-y69wwy40	245	10	novel	novel	JJ
cord-016197-y69wwy40	245	11	targets	target	NNS
cord-016197-y69wwy40	245	12	with	with	IN
cord-016197-y69wwy40	245	13	biological	biological	JJ
cord-016197-y69wwy40	245	14	and	and	CC
cord-016197-y69wwy40	245	15	clinical	clinical	JJ
cord-016197-y69wwy40	245	16	relevance	relevance	NN
cord-016197-y69wwy40	245	17	and	and	CC
cord-016197-y69wwy40	245	18	HTS	HTS	NNP
cord-016197-y69wwy40	245	19	to	to	TO
cord-016197-y69wwy40	245	20	increase	increase	VB
cord-016197-y69wwy40	245	21	the	the	DT
cord-016197-y69wwy40	245	22	chance	chance	NN
cord-016197-y69wwy40	245	23	of	of	IN
cord-016197-y69wwy40	245	24	"	"	``
cord-016197-y69wwy40	245	25	hits	hit	NNS
cord-016197-y69wwy40	245	26	"	"	''
cord-016197-y69wwy40	245	27	may	may	MD
cord-016197-y69wwy40	245	28	result	result	VB
cord-016197-y69wwy40	245	29	,	,	,
cord-016197-y69wwy40	245	30	in	in	IN
cord-016197-y69wwy40	245	31	time	time	NN
cord-016197-y69wwy40	245	32	,	,	,
cord-016197-y69wwy40	245	33	in	in	IN
cord-016197-y69wwy40	245	34	a	a	DT
cord-016197-y69wwy40	245	35	range	range	NN
cord-016197-y69wwy40	245	36	of	of	IN
cord-016197-y69wwy40	245	37	novel	novel	JJ
cord-016197-y69wwy40	245	38	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	245	39	for	for	IN
cord-016197-y69wwy40	245	40	development	development	NN
cord-016197-y69wwy40	245	41	(	(	-LRB-
cord-016197-y69wwy40	245	42	Mills	Mills	NNPS
cord-016197-y69wwy40	245	43	,	,	,
cord-016197-y69wwy40	245	44	2003	2003	CD
cord-016197-y69wwy40	245	45	;	;	:
cord-016197-y69wwy40	245	46	Rasmussen	Rasmussen	NNP
cord-016197-y69wwy40	245	47	and	and	CC
cord-016197-y69wwy40	245	48	Projan	Projan	NNP
cord-016197-y69wwy40	245	49	,	,	,
cord-016197-y69wwy40	245	50	2003	2003	CD
cord-016197-y69wwy40	245	51	)	)	-RRB-
cord-016197-y69wwy40	245	52	.	.	.
cord-016197-y69wwy40	246	1	Many	many	JJ
cord-016197-y69wwy40	246	2	,	,	,
cord-016197-y69wwy40	246	3	if	if	IN
cord-016197-y69wwy40	246	4	not	not	RB
cord-016197-y69wwy40	246	5	all	all	DT
cord-016197-y69wwy40	246	6	,	,	,
cord-016197-y69wwy40	246	7	of	of	IN
cord-016197-y69wwy40	246	8	the	the	DT
cord-016197-y69wwy40	246	9	bacterial	bacterial	JJ
cord-016197-y69wwy40	246	10	targets	target	NNS
cord-016197-y69wwy40	246	11	have	have	VBP
cord-016197-y69wwy40	246	12	now	now	RB
cord-016197-y69wwy40	246	13	been	be	VBN
cord-016197-y69wwy40	246	14	identified	identify	VBN
cord-016197-y69wwy40	246	15	,	,	,
cord-016197-y69wwy40	246	16	but	but	CC
cord-016197-y69wwy40	246	17	HTS	HTS	NNP
cord-016197-y69wwy40	246	18	has	have	VBZ
cord-016197-y69wwy40	246	19	yet	yet	RB
cord-016197-y69wwy40	246	20	to	to	TO
cord-016197-y69wwy40	246	21	deliver	deliver	VB
cord-016197-y69wwy40	246	22	the	the	DT
cord-016197-y69wwy40	246	23	range	range	NN
cord-016197-y69wwy40	246	24	of	of	IN
cord-016197-y69wwy40	246	25	novel	novel	JJ
cord-016197-y69wwy40	246	26	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	246	27	compounds	compound	NNS
cord-016197-y69wwy40	246	28	that	that	WDT
cord-016197-y69wwy40	246	29	hit	hit	VBD
cord-016197-y69wwy40	246	30	these	these	DT
cord-016197-y69wwy40	246	31	targets	target	NNS
cord-016197-y69wwy40	246	32	.	.	.
cord-016197-y69wwy40	247	1	Encouragingly	encouragingly	RB
cord-016197-y69wwy40	247	2	,	,	,
cord-016197-y69wwy40	247	3	the	the	DT
cord-016197-y69wwy40	247	4	most	most	RBS
cord-016197-y69wwy40	247	5	advanced	advanced	JJ
cord-016197-y69wwy40	247	6	HTS	HTS	NNP
cord-016197-y69wwy40	247	7	plants	plant	NNS
cord-016197-y69wwy40	247	8	now	now	RB
cord-016197-y69wwy40	247	9	have	have	VBP
cord-016197-y69wwy40	247	10	the	the	DT
cord-016197-y69wwy40	247	11	capacity	capacity	NN
cord-016197-y69wwy40	247	12	to	to	TO
cord-016197-y69wwy40	247	13	screen	screen	VB
cord-016197-y69wwy40	247	14	300,000	300,000	CD
cord-016197-y69wwy40	247	15	compounds	compound	NNS
cord-016197-y69wwy40	247	16	per	per	IN
cord-016197-y69wwy40	247	17	day	day	NN
cord-016197-y69wwy40	247	18	.	.	.
cord-016197-y69wwy40	248	1	Worryingly	worryingly	RB
cord-016197-y69wwy40	248	2	,	,	,
cord-016197-y69wwy40	248	3	there	there	EX
cord-016197-y69wwy40	248	4	are	be	VBP
cord-016197-y69wwy40	248	5	increasing	increase	VBG
cord-016197-y69wwy40	248	6	hurdles	hurdle	NNS
cord-016197-y69wwy40	248	7	in	in	IN
cord-016197-y69wwy40	248	8	the	the	DT
cord-016197-y69wwy40	248	9	development	development	NN
cord-016197-y69wwy40	248	10	and	and	CC
cord-016197-y69wwy40	248	11	commercialization	commercialization	NN
cord-016197-y69wwy40	248	12	of	of	IN
cord-016197-y69wwy40	248	13	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	248	14	agents	agent	NNS
cord-016197-y69wwy40	248	15	that	that	WDT
cord-016197-y69wwy40	248	16	might	may	MD
cord-016197-y69wwy40	248	17	adversely	adversely	RB
cord-016197-y69wwy40	248	18	impact	impact	VB
cord-016197-y69wwy40	248	19	the	the	DT
cord-016197-y69wwy40	248	20	willingness	willingness	NN
cord-016197-y69wwy40	248	21	of	of	IN
cord-016197-y69wwy40	248	22	companies	company	NNS
cord-016197-y69wwy40	248	23	to	to	TO
cord-016197-y69wwy40	248	24	initiate	initiate	VB
cord-016197-y69wwy40	248	25	or	or	CC
cord-016197-y69wwy40	248	26	continue	continue	VB
cord-016197-y69wwy40	248	27	investing	invest	VBG
cord-016197-y69wwy40	248	28	in	in	IN
cord-016197-y69wwy40	248	29	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	248	30	discovery	discovery	NN
cord-016197-y69wwy40	248	31	research	research	NN
cord-016197-y69wwy40	248	32	.	.	.
cord-016197-y69wwy40	249	1	New	new	JJ
cord-016197-y69wwy40	249	2	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	249	3	are	be	VBP
cord-016197-y69wwy40	249	4	unlikely	unlikely	JJ
cord-016197-y69wwy40	249	5	to	to	TO
cord-016197-y69wwy40	249	6	be	be	VB
cord-016197-y69wwy40	249	7	recommended	recommend	VBN
cord-016197-y69wwy40	249	8	as	as	IN
cord-016197-y69wwy40	249	9	first	first	JJ
cord-016197-y69wwy40	249	10	-	-	HYPH
cord-016197-y69wwy40	249	11	line	line	NN
cord-016197-y69wwy40	249	12	clinical	clinical	JJ
cord-016197-y69wwy40	249	13	agents	agent	NNS
cord-016197-y69wwy40	249	14	in	in	IN
cord-016197-y69wwy40	249	15	policies	policy	NNS
cord-016197-y69wwy40	249	16	designed	design	VBN
cord-016197-y69wwy40	249	17	to	to	TO
cord-016197-y69wwy40	249	18	control	control	VB
cord-016197-y69wwy40	249	19	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	249	20	use	use	NN
cord-016197-y69wwy40	249	21	unless	unless	IN
cord-016197-y69wwy40	249	22	they	-PRON-	PRP
cord-016197-y69wwy40	249	23	offer	offer	VBP
cord-016197-y69wwy40	249	24	benefits	benefit	NNS
cord-016197-y69wwy40	249	25	,	,	,
cord-016197-y69wwy40	249	26	often	often	RB
cord-016197-y69wwy40	249	27	assessed	assess	VBN
cord-016197-y69wwy40	249	28	in	in	IN
cord-016197-y69wwy40	249	29	relation	relation	NN
cord-016197-y69wwy40	249	30	to	to	TO
cord-016197-y69wwy40	249	31	cost	cost	VB
cord-016197-y69wwy40	249	32	over	over	IN
cord-016197-y69wwy40	249	33	existing	exist	VBG
cord-016197-y69wwy40	249	34	branded	branded	JJ
cord-016197-y69wwy40	249	35	or	or	CC
cord-016197-y69wwy40	249	36	generic	generic	JJ
cord-016197-y69wwy40	249	37	agents	agent	NNS
cord-016197-y69wwy40	249	38	.	.	.
cord-016197-y69wwy40	250	1	Efficacy	efficacy	NN
cord-016197-y69wwy40	250	2	against	against	IN
cord-016197-y69wwy40	250	3	organisms	organism	NNS
cord-016197-y69wwy40	250	4	resistant	resistant	JJ
cord-016197-y69wwy40	250	5	to	to	IN
cord-016197-y69wwy40	250	6	other	other	JJ
cord-016197-y69wwy40	250	7	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	250	8	choices	choice	NNS
cord-016197-y69wwy40	250	9	is	be	VBZ
cord-016197-y69wwy40	250	10	a	a	DT
cord-016197-y69wwy40	250	11	potential	potential	JJ
cord-016197-y69wwy40	250	12	benefit	benefit	NN
cord-016197-y69wwy40	250	13	but	but	CC
cord-016197-y69wwy40	250	14	if	if	IN
cord-016197-y69wwy40	250	15	it	-PRON-	PRP
cord-016197-y69wwy40	250	16	is	be	VBZ
cord-016197-y69wwy40	250	17	the	the	DT
cord-016197-y69wwy40	250	18	sole	sole	JJ
cord-016197-y69wwy40	250	19	indication	indication	NN
cord-016197-y69wwy40	250	20	it	-PRON-	PRP
cord-016197-y69wwy40	250	21	may	may	MD
cord-016197-y69wwy40	250	22	be	be	VB
cord-016197-y69wwy40	250	23	of	of	IN
cord-016197-y69wwy40	250	24	limited	limited	JJ
cord-016197-y69wwy40	250	25	commercial	commercial	JJ
cord-016197-y69wwy40	250	26	attractiveness	attractiveness	NN
cord-016197-y69wwy40	250	27	.	.	.
cord-016197-y69wwy40	251	1	There	there	EX
cord-016197-y69wwy40	251	2	are	be	VBP
cord-016197-y69wwy40	251	3	a	a	DT
cord-016197-y69wwy40	251	4	number	number	NN
cord-016197-y69wwy40	251	5	of	of	IN
cord-016197-y69wwy40	251	6	significant	significant	JJ
cord-016197-y69wwy40	251	7	hurdles	hurdle	NNS
cord-016197-y69wwy40	251	8	in	in	IN
cord-016197-y69wwy40	251	9	being	be	VBG
cord-016197-y69wwy40	251	10	able	able	JJ
cord-016197-y69wwy40	251	11	to	to	TO
cord-016197-y69wwy40	251	12	demonstrate	demonstrate	VB
cord-016197-y69wwy40	251	13	and	and	CC
cord-016197-y69wwy40	251	14	use	use	VB
cord-016197-y69wwy40	251	15	differential	differential	JJ
cord-016197-y69wwy40	251	16	benefits	benefit	NNS
cord-016197-y69wwy40	251	17	.	.	.
cord-016197-y69wwy40	252	1	These	these	DT
cord-016197-y69wwy40	252	2	relate	relate	VBP
cord-016197-y69wwy40	252	3	to	to	IN
cord-016197-y69wwy40	252	4	governmental/	governmental/	CD
cord-016197-y69wwy40	252	5	regulatory	regulatory	JJ
cord-016197-y69wwy40	252	6	policy	policy	NN
cord-016197-y69wwy40	252	7	with	with	IN
cord-016197-y69wwy40	252	8	respect	respect	NN
cord-016197-y69wwy40	252	9	to	to	IN
cord-016197-y69wwy40	252	10	clinical	clinical	JJ
cord-016197-y69wwy40	252	11	development	development	NN
cord-016197-y69wwy40	252	12	,	,	,
cord-016197-y69wwy40	252	13	product	product	NN
cord-016197-y69wwy40	252	14	labelling	labelling	NN
cord-016197-y69wwy40	252	15	,	,	,
cord-016197-y69wwy40	252	16	and	and	CC
cord-016197-y69wwy40	252	17	promotion	promotion	NN
cord-016197-y69wwy40	252	18	.	.	.
cord-016197-y69wwy40	253	1	Shlaes	Shlaes	NNP
cord-016197-y69wwy40	253	2	and	and	CC
cord-016197-y69wwy40	253	3	Ryan	Ryan	NNP
cord-016197-y69wwy40	253	4	(	(	-LRB-
cord-016197-y69wwy40	253	5	2003	2003	CD
cord-016197-y69wwy40	253	6	)	)	-RRB-
cord-016197-y69wwy40	253	7	reviewed	review	VBD
cord-016197-y69wwy40	253	8	the	the	DT
cord-016197-y69wwy40	253	9	strategic	strategic	JJ
cord-016197-y69wwy40	253	10	and	and	CC
cord-016197-y69wwy40	253	11	regulatory	regulatory	JJ
cord-016197-y69wwy40	253	12	considerations	consideration	NNS
cord-016197-y69wwy40	253	13	in	in	IN
cord-016197-y69wwy40	253	14	the	the	DT
cord-016197-y69wwy40	253	15	clinical	clinical	JJ
cord-016197-y69wwy40	253	16	development	development	NN
cord-016197-y69wwy40	253	17	of	of	IN
cord-016197-y69wwy40	253	18	anti	anti	JJ
cord-016197-y69wwy40	253	19	-	-	JJ
cord-016197-y69wwy40	253	20	infectives	infective	NNS
cord-016197-y69wwy40	253	21	.	.	.
cord-016197-y69wwy40	254	1	A	a	DT
cord-016197-y69wwy40	254	2	new	new	JJ
cord-016197-y69wwy40	254	3	and	and	CC
cord-016197-y69wwy40	254	4	evolving	evolving	JJ
cord-016197-y69wwy40	254	5	set	set	NN
cord-016197-y69wwy40	254	6	of	of	IN
cord-016197-y69wwy40	254	7	challenges	challenge	NNS
cord-016197-y69wwy40	254	8	exists	exist	VBZ
cord-016197-y69wwy40	254	9	for	for	IN
cord-016197-y69wwy40	254	10	Pharma	Pharma	NNS
cord-016197-y69wwy40	254	11	in	in	IN
cord-016197-y69wwy40	254	12	the	the	DT
cord-016197-y69wwy40	254	13	clinical	clinical	JJ
cord-016197-y69wwy40	254	14	development	development	NN
cord-016197-y69wwy40	254	15	of	of	IN
cord-016197-y69wwy40	254	16	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	254	17	with	with	IN
cord-016197-y69wwy40	254	18	a	a	DT
cord-016197-y69wwy40	254	19	number	number	NN
cord-016197-y69wwy40	254	20	of	of	IN
cord-016197-y69wwy40	254	21	requirements	requirement	NNS
cord-016197-y69wwy40	254	22	from	from	IN
cord-016197-y69wwy40	254	23	existing	exist	VBG
cord-016197-y69wwy40	254	24	or	or	CC
cord-016197-y69wwy40	254	25	proposed	propose	VBN
cord-016197-y69wwy40	254	26	regulatory	regulatory	JJ
cord-016197-y69wwy40	254	27	guidelines	guideline	NNS
cord-016197-y69wwy40	254	28	posing	pose	VBG
cord-016197-y69wwy40	254	29	significant	significant	JJ
cord-016197-y69wwy40	254	30	hurdles	hurdle	NNS
cord-016197-y69wwy40	254	31	and	and	CC
cord-016197-y69wwy40	254	32	complexity	complexity	NN
cord-016197-y69wwy40	254	33	.	.	.
cord-016197-y69wwy40	255	1	The	the	DT
cord-016197-y69wwy40	255	2	key	key	JJ
cord-016197-y69wwy40	255	3	points	point	NNS
cord-016197-y69wwy40	255	4	of	of	IN
cord-016197-y69wwy40	255	5	concern	concern	NN
cord-016197-y69wwy40	255	6	to	to	IN
cord-016197-y69wwy40	255	7	Pharma	Pharma	NNP
cord-016197-y69wwy40	255	8	are	be	VBP
cord-016197-y69wwy40	255	9	listed	list	VBN
cord-016197-y69wwy40	255	10	below	below	RB
cord-016197-y69wwy40	255	11	.	.	.
cord-016197-y69wwy40	256	1	1	1	LS
cord-016197-y69wwy40	256	2	.	.	.
cord-016197-y69wwy40	257	1	Removal	removal	NN
cord-016197-y69wwy40	257	2	of	of	IN
cord-016197-y69wwy40	257	3	in	in	FW
cord-016197-y69wwy40	257	4	vitro	vitro	FW
cord-016197-y69wwy40	257	5	activity	activity	NN
cord-016197-y69wwy40	257	6	from	from	IN
cord-016197-y69wwy40	257	7	product	product	NN
cord-016197-y69wwy40	257	8	label	label	NN
cord-016197-y69wwy40	257	9	(	(	-LRB-
cord-016197-y69wwy40	257	10	FDA)-limits	fda)-limit	NNS
cord-016197-y69wwy40	257	11	potential	potential	NN
cord-016197-y69wwy40	257	12	for	for	IN
cord-016197-y69wwy40	257	13	description	description	NN
cord-016197-y69wwy40	257	14	of	of	IN
cord-016197-y69wwy40	257	15	agents	agent	NNS
cord-016197-y69wwy40	257	16	'	'	POS
cord-016197-y69wwy40	257	17	full	full	JJ
cord-016197-y69wwy40	257	18	spectrum	spectrum	NN
cord-016197-y69wwy40	257	19	of	of	IN
cord-016197-y69wwy40	257	20	activity	activity	NN
cord-016197-y69wwy40	257	21	(	(	-LRB-
cord-016197-y69wwy40	257	22	such	such	JJ
cord-016197-y69wwy40	257	23	as	as	IN
cord-016197-y69wwy40	257	24	against	against	IN
cord-016197-y69wwy40	257	25	rare	rare	JJ
cord-016197-y69wwy40	257	26	or	or	CC
cord-016197-y69wwy40	257	27	bioterrorism	bioterrorism	NN
cord-016197-y69wwy40	257	28	pathogens	pathogen	NNS
cord-016197-y69wwy40	257	29	)	)	-RRB-
cord-016197-y69wwy40	257	30	,	,	,
cord-016197-y69wwy40	258	1	differentiation	differentiation	NN
cord-016197-y69wwy40	258	2	and	and	CC
cord-016197-y69wwy40	258	3	promotion	promotion	NN
cord-016197-y69wwy40	258	4	.	.	.
cord-016197-y69wwy40	259	1	2	2	LS
cord-016197-y69wwy40	259	2	.	.	.
cord-016197-y69wwy40	260	1	Post	post	JJ
cord-016197-y69wwy40	260	2	-	-	JJ
cord-016197-y69wwy40	260	3	marketing	marketing	JJ
cord-016197-y69wwy40	260	4	surveillance	surveillance	NN
cord-016197-y69wwy40	260	5	of	of	IN
cord-016197-y69wwy40	260	6	resistance	resistance	NN
cord-016197-y69wwy40	260	7	and	and	CC
cord-016197-y69wwy40	260	8	label	label	NN
cord-016197-y69wwy40	260	9	updates	update	NNS
cord-016197-y69wwy40	260	10	(	(	-LRB-
cord-016197-y69wwy40	260	11	as	as	IN
cord-016197-y69wwy40	260	12	required	require	VBN
cord-016197-y69wwy40	260	13	(	(	-LRB-
cord-016197-y69wwy40	260	14	FDA	FDA	NNP
cord-016197-y69wwy40	260	15	and	and	CC
cord-016197-y69wwy40	260	16	national	national	JJ
cord-016197-y69wwy40	260	17	EU	EU	NNP
cord-016197-y69wwy40	260	18	agencies	agency	NNS
cord-016197-y69wwy40	260	19	)	)	-RRB-
cord-016197-y69wwy40	260	20	)	)	-RRB-
cord-016197-y69wwy40	261	1	-presents	-present	NNS
cord-016197-y69wwy40	262	1	"	"	``
cord-016197-y69wwy40	262	2	unlevel	unlevel	JJ
cord-016197-y69wwy40	262	3	playing	playing	NN
cord-016197-y69wwy40	262	4	field	field	NN
cord-016197-y69wwy40	262	5	"	"	''
cord-016197-y69wwy40	262	6	with	with	IN
cord-016197-y69wwy40	262	7	established	establish	VBN
cord-016197-y69wwy40	262	8	/	/	SYM
cord-016197-y69wwy40	262	9	older	old	JJR
cord-016197-y69wwy40	262	10	products	product	NNS
cord-016197-y69wwy40	262	11	.	.	.
cord-016197-y69wwy40	263	1	3	3	LS
cord-016197-y69wwy40	263	2	.	.	.
cord-016197-y69wwy40	264	1	Requirement	requirement	NN
cord-016197-y69wwy40	264	2	for	for	IN
cord-016197-y69wwy40	264	3	in	in	FW
cord-016197-y69wwy40	264	4	vitro	vitro	FW
cord-016197-y69wwy40	264	5	percentage	percentage	NN
cord-016197-y69wwy40	264	6	susceptibility	susceptibility	NN
cord-016197-y69wwy40	264	7	of	of	IN
cord-016197-y69wwy40	264	8	organisms	organism	NNS
cord-016197-y69wwy40	264	9	from	from	IN
cord-016197-y69wwy40	264	10	EU	EU	NNP
cord-016197-y69wwy40	264	11	countries	country	NNS
cord-016197-y69wwy40	264	12	(	(	-LRB-
cord-016197-y69wwy40	264	13	Committee	Committee	NNP
cord-016197-y69wwy40	264	14	for	for	IN
cord-016197-y69wwy40	264	15	Proprietary	Proprietary	NNP
cord-016197-y69wwy40	264	16	Medicinal	Medicinal	NNP
cord-016197-y69wwy40	264	17	Products	Products	NNPS
cord-016197-y69wwy40	264	18	[	[	-LRB-
cord-016197-y69wwy40	264	19	CPMP])requires	cpmp])require	NNS
cord-016197-y69wwy40	264	20	product	product	NN
cord-016197-y69wwy40	264	21	-	-	HYPH
cord-016197-y69wwy40	264	22	specific	specific	JJ
cord-016197-y69wwy40	264	23	broad	broad	JJ
cord-016197-y69wwy40	264	24	surveillance	surveillance	NN
cord-016197-y69wwy40	264	25	(	(	-LRB-
cord-016197-y69wwy40	264	26	organisms	organism	NNS
cord-016197-y69wwy40	264	27	and	and	CC
cord-016197-y69wwy40	264	28	geography	geography	NN
cord-016197-y69wwy40	264	29	)	)	-RRB-
cord-016197-y69wwy40	264	30	.	.	.
cord-016197-y69wwy40	265	1	4	4	LS
cord-016197-y69wwy40	265	2	.	.	.
cord-016197-y69wwy40	266	1	Powering	power	VBG
cord-016197-y69wwy40	266	2	of	of	IN
cord-016197-y69wwy40	266	3	clinical	clinical	JJ
cord-016197-y69wwy40	266	4	trials	trial	NNS
cord-016197-y69wwy40	266	5	to	to	IN
cord-016197-y69wwy40	266	6	10	10	CD
cord-016197-y69wwy40	266	7	%	%	NN
cord-016197-y69wwy40	266	8	non	non	JJ
cord-016197-y69wwy40	266	9	-	-	JJ
cord-016197-y69wwy40	266	10	inferiority	inferiority	JJ
cord-016197-y69wwy40	266	11	powered	power	VBN
cord-016197-y69wwy40	266	12	at	at	IN
cord-016197-y69wwy40	266	13	90	90	CD
cord-016197-y69wwy40	266	14	%	%	NN
cord-016197-y69wwy40	266	15	level	level	NN
cord-016197-y69wwy40	266	16	(	(	-LRB-
cord-016197-y69wwy40	266	17	FDA	FDA	NNP
cord-016197-y69wwy40	266	18	,	,	,
cord-016197-y69wwy40	266	19	CPMP)-substantially	cpmp)-substantially	RB
cord-016197-y69wwy40	266	20	increased	increase	VBN
cord-016197-y69wwy40	266	21	patient	patient	JJ
cord-016197-y69wwy40	266	22	numbers	number	NNS
cord-016197-y69wwy40	266	23	and	and	CC
cord-016197-y69wwy40	266	24	cost	cost	NN
cord-016197-y69wwy40	266	25	.	.	.
cord-016197-y69wwy40	267	1	5	5	LS
cord-016197-y69wwy40	267	2	.	.	.
cord-016197-y69wwy40	268	1	Placebo	placebo	NN
cord-016197-y69wwy40	268	2	-	-	HYPH
cord-016197-y69wwy40	268	3	controlled	control	VBN
cord-016197-y69wwy40	268	4	superiority	superiority	NN
cord-016197-y69wwy40	268	5	trials	trial	NNS
cord-016197-y69wwy40	268	6	requested	request	VBN
cord-016197-y69wwy40	268	7	for	for	IN
cord-016197-y69wwy40	268	8	acute	acute	JJ
cord-016197-y69wwy40	268	9	otitis	otitis	NN
cord-016197-y69wwy40	268	10	media	medium	NNS
cord-016197-y69wwy40	268	11	and	and	CC
cord-016197-y69wwy40	268	12	acute	acute	JJ
cord-016197-y69wwy40	268	13	exacerbations	exacerbation	NNS
cord-016197-y69wwy40	268	14	of	of	IN
cord-016197-y69wwy40	268	15	chronic	chronic	JJ
cord-016197-y69wwy40	268	16	bronchitis	bronchitis	NN
cord-016197-y69wwy40	268	17	(	(	-LRB-
cord-016197-y69wwy40	268	18	FDA	FDA	NNP
cord-016197-y69wwy40	268	19	,	,	,
cord-016197-y69wwy40	268	20	CPMP)-increased	cpmp)-increase	VBN
cord-016197-y69wwy40	268	21	patient	patient	NN
cord-016197-y69wwy40	268	22	numbers	number	NNS
cord-016197-y69wwy40	268	23	and	and	CC
cord-016197-y69wwy40	268	24	increased	increase	VBN
cord-016197-y69wwy40	268	25	risk	risk	NN
cord-016197-y69wwy40	268	26	of	of	IN
cord-016197-y69wwy40	268	27	not	not	RB
cord-016197-y69wwy40	268	28	achieving	achieve	VBG
cord-016197-y69wwy40	268	29	relevant	relevant	JJ
cord-016197-y69wwy40	268	30	outcomes	outcome	NNS
cord-016197-y69wwy40	268	31	.	.	.
cord-016197-y69wwy40	269	1	6	6	LS
cord-016197-y69wwy40	269	2	.	.	.
cord-016197-y69wwy40	270	1	Paediatric	paediatric	JJ
cord-016197-y69wwy40	270	2	rule	rule	NN
cord-016197-y69wwy40	270	3	(	(	-LRB-
cord-016197-y69wwy40	270	4	FDA	FDA	NNP
cord-016197-y69wwy40	270	5	)	)	-RRB-
cord-016197-y69wwy40	270	6	;	;	:
cord-016197-y69wwy40	271	1	the	the	DT
cord-016197-y69wwy40	271	2	requirement	requirement	NN
cord-016197-y69wwy40	271	3	to	to	TO
cord-016197-y69wwy40	271	4	progress	progress	VB
cord-016197-y69wwy40	271	5	paediatric	paediatric	JJ
cord-016197-y69wwy40	271	6	indications/	indications/	CD
cord-016197-y69wwy40	271	7	registration	registration	NN
cord-016197-y69wwy40	271	8	-	-	HYPH
cord-016197-y69wwy40	271	9	increased	increase	VBN
cord-016197-y69wwy40	271	10	or	or	CC
cord-016197-y69wwy40	271	11	earlier	early	JJR
cord-016197-y69wwy40	271	12	resource	resource	NN
cord-016197-y69wwy40	271	13	/	/	SYM
cord-016197-y69wwy40	271	14	cost	cost	NN
cord-016197-y69wwy40	271	15	for	for	IN
cord-016197-y69wwy40	271	16	paediatric	paediatric	JJ
cord-016197-y69wwy40	271	17	studies	study	NNS
cord-016197-y69wwy40	271	18	.	.	.
cord-016197-y69wwy40	272	1	7	7	CD
cord-016197-y69wwy40	272	2	.	.	.
cord-016197-y69wwy40	273	1	Specific	specific	JJ
cord-016197-y69wwy40	273	2	indications	indication	NNS
cord-016197-y69wwy40	273	3	,	,	,
cord-016197-y69wwy40	273	4	for	for	IN
cord-016197-y69wwy40	273	5	example	example	NN
cord-016197-y69wwy40	273	6	,	,	,
cord-016197-y69wwy40	273	7	pharyngitis	pharyngitis	NN
cord-016197-y69wwy40	273	8	,	,	,
cord-016197-y69wwy40	273	9	otitis	otitis	NN
cord-016197-y69wwy40	273	10	media	medium	NNS
cord-016197-y69wwy40	273	11	,	,	,
cord-016197-y69wwy40	273	12	rather	rather	RB
cord-016197-y69wwy40	273	13	than	than	IN
cord-016197-y69wwy40	273	14	upper	upper	JJ
cord-016197-y69wwy40	273	15	respiratory	respiratory	JJ
cord-016197-y69wwy40	273	16	tract	tract	NN
cord-016197-y69wwy40	273	17	infection	infection	NN
cord-016197-y69wwy40	273	18	(	(	-LRB-
cord-016197-y69wwy40	273	19	FDA	FDA	NNP
cord-016197-y69wwy40	273	20	,	,	,
cord-016197-y69wwy40	273	21	CPMP)-larger	cpmp)-larger	CD
cord-016197-y69wwy40	273	22	number	number	NN
cord-016197-y69wwy40	273	23	of	of	IN
cord-016197-y69wwy40	273	24	Phase	Phase	NNP
cord-016197-y69wwy40	273	25	III	III	NNP
cord-016197-y69wwy40	273	26	randomized	randomized	JJ
cord-016197-y69wwy40	273	27	controlled	control	VBN
cord-016197-y69wwy40	273	28	comparator	comparator	NN
cord-016197-y69wwy40	273	29	studies	study	NNS
cord-016197-y69wwy40	273	30	required	require	VBN
cord-016197-y69wwy40	273	31	to	to	TO
cord-016197-y69wwy40	273	32	achieve	achieve	VB
cord-016197-y69wwy40	273	33	a	a	DT
cord-016197-y69wwy40	273	34	broad	broad	JJ
cord-016197-y69wwy40	273	35	label	label	NN
cord-016197-y69wwy40	273	36	.	.	.
cord-016197-y69wwy40	274	1	8	8	CD
cord-016197-y69wwy40	274	2	.	.	.
cord-016197-y69wwy40	275	1	Bacteriological	bacteriological	JJ
cord-016197-y69wwy40	275	2	study	study	NN
cord-016197-y69wwy40	275	3	populations	population	NNS
cord-016197-y69wwy40	275	4	and	and	CC
cord-016197-y69wwy40	275	5	endpoints	endpoint	NNS
cord-016197-y69wwy40	275	6	requirements	requirement	NNS
cord-016197-y69wwy40	275	7	(	(	-LRB-
cord-016197-y69wwy40	275	8	FDA	FDA	NNP
cord-016197-y69wwy40	275	9	,	,	,
cord-016197-y69wwy40	275	10	CPMP)-bacteriological	CPMP)-bacteriological	NNP
cord-016197-y69wwy40	275	11	endpoints	endpoint	NNS
cord-016197-y69wwy40	275	12	required	require	VBN
cord-016197-y69wwy40	275	13	for	for	IN
cord-016197-y69wwy40	275	14	breakpoints	breakpoint	NNS
cord-016197-y69wwy40	275	15	,	,	,
cord-016197-y69wwy40	275	16	labelling	labelling	NN
cord-016197-y69wwy40	275	17	,	,	,
cord-016197-y69wwy40	275	18	and	and	CC
cord-016197-y69wwy40	275	19	differentiation	differentiation	NN
cord-016197-y69wwy40	275	20	.	.	.
cord-016197-y69wwy40	276	1	9	9	LS
cord-016197-y69wwy40	276	2	.	.	.
cord-016197-y69wwy40	277	1	National	national	JJ
cord-016197-y69wwy40	277	2	comparators	comparator	NNS
cord-016197-y69wwy40	277	3	and	and	CC
cord-016197-y69wwy40	277	4	resistance	resistance	NN
cord-016197-y69wwy40	277	5	in	in	IN
cord-016197-y69wwy40	277	6	EU	EU	NNP
cord-016197-y69wwy40	277	7	(	(	-LRB-
cord-016197-y69wwy40	277	8	CPMP)-additional	CPMP)-additional	NNP
cord-016197-y69wwy40	277	9	studies	study	NNS
cord-016197-y69wwy40	277	10	needed	need	VBD
cord-016197-y69wwy40	277	11	to	to	TO
cord-016197-y69wwy40	277	12	address	address	VB
cord-016197-y69wwy40	277	13	national	national	JJ
cord-016197-y69wwy40	277	14	comparators	comparator	NNS
cord-016197-y69wwy40	277	15	.	.	.
cord-016197-y69wwy40	278	1	The	the	DT
cord-016197-y69wwy40	278	2	regulatory	regulatory	JJ
cord-016197-y69wwy40	278	3	guidelines	guideline	NNS
cord-016197-y69wwy40	278	4	are	be	VBP
cord-016197-y69wwy40	278	5	increasingly	increasingly	RB
cord-016197-y69wwy40	278	6	focusing	focus	VBG
cord-016197-y69wwy40	278	7	on	on	IN
cord-016197-y69wwy40	278	8	the	the	DT
cord-016197-y69wwy40	278	9	need	need	NN
cord-016197-y69wwy40	278	10	for	for	IN
cord-016197-y69wwy40	278	11	demonstrations	demonstration	NNS
cord-016197-y69wwy40	278	12	of	of	IN
cord-016197-y69wwy40	278	13	non	non	JJ
cord-016197-y69wwy40	278	14	-	-	JJ
cord-016197-y69wwy40	278	15	inferior	inferior	JJ
cord-016197-y69wwy40	278	16	clinical	clinical	JJ
cord-016197-y69wwy40	278	17	efficacy	efficacy	NN
cord-016197-y69wwy40	278	18	in	in	IN
cord-016197-y69wwy40	278	19	randomized	randomized	JJ
cord-016197-y69wwy40	278	20	controlled	control	VBN
cord-016197-y69wwy40	278	21	trials	trial	NNS
cord-016197-y69wwy40	278	22	in	in	IN
cord-016197-y69wwy40	278	23	the	the	DT
cord-016197-y69wwy40	278	24	specific	specific	JJ
cord-016197-y69wwy40	278	25	indication	indication	NN
cord-016197-y69wwy40	278	26	.	.	.
cord-016197-y69wwy40	279	1	In	in	IN
cord-016197-y69wwy40	279	2	the	the	DT
cord-016197-y69wwy40	279	3	United	United	NNP
cord-016197-y69wwy40	279	4	States	States	NNP
cord-016197-y69wwy40	279	5	,	,	,
cord-016197-y69wwy40	279	6	inclusion	inclusion	NN
cord-016197-y69wwy40	279	7	in	in	IN
cord-016197-y69wwy40	279	8	the	the	DT
cord-016197-y69wwy40	279	9	product	product	NN
cord-016197-y69wwy40	279	10	label	label	NN
cord-016197-y69wwy40	279	11	of	of	IN
cord-016197-y69wwy40	279	12	only	only	RB
cord-016197-y69wwy40	279	13	those	those	DT
cord-016197-y69wwy40	279	14	organisms	organism	NNS
cord-016197-y69wwy40	279	15	isolated	isolate	VBN
cord-016197-y69wwy40	279	16	from	from	IN
cord-016197-y69wwy40	279	17	the	the	DT
cord-016197-y69wwy40	279	18	indication	indication	NN
cord-016197-y69wwy40	279	19	under	under	IN
cord-016197-y69wwy40	279	20	study	study	NN
cord-016197-y69wwy40	279	21	and	and	CC
cord-016197-y69wwy40	279	22	for	for	IN
cord-016197-y69wwy40	279	23	which	which	WDT
cord-016197-y69wwy40	279	24	clinical	clinical	JJ
cord-016197-y69wwy40	279	25	cure	cure	NN
cord-016197-y69wwy40	279	26	was	be	VBD
cord-016197-y69wwy40	279	27	achieved	achieve	VBN
cord-016197-y69wwy40	279	28	is	be	VBZ
cord-016197-y69wwy40	279	29	proposed	propose	VBN
cord-016197-y69wwy40	279	30	,	,	,
cord-016197-y69wwy40	279	31	irrespective	irrespective	RB
cord-016197-y69wwy40	279	32	of	of	IN
cord-016197-y69wwy40	279	33	the	the	DT
cord-016197-y69wwy40	279	34	in	in	FW
cord-016197-y69wwy40	279	35	vitro	vitro	FW
cord-016197-y69wwy40	279	36	activity	activity	NN
cord-016197-y69wwy40	279	37	spectrum	spectrum	NN
cord-016197-y69wwy40	279	38	.	.	.
cord-016197-y69wwy40	280	1	Label	label	NN
cord-016197-y69wwy40	280	2	indications	indication	NNS
cord-016197-y69wwy40	280	3	are	be	VBP
cord-016197-y69wwy40	280	4	a	a	DT
cord-016197-y69wwy40	280	5	key	key	JJ
cord-016197-y69wwy40	280	6	point	point	NN
cord-016197-y69wwy40	280	7	to	to	TO
cord-016197-y69wwy40	280	8	control	control	VB
cord-016197-y69wwy40	280	9	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	280	10	use	use	NN
cord-016197-y69wwy40	280	11	(	(	-LRB-
cord-016197-y69wwy40	280	12	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	280	13	,	,	,
cord-016197-y69wwy40	280	14	2001	2001	CD
cord-016197-y69wwy40	280	15	)	)	-RRB-
cord-016197-y69wwy40	280	16	and	and	CC
cord-016197-y69wwy40	280	17	any	any	DT
cord-016197-y69wwy40	280	18	information	information	NN
cord-016197-y69wwy40	280	19	given	give	VBN
cord-016197-y69wwy40	280	20	to	to	IN
cord-016197-y69wwy40	280	21	the	the	DT
cord-016197-y69wwy40	280	22	prescriber	prescriber	NN
cord-016197-y69wwy40	280	23	that	that	WDT
cord-016197-y69wwy40	280	24	is	be	VBZ
cord-016197-y69wwy40	280	25	able	able	JJ
cord-016197-y69wwy40	280	26	to	to	TO
cord-016197-y69wwy40	280	27	help	help	VB
cord-016197-y69wwy40	280	28	select	select	VB
cord-016197-y69wwy40	280	29	for	for	IN
cord-016197-y69wwy40	280	30	proper	proper	JJ
cord-016197-y69wwy40	280	31	indications	indication	NNS
cord-016197-y69wwy40	280	32	is	be	VBZ
cord-016197-y69wwy40	280	33	potentially	potentially	RB
cord-016197-y69wwy40	280	34	an	an	DT
cord-016197-y69wwy40	280	35	important	important	JJ
cord-016197-y69wwy40	280	36	tool	tool	NN
cord-016197-y69wwy40	280	37	for	for	IN
cord-016197-y69wwy40	280	38	good	good	JJ
cord-016197-y69wwy40	280	39	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	280	40	practice	practice	NN
cord-016197-y69wwy40	281	1	(	(	-LRB-
cord-016197-y69wwy40	281	2	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	281	3	,	,	,
cord-016197-y69wwy40	281	4	2001	2001	CD
cord-016197-y69wwy40	281	5	)	)	-RRB-
cord-016197-y69wwy40	281	6	.	.	.
cord-016197-y69wwy40	282	1	However	however	RB
cord-016197-y69wwy40	282	2	,	,	,
cord-016197-y69wwy40	282	3	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	282	4	(	(	-LRB-
cord-016197-y69wwy40	282	5	2001	2001	CD
cord-016197-y69wwy40	282	6	)	)	-RRB-
cord-016197-y69wwy40	282	7	also	also	RB
cord-016197-y69wwy40	282	8	states	state	VBZ
cord-016197-y69wwy40	282	9	that	that	IN
cord-016197-y69wwy40	282	10	there	there	EX
cord-016197-y69wwy40	282	11	is	be	VBZ
cord-016197-y69wwy40	282	12	a	a	DT
cord-016197-y69wwy40	282	13	critical	critical	JJ
cord-016197-y69wwy40	282	14	need	need	NN
cord-016197-y69wwy40	282	15	for	for	IN
cord-016197-y69wwy40	282	16	trials	trial	NNS
cord-016197-y69wwy40	282	17	to	to	TO
cord-016197-y69wwy40	282	18	select	select	VB
cord-016197-y69wwy40	282	19	for	for	IN
cord-016197-y69wwy40	282	20	those	those	DT
cord-016197-y69wwy40	282	21	patient	patient	JJ
cord-016197-y69wwy40	282	22	populations	population	NNS
cord-016197-y69wwy40	282	23	who	who	WP
cord-016197-y69wwy40	282	24	really	really	RB
cord-016197-y69wwy40	282	25	need	need	VBP
cord-016197-y69wwy40	282	26	antibiotics	antibiotic	NNS
cord-016197-y69wwy40	282	27	,	,	,
cord-016197-y69wwy40	282	28	or	or	CC
cord-016197-y69wwy40	282	29	to	to	TO
cord-016197-y69wwy40	282	30	look	look	VB
cord-016197-y69wwy40	282	31	for	for	IN
cord-016197-y69wwy40	282	32	new	new	JJ
cord-016197-y69wwy40	282	33	endpoints	endpoint	NNS
cord-016197-y69wwy40	282	34	able	able	JJ
cord-016197-y69wwy40	282	35	to	to	TO
cord-016197-y69wwy40	282	36	differentiate	differentiate	VB
cord-016197-y69wwy40	282	37	between	between	IN
cord-016197-y69wwy40	282	38	drugs	drug	NNS
cord-016197-y69wwy40	282	39	,	,	,
cord-016197-y69wwy40	282	40	rather	rather	RB
cord-016197-y69wwy40	282	41	than	than	IN
cord-016197-y69wwy40	282	42	only	only	RB
cord-016197-y69wwy40	282	43	demonstrating	demonstrate	VBG
cord-016197-y69wwy40	282	44	equivalence	equivalence	NN
cord-016197-y69wwy40	282	45	.	.	.
cord-016197-y69wwy40	283	1	This	this	DT
cord-016197-y69wwy40	283	2	approach	approach	NN
cord-016197-y69wwy40	283	3	may	may	MD
cord-016197-y69wwy40	283	4	ensure	ensure	VB
cord-016197-y69wwy40	283	5	that	that	IN
cord-016197-y69wwy40	283	6	clinical	clinical	JJ
cord-016197-y69wwy40	283	7	evidence	evidence	NN
cord-016197-y69wwy40	283	8	supports	support	VBZ
cord-016197-y69wwy40	283	9	the	the	DT
cord-016197-y69wwy40	283	10	claim	claim	NN
cord-016197-y69wwy40	283	11	for	for	IN
cord-016197-y69wwy40	283	12	beneficial	beneficial	JJ
cord-016197-y69wwy40	283	13	activity	activity	NN
cord-016197-y69wwy40	283	14	against	against	IN
cord-016197-y69wwy40	283	15	a	a	DT
cord-016197-y69wwy40	283	16	particular	particular	JJ
cord-016197-y69wwy40	283	17	organism	organism	NN
cord-016197-y69wwy40	283	18	in	in	IN
cord-016197-y69wwy40	283	19	a	a	DT
cord-016197-y69wwy40	283	20	particular	particular	JJ
cord-016197-y69wwy40	283	21	indication	indication	NN
cord-016197-y69wwy40	283	22	,	,	,
cord-016197-y69wwy40	283	23	or	or	CC
cord-016197-y69wwy40	283	24	population	population	NN
cord-016197-y69wwy40	283	25	,	,	,
cord-016197-y69wwy40	283	26	but	but	CC
cord-016197-y69wwy40	283	27	inevitably	inevitably	RB
cord-016197-y69wwy40	283	28	will	will	MD
cord-016197-y69wwy40	283	29	restrict	restrict	VB
cord-016197-y69wwy40	283	30	the	the	DT
cord-016197-y69wwy40	283	31	breadth	breadth	NN
cord-016197-y69wwy40	283	32	of	of	IN
cord-016197-y69wwy40	283	33	label	label	NN
cord-016197-y69wwy40	283	34	.	.	.
cord-016197-y69wwy40	284	1	The	the	DT
cord-016197-y69wwy40	284	2	commercial	commercial	JJ
cord-016197-y69wwy40	284	3	implications	implication	NNS
cord-016197-y69wwy40	284	4	of	of	IN
cord-016197-y69wwy40	284	5	limited	limited	JJ
cord-016197-y69wwy40	284	6	labels	label	NNS
cord-016197-y69wwy40	284	7	based	base	VBN
cord-016197-y69wwy40	284	8	on	on	IN
cord-016197-y69wwy40	284	9	proof	proof	NN
cord-016197-y69wwy40	284	10	of	of	IN
cord-016197-y69wwy40	284	11	superior	superior	JJ
cord-016197-y69wwy40	284	12	benefits	benefit	NNS
cord-016197-y69wwy40	284	13	(	(	-LRB-
cord-016197-y69wwy40	284	14	and	and	CC
cord-016197-y69wwy40	284	15	not	not	RB
cord-016197-y69wwy40	284	16	just	just	RB
cord-016197-y69wwy40	284	17	equivalence	equivalence	NN
cord-016197-y69wwy40	284	18	)	)	-RRB-
cord-016197-y69wwy40	284	19	,	,	,
cord-016197-y69wwy40	284	20	compared	compare	VBN
cord-016197-y69wwy40	284	21	with	with	IN
cord-016197-y69wwy40	284	22	broader	broad	JJR
cord-016197-y69wwy40	284	23	labelling	labelling	NN
cord-016197-y69wwy40	284	24	based	base	VBN
cord-016197-y69wwy40	284	25	on	on	IN
cord-016197-y69wwy40	284	26	equivalence	equivalence	NN
cord-016197-y69wwy40	284	27	will	will	MD
cord-016197-y69wwy40	284	28	be	be	VB
cord-016197-y69wwy40	284	29	critical	critical	JJ
cord-016197-y69wwy40	284	30	to	to	IN
cord-016197-y69wwy40	284	31	Pharma	Pharma	NNP
cord-016197-y69wwy40	284	32	.	.	.
cord-016197-y69wwy40	285	1	The	the	DT
cord-016197-y69wwy40	285	2	value	value	NN
cord-016197-y69wwy40	285	3	of	of	IN
cord-016197-y69wwy40	285	4	studying	study	VBG
cord-016197-y69wwy40	285	5	new	new	JJ
cord-016197-y69wwy40	285	6	endpoints	endpoint	NNS
cord-016197-y69wwy40	285	7	for	for	IN
cord-016197-y69wwy40	285	8	differentiation	differentiation	NN
cord-016197-y69wwy40	285	9	will	will	MD
cord-016197-y69wwy40	285	10	also	also	RB
cord-016197-y69wwy40	285	11	be	be	VB
cord-016197-y69wwy40	285	12	dependent	dependent	JJ
cord-016197-y69wwy40	285	13	on	on	IN
cord-016197-y69wwy40	285	14	acceptance	acceptance	NN
cord-016197-y69wwy40	285	15	of	of	IN
cord-016197-y69wwy40	285	16	the	the	DT
cord-016197-y69wwy40	285	17	endpoints	endpoint	NNS
cord-016197-y69wwy40	285	18	by	by	IN
cord-016197-y69wwy40	285	19	regulators	regulator	NNS
cord-016197-y69wwy40	285	20	,	,	,
cord-016197-y69wwy40	285	21	and	and	CC
cord-016197-y69wwy40	285	22	their	-PRON-	PRP$
cord-016197-y69wwy40	285	23	incorporation	incorporation	NN
cord-016197-y69wwy40	285	24	into	into	IN
cord-016197-y69wwy40	285	25	product	product	NN
cord-016197-y69wwy40	285	26	labelling	labelling	NN
cord-016197-y69wwy40	285	27	,	,	,
cord-016197-y69wwy40	285	28	enabling	enable	VBG
cord-016197-y69wwy40	285	29	promotion	promotion	NN
cord-016197-y69wwy40	285	30	and	and	CC
cord-016197-y69wwy40	285	31	communication	communication	NN
cord-016197-y69wwy40	285	32	.	.	.
cord-016197-y69wwy40	286	1	The	the	DT
cord-016197-y69wwy40	286	2	differential	differential	JJ
cord-016197-y69wwy40	286	3	benefits	benefit	NNS
cord-016197-y69wwy40	286	4	would	would	MD
cord-016197-y69wwy40	286	5	also	also	RB
cord-016197-y69wwy40	286	6	need	need	VB
cord-016197-y69wwy40	286	7	to	to	TO
cord-016197-y69wwy40	286	8	translate	translate	VB
cord-016197-y69wwy40	286	9	into	into	IN
cord-016197-y69wwy40	286	10	guidelines	guideline	NNS
cord-016197-y69wwy40	286	11	and	and	CC
cord-016197-y69wwy40	286	12	formulary	formulary	NN
cord-016197-y69wwy40	286	13	inclusion	inclusion	NN
cord-016197-y69wwy40	286	14	.	.	.
cord-016197-y69wwy40	287	1	It	-PRON-	PRP
cord-016197-y69wwy40	287	2	has	have	VBZ
cord-016197-y69wwy40	287	3	been	be	VBN
cord-016197-y69wwy40	287	4	argued	argue	VBN
cord-016197-y69wwy40	287	5	by	by	IN
cord-016197-y69wwy40	287	6	Monnet	Monnet	NNP
cord-016197-y69wwy40	287	7	and	and	CC
cord-016197-y69wwy40	287	8	Sorensen	Sorensen	NNP
cord-016197-y69wwy40	287	9	(	(	-LRB-
cord-016197-y69wwy40	287	10	2001	2001	CD
cord-016197-y69wwy40	287	11	)	)	-RRB-
cord-016197-y69wwy40	287	12	,	,	,
cord-016197-y69wwy40	287	13	that	that	IN
cord-016197-y69wwy40	287	14	antimicrobials	antimicrobial	NNS
cord-016197-y69wwy40	287	15	that	that	WDT
cord-016197-y69wwy40	287	16	represent	represent	VBP
cord-016197-y69wwy40	287	17	real	real	JJ
cord-016197-y69wwy40	287	18	innovations	innovation	NNS
cord-016197-y69wwy40	287	19	are	be	VBP
cord-016197-y69wwy40	287	20	readily	readily	RB
cord-016197-y69wwy40	287	21	accepted	accept	VBN
cord-016197-y69wwy40	287	22	by	by	IN
cord-016197-y69wwy40	287	23	hospital	hospital	NN
cord-016197-y69wwy40	287	24	prescribers	prescriber	NNS
cord-016197-y69wwy40	287	25	and	and	CC
cord-016197-y69wwy40	287	26	naturally	naturally	RB
cord-016197-y69wwy40	287	27	gain	gain	VB
cord-016197-y69wwy40	287	28	market	market	NN
cord-016197-y69wwy40	287	29	shares	share	NNS
cord-016197-y69wwy40	287	30	.	.	.
cord-016197-y69wwy40	288	1	The	the	DT
cord-016197-y69wwy40	288	2	hurdle	hurdle	NN
cord-016197-y69wwy40	288	3	is	be	VBZ
cord-016197-y69wwy40	288	4	in	in	IN
cord-016197-y69wwy40	288	5	being	be	VBG
cord-016197-y69wwy40	288	6	able	able	JJ
cord-016197-y69wwy40	288	7	to	to	TO
cord-016197-y69wwy40	288	8	demonstrate	demonstrate	VB
cord-016197-y69wwy40	288	9	the	the	DT
cord-016197-y69wwy40	288	10	innovative	innovative	JJ
cord-016197-y69wwy40	288	11	benefits	benefit	NNS
cord-016197-y69wwy40	288	12	to	to	IN
cord-016197-y69wwy40	288	13	the	the	DT
cord-016197-y69wwy40	288	14	satisfaction	satisfaction	NN
cord-016197-y69wwy40	288	15	of	of	IN
cord-016197-y69wwy40	288	16	the	the	DT
cord-016197-y69wwy40	288	17	regulators	regulator	NNS
cord-016197-y69wwy40	288	18	and	and	CC
cord-016197-y69wwy40	288	19	decision	decision	NN
cord-016197-y69wwy40	288	20	-	-	HYPH
cord-016197-y69wwy40	288	21	makers	maker	NNS
cord-016197-y69wwy40	288	22	,	,	,
cord-016197-y69wwy40	288	23	and	and	CC
cord-016197-y69wwy40	288	24	in	in	IN
cord-016197-y69wwy40	288	25	there	there	EX
cord-016197-y69wwy40	288	26	being	be	VBG
cord-016197-y69wwy40	288	27	sufficient	sufficient	JJ
cord-016197-y69wwy40	288	28	commercial	commercial	JJ
cord-016197-y69wwy40	288	29	return	return	NN
cord-016197-y69wwy40	288	30	from	from	IN
cord-016197-y69wwy40	288	31	use	use	NN
cord-016197-y69wwy40	288	32	in	in	IN
cord-016197-y69wwy40	288	33	a	a	DT
cord-016197-y69wwy40	288	34	narrow	narrow	RB
cord-016197-y69wwy40	288	35	-	-	HYPH
cord-016197-y69wwy40	288	36	defined	define	VBN
cord-016197-y69wwy40	288	37	patient	patient	NN
cord-016197-y69wwy40	288	38	group	group	NN
cord-016197-y69wwy40	288	39	.	.	.
cord-016197-y69wwy40	289	1	A	a	DT
cord-016197-y69wwy40	289	2	particular	particular	JJ
cord-016197-y69wwy40	289	3	issue	issue	NN
cord-016197-y69wwy40	289	4	is	be	VBZ
cord-016197-y69wwy40	289	5	that	that	IN
cord-016197-y69wwy40	289	6	there	there	EX
cord-016197-y69wwy40	289	7	will	will	MD
cord-016197-y69wwy40	289	8	be	be	VB
cord-016197-y69wwy40	289	9	significant	significant	JJ
cord-016197-y69wwy40	289	10	hurdles	hurdle	NNS
cord-016197-y69wwy40	289	11	in	in	IN
cord-016197-y69wwy40	289	12	the	the	DT
cord-016197-y69wwy40	289	13	ability	ability	NN
cord-016197-y69wwy40	289	14	of	of	IN
cord-016197-y69wwy40	289	15	Pharma	Pharma	NNPS
cord-016197-y69wwy40	289	16	to	to	TO
cord-016197-y69wwy40	289	17	demonstrate	demonstrate	VB
cord-016197-y69wwy40	289	18	clinical	clinical	JJ
cord-016197-y69wwy40	289	19	efficacy	efficacy	NN
cord-016197-y69wwy40	289	20	against	against	IN
cord-016197-y69wwy40	289	21	emerging	emerge	VBG
cord-016197-y69wwy40	289	22	resistant	resistant	JJ
cord-016197-y69wwy40	289	23	organisms	organism	NNS
cord-016197-y69wwy40	289	24	,	,	,
cord-016197-y69wwy40	289	25	which	which	WDT
cord-016197-y69wwy40	289	26	may	may	MD
cord-016197-y69wwy40	289	27	only	only	RB
cord-016197-y69wwy40	289	28	rarely	rarely	RB
cord-016197-y69wwy40	289	29	be	be	VB
cord-016197-y69wwy40	289	30	isolated	isolate	VBN
cord-016197-y69wwy40	289	31	in	in	IN
cord-016197-y69wwy40	289	32	clinical	clinical	JJ
cord-016197-y69wwy40	289	33	trials	trial	NNS
cord-016197-y69wwy40	289	34	.	.	.
cord-016197-y69wwy40	290	1	PK	PK	NNP
cord-016197-y69wwy40	290	2	/	/	SYM
cord-016197-y69wwy40	290	3	PD	PD	NNP
cord-016197-y69wwy40	290	4	data	datum	NNS
cord-016197-y69wwy40	290	5	which	which	WDT
cord-016197-y69wwy40	290	6	allow	allow	VBP
cord-016197-y69wwy40	290	7	predictions	prediction	NNS
cord-016197-y69wwy40	290	8	of	of	IN
cord-016197-y69wwy40	290	9	bacteriological	bacteriological	JJ
cord-016197-y69wwy40	290	10	efficacy	efficacy	NN
cord-016197-y69wwy40	290	11	to	to	TO
cord-016197-y69wwy40	290	12	be	be	VB
cord-016197-y69wwy40	290	13	made	make	VBN
cord-016197-y69wwy40	290	14	and	and	CC
cord-016197-y69wwy40	290	15	tested	test	VBN
cord-016197-y69wwy40	290	16	,	,	,
cord-016197-y69wwy40	290	17	for	for	IN
cord-016197-y69wwy40	290	18	example	example	NN
cord-016197-y69wwy40	290	19	,	,	,
cord-016197-y69wwy40	290	20	in	in	IN
cord-016197-y69wwy40	290	21	in	in	IN
cord-016197-y69wwy40	290	22	vivo	vivo	NN
cord-016197-y69wwy40	290	23	infection	infection	NN
cord-016197-y69wwy40	290	24	models	model	NNS
cord-016197-y69wwy40	290	25	of	of	IN
cord-016197-y69wwy40	290	26	simulated	simulated	JJ
cord-016197-y69wwy40	290	27	human	human	JJ
cord-016197-y69wwy40	290	28	PK	PK	NNP
cord-016197-y69wwy40	290	29	,	,	,
cord-016197-y69wwy40	290	30	or	or	CC
cord-016197-y69wwy40	290	31	in	in	IN
cord-016197-y69wwy40	290	32	small	small	JJ
cord-016197-y69wwy40	290	33	PD	PD	NNP
cord-016197-y69wwy40	290	34	studies	study	NNS
cord-016197-y69wwy40	290	35	in	in	IN
cord-016197-y69wwy40	290	36	patients	patient	NNS
cord-016197-y69wwy40	290	37	,	,	,
cord-016197-y69wwy40	290	38	have	have	VBP
cord-016197-y69wwy40	290	39	been	be	VBN
cord-016197-y69wwy40	290	40	proposed	propose	VBN
cord-016197-y69wwy40	290	41	by	by	IN
cord-016197-y69wwy40	290	42	a	a	DT
cord-016197-y69wwy40	290	43	number	number	NN
cord-016197-y69wwy40	290	44	of	of	IN
cord-016197-y69wwy40	290	45	bodies	body	NNS
cord-016197-y69wwy40	290	46	,	,	,
cord-016197-y69wwy40	290	47	including	include	VBG
cord-016197-y69wwy40	290	48	the	the	DT
cord-016197-y69wwy40	290	49	EU	EU	NNP
cord-016197-y69wwy40	290	50	CPMP	CPMP	NNP
cord-016197-y69wwy40	290	51	(	(	-LRB-
cord-016197-y69wwy40	290	52	EMEA	EMEA	NNP
cord-016197-y69wwy40	290	53	)	)	-RRB-
cord-016197-y69wwy40	290	54	.	.	.
cord-016197-y69wwy40	291	1	However	however	RB
cord-016197-y69wwy40	291	2	,	,	,
cord-016197-y69wwy40	291	3	the	the	DT
cord-016197-y69wwy40	291	4	use	use	NN
cord-016197-y69wwy40	291	5	of	of	IN
cord-016197-y69wwy40	291	6	such	such	JJ
cord-016197-y69wwy40	291	7	data	datum	NNS
cord-016197-y69wwy40	291	8	has	have	VBZ
cord-016197-y69wwy40	291	9	yet	yet	RB
cord-016197-y69wwy40	291	10	to	to	TO
cord-016197-y69wwy40	291	11	be	be	VB
cord-016197-y69wwy40	291	12	fully	fully	RB
cord-016197-y69wwy40	291	13	accepted	accept	VBN
cord-016197-y69wwy40	291	14	and	and	CC
cord-016197-y69wwy40	291	15	adopted	adopt	VBN
cord-016197-y69wwy40	291	16	by	by	IN
cord-016197-y69wwy40	291	17	the	the	DT
cord-016197-y69wwy40	291	18	FDA	FDA	NNP
cord-016197-y69wwy40	291	19	as	as	IN
cord-016197-y69wwy40	291	20	a	a	DT
cord-016197-y69wwy40	291	21	surrogate	surrogate	NN
cord-016197-y69wwy40	291	22	for	for	IN
cord-016197-y69wwy40	291	23	clinical	clinical	JJ
cord-016197-y69wwy40	291	24	efficacy	efficacy	NN
cord-016197-y69wwy40	291	25	and	and	CC
cord-016197-y69wwy40	291	26	breakpoint	breakpoint	NN
cord-016197-y69wwy40	291	27	determination	determination	NN
cord-016197-y69wwy40	291	28	.	.	.
cord-016197-y69wwy40	292	1	PK	PK	NNP
cord-016197-y69wwy40	292	2	/	/	SYM
cord-016197-y69wwy40	292	3	PD	PD	NNP
cord-016197-y69wwy40	292	4	data	datum	NNS
cord-016197-y69wwy40	292	5	are	be	VBP
cord-016197-y69wwy40	292	6	of	of	IN
cord-016197-y69wwy40	292	7	particular	particular	JJ
cord-016197-y69wwy40	292	8	interest	interest	NN
cord-016197-y69wwy40	292	9	when	when	WRB
cord-016197-y69wwy40	292	10	trying	try	VBG
cord-016197-y69wwy40	292	11	to	to	TO
cord-016197-y69wwy40	292	12	define	define	VB
cord-016197-y69wwy40	292	13	the	the	DT
cord-016197-y69wwy40	292	14	best	good	JJS
cord-016197-y69wwy40	292	15	dosage	dosage	NN
cord-016197-y69wwy40	292	16	and	and	CC
cord-016197-y69wwy40	292	17	dosing	dose	VBG
cord-016197-y69wwy40	292	18	regimens	regimen	NNS
cord-016197-y69wwy40	292	19	for	for	IN
cord-016197-y69wwy40	292	20	new	new	JJ
cord-016197-y69wwy40	292	21	compounds	compound	NNS
cord-016197-y69wwy40	292	22	.	.	.
cord-016197-y69wwy40	293	1	As	as	IN
cord-016197-y69wwy40	293	2	the	the	DT
cord-016197-y69wwy40	293	3	bacteriological	bacteriological	JJ
cord-016197-y69wwy40	293	4	endpoint	endpoint	NN
cord-016197-y69wwy40	293	5	correctly	correctly	RB
cord-016197-y69wwy40	293	6	defines	define	VBZ
cord-016197-y69wwy40	293	7	the	the	DT
cord-016197-y69wwy40	293	8	outcome	outcome	NN
cord-016197-y69wwy40	293	9	in	in	IN
cord-016197-y69wwy40	293	10	an	an	DT
cord-016197-y69wwy40	293	11	infectious	infectious	JJ
cord-016197-y69wwy40	293	12	process	process	NN
cord-016197-y69wwy40	293	13	it	-PRON-	PRP
cord-016197-y69wwy40	293	14	would	would	MD
cord-016197-y69wwy40	293	15	serve	serve	VB
cord-016197-y69wwy40	293	16	to	to	TO
cord-016197-y69wwy40	293	17	assess	assess	VB
cord-016197-y69wwy40	293	18	the	the	DT
cord-016197-y69wwy40	293	19	PK	PK	NNP
cord-016197-y69wwy40	293	20	/	/	SYM
cord-016197-y69wwy40	293	21	PD	PD	NNP
cord-016197-y69wwy40	293	22	relationship	relationship	NN
cord-016197-y69wwy40	293	23	of	of	IN
cord-016197-y69wwy40	293	24	a	a	DT
cord-016197-y69wwy40	293	25	drug	drug	NN
cord-016197-y69wwy40	293	26	(	(	-LRB-
cord-016197-y69wwy40	293	27	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	293	28	,	,	,
cord-016197-y69wwy40	293	29	2001	2001	CD
cord-016197-y69wwy40	293	30	)	)	-RRB-
cord-016197-y69wwy40	293	31	.	.	.
cord-016197-y69wwy40	294	1	Using	use	VBG
cord-016197-y69wwy40	294	2	PK	PK	NNP
cord-016197-y69wwy40	294	3	/	/	SYM
cord-016197-y69wwy40	294	4	PD	PD	NNP
cord-016197-y69wwy40	294	5	data	datum	NNS
cord-016197-y69wwy40	294	6	to	to	TO
cord-016197-y69wwy40	294	7	predict	predict	VB
cord-016197-y69wwy40	294	8	bacterial	bacterial	JJ
cord-016197-y69wwy40	294	9	eradication	eradication	NN
cord-016197-y69wwy40	294	10	or	or	CC
cord-016197-y69wwy40	294	11	clinical	clinical	JJ
cord-016197-y69wwy40	294	12	outcome	outcome	NN
cord-016197-y69wwy40	294	13	should	should	MD
cord-016197-y69wwy40	294	14	be	be	VB
cord-016197-y69wwy40	294	15	considered	consider	VBN
cord-016197-y69wwy40	294	16	as	as	IN
cord-016197-y69wwy40	294	17	the	the	DT
cord-016197-y69wwy40	294	18	only	only	JJ
cord-016197-y69wwy40	294	19	way	way	NN
cord-016197-y69wwy40	294	20	to	to	TO
cord-016197-y69wwy40	294	21	select	select	VB
cord-016197-y69wwy40	294	22	for	for	IN
cord-016197-y69wwy40	294	23	optimal	optimal	JJ
cord-016197-y69wwy40	294	24	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	294	25	regimens	regimen	NNS
cord-016197-y69wwy40	294	26	regarding	regard	VBG
cord-016197-y69wwy40	294	27	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	294	28	choice	choice	NN
cord-016197-y69wwy40	294	29	and	and	CC
cord-016197-y69wwy40	294	30	dosing	dose	VBG
cord-016197-y69wwy40	294	31	regimen	regimen	NN
cord-016197-y69wwy40	294	32	as	as	RB
cord-016197-y69wwy40	294	33	well	well	RB
cord-016197-y69wwy40	294	34	as	as	IN
cord-016197-y69wwy40	294	35	determining	determine	VBG
cord-016197-y69wwy40	294	36	the	the	DT
cord-016197-y69wwy40	294	37	optimal	optimal	JJ
cord-016197-y69wwy40	294	38	therapy	therapy	NN
cord-016197-y69wwy40	294	39	duration	duration	NN
cord-016197-y69wwy40	294	40	(	(	-LRB-
cord-016197-y69wwy40	294	41	Ball	ball	NN
cord-016197-y69wwy40	294	42	et	et	FW
cord-016197-y69wwy40	294	43	al	al	NNP
cord-016197-y69wwy40	294	44	.	.	NNP
cord-016197-y69wwy40	294	45	,	,	,
cord-016197-y69wwy40	294	46	2002	2002	CD
cord-016197-y69wwy40	294	47	;	;	:
cord-016197-y69wwy40	294	48	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	294	49	,	,	,
cord-016197-y69wwy40	294	50	2001	2001	CD
cord-016197-y69wwy40	294	51	)	)	-RRB-
cord-016197-y69wwy40	294	52	.	.	.
cord-016197-y69wwy40	295	1	A	a	DT
cord-016197-y69wwy40	295	2	greater	great	JJR
cord-016197-y69wwy40	295	3	role	role	NN
cord-016197-y69wwy40	295	4	of	of	IN
cord-016197-y69wwy40	295	5	predictive	predictive	JJ
cord-016197-y69wwy40	295	6	PK	PK	NNP
cord-016197-y69wwy40	295	7	/	/	SYM
cord-016197-y69wwy40	295	8	PD	PD	NNP
cord-016197-y69wwy40	295	9	data	datum	NNS
cord-016197-y69wwy40	295	10	and	and	CC
cord-016197-y69wwy40	295	11	modelling	modelling	NN
cord-016197-y69wwy40	295	12	under	under	IN
cord-016197-y69wwy40	295	13	certain	certain	JJ
cord-016197-y69wwy40	295	14	circumstances	circumstance	NNS
cord-016197-y69wwy40	295	15	and	and	CC
cord-016197-y69wwy40	295	16	for	for	IN
cord-016197-y69wwy40	295	17	specific	specific	JJ
cord-016197-y69wwy40	295	18	target	target	NN
cord-016197-y69wwy40	295	19	populations	population	NNS
cord-016197-y69wwy40	295	20	,	,	,
cord-016197-y69wwy40	295	21	has	have	VBZ
cord-016197-y69wwy40	295	22	been	be	VBN
cord-016197-y69wwy40	295	23	proposed	propose	VBN
cord-016197-y69wwy40	295	24	by	by	IN
cord-016197-y69wwy40	295	25	CPMP	CPMP	NNP
cord-016197-y69wwy40	295	26	(	(	-LRB-
cord-016197-y69wwy40	295	27	EMEA	EMEA	NNP
cord-016197-y69wwy40	295	28	)	)	-RRB-
cord-016197-y69wwy40	295	29	and	and	CC
cord-016197-y69wwy40	295	30	is	be	VBZ
cord-016197-y69wwy40	295	31	supported	support	VBN
cord-016197-y69wwy40	295	32	in	in	IN
cord-016197-y69wwy40	295	33	general	general	JJ
cord-016197-y69wwy40	295	34	by	by	IN
cord-016197-y69wwy40	295	35	Pharma	Pharma	NNP
cord-016197-y69wwy40	295	36	.	.	.
cord-016197-y69wwy40	296	1	Global	Global	NNP
cord-016197-y69wwy40	296	2	Pharma	Pharma	NNP
cord-016197-y69wwy40	296	3	need	need	VBP
cord-016197-y69wwy40	296	4	to	to	TO
cord-016197-y69wwy40	296	5	conduct	conduct	VB
cord-016197-y69wwy40	296	6	clinical	clinical	JJ
cord-016197-y69wwy40	296	7	development	development	NN
cord-016197-y69wwy40	296	8	programmes	programme	NNS
cord-016197-y69wwy40	296	9	that	that	WDT
cord-016197-y69wwy40	296	10	satisfy	satisfy	VBP
cord-016197-y69wwy40	296	11	the	the	DT
cord-016197-y69wwy40	296	12	highest	high	JJS
cord-016197-y69wwy40	296	13	requirements	requirement	NNS
cord-016197-y69wwy40	296	14	of	of	IN
cord-016197-y69wwy40	296	15	both	both	CC
cord-016197-y69wwy40	296	16	FDA	FDA	NNP
cord-016197-y69wwy40	296	17	and	and	CC
cord-016197-y69wwy40	296	18	EMEA	EMEA	NNP
cord-016197-y69wwy40	296	19	.	.	.
cord-016197-y69wwy40	297	1	In	in	IN
cord-016197-y69wwy40	297	2	Europe	Europe	NNP
cord-016197-y69wwy40	297	3	,	,	,
cord-016197-y69wwy40	297	4	there	there	EX
cord-016197-y69wwy40	297	5	is	be	VBZ
cord-016197-y69wwy40	297	6	a	a	DT
cord-016197-y69wwy40	297	7	need	need	NN
cord-016197-y69wwy40	297	8	to	to	TO
cord-016197-y69wwy40	297	9	include	include	VB
cord-016197-y69wwy40	297	10	comparative	comparative	JJ
cord-016197-y69wwy40	297	11	agents	agent	NNS
cord-016197-y69wwy40	297	12	approved	approve	VBN
cord-016197-y69wwy40	297	13	and	and	CC
cord-016197-y69wwy40	297	14	relevant	relevant	JJ
cord-016197-y69wwy40	297	15	to	to	IN
cord-016197-y69wwy40	297	16	individual	individual	JJ
cord-016197-y69wwy40	297	17	EU	EU	NNP
cord-016197-y69wwy40	297	18	countries	country	NNS
cord-016197-y69wwy40	297	19	,	,	,
cord-016197-y69wwy40	297	20	or	or	CC
cord-016197-y69wwy40	297	21	for	for	IN
cord-016197-y69wwy40	297	22	which	which	WDT
cord-016197-y69wwy40	297	23	a	a	DT
cord-016197-y69wwy40	297	24	consensus	consensus	NN
cord-016197-y69wwy40	297	25	justification	justification	NN
cord-016197-y69wwy40	297	26	can	can	MD
cord-016197-y69wwy40	297	27	be	be	VB
cord-016197-y69wwy40	297	28	argued	argue	VBN
cord-016197-y69wwy40	297	29	,	,	,
cord-016197-y69wwy40	297	30	for	for	IN
cord-016197-y69wwy40	297	31	technical	technical	JJ
cord-016197-y69wwy40	297	32	approval	approval	NN
cord-016197-y69wwy40	297	33	(	(	-LRB-
cord-016197-y69wwy40	297	34	EMEA	EMEA	NNP
cord-016197-y69wwy40	297	35	)	)	-RRB-
cord-016197-y69wwy40	297	36	.	.	.
cord-016197-y69wwy40	298	1	Phase	phase	NN
cord-016197-y69wwy40	298	2	III	iii	CD
cord-016197-y69wwy40	298	3	clinical	clinical	JJ
cord-016197-y69wwy40	298	4	trials	trial	NNS
cord-016197-y69wwy40	298	5	are	be	VBP
cord-016197-y69wwy40	298	6	designed	design	VBN
cord-016197-y69wwy40	298	7	primarily	primarily	RB
cord-016197-y69wwy40	298	8	to	to	TO
cord-016197-y69wwy40	298	9	meet	meet	VB
cord-016197-y69wwy40	298	10	the	the	DT
cord-016197-y69wwy40	298	11	requirements	requirement	NNS
cord-016197-y69wwy40	298	12	of	of	IN
cord-016197-y69wwy40	298	13	the	the	DT
cord-016197-y69wwy40	298	14	regulators	regulator	NNS
cord-016197-y69wwy40	298	15	.	.	.
cord-016197-y69wwy40	299	1	However	however	RB
cord-016197-y69wwy40	299	2	,	,	,
cord-016197-y69wwy40	299	3	these	these	DT
cord-016197-y69wwy40	299	4	traditional	traditional	JJ
cord-016197-y69wwy40	299	5	comparative	comparative	JJ
cord-016197-y69wwy40	299	6	noninferiority	noninferiority	NN
cord-016197-y69wwy40	299	7	trials	trial	NNS
cord-016197-y69wwy40	299	8	fail	fail	VBP
cord-016197-y69wwy40	299	9	to	to	TO
cord-016197-y69wwy40	299	10	provide	provide	VB
cord-016197-y69wwy40	299	11	important	important	JJ
cord-016197-y69wwy40	299	12	evidence	evidence	NN
cord-016197-y69wwy40	299	13	of	of	IN
cord-016197-y69wwy40	299	14	potential	potential	JJ
cord-016197-y69wwy40	299	15	benefits	benefit	NNS
cord-016197-y69wwy40	299	16	over	over	IN
cord-016197-y69wwy40	299	17	existing	exist	VBG
cord-016197-y69wwy40	299	18	therapies	therapy	NNS
cord-016197-y69wwy40	299	19	.	.	.
cord-016197-y69wwy40	300	1	With	with	IN
cord-016197-y69wwy40	300	2	clinical	clinical	JJ
cord-016197-y69wwy40	300	3	success	success	NN
cord-016197-y69wwy40	300	4	for	for	IN
cord-016197-y69wwy40	300	5	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	300	6	in	in	IN
cord-016197-y69wwy40	300	7	the	the	DT
cord-016197-y69wwy40	300	8	85	85	CD
cord-016197-y69wwy40	300	9	%	%	NN
cord-016197-y69wwy40	300	10	or	or	CC
cord-016197-y69wwy40	300	11	more	more	JJR
cord-016197-y69wwy40	300	12	level	level	NN
cord-016197-y69wwy40	300	13	,	,	,
cord-016197-y69wwy40	300	14	demonstrations	demonstration	NNS
cord-016197-y69wwy40	300	15	of	of	IN
cord-016197-y69wwy40	300	16	superiority	superiority	NN
cord-016197-y69wwy40	300	17	require	require	VBP
cord-016197-y69wwy40	300	18	vast	vast	JJ
cord-016197-y69wwy40	300	19	patient	patient	JJ
cord-016197-y69wwy40	300	20	populations	population	NNS
cord-016197-y69wwy40	300	21	.	.	.
cord-016197-y69wwy40	301	1	Pharma	Pharma	NNS
cord-016197-y69wwy40	301	2	rely	rely	VBP
cord-016197-y69wwy40	301	3	on	on	IN
cord-016197-y69wwy40	301	4	other	other	JJ
cord-016197-y69wwy40	301	5	data	datum	NNS
cord-016197-y69wwy40	301	6	to	to	TO
cord-016197-y69wwy40	301	7	indicate	indicate	VB
cord-016197-y69wwy40	301	8	superiority	superiority	NN
cord-016197-y69wwy40	301	9	and	and	CC
cord-016197-y69wwy40	301	10	benefit	benefit	NN
cord-016197-y69wwy40	301	11	,	,	,
cord-016197-y69wwy40	301	12	ranging	range	VBG
cord-016197-y69wwy40	301	13	from	from	IN
cord-016197-y69wwy40	301	14	potency	potency	NN
cord-016197-y69wwy40	301	15	(	(	-LRB-
cord-016197-y69wwy40	301	16	minimum	minimum	JJ
cord-016197-y69wwy40	301	17	inhibitory	inhibitory	JJ
cord-016197-y69wwy40	301	18	concentrations	concentration	NNS
cord-016197-y69wwy40	301	19	,	,	,
cord-016197-y69wwy40	301	20	etc	etc	FW
cord-016197-y69wwy40	301	21	.	.	.
cord-016197-y69wwy40	301	22	)	)	-RRB-
cord-016197-y69wwy40	301	23	,	,	,
cord-016197-y69wwy40	301	24	per	per	IN
cord-016197-y69wwy40	301	25	cent	cent	NN
cord-016197-y69wwy40	301	26	susceptibility	susceptibility	NN
cord-016197-y69wwy40	301	27	based	base	VBN
cord-016197-y69wwy40	301	28	on	on	IN
cord-016197-y69wwy40	301	29	breakpoint	breakpoint	NN
cord-016197-y69wwy40	301	30	,	,	,
cord-016197-y69wwy40	301	31	in	in	IN
cord-016197-y69wwy40	301	32	vitro	vitro	FW
cord-016197-y69wwy40	301	33	and	and	CC
cord-016197-y69wwy40	301	34	in	in	IN
cord-016197-y69wwy40	301	35	vivo	vivo	NN
cord-016197-y69wwy40	301	36	models	model	NNS
cord-016197-y69wwy40	301	37	,	,	,
cord-016197-y69wwy40	301	38	PK	PK	NNP
cord-016197-y69wwy40	301	39	/	/	SYM
cord-016197-y69wwy40	301	40	PD	PD	NNP
cord-016197-y69wwy40	301	41	,	,	,
cord-016197-y69wwy40	301	42	and	and	CC
cord-016197-y69wwy40	301	43	defined	define	VBD
cord-016197-y69wwy40	301	44	clinical	clinical	JJ
cord-016197-y69wwy40	301	45	studies	study	NNS
cord-016197-y69wwy40	301	46	to	to	TO
cord-016197-y69wwy40	301	47	demonstrate	demonstrate	VB
cord-016197-y69wwy40	301	48	bacteriological	bacteriological	JJ
cord-016197-y69wwy40	301	49	and	and	CC
cord-016197-y69wwy40	301	50	health	health	NN
cord-016197-y69wwy40	301	51	-	-	HYPH
cord-016197-y69wwy40	301	52	outcome	outcome	NN
cord-016197-y69wwy40	301	53	benefits	benefit	NNS
cord-016197-y69wwy40	301	54	.	.	.
cord-016197-y69wwy40	302	1	Much	much	JJ
cord-016197-y69wwy40	302	2	of	of	IN
cord-016197-y69wwy40	302	3	the	the	DT
cord-016197-y69wwy40	302	4	clinical	clinical	JJ
cord-016197-y69wwy40	302	5	work	work	NN
cord-016197-y69wwy40	302	6	undertaken	undertake	VBN
cord-016197-y69wwy40	302	7	to	to	TO
cord-016197-y69wwy40	302	8	secure	secure	VB
cord-016197-y69wwy40	302	9	regulatory	regulatory	JJ
cord-016197-y69wwy40	302	10	approval	approval	NN
cord-016197-y69wwy40	302	11	fails	fail	VBZ
cord-016197-y69wwy40	302	12	to	to	TO
cord-016197-y69wwy40	302	13	best	best	RB
cord-016197-y69wwy40	302	14	demonstrate	demonstrate	VB
cord-016197-y69wwy40	302	15	the	the	DT
cord-016197-y69wwy40	302	16	role	role	NN
cord-016197-y69wwy40	302	17	and	and	CC
cord-016197-y69wwy40	302	18	clinical	clinical	JJ
cord-016197-y69wwy40	302	19	benefits	benefit	NNS
cord-016197-y69wwy40	302	20	of	of	IN
cord-016197-y69wwy40	302	21	new	new	JJ
cord-016197-y69wwy40	302	22	agents	agent	NNS
cord-016197-y69wwy40	302	23	(	(	-LRB-
cord-016197-y69wwy40	303	1	Bax	Bax	NNP
cord-016197-y69wwy40	303	2	et	et	NNP
cord-016197-y69wwy40	303	3	al	al	NNP
cord-016197-y69wwy40	303	4	.	.	NNP
cord-016197-y69wwy40	303	5	,	,	,
cord-016197-y69wwy40	304	1	1999	1999	LS
cord-016197-y69wwy40	304	2	)	)	-RRB-
cord-016197-y69wwy40	304	3	and	and	CC
cord-016197-y69wwy40	304	4	yet	yet	RB
cord-016197-y69wwy40	304	5	is	be	VBZ
cord-016197-y69wwy40	304	6	often	often	RB
cord-016197-y69wwy40	304	7	used	use	VBN
cord-016197-y69wwy40	304	8	as	as	IN
cord-016197-y69wwy40	304	9	the	the	DT
cord-016197-y69wwy40	304	10	evidence	evidence	NN
cord-016197-y69wwy40	304	11	base	base	NN
cord-016197-y69wwy40	304	12	for	for	IN
cord-016197-y69wwy40	304	13	reimbursement	reimbursement	NN
cord-016197-y69wwy40	304	14	,	,	,
cord-016197-y69wwy40	304	15	guidelines	guideline	NNS
cord-016197-y69wwy40	304	16	,	,	,
cord-016197-y69wwy40	304	17	and	and	CC
cord-016197-y69wwy40	304	18	policies	policy	NNS
cord-016197-y69wwy40	304	19	.	.	.
cord-016197-y69wwy40	305	1	There	there	EX
cord-016197-y69wwy40	305	2	has	have	VBZ
cord-016197-y69wwy40	305	3	also	also	RB
cord-016197-y69wwy40	305	4	been	be	VBN
cord-016197-y69wwy40	305	5	a	a	DT
cord-016197-y69wwy40	305	6	proposal	proposal	NN
cord-016197-y69wwy40	305	7	to	to	TO
cord-016197-y69wwy40	305	8	update	update	VB
cord-016197-y69wwy40	305	9	and	and	CC
cord-016197-y69wwy40	305	10	harmonize	harmonize	VB
cord-016197-y69wwy40	305	11	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	305	12	product	product	NN
cord-016197-y69wwy40	305	13	labels	label	NNS
cord-016197-y69wwy40	305	14	between	between	IN
cord-016197-y69wwy40	305	15	European	european	JJ
cord-016197-y69wwy40	305	16	countries	country	NNS
cord-016197-y69wwy40	305	17	,	,	,
cord-016197-y69wwy40	305	18	particularly	particularly	RB
cord-016197-y69wwy40	305	19	for	for	IN
cord-016197-y69wwy40	305	20	"	"	``
cord-016197-y69wwy40	305	21	old	old	JJ
cord-016197-y69wwy40	305	22	"	"	''
cord-016197-y69wwy40	305	23	antibiotics	antibiotic	NNS
cord-016197-y69wwy40	305	24	and	and	CC
cord-016197-y69wwy40	305	25	their	-PRON-	PRP$
cord-016197-y69wwy40	305	26	datasheets	datasheet	NNS
cord-016197-y69wwy40	305	27	(	(	-LRB-
cord-016197-y69wwy40	305	28	summary	summary	NN
cord-016197-y69wwy40	305	29	of	of	IN
cord-016197-y69wwy40	305	30	product	product	NN
cord-016197-y69wwy40	305	31	characteristics	characteristic	NNS
cord-016197-y69wwy40	305	32	)	)	-RRB-
cord-016197-y69wwy40	305	33	at	at	IN
cord-016197-y69wwy40	305	34	the	the	DT
cord-016197-y69wwy40	305	35	time	time	NN
cord-016197-y69wwy40	305	36	of	of	IN
cord-016197-y69wwy40	305	37	generic	generic	JJ
cord-016197-y69wwy40	305	38	introductions	introduction	NNS
cord-016197-y69wwy40	305	39	because	because	IN
cord-016197-y69wwy40	305	40	lack	lack	NN
cord-016197-y69wwy40	305	41	of	of	IN
cord-016197-y69wwy40	305	42	relevant	relevant	JJ
cord-016197-y69wwy40	305	43	product	product	NN
cord-016197-y69wwy40	305	44	information	information	NN
cord-016197-y69wwy40	305	45	promotes	promote	VBZ
cord-016197-y69wwy40	305	46	inappropriate	inappropriate	JJ
cord-016197-y69wwy40	305	47	use	use	NN
cord-016197-y69wwy40	305	48	(	(	-LRB-
cord-016197-y69wwy40	305	49	European	European	NNP
cord-016197-y69wwy40	305	50	Conference	Conference	NNP
cord-016197-y69wwy40	305	51	on	on	IN
cord-016197-y69wwy40	305	52	Antibiotic	Antibiotic	NNP
cord-016197-y69wwy40	305	53	Use	Use	NNP
cord-016197-y69wwy40	305	54	in	in	IN
cord-016197-y69wwy40	305	55	Europe	Europe	NNP
cord-016197-y69wwy40	305	56	,	,	,
cord-016197-y69wwy40	305	57	15	15	CD
cord-016197-y69wwy40	305	58	-	-	SYM
cord-016197-y69wwy40	305	59	17	17	CD
cord-016197-y69wwy40	305	60	November	November	NNP
cord-016197-y69wwy40	305	61	,	,	,
cord-016197-y69wwy40	305	62	2001	2001	CD
cord-016197-y69wwy40	305	63	;	;	:
cord-016197-y69wwy40	305	64	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	305	65	,	,	,
cord-016197-y69wwy40	305	66	2001	2001	CD
cord-016197-y69wwy40	305	67	)	)	-RRB-
cord-016197-y69wwy40	305	68	.	.	.
cord-016197-y69wwy40	306	1	The	the	DT
cord-016197-y69wwy40	306	2	burden	burden	NN
cord-016197-y69wwy40	306	3	of	of	IN
cord-016197-y69wwy40	306	4	cost	cost	NN
cord-016197-y69wwy40	306	5	to	to	TO
cord-016197-y69wwy40	306	6	provide	provide	VB
cord-016197-y69wwy40	306	7	new	new	JJ
cord-016197-y69wwy40	306	8	data	datum	NNS
cord-016197-y69wwy40	306	9	to	to	TO
cord-016197-y69wwy40	306	10	demonstrate	demonstrate	VB
cord-016197-y69wwy40	306	11	the	the	DT
cord-016197-y69wwy40	306	12	benefits	benefit	NNS
cord-016197-y69wwy40	306	13	of	of	IN
cord-016197-y69wwy40	306	14	marketed	market	VBN
cord-016197-y69wwy40	306	15	and	and	CC
cord-016197-y69wwy40	306	16	new	new	JJ
cord-016197-y69wwy40	306	17	agents	agent	NNS
cord-016197-y69wwy40	306	18	would	would	MD
cord-016197-y69wwy40	306	19	lie	lie	VB
cord-016197-y69wwy40	306	20	with	with	IN
cord-016197-y69wwy40	306	21	the	the	DT
cord-016197-y69wwy40	306	22	Pharma	Pharma	NNP
cord-016197-y69wwy40	306	23	R&D	r&d	NN
cord-016197-y69wwy40	306	24	companies	company	NNS
cord-016197-y69wwy40	306	25	.	.	.
cord-016197-y69wwy40	307	1	Failure	failure	NN
cord-016197-y69wwy40	307	2	to	to	TO
cord-016197-y69wwy40	307	3	produce	produce	VB
cord-016197-y69wwy40	307	4	data	datum	NNS
cord-016197-y69wwy40	307	5	to	to	TO
cord-016197-y69wwy40	307	6	support	support	VB
cord-016197-y69wwy40	307	7	current	current	JJ
cord-016197-y69wwy40	307	8	claims	claim	NNS
cord-016197-y69wwy40	307	9	could	could	MD
cord-016197-y69wwy40	307	10	result	result	VB
cord-016197-y69wwy40	307	11	in	in	IN
cord-016197-y69wwy40	307	12	removal	removal	NN
cord-016197-y69wwy40	307	13	of	of	IN
cord-016197-y69wwy40	307	14	differentiation	differentiation	NN
cord-016197-y69wwy40	307	15	from	from	IN
cord-016197-y69wwy40	307	16	established	established	JJ
cord-016197-y69wwy40	307	17	branded	brand	VBN
cord-016197-y69wwy40	307	18	products	product	NNS
cord-016197-y69wwy40	307	19	,	,	,
cord-016197-y69wwy40	307	20	while	while	IN
cord-016197-y69wwy40	307	21	provision	provision	NN
cord-016197-y69wwy40	307	22	of	of	IN
cord-016197-y69wwy40	307	23	data	datum	NNS
cord-016197-y69wwy40	307	24	may	may	MD
cord-016197-y69wwy40	307	25	strengthen	strengthen	VB
cord-016197-y69wwy40	307	26	the	the	DT
cord-016197-y69wwy40	307	27	labels	label	NNS
cord-016197-y69wwy40	307	28	of	of	IN
cord-016197-y69wwy40	307	29	generic	generic	JJ
cord-016197-y69wwy40	307	30	products	product	NNS
cord-016197-y69wwy40	307	31	.	.	.
cord-016197-y69wwy40	308	1	Bax	Bax	NNP
cord-016197-y69wwy40	308	2	et	et	NNP
cord-016197-y69wwy40	308	3	al	al	NNP
cord-016197-y69wwy40	308	4	.	.	.
cord-016197-y69wwy40	309	1	at	at	IN
cord-016197-y69wwy40	309	2	the	the	DT
cord-016197-y69wwy40	309	3	Whitley	Whitley	NNP
cord-016197-y69wwy40	309	4	Park	Park	NNP
cord-016197-y69wwy40	309	5	Symposium	Symposium	NNP
cord-016197-y69wwy40	309	6	in	in	IN
cord-016197-y69wwy40	309	7	1999	1999	CD
cord-016197-y69wwy40	309	8	reviewed	review	VBD
cord-016197-y69wwy40	309	9	the	the	DT
cord-016197-y69wwy40	309	10	limitations	limitation	NNS
cord-016197-y69wwy40	309	11	of	of	IN
cord-016197-y69wwy40	309	12	the	the	DT
cord-016197-y69wwy40	309	13	current	current	JJ
cord-016197-y69wwy40	309	14	clinical	clinical	JJ
cord-016197-y69wwy40	309	15	evaluation	evaluation	NN
cord-016197-y69wwy40	309	16	process	process	NN
cord-016197-y69wwy40	309	17	and	and	CC
cord-016197-y69wwy40	309	18	stated	state	VBD
cord-016197-y69wwy40	309	19	that	that	IN
cord-016197-y69wwy40	309	20	the	the	DT
cord-016197-y69wwy40	309	21	lack	lack	NN
cord-016197-y69wwy40	309	22	of	of	IN
cord-016197-y69wwy40	309	23	development	development	NN
cord-016197-y69wwy40	309	24	in	in	IN
cord-016197-y69wwy40	309	25	how	how	WRB
cord-016197-y69wwy40	309	26	to	to	TO
cord-016197-y69wwy40	309	27	define	define	VB
cord-016197-y69wwy40	309	28	precisely	precisely	RB
cord-016197-y69wwy40	309	29	both	both	DT
cord-016197-y69wwy40	309	30	drug	drug	NN
cord-016197-y69wwy40	309	31	value	value	NN
cord-016197-y69wwy40	309	32	and	and	CC
cord-016197-y69wwy40	309	33	appropriate	appropriate	JJ
cord-016197-y69wwy40	309	34	use	use	NN
cord-016197-y69wwy40	309	35	will	will	MD
cord-016197-y69wwy40	309	36	seriously	seriously	RB
cord-016197-y69wwy40	309	37	hamper	hamper	VB
cord-016197-y69wwy40	309	38	the	the	DT
cord-016197-y69wwy40	309	39	drug	drug	NN
cord-016197-y69wwy40	309	40	industry	industry	NN
cord-016197-y69wwy40	309	41	's	's	POS
cord-016197-y69wwy40	309	42	ability	ability	NN
cord-016197-y69wwy40	309	43	to	to	TO
cord-016197-y69wwy40	309	44	develop	develop	VB
cord-016197-y69wwy40	309	45	important	important	JJ
cord-016197-y69wwy40	309	46	new	new	JJ
cord-016197-y69wwy40	309	47	medicines	medicine	NNS
cord-016197-y69wwy40	309	48	discovered	discover	VBN
cord-016197-y69wwy40	309	49	by	by	IN
cord-016197-y69wwy40	309	50	new	new	JJ
cord-016197-y69wwy40	309	51	technologies	technology	NNS
cord-016197-y69wwy40	309	52	(	(	-LRB-
cord-016197-y69wwy40	309	53	Bax	Bax	NNP
cord-016197-y69wwy40	309	54	et	et	NNP
cord-016197-y69wwy40	309	55	al	al	NNP
cord-016197-y69wwy40	309	56	.	.	NNP
cord-016197-y69wwy40	309	57	,	,	,
cord-016197-y69wwy40	309	58	1999	1999	CD
cord-016197-y69wwy40	309	59	)	)	-RRB-
cord-016197-y69wwy40	309	60	.	.	.
cord-016197-y69wwy40	310	1	The	the	DT
cord-016197-y69wwy40	310	2	authors	author	NNS
cord-016197-y69wwy40	310	3	suggested	suggest	VBD
cord-016197-y69wwy40	310	4	that	that	IN
cord-016197-y69wwy40	310	5	what	what	WP
cord-016197-y69wwy40	310	6	is	be	VBZ
cord-016197-y69wwy40	310	7	needed	need	VBN
cord-016197-y69wwy40	310	8	is	be	VBZ
cord-016197-y69wwy40	310	9	further	further	JJ
cord-016197-y69wwy40	310	10	and	and	CC
cord-016197-y69wwy40	310	11	much	much	RB
cord-016197-y69wwy40	310	12	more	more	RBR
cord-016197-y69wwy40	310	13	rapid	rapid	JJ
cord-016197-y69wwy40	310	14	development	development	NN
cord-016197-y69wwy40	310	15	of	of	IN
cord-016197-y69wwy40	310	16	conventional	conventional	JJ
cord-016197-y69wwy40	310	17	means	mean	NNS
cord-016197-y69wwy40	310	18	of	of	IN
cord-016197-y69wwy40	310	19	drug	drug	NN
cord-016197-y69wwy40	310	20	evaluation	evaluation	NN
cord-016197-y69wwy40	310	21	,	,	,
cord-016197-y69wwy40	310	22	such	such	JJ
cord-016197-y69wwy40	310	23	as	as	IN
cord-016197-y69wwy40	310	24	the	the	DT
cord-016197-y69wwy40	310	25	clinical	clinical	JJ
cord-016197-y69wwy40	310	26	trial	trial	NN
cord-016197-y69wwy40	310	27	,	,	,
cord-016197-y69wwy40	310	28	as	as	RB
cord-016197-y69wwy40	310	29	well	well	RB
cord-016197-y69wwy40	310	30	as	as	IN
cord-016197-y69wwy40	310	31	visionary	visionary	JJ
cord-016197-y69wwy40	310	32	use	use	NN
cord-016197-y69wwy40	310	33	of	of	IN
cord-016197-y69wwy40	310	34	new	new	JJ
cord-016197-y69wwy40	310	35	methods	method	NNS
cord-016197-y69wwy40	310	36	in	in	IN
cord-016197-y69wwy40	310	37	epidemiology	epidemiology	NN
cord-016197-y69wwy40	310	38	,	,	,
cord-016197-y69wwy40	310	39	and	and	CC
cord-016197-y69wwy40	310	40	new	new	JJ
cord-016197-y69wwy40	310	41	use	use	NN
cord-016197-y69wwy40	310	42	of	of	IN
cord-016197-y69wwy40	310	43	electronic	electronic	JJ
cord-016197-y69wwy40	310	44	data	datum	NNS
cord-016197-y69wwy40	310	45	merged	merge	VBN
cord-016197-y69wwy40	310	46	in	in	IN
cord-016197-y69wwy40	310	47	a	a	DT
cord-016197-y69wwy40	310	48	way	way	NN
cord-016197-y69wwy40	310	49	that	that	WDT
cord-016197-y69wwy40	310	50	identifies	identify	VBZ
cord-016197-y69wwy40	310	51	drug	drug	NN
cord-016197-y69wwy40	310	52	effects	effect	NNS
cord-016197-y69wwy40	310	53	on	on	IN
cord-016197-y69wwy40	310	54	both	both	CC
cord-016197-y69wwy40	310	55	a	a	DT
cord-016197-y69wwy40	310	56	population	population	NN
cord-016197-y69wwy40	310	57	and	and	CC
cord-016197-y69wwy40	310	58	individual	individual	JJ
cord-016197-y69wwy40	310	59	basis	basis	NN
cord-016197-y69wwy40	310	60	.	.	.
cord-016197-y69wwy40	311	1	The	the	DT
cord-016197-y69wwy40	311	2	role	role	NN
cord-016197-y69wwy40	311	3	of	of	IN
cord-016197-y69wwy40	311	4	R&D	r&d	NN
cord-016197-y69wwy40	311	5	-	-	HYPH
cord-016197-y69wwy40	311	6	based	base	VBN
cord-016197-y69wwy40	311	7	Pharma	Pharma	NNP
cord-016197-y69wwy40	311	8	is	be	VBZ
cord-016197-y69wwy40	311	9	to	to	TO
cord-016197-y69wwy40	311	10	discover	discover	VB
cord-016197-y69wwy40	311	11	,	,	,
cord-016197-y69wwy40	311	12	develop	develop	VB
cord-016197-y69wwy40	311	13	,	,	,
cord-016197-y69wwy40	311	14	and	and	CC
cord-016197-y69wwy40	311	15	commercialize	commercialize	VB
cord-016197-y69wwy40	311	16	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	311	17	.	.	.
cord-016197-y69wwy40	312	1	There	there	EX
cord-016197-y69wwy40	312	2	is	be	VBZ
cord-016197-y69wwy40	312	3	a	a	DT
cord-016197-y69wwy40	312	4	danger	danger	NN
cord-016197-y69wwy40	312	5	that	that	IN
cord-016197-y69wwy40	312	6	the	the	DT
cord-016197-y69wwy40	312	7	wide	wide	JJ
cord-016197-y69wwy40	312	8	range	range	NN
cord-016197-y69wwy40	312	9	of	of	IN
cord-016197-y69wwy40	312	10	policies	policy	NNS
cord-016197-y69wwy40	312	11	which	which	WDT
cord-016197-y69wwy40	312	12	have	have	VBP
cord-016197-y69wwy40	312	13	been	be	VBN
cord-016197-y69wwy40	312	14	introduced	introduce	VBN
cord-016197-y69wwy40	312	15	under	under	IN
cord-016197-y69wwy40	312	16	the	the	DT
cord-016197-y69wwy40	312	17	auspices	auspex	NNS
cord-016197-y69wwy40	312	18	of	of	IN
cord-016197-y69wwy40	312	19	"	"	``
cord-016197-y69wwy40	312	20	combating	combat	VBG
cord-016197-y69wwy40	312	21	resistance	resistance	NN
cord-016197-y69wwy40	312	22	"	"	''
cord-016197-y69wwy40	312	23	will	will	MD
cord-016197-y69wwy40	312	24	themselves	-PRON-	PRP
cord-016197-y69wwy40	312	25	hamper	hamper	VB
cord-016197-y69wwy40	312	26	Pharma	Pharma	NNP
cord-016197-y69wwy40	312	27	's	's	POS
cord-016197-y69wwy40	312	28	ability	ability	NN
cord-016197-y69wwy40	312	29	to	to	TO
cord-016197-y69wwy40	312	30	deliver	deliver	VB
cord-016197-y69wwy40	312	31	a	a	DT
cord-016197-y69wwy40	312	32	key	key	JJ
cord-016197-y69wwy40	312	33	strategy	strategy	NN
cord-016197-y69wwy40	312	34	,	,	,
cord-016197-y69wwy40	312	35	if	if	IN
cord-016197-y69wwy40	312	36	not	not	RB
cord-016197-y69wwy40	312	37	the	the	DT
cord-016197-y69wwy40	312	38	most	most	RBS
cord-016197-y69wwy40	312	39	important	important	JJ
cord-016197-y69wwy40	312	40	weapon	weapon	NN
cord-016197-y69wwy40	312	41	in	in	IN
cord-016197-y69wwy40	312	42	the	the	DT
cord-016197-y69wwy40	312	43	battle	battle	NN
cord-016197-y69wwy40	312	44	against	against	IN
cord-016197-y69wwy40	312	45	bacterial	bacterial	JJ
cord-016197-y69wwy40	312	46	infection	infection	NN
cord-016197-y69wwy40	312	47	and	and	CC
cord-016197-y69wwy40	312	48	resistance	resistance	NN
cord-016197-y69wwy40	312	49	,	,	,
cord-016197-y69wwy40	312	50	the	the	DT
cord-016197-y69wwy40	312	51	introduction	introduction	NN
cord-016197-y69wwy40	312	52	of	of	IN
cord-016197-y69wwy40	312	53	novel	novel	JJ
cord-016197-y69wwy40	312	54	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	312	55	.	.	.
cord-016197-y69wwy40	313	1	Policies	policy	NNS
cord-016197-y69wwy40	313	2	and	and	CC
cord-016197-y69wwy40	313	3	improvements	improvement	NNS
cord-016197-y69wwy40	313	4	in	in	IN
cord-016197-y69wwy40	313	5	the	the	DT
cord-016197-y69wwy40	313	6	quality	quality	NN
cord-016197-y69wwy40	313	7	of	of	IN
cord-016197-y69wwy40	313	8	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	313	9	prescribing	prescribing	NN
cord-016197-y69wwy40	313	10	have	have	VBP
cord-016197-y69wwy40	313	11	an	an	DT
cord-016197-y69wwy40	313	12	important	important	JJ
cord-016197-y69wwy40	313	13	role	role	NN
cord-016197-y69wwy40	313	14	to	to	TO
cord-016197-y69wwy40	313	15	play	play	VB
cord-016197-y69wwy40	313	16	,	,	,
cord-016197-y69wwy40	313	17	as	as	IN
cord-016197-y69wwy40	313	18	do	do	VB
cord-016197-y69wwy40	313	19	diagnostics	diagnostic	NNS
cord-016197-y69wwy40	313	20	,	,	,
cord-016197-y69wwy40	313	21	vaccines	vaccine	NNS
cord-016197-y69wwy40	313	22	,	,	,
cord-016197-y69wwy40	313	23	infection	infection	NN
cord-016197-y69wwy40	313	24	control	control	NN
cord-016197-y69wwy40	313	25	,	,	,
cord-016197-y69wwy40	313	26	and	and	CC
cord-016197-y69wwy40	313	27	other	other	JJ
cord-016197-y69wwy40	313	28	interventions	intervention	NNS
cord-016197-y69wwy40	313	29	.	.	.
cord-016197-y69wwy40	314	1	Pharma	Pharma	NNP
cord-016197-y69wwy40	314	2	is	be	VBZ
cord-016197-y69wwy40	314	3	clearly	clearly	RB
cord-016197-y69wwy40	314	4	an	an	DT
cord-016197-y69wwy40	314	5	important	important	JJ
cord-016197-y69wwy40	314	6	partner	partner	NN
cord-016197-y69wwy40	314	7	along	along	IN
cord-016197-y69wwy40	314	8	with	with	IN
cord-016197-y69wwy40	314	9	government	government	NN
cord-016197-y69wwy40	314	10	,	,	,
cord-016197-y69wwy40	314	11	NGOs	NGOs	NNPS
cord-016197-y69wwy40	314	12	,	,	,
cord-016197-y69wwy40	314	13	regulators	regulator	NNS
cord-016197-y69wwy40	314	14	,	,	,
cord-016197-y69wwy40	314	15	infectious	infectious	JJ
cord-016197-y69wwy40	314	16	diseases	disease	NNS
cord-016197-y69wwy40	314	17	experts	expert	NNS
cord-016197-y69wwy40	314	18	,	,	,
cord-016197-y69wwy40	314	19	practioners	practioner	NNS
cord-016197-y69wwy40	314	20	,	,	,
cord-016197-y69wwy40	314	21	and	and	CC
cord-016197-y69wwy40	314	22	patients	patient	NNS
cord-016197-y69wwy40	314	23	in	in	IN
cord-016197-y69wwy40	314	24	the	the	DT
cord-016197-y69wwy40	314	25	battle	battle	NN
cord-016197-y69wwy40	314	26	against	against	IN
cord-016197-y69wwy40	314	27	bacterial	bacterial	JJ
cord-016197-y69wwy40	314	28	infection	infection	NN
cord-016197-y69wwy40	314	29	.	.	.
cord-016197-y69wwy40	315	1	The	the	DT
cord-016197-y69wwy40	315	2	"	"	``
cord-016197-y69wwy40	315	3	conflicts	conflict	NNS
cord-016197-y69wwy40	315	4	of	of	IN
cord-016197-y69wwy40	315	5	interest	interest	NN
cord-016197-y69wwy40	315	6	between	between	IN
cord-016197-y69wwy40	315	7	the	the	DT
cord-016197-y69wwy40	315	8	prescriber	prescriber	NN
cord-016197-y69wwy40	315	9	,	,	,
cord-016197-y69wwy40	315	10	the	the	DT
cord-016197-y69wwy40	315	11	regulator	regulator	NN
cord-016197-y69wwy40	315	12	,	,	,
cord-016197-y69wwy40	315	13	and	and	CC
cord-016197-y69wwy40	315	14	the	the	DT
cord-016197-y69wwy40	315	15	profit	profit	NN
cord-016197-y69wwy40	315	16	maker	maker	NN
cord-016197-y69wwy40	315	17	"	"	''
cord-016197-y69wwy40	315	18	was	be	VBD
cord-016197-y69wwy40	315	19	the	the	DT
cord-016197-y69wwy40	315	20	subject	subject	NN
cord-016197-y69wwy40	315	21	of	of	IN
cord-016197-y69wwy40	315	22	a	a	DT
cord-016197-y69wwy40	315	23	supplement	supplement	NN
cord-016197-y69wwy40	315	24	to	to	IN
cord-016197-y69wwy40	315	25	Clinical	Clinical	NNP
cord-016197-y69wwy40	315	26	Microbiology	Microbiology	NNP
cord-016197-y69wwy40	315	27	and	and	CC
cord-016197-y69wwy40	315	28	Infection	Infection	NNP
cord-016197-y69wwy40	315	29	.	.	.
cord-016197-y69wwy40	316	1	The	the	DT
cord-016197-y69wwy40	316	2	editor	editor	NN
cord-016197-y69wwy40	316	3	(	(	-LRB-
cord-016197-y69wwy40	316	4	Gould	Gould	NNP
cord-016197-y69wwy40	316	5	,	,	,
cord-016197-y69wwy40	316	6	2001a	2001a	CD
cord-016197-y69wwy40	316	7	)	)	-RRB-
cord-016197-y69wwy40	316	8	,	,	,
cord-016197-y69wwy40	316	9	recognized	recognize	VBD
cord-016197-y69wwy40	316	10	that	that	IN
cord-016197-y69wwy40	316	11	the	the	DT
cord-016197-y69wwy40	316	12	calls	call	NNS
cord-016197-y69wwy40	316	13	for	for	IN
cord-016197-y69wwy40	316	14	restrained	restrained	JJ
cord-016197-y69wwy40	316	15	use	use	NN
cord-016197-y69wwy40	316	16	of	of	IN
cord-016197-y69wwy40	316	17	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	316	18	to	to	TO
cord-016197-y69wwy40	316	19	combat	combat	VB
cord-016197-y69wwy40	316	20	and	and	CC
cord-016197-y69wwy40	316	21	control	control	NN
cord-016197-y69wwy40	316	22	resistance	resistance	NN
cord-016197-y69wwy40	316	23	counters	counter	VBZ
cord-016197-y69wwy40	316	24	the	the	DT
cord-016197-y69wwy40	316	25	natural	natural	JJ
cord-016197-y69wwy40	316	26	instincts	instinct	NNS
cord-016197-y69wwy40	316	27	of	of	IN
cord-016197-y69wwy40	316	28	doctors	doctor	NNS
cord-016197-y69wwy40	316	29	to	to	TO
cord-016197-y69wwy40	316	30	do	do	VB
cord-016197-y69wwy40	316	31	the	the	DT
cord-016197-y69wwy40	316	32	best	good	JJS
cord-016197-y69wwy40	316	33	for	for	IN
cord-016197-y69wwy40	316	34	their	-PRON-	PRP$
cord-016197-y69wwy40	316	35	patients	patient	NNS
cord-016197-y69wwy40	316	36	and	and	CC
cord-016197-y69wwy40	316	37	of	of	IN
cord-016197-y69wwy40	316	38	Pharma	Pharma	NNP
cord-016197-y69wwy40	316	39	,	,	,
cord-016197-y69wwy40	316	40	which	which	WDT
cord-016197-y69wwy40	316	41	of	of	IN
cord-016197-y69wwy40	316	42	necessity	necessity	NN
cord-016197-y69wwy40	316	43	,	,	,
cord-016197-y69wwy40	316	44	needs	need	VBZ
cord-016197-y69wwy40	316	45	to	to	TO
cord-016197-y69wwy40	316	46	profit	profit	VB
cord-016197-y69wwy40	316	47	to	to	TO
cord-016197-y69wwy40	316	48	exist	exist	VB
cord-016197-y69wwy40	316	49	and	and	CC
cord-016197-y69wwy40	316	50	continue	continue	VB
cord-016197-y69wwy40	316	51	.	.	.
cord-016197-y69wwy40	317	1	It	-PRON-	PRP
cord-016197-y69wwy40	317	2	is	be	VBZ
cord-016197-y69wwy40	317	3	,	,	,
cord-016197-y69wwy40	317	4	however	however	RB
cord-016197-y69wwy40	317	5	,	,	,
cord-016197-y69wwy40	317	6	unfortunate	unfortunate	JJ
cord-016197-y69wwy40	317	7	that	that	IN
cord-016197-y69wwy40	317	8	Pharma	Pharma	NNP
cord-016197-y69wwy40	317	9	can	can	MD
cord-016197-y69wwy40	317	10	be	be	VB
cord-016197-y69wwy40	317	11	regarded	regard	VBN
cord-016197-y69wwy40	317	12	first	first	RB
cord-016197-y69wwy40	317	13	as	as	IN
cord-016197-y69wwy40	317	14	"	"	``
cord-016197-y69wwy40	317	15	profit	profit	NN
cord-016197-y69wwy40	317	16	makers	maker	NNS
cord-016197-y69wwy40	317	17	"	"	''
cord-016197-y69wwy40	317	18	and	and	CC
cord-016197-y69wwy40	317	19	can	can	MD
cord-016197-y69wwy40	317	20	even	even	RB
cord-016197-y69wwy40	317	21	be	be	VB
cord-016197-y69wwy40	317	22	excluded	exclude	VBN
cord-016197-y69wwy40	317	23	from	from	IN
cord-016197-y69wwy40	317	24	contributing	contribute	VBG
cord-016197-y69wwy40	317	25	to	to	IN
cord-016197-y69wwy40	317	26	debates	debate	NNS
cord-016197-y69wwy40	317	27	on	on	IN
cord-016197-y69wwy40	317	28	the	the	DT
cord-016197-y69wwy40	317	29	subject	subject	NN
cord-016197-y69wwy40	317	30	of	of	IN
cord-016197-y69wwy40	317	31	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	317	32	use	use	NN
cord-016197-y69wwy40	317	33	(	(	-LRB-
cord-016197-y69wwy40	317	34	European	European	NNP
cord-016197-y69wwy40	317	35	Conference	Conference	NNP
cord-016197-y69wwy40	317	36	on	on	IN
cord-016197-y69wwy40	317	37	Antibiotic	Antibiotic	NNP
cord-016197-y69wwy40	317	38	Use	Use	NNP
cord-016197-y69wwy40	317	39	in	in	IN
cord-016197-y69wwy40	317	40	Europe	Europe	NNP
cord-016197-y69wwy40	317	41	,	,	,
cord-016197-y69wwy40	317	42	15	15	CD
cord-016197-y69wwy40	317	43	-	-	SYM
cord-016197-y69wwy40	317	44	17	17	CD
cord-016197-y69wwy40	317	45	November	November	NNP
cord-016197-y69wwy40	317	46	2001	2001	CD
cord-016197-y69wwy40	317	47	)	)	-RRB-
cord-016197-y69wwy40	317	48	.	.	.
cord-016197-y69wwy40	318	1	There	there	EX
cord-016197-y69wwy40	318	2	needs	need	VBZ
cord-016197-y69wwy40	318	3	to	to	TO
cord-016197-y69wwy40	318	4	be	be	VB
cord-016197-y69wwy40	318	5	a	a	DT
cord-016197-y69wwy40	318	6	distinction	distinction	NN
cord-016197-y69wwy40	318	7	between	between	IN
cord-016197-y69wwy40	318	8	companies	company	NNS
cord-016197-y69wwy40	318	9	which	which	WDT
cord-016197-y69wwy40	318	10	are	be	VBP
cord-016197-y69wwy40	318	11	solely	solely	RB
cord-016197-y69wwy40	318	12	suppliers	supplier	NNS
cord-016197-y69wwy40	318	13	of	of	IN
cord-016197-y69wwy40	318	14	generic	generic	JJ
cord-016197-y69wwy40	318	15	products	product	NNS
cord-016197-y69wwy40	318	16	and	and	CC
cord-016197-y69wwy40	318	17	those	those	DT
cord-016197-y69wwy40	318	18	who	who	WP
cord-016197-y69wwy40	318	19	have	have	VBP
cord-016197-y69wwy40	318	20	the	the	DT
cord-016197-y69wwy40	318	21	objective	objective	NN
cord-016197-y69wwy40	318	22	,	,	,
cord-016197-y69wwy40	318	23	dedication	dedication	NN
cord-016197-y69wwy40	318	24	,	,	,
cord-016197-y69wwy40	318	25	and	and	CC
cord-016197-y69wwy40	318	26	expertise	expertise	NN
cord-016197-y69wwy40	318	27	to	to	TO
cord-016197-y69wwy40	318	28	discover	discover	VB
cord-016197-y69wwy40	318	29	and	and	CC
cord-016197-y69wwy40	318	30	introduce	introduce	VB
cord-016197-y69wwy40	318	31	new	new	JJ
cord-016197-y69wwy40	318	32	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	318	33	.	.	.
cord-016197-y69wwy40	319	1	These	these	DT
cord-016197-y69wwy40	319	2	are	be	VBP
cord-016197-y69wwy40	319	3	undoubtedly	undoubtedly	RB
cord-016197-y69wwy40	319	4	profit	profit	NN
cord-016197-y69wwy40	319	5	makers	maker	NNS
cord-016197-y69wwy40	319	6	,	,	,
cord-016197-y69wwy40	319	7	being	be	VBG
cord-016197-y69wwy40	319	8	subject	subject	JJ
cord-016197-y69wwy40	319	9	to	to	IN
cord-016197-y69wwy40	319	10	commercial	commercial	JJ
cord-016197-y69wwy40	319	11	and	and	CC
cord-016197-y69wwy40	319	12	shareholder	shareholder	NN
cord-016197-y69wwy40	319	13	expectations	expectation	NNS
cord-016197-y69wwy40	319	14	,	,	,
cord-016197-y69wwy40	319	15	but	but	CC
cord-016197-y69wwy40	319	16	perhaps	perhaps	RB
cord-016197-y69wwy40	319	17	should	should	MD
cord-016197-y69wwy40	319	18	be	be	VB
cord-016197-y69wwy40	319	19	considered	consider	VBN
cord-016197-y69wwy40	319	20	foremost	foremost	JJ
cord-016197-y69wwy40	319	21	as	as	IN
cord-016197-y69wwy40	319	22	"	"	``
cord-016197-y69wwy40	319	23	providers	provider	NNS
cord-016197-y69wwy40	319	24	"	"	''
cord-016197-y69wwy40	319	25	with	with	IN
cord-016197-y69wwy40	319	26	respect	respect	NN
cord-016197-y69wwy40	319	27	to	to	IN
cord-016197-y69wwy40	319	28	new	new	JJ
cord-016197-y69wwy40	319	29	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	319	30	solutions	solution	NNS
cord-016197-y69wwy40	319	31	.	.	.
cord-016197-y69wwy40	320	1	Gould	Gould	NNP
cord-016197-y69wwy40	320	2	describes	describe	VBZ
cord-016197-y69wwy40	320	3	an	an	DT
cord-016197-y69wwy40	320	4	international	international	JJ
cord-016197-y69wwy40	320	5	partnership	partnership	NN
cord-016197-y69wwy40	320	6	of	of	IN
cord-016197-y69wwy40	320	7	medical	medical	JJ
cord-016197-y69wwy40	320	8	societies	society	NNS
cord-016197-y69wwy40	320	9	and	and	CC
cord-016197-y69wwy40	320	10	industry	industry	NN
cord-016197-y69wwy40	320	11	,	,	,
cord-016197-y69wwy40	320	12	in	in	IN
cord-016197-y69wwy40	320	13	association	association	NN
cord-016197-y69wwy40	320	14	with	with	IN
cord-016197-y69wwy40	320	15	regulators	regulator	NNS
cord-016197-y69wwy40	320	16	as	as	IN
cord-016197-y69wwy40	320	17	a	a	DT
cord-016197-y69wwy40	320	18	model	model	NN
cord-016197-y69wwy40	320	19	for	for	IN
cord-016197-y69wwy40	320	20	the	the	DT
cord-016197-y69wwy40	320	21	future	future	NN
cord-016197-y69wwy40	320	22	in	in	IN
cord-016197-y69wwy40	320	23	the	the	DT
cord-016197-y69wwy40	320	24	battle	battle	NN
cord-016197-y69wwy40	320	25	against	against	IN
cord-016197-y69wwy40	320	26	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	320	27	resistance	resistance	NN
cord-016197-y69wwy40	320	28	(	(	-LRB-
cord-016197-y69wwy40	320	29	Gould	Gould	NNP
cord-016197-y69wwy40	320	30	,	,	,
cord-016197-y69wwy40	320	31	2001b	2001b	CD
cord-016197-y69wwy40	320	32	)	)	-RRB-
cord-016197-y69wwy40	320	33	.	.	.
cord-016197-y69wwy40	321	1	Schlemmer	Schlemmer	NNP
cord-016197-y69wwy40	321	2	(	(	-LRB-
cord-016197-y69wwy40	321	3	2001	2001	CD
cord-016197-y69wwy40	321	4	)	)	-RRB-
cord-016197-y69wwy40	321	5	highlighted	highlight	VBD
cord-016197-y69wwy40	321	6	that	that	IN
cord-016197-y69wwy40	321	7	while	while	IN
cord-016197-y69wwy40	321	8	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	321	9	policies	policy	NNS
cord-016197-y69wwy40	321	10	were	be	VBD
cord-016197-y69wwy40	321	11	the	the	DT
cord-016197-y69wwy40	321	12	keystone	keystone	NNP
cord-016197-y69wwy40	321	13	in	in	IN
cord-016197-y69wwy40	321	14	promotion	promotion	NN
cord-016197-y69wwy40	321	15	of	of	IN
cord-016197-y69wwy40	321	16	good	good	JJ
cord-016197-y69wwy40	321	17	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	321	18	practice	practice	NN
cord-016197-y69wwy40	321	19	,	,	,
cord-016197-y69wwy40	321	20	more	more	RBR
cord-016197-y69wwy40	321	21	accurate	accurate	JJ
cord-016197-y69wwy40	321	22	and	and	CC
cord-016197-y69wwy40	321	23	relevant	relevant	JJ
cord-016197-y69wwy40	321	24	information	information	NN
cord-016197-y69wwy40	321	25	on	on	IN
cord-016197-y69wwy40	321	26	antibiotics	antibiotic	NNS
cord-016197-y69wwy40	321	27	is	be	VBZ
cord-016197-y69wwy40	321	28	urgently	urgently	RB
cord-016197-y69wwy40	321	29	needed	need	VBN
cord-016197-y69wwy40	321	30	and	and	CC
cord-016197-y69wwy40	321	31	that	that	IN
cord-016197-y69wwy40	321	32	it	-PRON-	PRP
cord-016197-y69wwy40	321	33	is	be	VBZ
cord-016197-y69wwy40	321	34	the	the	DT
cord-016197-y69wwy40	321	35	responsibility	responsibility	NN
cord-016197-y69wwy40	321	36	of	of	IN
cord-016197-y69wwy40	321	37	Pharma	Pharma	NNP
cord-016197-y69wwy40	321	38	and	and	CC
cord-016197-y69wwy40	321	39	regulators	regulator	NNS
cord-016197-y69wwy40	321	40	to	to	TO
cord-016197-y69wwy40	321	41	move	move	VB
cord-016197-y69wwy40	321	42	together	together	RB
cord-016197-y69wwy40	321	43	towards	towards	IN
cord-016197-y69wwy40	321	44	an	an	DT
cord-016197-y69wwy40	321	45	improvement	improvement	NN
cord-016197-y69wwy40	321	46	in	in	IN
cord-016197-y69wwy40	321	47	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	321	48	evaluation	evaluation	NN
cord-016197-y69wwy40	321	49	.	.	.
cord-016197-y69wwy40	322	1	The	the	DT
cord-016197-y69wwy40	322	2	objective	objective	NN
cord-016197-y69wwy40	322	3	would	would	MD
cord-016197-y69wwy40	322	4	be	be	VB
cord-016197-y69wwy40	322	5	to	to	TO
cord-016197-y69wwy40	322	6	give	give	VB
cord-016197-y69wwy40	322	7	prescribers	prescriber	NNS
cord-016197-y69wwy40	322	8	more	more	RBR
cord-016197-y69wwy40	322	9	critical	critical	JJ
cord-016197-y69wwy40	322	10	product	product	NN
cord-016197-y69wwy40	322	11	information	information	NN
cord-016197-y69wwy40	322	12	and	and	CC
cord-016197-y69wwy40	322	13	to	to	TO
cord-016197-y69wwy40	322	14	help	help	VB
cord-016197-y69wwy40	322	15	the	the	DT
cord-016197-y69wwy40	322	16	experts	expert	NNS
cord-016197-y69wwy40	322	17	create	create	VB
cord-016197-y69wwy40	322	18	better	well	JJR
cord-016197-y69wwy40	322	19	guidelines	guideline	NNS
cord-016197-y69wwy40	322	20	.	.	.
cord-016197-y69wwy40	323	1	WHO	who	WP
cord-016197-y69wwy40	323	2	included	include	VBD
cord-016197-y69wwy40	323	3	Pharma	Pharma	NNP
cord-016197-y69wwy40	323	4	via	via	IN
cord-016197-y69wwy40	323	5	the	the	DT
cord-016197-y69wwy40	323	6	International	International	NNP
cord-016197-y69wwy40	323	7	Federation	Federation	NNP
cord-016197-y69wwy40	323	8	of	of	IN
cord-016197-y69wwy40	323	9	Pharmaceutical	Pharmaceutical	NNP
cord-016197-y69wwy40	323	10	Manufacturers	Manufacturers	NNPS
cord-016197-y69wwy40	323	11	Association	Association	NNP
cord-016197-y69wwy40	323	12	(	(	-LRB-
cord-016197-y69wwy40	323	13	IFPMA	IFPMA	NNP
cord-016197-y69wwy40	323	14	)	)	-RRB-
cord-016197-y69wwy40	324	1	in	in	IN
cord-016197-y69wwy40	324	2	consultation	consultation	NN
cord-016197-y69wwy40	324	3	on	on	IN
cord-016197-y69wwy40	324	4	their	-PRON-	PRP$
cord-016197-y69wwy40	324	5	Containment	Containment	NNP
cord-016197-y69wwy40	324	6	Strategy	Strategy	NNP
cord-016197-y69wwy40	324	7	and	and	CC
cord-016197-y69wwy40	324	8	Model	Model	NNP
cord-016197-y69wwy40	324	9	Prescribing	Prescribing	NNP
cord-016197-y69wwy40	324	10	Guidelines	Guidelines	NNPS
cord-016197-y69wwy40	324	11	(	(	-LRB-
cord-016197-y69wwy40	324	12	www.who.int/emc/amr.html	www.who.int/emc/amr.html	NNP
cord-016197-y69wwy40	324	13	)	)	-RRB-
cord-016197-y69wwy40	324	14	and	and	CC
cord-016197-y69wwy40	324	15	the	the	DT
cord-016197-y69wwy40	324	16	European	European	NNP
cord-016197-y69wwy40	324	17	Federation	Federation	NNP
cord-016197-y69wwy40	324	18	of	of	IN
cord-016197-y69wwy40	324	19	Pharmaceutical	Pharmaceutical	NNP
cord-016197-y69wwy40	324	20	Industries	Industries	NNPS
cord-016197-y69wwy40	324	21	and	and	CC
cord-016197-y69wwy40	324	22	Associations	Associations	NNPS
cord-016197-y69wwy40	324	23	(	(	-LRB-
cord-016197-y69wwy40	324	24	EFPIA	EFPIA	NNP
cord-016197-y69wwy40	324	25	)	)	-RRB-
cord-016197-y69wwy40	324	26	have	have	VBP
cord-016197-y69wwy40	324	27	represented	represent	VBN
cord-016197-y69wwy40	324	28	Pharma	Pharma	NNP
cord-016197-y69wwy40	324	29	in	in	IN
cord-016197-y69wwy40	324	30	EU	EU	NNP
cord-016197-y69wwy40	324	31	and	and	CC
cord-016197-y69wwy40	324	32	EMEA	EMEA	NNP
cord-016197-y69wwy40	324	33	discussions	discussion	NNS
cord-016197-y69wwy40	324	34	and	and	CC
cord-016197-y69wwy40	324	35	consultations	consultation	NNS
cord-016197-y69wwy40	324	36	on	on	IN
cord-016197-y69wwy40	324	37	clinical	clinical	JJ
cord-016197-y69wwy40	324	38	trial	trial	NN
cord-016197-y69wwy40	324	39	guidelines	guideline	NNS
cord-016197-y69wwy40	324	40	and	and	CC
cord-016197-y69wwy40	324	41	labelling	labelling	NN
cord-016197-y69wwy40	324	42	.	.	.
cord-016197-y69wwy40	325	1	In	in	IN
cord-016197-y69wwy40	325	2	the	the	DT
cord-016197-y69wwy40	325	3	United	United	NNP
cord-016197-y69wwy40	325	4	States	States	NNP
cord-016197-y69wwy40	325	5	a	a	DT
cord-016197-y69wwy40	325	6	multiagency	multiagency	JJ
cord-016197-y69wwy40	325	7	task	task	NN
cord-016197-y69wwy40	325	8	force	force	NN
cord-016197-y69wwy40	325	9	of	of	IN
cord-016197-y69wwy40	325	10	FDA	FDA	NNP
cord-016197-y69wwy40	325	11	,	,	,
cord-016197-y69wwy40	325	12	CDC	CDC	NNP
cord-016197-y69wwy40	325	13	and	and	CC
cord-016197-y69wwy40	325	14	the	the	DT
cord-016197-y69wwy40	325	15	National	National	NNP
cord-016197-y69wwy40	325	16	Institute	Institute	NNP
cord-016197-y69wwy40	325	17	of	of	IN
cord-016197-y69wwy40	325	18	Health	Health	NNP
cord-016197-y69wwy40	325	19	(	(	-LRB-
cord-016197-y69wwy40	325	20	NIH	NIH	NNP
cord-016197-y69wwy40	325	21	)	)	-RRB-
cord-016197-y69wwy40	325	22	issued	issue	VBD
cord-016197-y69wwy40	325	23	a	a	DT
cord-016197-y69wwy40	325	24	document	document	NN
cord-016197-y69wwy40	325	25	entitled	entitle	VBN
cord-016197-y69wwy40	325	26	Public	Public	NNP
cord-016197-y69wwy40	325	27	Health	Health	NNP
cord-016197-y69wwy40	325	28	Action	Action	NNP
cord-016197-y69wwy40	325	29	Plan	Plan	NNP
cord-016197-y69wwy40	325	30	to	to	IN
cord-016197-y69wwy40	325	31	Combat	Combat	NNP
cord-016197-y69wwy40	325	32	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	325	33	Resistance	Resistance	NNP
cord-016197-y69wwy40	325	34	in	in	IN
cord-016197-y69wwy40	325	35	2001	2001	CD
cord-016197-y69wwy40	325	36	with	with	IN
cord-016197-y69wwy40	325	37	a	a	DT
cord-016197-y69wwy40	325	38	priority	priority	NN
cord-016197-y69wwy40	325	39	to	to	TO
cord-016197-y69wwy40	325	40	create	create	VB
cord-016197-y69wwy40	325	41	an	an	DT
cord-016197-y69wwy40	325	42	interagency	interagency	NN
cord-016197-y69wwy40	325	43	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	325	44	resistance	resistance	NN
cord-016197-y69wwy40	325	45	product	product	NN
cord-016197-y69wwy40	325	46	development	development	NN
cord-016197-y69wwy40	325	47	working	work	VBG
cord-016197-y69wwy40	325	48	group	group	NN
cord-016197-y69wwy40	325	49	coordinated	coordinate	VBN
cord-016197-y69wwy40	325	50	by	by	IN
cord-016197-y69wwy40	325	51	the	the	DT
cord-016197-y69wwy40	325	52	FDA	FDA	NNP
cord-016197-y69wwy40	325	53	,	,	,
cord-016197-y69wwy40	325	54	US	US	NNP
cord-016197-y69wwy40	325	55	Department	Department	NNP
cord-016197-y69wwy40	325	56	of	of	IN
cord-016197-y69wwy40	325	57	Agriculture	Agriculture	NNP
cord-016197-y69wwy40	325	58	(	(	-LRB-
cord-016197-y69wwy40	325	59	USDA	USDA	NNP
cord-016197-y69wwy40	325	60	)	)	-RRB-
cord-016197-y69wwy40	325	61	,	,	,
cord-016197-y69wwy40	325	62	and	and	CC
cord-016197-y69wwy40	325	63	CDC	CDC	NNP
cord-016197-y69wwy40	325	64	(	(	-LRB-
cord-016197-y69wwy40	325	65	Shlaes	Shlaes	NNP
cord-016197-y69wwy40	325	66	and	and	CC
cord-016197-y69wwy40	325	67	Ryan	Ryan	NNP
cord-016197-y69wwy40	325	68	,	,	,
cord-016197-y69wwy40	325	69	2003	2003	CD
cord-016197-y69wwy40	325	70	)	)	-RRB-
cord-016197-y69wwy40	325	71	.	.	.
cord-016197-y69wwy40	326	1	A	a	DT
cord-016197-y69wwy40	326	2	second	second	JJ
cord-016197-y69wwy40	326	3	priority	priority	NN
cord-016197-y69wwy40	326	4	was	be	VBD
cord-016197-y69wwy40	326	5	to	to	TO
cord-016197-y69wwy40	326	6	,	,	,
cord-016197-y69wwy40	326	7	"	"	``
cord-016197-y69wwy40	326	8	Investigate	investigate	VB
cord-016197-y69wwy40	326	9	and	and	CC
cord-016197-y69wwy40	326	10	act	act	VB
cord-016197-y69wwy40	326	11	upon	upon	IN
cord-016197-y69wwy40	326	12	potential	potential	JJ
cord-016197-y69wwy40	326	13	approaches	approach	NNS
cord-016197-y69wwy40	326	14	for	for	IN
cord-016197-y69wwy40	326	15	stimulating	stimulate	VBG
cord-016197-y69wwy40	326	16	and	and	CC
cord-016197-y69wwy40	326	17	speeding	speed	VBG
cord-016197-y69wwy40	326	18	the	the	DT
cord-016197-y69wwy40	326	19	entire	entire	JJ
cord-016197-y69wwy40	326	20	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	326	21	resistance	resistance	NN
cord-016197-y69wwy40	326	22	product	product	NN
cord-016197-y69wwy40	326	23	development	development	NN
cord-016197-y69wwy40	326	24	process	process	NN
cord-016197-y69wwy40	326	25	,	,	,
cord-016197-y69wwy40	326	26	from	from	IN
cord-016197-y69wwy40	326	27	drug	drug	NN
cord-016197-y69wwy40	326	28	discovery	discovery	NN
cord-016197-y69wwy40	326	29	through	through	IN
cord-016197-y69wwy40	326	30	licensing	licensing	NN
cord-016197-y69wwy40	326	31	,	,	,
cord-016197-y69wwy40	326	32	"	"	''
cord-016197-y69wwy40	326	33	including	include	VBG
cord-016197-y69wwy40	326	34	exploring	explore	VBG
cord-016197-y69wwy40	326	35	the	the	DT
cord-016197-y69wwy40	326	36	economics	economic	NNS
cord-016197-y69wwy40	326	37	of	of	IN
cord-016197-y69wwy40	326	38	the	the	DT
cord-016197-y69wwy40	326	39	situation	situation	NN
cord-016197-y69wwy40	326	40	and	and	CC
cord-016197-y69wwy40	326	41	incentives	incentive	NNS
cord-016197-y69wwy40	326	42	.	.	.
cord-016197-y69wwy40	327	1	While	while	IN
cord-016197-y69wwy40	327	2	Monnet	Monnet	NNP
cord-016197-y69wwy40	327	3	and	and	CC
cord-016197-y69wwy40	327	4	Sorensen	Sorensen	NNP
cord-016197-y69wwy40	327	5	(	(	-LRB-
cord-016197-y69wwy40	327	6	2001	2001	CD
cord-016197-y69wwy40	327	7	)	)	-RRB-
cord-016197-y69wwy40	327	8	argue	argue	VBP
cord-016197-y69wwy40	327	9	that	that	IN
cord-016197-y69wwy40	327	10	much	much	JJ
cord-016197-y69wwy40	327	11	investment	investment	NN
cord-016197-y69wwy40	327	12	from	from	IN
cord-016197-y69wwy40	327	13	Pharma	Pharma	NNP
cord-016197-y69wwy40	327	14	is	be	VBZ
cord-016197-y69wwy40	327	15	into	into	IN
cord-016197-y69wwy40	327	16	marketing	marketing	NN
cord-016197-y69wwy40	327	17	and	and	CC
cord-016197-y69wwy40	327	18	not	not	RB
cord-016197-y69wwy40	327	19	R&D	r&d	NN
cord-016197-y69wwy40	327	20	and	and	CC
cord-016197-y69wwy40	327	21	that	that	IN
cord-016197-y69wwy40	327	22	the	the	DT
cord-016197-y69wwy40	327	23	so	so	RB
cord-016197-y69wwy40	327	24	-	-	HYPH
cord-016197-y69wwy40	327	25	called	call	VBN
cord-016197-y69wwy40	327	26	"	"	``
cord-016197-y69wwy40	327	27	R&D	R&D	NNP
cord-016197-y69wwy40	327	28	Scare	Scare	NNP
cord-016197-y69wwy40	327	29	Card	Card	NNP
cord-016197-y69wwy40	327	30	"	"	''
cord-016197-y69wwy40	327	31	is	be	VBZ
cord-016197-y69wwy40	327	32	not	not	RB
cord-016197-y69wwy40	327	33	justified	justify	VBN
cord-016197-y69wwy40	327	34	,	,	,
cord-016197-y69wwy40	327	35	it	-PRON-	PRP
cord-016197-y69wwy40	327	36	is	be	VBZ
cord-016197-y69wwy40	327	37	clear	clear	JJ
cord-016197-y69wwy40	327	38	that	that	IN
cord-016197-y69wwy40	327	39	Pharma	Pharma	NNS
cord-016197-y69wwy40	327	40	companies	company	NNS
cord-016197-y69wwy40	327	41	are	be	VBP
cord-016197-y69wwy40	327	42	increasingly	increasingly	RB
cord-016197-y69wwy40	327	43	taking	take	VBG
cord-016197-y69wwy40	327	44	the	the	DT
cord-016197-y69wwy40	327	45	commercial	commercial	JJ
cord-016197-y69wwy40	327	46	decision	decision	NN
cord-016197-y69wwy40	327	47	not	not	RB
cord-016197-y69wwy40	327	48	to	to	TO
cord-016197-y69wwy40	327	49	invest	invest	VB
cord-016197-y69wwy40	327	50	in	in	IN
cord-016197-y69wwy40	327	51	R&D	r&d	NN
cord-016197-y69wwy40	327	52	for	for	IN
cord-016197-y69wwy40	327	53	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	327	54	,	,	,
cord-016197-y69wwy40	327	55	but	but	CC
cord-016197-y69wwy40	327	56	in	in	IN
cord-016197-y69wwy40	327	57	other	other	JJ
cord-016197-y69wwy40	327	58	areas	area	NNS
cord-016197-y69wwy40	327	59	.	.	.
cord-016197-y69wwy40	328	1	According	accord	VBG
cord-016197-y69wwy40	328	2	to	to	IN
cord-016197-y69wwy40	328	3	Shlaes	Shlaes	NNP
cord-016197-y69wwy40	328	4	and	and	CC
cord-016197-y69wwy40	328	5	Ryan	Ryan	NNP
cord-016197-y69wwy40	328	6	,	,	,
cord-016197-y69wwy40	328	7	incentives	incentive	NNS
cord-016197-y69wwy40	328	8	for	for	IN
cord-016197-y69wwy40	328	9	increasing	increase	VBG
cord-016197-y69wwy40	328	10	Pharma	Pharma	NNP
cord-016197-y69wwy40	328	11	R&D	r&d	NN
cord-016197-y69wwy40	328	12	into	into	IN
cord-016197-y69wwy40	328	13	priority	priority	JJ
cord-016197-y69wwy40	328	14	infectious	infectious	JJ
cord-016197-y69wwy40	328	15	diseases	disease	NNS
cord-016197-y69wwy40	328	16	include	include	VBP
cord-016197-y69wwy40	328	17	the	the	DT
cord-016197-y69wwy40	328	18	need	need	NN
cord-016197-y69wwy40	328	19	for	for	IN
cord-016197-y69wwy40	328	20	more	more	JJR
cord-016197-y69wwy40	328	21	information	information	NN
cord-016197-y69wwy40	328	22	on	on	IN
cord-016197-y69wwy40	328	23	the	the	DT
cord-016197-y69wwy40	328	24	market	market	NN
cord-016197-y69wwy40	328	25	and	and	CC
cord-016197-y69wwy40	328	26	disease	disease	NN
cord-016197-y69wwy40	328	27	areas	area	NNS
cord-016197-y69wwy40	328	28	(	(	-LRB-
cord-016197-y69wwy40	328	29	based	base	VBN
cord-016197-y69wwy40	328	30	on	on	IN
cord-016197-y69wwy40	328	31	market	market	NN
cord-016197-y69wwy40	328	32	identification	identification	NN
cord-016197-y69wwy40	328	33	,	,	,
cord-016197-y69wwy40	328	34	disease	disease	NN
cord-016197-y69wwy40	328	35	-	-	HYPH
cord-016197-y69wwy40	328	36	specific	specific	JJ
cord-016197-y69wwy40	328	37	bioinformatic	bioinformatic	JJ
cord-016197-y69wwy40	328	38	systems	system	NNS
cord-016197-y69wwy40	328	39	,	,	,
cord-016197-y69wwy40	328	40	development	development	NN
cord-016197-y69wwy40	328	41	of	of	IN
cord-016197-y69wwy40	328	42	surrogate	surrogate	JJ
cord-016197-y69wwy40	328	43	endpoints	endpoint	NNS
cord-016197-y69wwy40	328	44	)	)	-RRB-
cord-016197-y69wwy40	328	45	,	,	,
cord-016197-y69wwy40	328	46	more	more	JJR
cord-016197-y69wwy40	328	47	predictability	predictability	NN
cord-016197-y69wwy40	328	48	(	(	-LRB-
cord-016197-y69wwy40	328	49	based	base	VBN
cord-016197-y69wwy40	328	50	on	on	IN
cord-016197-y69wwy40	328	51	market	market	NN
cord-016197-y69wwy40	328	52	assessment	assessment	NN
cord-016197-y69wwy40	328	53	,	,	,
cord-016197-y69wwy40	328	54	international	international	JJ
cord-016197-y69wwy40	328	55	regulatory	regulatory	JJ
cord-016197-y69wwy40	328	56	harmonization	harmonization	NN
cord-016197-y69wwy40	328	57	,	,	,
cord-016197-y69wwy40	328	58	and	and	CC
cord-016197-y69wwy40	328	59	reinforcement	reinforcement	NN
cord-016197-y69wwy40	328	60	of	of	IN
cord-016197-y69wwy40	328	61	intellectual	intellectual	JJ
cord-016197-y69wwy40	328	62	property	property	NN
cord-016197-y69wwy40	328	63	rights	right	NNS
cord-016197-y69wwy40	328	64	)	)	-RRB-
cord-016197-y69wwy40	328	65	,	,	,
cord-016197-y69wwy40	328	66	and	and	CC
cord-016197-y69wwy40	328	67	more	more	JJR
cord-016197-y69wwy40	328	68	cost	cost	NN
cord-016197-y69wwy40	328	69	-	-	HYPH
cord-016197-y69wwy40	328	70	risk	risk	NN
cord-016197-y69wwy40	328	71	sharing	sharing	NN
cord-016197-y69wwy40	328	72	(	(	-LRB-
cord-016197-y69wwy40	328	73	market	market	NN
cord-016197-y69wwy40	328	74	creation	creation	NN
cord-016197-y69wwy40	328	75	,	,	,
cord-016197-y69wwy40	328	76	patent	patent	NN
cord-016197-y69wwy40	328	77	extension	extension	NN
cord-016197-y69wwy40	328	78	,	,	,
cord-016197-y69wwy40	328	79	orphan	orphan	NN
cord-016197-y69wwy40	328	80	drug	drug	NN
cord-016197-y69wwy40	328	81	legislation	legislation	NN
cord-016197-y69wwy40	328	82	)	)	-RRB-
cord-016197-y69wwy40	328	83	(	(	-LRB-
cord-016197-y69wwy40	328	84	Shlaes	Shlaes	NNP
cord-016197-y69wwy40	328	85	and	and	CC
cord-016197-y69wwy40	328	86	Ryan	Ryan	NNP
cord-016197-y69wwy40	328	87	,	,	,
cord-016197-y69wwy40	328	88	2003	2003	CD
cord-016197-y69wwy40	328	89	)	)	-RRB-
cord-016197-y69wwy40	328	90	.	.	.
cord-016197-y69wwy40	329	1	A	a	DT
cord-016197-y69wwy40	329	2	number	number	NN
cord-016197-y69wwy40	329	3	of	of	IN
cord-016197-y69wwy40	329	4	bodies	body	NNS
cord-016197-y69wwy40	329	5	,	,	,
cord-016197-y69wwy40	329	6	such	such	JJ
cord-016197-y69wwy40	329	7	as	as	IN
cord-016197-y69wwy40	329	8	WHO	WHO	NNP
cord-016197-y69wwy40	329	9	,	,	,
cord-016197-y69wwy40	329	10	IDSA	IDSA	NNP
cord-016197-y69wwy40	329	11	,	,	,
cord-016197-y69wwy40	329	12	and	and	CC
cord-016197-y69wwy40	329	13	EU	EU	NNP
cord-016197-y69wwy40	329	14	task	task	NN
cord-016197-y69wwy40	329	15	forces	force	NNS
cord-016197-y69wwy40	329	16	have	have	VBP
cord-016197-y69wwy40	329	17	begun	begin	VBN
cord-016197-y69wwy40	329	18	processes	process	NNS
cord-016197-y69wwy40	329	19	to	to	TO
cord-016197-y69wwy40	329	20	assess	assess	VB
cord-016197-y69wwy40	329	21	the	the	DT
cord-016197-y69wwy40	329	22	situation	situation	NN
cord-016197-y69wwy40	329	23	and	and	CC
cord-016197-y69wwy40	329	24	identify	identify	VB
cord-016197-y69wwy40	329	25	some	some	DT
cord-016197-y69wwy40	329	26	areas	area	NNS
cord-016197-y69wwy40	329	27	of	of	IN
cord-016197-y69wwy40	329	28	action	action	NN
cord-016197-y69wwy40	329	29	.	.	.
cord-016197-y69wwy40	330	1	These	these	DT
cord-016197-y69wwy40	330	2	include	include	VBP
cord-016197-y69wwy40	330	3	:	:	:
cord-016197-y69wwy40	331	1	•	•	XX
cord-016197-y69wwy40	331	2	summarizing	summarize	VBG
cord-016197-y69wwy40	331	3	the	the	DT
cord-016197-y69wwy40	331	4	value	value	NN
cord-016197-y69wwy40	331	5	of	of	IN
cord-016197-y69wwy40	331	6	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	331	7	•	•	NNS
cord-016197-y69wwy40	331	8	identifying	identify	VBG
cord-016197-y69wwy40	331	9	the	the	DT
cord-016197-y69wwy40	331	10	status	status	NN
cord-016197-y69wwy40	331	11	of	of	IN
cord-016197-y69wwy40	331	12	clinically	clinically	RB
cord-016197-y69wwy40	331	13	relevant	relevant	JJ
cord-016197-y69wwy40	331	14	resistance	resistance	NN
cord-016197-y69wwy40	331	15	and	and	CC
cord-016197-y69wwy40	331	16	priority	priority	NN
cord-016197-y69wwy40	331	17	pathogens	pathogen	NNS
cord-016197-y69wwy40	332	1	•	•	XX
cord-016197-y69wwy40	332	2	evaluating	evaluate	VBG
cord-016197-y69wwy40	332	3	the	the	DT
cord-016197-y69wwy40	332	4	state	state	NN
cord-016197-y69wwy40	332	5	of	of	IN
cord-016197-y69wwy40	332	6	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	332	7	research	research	NN
cord-016197-y69wwy40	332	8	/	/	SYM
cord-016197-y69wwy40	332	9	regulatory	regulatory	JJ
cord-016197-y69wwy40	332	10	submissions	submission	NNS
cord-016197-y69wwy40	332	11	/	/	SYM
cord-016197-y69wwy40	332	12	industry	industry	NN
cord-016197-y69wwy40	332	13	involvement	involvement	NN
cord-016197-y69wwy40	332	14	and	and	CC
cord-016197-y69wwy40	332	15	outlook	outlook	NN
cord-016197-y69wwy40	333	1	•	•	NNP
cord-016197-y69wwy40	333	2	maintaining	maintain	VBG
cord-016197-y69wwy40	333	3	databases	database	NNS
cord-016197-y69wwy40	333	4	of	of	IN
cord-016197-y69wwy40	333	5	funding	funding	NN
cord-016197-y69wwy40	333	6	agencies	agency	NNS
cord-016197-y69wwy40	333	7	,	,	,
cord-016197-y69wwy40	333	8	their	-PRON-	PRP$
cord-016197-y69wwy40	333	9	research	research	NN
cord-016197-y69wwy40	333	10	interests	interest	NNS
cord-016197-y69wwy40	333	11	,	,	,
cord-016197-y69wwy40	333	12	new	new	JJ
cord-016197-y69wwy40	333	13	opportunities	opportunity	NNS
cord-016197-y69wwy40	333	14	for	for	IN
cord-016197-y69wwy40	333	15	funding	funding	NN
cord-016197-y69wwy40	334	1	•	•	NNS
cord-016197-y69wwy40	334	2	documenting	document	VBG
cord-016197-y69wwy40	334	3	the	the	DT
cord-016197-y69wwy40	334	4	vulnerabilities	vulnerability	NNS
cord-016197-y69wwy40	334	5	related	relate	VBN
cord-016197-y69wwy40	334	6	to	to	IN
cord-016197-y69wwy40	334	7	the	the	DT
cord-016197-y69wwy40	334	8	manufacture	manufacture	NN
cord-016197-y69wwy40	334	9	of	of	IN
cord-016197-y69wwy40	334	10	antibacterials/	antibacterials/	CD
cord-016197-y69wwy40	334	11	shortages	shortage	NNS
cord-016197-y69wwy40	334	12	/	/	SYM
cord-016197-y69wwy40	334	13	negative	negative	JJ
cord-016197-y69wwy40	334	14	impacts	impact	NNS
cord-016197-y69wwy40	334	15	on	on	IN
cord-016197-y69wwy40	334	16	public	public	JJ
cord-016197-y69wwy40	334	17	health	health	NN
cord-016197-y69wwy40	334	18	:	:	:
cord-016197-y69wwy40	335	1	gap	gap	NN
cord-016197-y69wwy40	335	2	analysis	analysis	NN
cord-016197-y69wwy40	336	1	•	•	LS
cord-016197-y69wwy40	336	2	undertaking	undertake	VBG
cord-016197-y69wwy40	336	3	the	the	DT
cord-016197-y69wwy40	336	4	identification	identification	NN
cord-016197-y69wwy40	336	5	,	,	,
cord-016197-y69wwy40	336	6	prioritization	prioritization	NN
cord-016197-y69wwy40	336	7	,	,	,
cord-016197-y69wwy40	336	8	and	and	CC
cord-016197-y69wwy40	336	9	tracking	tracking	NN
cord-016197-y69wwy40	336	10	of	of	IN
cord-016197-y69wwy40	336	11	global	global	JJ
cord-016197-y69wwy40	336	12	public	public	JJ
cord-016197-y69wwy40	336	13	health	health	NN
cord-016197-y69wwy40	336	14	needs	need	NNS
cord-016197-y69wwy40	336	15	(	(	-LRB-
cord-016197-y69wwy40	336	16	a	a	DT
cord-016197-y69wwy40	336	17	global	global	JJ
cord-016197-y69wwy40	336	18	agenda	agenda	NN
cord-016197-y69wwy40	336	19	)	)	-RRB-
cord-016197-y69wwy40	337	1	•	•	NNP
cord-016197-y69wwy40	337	2	reviewing	review	VBG
cord-016197-y69wwy40	337	3	/	/	SYM
cord-016197-y69wwy40	337	4	documenting	document	VBG
cord-016197-y69wwy40	337	5	government	government	NN
cord-016197-y69wwy40	337	6	activities	activity	NNS
cord-016197-y69wwy40	337	7	to	to	TO
cord-016197-y69wwy40	337	8	foster	foster	VB
cord-016197-y69wwy40	337	9	development	development	NN
cord-016197-y69wwy40	337	10	of	of	IN
cord-016197-y69wwy40	337	11	new	new	JJ
cord-016197-y69wwy40	337	12	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	338	1	•	•	NNP
cord-016197-y69wwy40	339	1	reviewing	review	VBG
cord-016197-y69wwy40	339	2	recommendations	recommendation	NNS
cord-016197-y69wwy40	339	3	for	for	IN
cord-016197-y69wwy40	339	4	"	"	``
cord-016197-y69wwy40	339	5	incentivizing	incentivize	VBG
cord-016197-y69wwy40	339	6	"	"	''
cord-016197-y69wwy40	339	7	•	•	NNS
cord-016197-y69wwy40	339	8	modifying	modify	VBG
cord-016197-y69wwy40	339	9	regulatory	regulatory	JJ
cord-016197-y69wwy40	339	10	approval	approval	NN
cord-016197-y69wwy40	339	11	processes	process	NNS
cord-016197-y69wwy40	339	12	such	such	JJ
cord-016197-y69wwy40	339	13	as	as	IN
cord-016197-y69wwy40	339	14	priority	priority	NN
cord-016197-y69wwy40	339	15	review	review	NN
cord-016197-y69wwy40	339	16	,	,	,
cord-016197-y69wwy40	339	17	fast	fast	JJ
cord-016197-y69wwy40	339	18	track	track	NN
cord-016197-y69wwy40	339	19	,	,	,
cord-016197-y69wwy40	339	20	waiver	waiver	NN
cord-016197-y69wwy40	339	21	of	of	IN
cord-016197-y69wwy40	339	22	user	user	NN
cord-016197-y69wwy40	339	23	fees	fee	NNS
cord-016197-y69wwy40	339	24	,	,	,
cord-016197-y69wwy40	339	25	orphan	orphan	NN
cord-016197-y69wwy40	339	26	drug	drug	NN
cord-016197-y69wwy40	339	27	status	status	NN
cord-016197-y69wwy40	339	28	,	,	,
cord-016197-y69wwy40	339	29	modified	modify	VBN
cord-016197-y69wwy40	339	30	/	/	SYM
cord-016197-y69wwy40	339	31	smaller	small	JJR
cord-016197-y69wwy40	339	32	clinical	clinical	JJ
cord-016197-y69wwy40	339	33	trials	trial	NNS
cord-016197-y69wwy40	339	34	,	,	,
cord-016197-y69wwy40	340	1	and/or	and/or	CC
cord-016197-y69wwy40	340	2	reduced	reduced	JJ
cord-016197-y69wwy40	340	3	number	number	NN
cord-016197-y69wwy40	340	4	of	of	IN
cord-016197-y69wwy40	340	5	efficacy	efficacy	NN
cord-016197-y69wwy40	340	6	studies	study	NNS
cord-016197-y69wwy40	340	7	per	per	IN
cord-016197-y69wwy40	340	8	indication	indication	NN
cord-016197-y69wwy40	340	9	(	(	-LRB-
cord-016197-y69wwy40	340	10	and	and	CC
cord-016197-y69wwy40	340	11	use	use	NN
cord-016197-y69wwy40	340	12	of	of	IN
cord-016197-y69wwy40	340	13	surrogates	surrogate	NNS
cord-016197-y69wwy40	340	14	such	such	JJ
cord-016197-y69wwy40	340	15	as	as	IN
cord-016197-y69wwy40	340	16	PK	PK	NNP
cord-016197-y69wwy40	340	17	/	/	SYM
cord-016197-y69wwy40	340	18	PD	PD	NNP
cord-016197-y69wwy40	340	19	)	)	-RRB-
cord-016197-y69wwy40	341	1	•	•	NFP
cord-016197-y69wwy40	341	2	harmonizing	harmonize	VBG
cord-016197-y69wwy40	341	3	clinical	clinical	JJ
cord-016197-y69wwy40	341	4	trial	trial	NN
cord-016197-y69wwy40	341	5	methodologies	methodology	NNS
cord-016197-y69wwy40	341	6	and	and	CC
cord-016197-y69wwy40	341	7	implementing	implement	VBG
cord-016197-y69wwy40	341	8	coordinated	coordinated	JJ
cord-016197-y69wwy40	341	9	action	action	NN
cord-016197-y69wwy40	341	10	by	by	IN
cord-016197-y69wwy40	341	11	regulatory	regulatory	JJ
cord-016197-y69wwy40	341	12	agencies	agency	NNS
cord-016197-y69wwy40	341	13	in	in	IN
cord-016197-y69wwy40	341	14	registration	registration	NN
cord-016197-y69wwy40	341	15	of	of	IN
cord-016197-y69wwy40	341	16	new	new	JJ
cord-016197-y69wwy40	341	17	products	product	NNS
cord-016197-y69wwy40	341	18	•	•	NNP
cord-016197-y69wwy40	341	19	increasing	increase	VBG
cord-016197-y69wwy40	341	20	education	education	NN
cord-016197-y69wwy40	341	21	and	and	CC
cord-016197-y69wwy40	341	22	training	training	NN
cord-016197-y69wwy40	341	23	opportunities	opportunity	NNS
cord-016197-y69wwy40	341	24	.	.	.
cord-016197-y69wwy40	342	1	Research	research	NN
cord-016197-y69wwy40	342	2	-	-	HYPH
cord-016197-y69wwy40	342	3	based	base	VBN
cord-016197-y69wwy40	342	4	Pharma	Pharma	NNP
cord-016197-y69wwy40	342	5	needs	need	VBZ
cord-016197-y69wwy40	342	6	to	to	TO
cord-016197-y69wwy40	342	7	be	be	VB
cord-016197-y69wwy40	342	8	included	include	VBN
cord-016197-y69wwy40	342	9	as	as	IN
cord-016197-y69wwy40	342	10	a	a	DT
cord-016197-y69wwy40	342	11	partner	partner	NN
cord-016197-y69wwy40	342	12	in	in	IN
cord-016197-y69wwy40	342	13	these	these	DT
cord-016197-y69wwy40	342	14	collaborative	collaborative	JJ
cord-016197-y69wwy40	342	15	initiatives	initiative	NNS
cord-016197-y69wwy40	342	16	in	in	IN
cord-016197-y69wwy40	342	17	order	order	NN
cord-016197-y69wwy40	342	18	to	to	TO
cord-016197-y69wwy40	342	19	help	help	VB
cord-016197-y69wwy40	342	20	shape	shape	VB
cord-016197-y69wwy40	342	21	the	the	DT
cord-016197-y69wwy40	342	22	future	future	NN
cord-016197-y69wwy40	342	23	in	in	IN
cord-016197-y69wwy40	342	24	a	a	DT
cord-016197-y69wwy40	342	25	way	way	NN
cord-016197-y69wwy40	342	26	which	which	WDT
cord-016197-y69wwy40	342	27	will	will	MD
cord-016197-y69wwy40	342	28	be	be	VB
cord-016197-y69wwy40	342	29	conducive	conducive	JJ
cord-016197-y69wwy40	342	30	to	to	IN
cord-016197-y69wwy40	342	31	continued	continue	VBN
cord-016197-y69wwy40	342	32	investment	investment	NN
cord-016197-y69wwy40	342	33	into	into	IN
cord-016197-y69wwy40	342	34	R&D	r&d	NN
cord-016197-y69wwy40	342	35	for	for	IN
cord-016197-y69wwy40	342	36	new	new	JJ
cord-016197-y69wwy40	342	37	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	342	38	while	while	IN
cord-016197-y69wwy40	342	39	improving	improve	VBG
cord-016197-y69wwy40	342	40	their	-PRON-	PRP$
cord-016197-y69wwy40	342	41	use	use	NN
cord-016197-y69wwy40	342	42	and	and	CC
cord-016197-y69wwy40	342	43	sustainability	sustainability	NN
cord-016197-y69wwy40	342	44	.	.	.
cord-016197-y69wwy40	343	1	This	this	DT
cord-016197-y69wwy40	343	2	will	will	MD
cord-016197-y69wwy40	343	3	require	require	VB
cord-016197-y69wwy40	343	4	a	a	DT
cord-016197-y69wwy40	343	5	full	full	JJ
cord-016197-y69wwy40	343	6	consideration	consideration	NN
cord-016197-y69wwy40	343	7	of	of	IN
cord-016197-y69wwy40	343	8	the	the	DT
cord-016197-y69wwy40	343	9	contributing	contribute	VBG
cord-016197-y69wwy40	343	10	factors	factor	NNS
cord-016197-y69wwy40	343	11	,	,	,
cord-016197-y69wwy40	343	12	actions	action	NNS
cord-016197-y69wwy40	343	13	,	,	,
cord-016197-y69wwy40	343	14	and	and	CC
cord-016197-y69wwy40	343	15	impacts	impact	NNS
cord-016197-y69wwy40	343	16	in	in	IN
cord-016197-y69wwy40	343	17	order	order	NN
cord-016197-y69wwy40	343	18	to	to	TO
cord-016197-y69wwy40	343	19	find	find	VB
cord-016197-y69wwy40	343	20	a	a	DT
cord-016197-y69wwy40	343	21	way	way	NN
cord-016197-y69wwy40	343	22	to	to	TO
cord-016197-y69wwy40	343	23	maintain	maintain	VB
cord-016197-y69wwy40	343	24	a	a	DT
cord-016197-y69wwy40	343	25	critical	critical	JJ
cord-016197-y69wwy40	343	26	balance	balance	NN
cord-016197-y69wwy40	343	27	(	(	-LRB-
cord-016197-y69wwy40	343	28	Figure	figure	NN
cord-016197-y69wwy40	343	29	2	2	CD
cord-016197-y69wwy40	343	30	)	)	-RRB-
cord-016197-y69wwy40	343	31	.	.	.
cord-016197-y69wwy40	344	1	A	a	DT
cord-016197-y69wwy40	344	2	new	new	JJ
cord-016197-y69wwy40	344	3	model	model	NN
cord-016197-y69wwy40	344	4	may	may	MD
cord-016197-y69wwy40	344	5	need	need	VB
cord-016197-y69wwy40	344	6	to	to	TO
cord-016197-y69wwy40	344	7	be	be	VB
cord-016197-y69wwy40	344	8	defined	define	VBN
cord-016197-y69wwy40	344	9	which	which	WDT
cord-016197-y69wwy40	344	10	explores	explore	VBZ
cord-016197-y69wwy40	344	11	alternative	alternative	JJ
cord-016197-y69wwy40	344	12	roles	role	NNS
cord-016197-y69wwy40	344	13	of	of	IN
cord-016197-y69wwy40	344	14	small	small	JJ
cord-016197-y69wwy40	344	15	companies	company	NNS
cord-016197-y69wwy40	344	16	,	,	,
cord-016197-y69wwy40	344	17	government	government	NN
cord-016197-y69wwy40	344	18	,	,	,
cord-016197-y69wwy40	344	19	and	and	CC
cord-016197-y69wwy40	344	20	NGO	NGO	NNP
cord-016197-y69wwy40	344	21	bodies	body	NNS
cord-016197-y69wwy40	344	22	along	along	IN
cord-016197-y69wwy40	344	23	with	with	IN
cord-016197-y69wwy40	344	24	big	big	JJ
cord-016197-y69wwy40	344	25	Pharma	Pharma	NNS
cord-016197-y69wwy40	344	26	in	in	IN
cord-016197-y69wwy40	344	27	the	the	DT
cord-016197-y69wwy40	344	28	conduct	conduct	NN
cord-016197-y69wwy40	344	29	and	and	CC
cord-016197-y69wwy40	344	30	funding	funding	NN
cord-016197-y69wwy40	344	31	of	of	IN
cord-016197-y69wwy40	344	32	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	344	33	discovery	discovery	NN
cord-016197-y69wwy40	344	34	,	,	,
cord-016197-y69wwy40	344	35	development	development	NN
cord-016197-y69wwy40	344	36	,	,	,
cord-016197-y69wwy40	344	37	and	and	CC
cord-016197-y69wwy40	344	38	distribution	distribution	NN
cord-016197-y69wwy40	344	39	.	.	.
cord-016197-y69wwy40	345	1	Policies	policy	NNS
cord-016197-y69wwy40	345	2	are	be	VBP
cord-016197-y69wwy40	345	3	important	important	JJ
cord-016197-y69wwy40	345	4	and	and	CC
cord-016197-y69wwy40	345	5	necessary	necessary	JJ
cord-016197-y69wwy40	345	6	in	in	IN
cord-016197-y69wwy40	345	7	controlling	control	VBG
cord-016197-y69wwy40	345	8	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	345	9	use	use	NN
cord-016197-y69wwy40	345	10	in	in	IN
cord-016197-y69wwy40	345	11	an	an	DT
cord-016197-y69wwy40	345	12	attempt	attempt	NN
cord-016197-y69wwy40	345	13	to	to	TO
cord-016197-y69wwy40	345	14	preserve	preserve	VB
cord-016197-y69wwy40	345	15	the	the	DT
cord-016197-y69wwy40	345	16	utility	utility	NN
cord-016197-y69wwy40	345	17	of	of	IN
cord-016197-y69wwy40	345	18	existing	exist	VBG
cord-016197-y69wwy40	345	19	and	and	CC
cord-016197-y69wwy40	345	20	future	future	JJ
cord-016197-y69wwy40	345	21	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	345	22	.	.	.
cord-016197-y69wwy40	346	1	They	-PRON-	PRP
cord-016197-y69wwy40	346	2	should	should	MD
cord-016197-y69wwy40	346	3	aim	aim	VB
cord-016197-y69wwy40	346	4	to	to	TO
cord-016197-y69wwy40	346	5	minimize	minimize	VB
cord-016197-y69wwy40	346	6	unnecessary	unnecessary	JJ
cord-016197-y69wwy40	346	7	and	and	CC
cord-016197-y69wwy40	346	8	inappropriate	inappropriate	JJ
cord-016197-y69wwy40	346	9	use	use	NN
cord-016197-y69wwy40	346	10	,	,	,
cord-016197-y69wwy40	346	11	as	as	IN
cord-016197-y69wwy40	346	12	avoidable	avoidable	JJ
cord-016197-y69wwy40	346	13	risk	risk	NN
cord-016197-y69wwy40	346	14	factors	factor	NNS
cord-016197-y69wwy40	346	15	in	in	IN
cord-016197-y69wwy40	346	16	the	the	DT
cord-016197-y69wwy40	346	17	development	development	NN
cord-016197-y69wwy40	346	18	of	of	IN
cord-016197-y69wwy40	346	19	resistance	resistance	NN
cord-016197-y69wwy40	346	20	,	,	,
cord-016197-y69wwy40	346	21	while	while	IN
cord-016197-y69wwy40	346	22	maintaining	maintain	VBG
cord-016197-y69wwy40	346	23	or	or	CC
cord-016197-y69wwy40	346	24	improving	improve	VBG
cord-016197-y69wwy40	346	25	patient	patient	JJ
cord-016197-y69wwy40	346	26	outcomes	outcome	NNS
cord-016197-y69wwy40	346	27	.	.	.
cord-016197-y69wwy40	347	1	The	the	DT
cord-016197-y69wwy40	347	2	effect	effect	NN
cord-016197-y69wwy40	347	3	of	of	IN
cord-016197-y69wwy40	347	4	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	347	5	policies	policy	NNS
cord-016197-y69wwy40	347	6	on	on	IN
cord-016197-y69wwy40	347	7	the	the	DT
cord-016197-y69wwy40	347	8	containment	containment	NN
cord-016197-y69wwy40	347	9	or	or	CC
cord-016197-y69wwy40	347	10	reduction	reduction	NN
cord-016197-y69wwy40	347	11	of	of	IN
cord-016197-y69wwy40	347	12	resistance	resistance	NN
cord-016197-y69wwy40	347	13	is	be	VBZ
cord-016197-y69wwy40	347	14	largely	largely	RB
cord-016197-y69wwy40	347	15	unknown	unknown	JJ
cord-016197-y69wwy40	347	16	and	and	CC
cord-016197-y69wwy40	347	17	should	should	MD
cord-016197-y69wwy40	347	18	focus	focus	VB
cord-016197-y69wwy40	347	19	not	not	RB
cord-016197-y69wwy40	347	20	on	on	IN
cord-016197-y69wwy40	347	21	quantity	quantity	NN
cord-016197-y69wwy40	347	22	of	of	IN
cord-016197-y69wwy40	347	23	prescribing	prescribe	VBG
cord-016197-y69wwy40	347	24	alone	alone	RB
cord-016197-y69wwy40	347	25	but	but	CC
cord-016197-y69wwy40	347	26	on	on	IN
cord-016197-y69wwy40	347	27	quality	quality	NN
cord-016197-y69wwy40	347	28	to	to	TO
cord-016197-y69wwy40	347	29	ensure	ensure	VB
cord-016197-y69wwy40	347	30	appropriate	appropriate	JJ
cord-016197-y69wwy40	347	31	prescribing	prescribing	NN
cord-016197-y69wwy40	347	32	in	in	IN
cord-016197-y69wwy40	347	33	terms	term	NNS
cord-016197-y69wwy40	347	34	of	of	IN
cord-016197-y69wwy40	347	35	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	347	36	choice	choice	NN
cord-016197-y69wwy40	347	37	,	,	,
cord-016197-y69wwy40	347	38	dosage	dosage	NN
cord-016197-y69wwy40	347	39	,	,	,
cord-016197-y69wwy40	347	40	dosing	dose	VBG
cord-016197-y69wwy40	347	41	regimen	regimen	NN
cord-016197-y69wwy40	347	42	,	,	,
cord-016197-y69wwy40	347	43	or	or	CC
cord-016197-y69wwy40	347	44	duration	duration	NN
cord-016197-y69wwy40	347	45	.	.	.
cord-016197-y69wwy40	348	1	Policies	policy	NNS
cord-016197-y69wwy40	348	2	that	that	WDT
cord-016197-y69wwy40	348	3	relate	relate	VBP
cord-016197-y69wwy40	348	4	to	to	TO
cord-016197-y69wwy40	348	5	Figure	figure	NN
cord-016197-y69wwy40	348	6	2	2	CD
cord-016197-y69wwy40	348	7	.	.	.
cord-016197-y69wwy40	349	1	From	from	IN
cord-016197-y69wwy40	349	2	the	the	DT
cord-016197-y69wwy40	349	3	past	past	NN
cord-016197-y69wwy40	349	4	to	to	IN
cord-016197-y69wwy40	349	5	the	the	DT
cord-016197-y69wwy40	349	6	future	future	NN
cord-016197-y69wwy40	349	7	:	:	:
cord-016197-y69wwy40	349	8	Hypothetical	hypothetical	JJ
cord-016197-y69wwy40	349	9	potential	potential	JJ
cord-016197-y69wwy40	349	10	scenarios	scenario	NNS
cord-016197-y69wwy40	349	11	evolving	evolve	VBG
cord-016197-y69wwy40	349	12	from	from	IN
cord-016197-y69wwy40	349	13	the	the	DT
cord-016197-y69wwy40	349	14	relationship	relationship	NN
cord-016197-y69wwy40	349	15	between	between	IN
cord-016197-y69wwy40	349	16	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	349	17	need	need	NN
cord-016197-y69wwy40	349	18	/	/	SYM
cord-016197-y69wwy40	349	19	resistance	resistance	NN
cord-016197-y69wwy40	349	20	,	,	,
cord-016197-y69wwy40	349	21	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	349	22	productivity	productivity	NN
cord-016197-y69wwy40	349	23	and	and	CC
cord-016197-y69wwy40	349	24	policy	policy	NN
cord-016197-y69wwy40	349	25	.	.	.
cord-016197-y69wwy40	350	1	(	(	-LRB-
cord-016197-y69wwy40	350	2	a	a	LS
cord-016197-y69wwy40	350	3	)	)	-RRB-
cord-016197-y69wwy40	350	4	Sustainable	sustainable	JJ
cord-016197-y69wwy40	350	5	balance	balance	NN
cord-016197-y69wwy40	350	6	of	of	IN
cord-016197-y69wwy40	350	7	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	350	8	productivity	productivity	NN
cord-016197-y69wwy40	350	9	,	,	,
cord-016197-y69wwy40	350	10	resistance	resistance	NN
cord-016197-y69wwy40	350	11	,	,	,
cord-016197-y69wwy40	350	12	and	and	CC
cord-016197-y69wwy40	350	13	regulation	regulation	NN
cord-016197-y69wwy40	350	14	/	/	SYM
cord-016197-y69wwy40	350	15	policy	policy	NN
cord-016197-y69wwy40	350	16	;	;	:
cord-016197-y69wwy40	350	17	oscillations	oscillation	NNS
cord-016197-y69wwy40	350	18	may	may	MD
cord-016197-y69wwy40	350	19	decrease	decrease	VB
cord-016197-y69wwy40	350	20	over	over	IN
cord-016197-y69wwy40	350	21	time	time	NN
cord-016197-y69wwy40	350	22	with	with	IN
cord-016197-y69wwy40	350	23	better	well	JJR
cord-016197-y69wwy40	350	24	understanding	understanding	NN
cord-016197-y69wwy40	350	25	of	of	IN
cord-016197-y69wwy40	350	26	the	the	DT
cord-016197-y69wwy40	350	27	relationships	relationship	NNS
cord-016197-y69wwy40	350	28	and	and	CC
cord-016197-y69wwy40	350	29	balanced	balanced	JJ
cord-016197-y69wwy40	350	30	management	management	NN
cord-016197-y69wwy40	350	31	.	.	.
cord-016197-y69wwy40	351	1	(	(	-LRB-
cord-016197-y69wwy40	351	2	b	b	LS
cord-016197-y69wwy40	351	3	)	)	-RRB-
cord-016197-y69wwy40	351	4	Crisis	crisis	NN
cord-016197-y69wwy40	351	5	of	of	IN
cord-016197-y69wwy40	351	6	imbalance	imbalance	NN
cord-016197-y69wwy40	351	7	of	of	IN
cord-016197-y69wwy40	351	8	increased	increase	VBN
cord-016197-y69wwy40	351	9	policy	policy	NN
cord-016197-y69wwy40	351	10	/	/	SYM
cord-016197-y69wwy40	351	11	regulation	regulation	NN
cord-016197-y69wwy40	351	12	,	,	,
cord-016197-y69wwy40	351	13	decreased	decrease	VBD
cord-016197-y69wwy40	351	14	incentives	incentive	NNS
cord-016197-y69wwy40	351	15	and	and	CC
cord-016197-y69wwy40	351	16	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	351	17	productivity	productivity	NN
cord-016197-y69wwy40	351	18	and	and	CC
cord-016197-y69wwy40	351	19	increasing	increase	VBG
cord-016197-y69wwy40	351	20	/	/	SYM
cord-016197-y69wwy40	351	21	uncontrolled	uncontrolled	JJ
cord-016197-y69wwy40	351	22	resistance	resistance	NN
cord-016197-y69wwy40	351	23	.	.	.
cord-016197-y69wwy40	352	1	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	352	2	use	use	NN
cord-016197-y69wwy40	352	3	have	have	VBP
cord-016197-y69wwy40	352	4	the	the	DT
cord-016197-y69wwy40	352	5	potential	potential	NN
cord-016197-y69wwy40	352	6	to	to	TO
cord-016197-y69wwy40	352	7	reduce	reduce	VB
cord-016197-y69wwy40	352	8	the	the	DT
cord-016197-y69wwy40	352	9	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	352	10	market	market	NN
cord-016197-y69wwy40	352	11	size	size	NN
cord-016197-y69wwy40	352	12	and	and	CC
cord-016197-y69wwy40	352	13	commercial	commercial	JJ
cord-016197-y69wwy40	352	14	attractiveness	attractiveness	NN
cord-016197-y69wwy40	352	15	relative	relative	JJ
cord-016197-y69wwy40	352	16	to	to	IN
cord-016197-y69wwy40	352	17	other	other	JJ
cord-016197-y69wwy40	352	18	therapeutic	therapeutic	JJ
cord-016197-y69wwy40	352	19	areas	area	NNS
cord-016197-y69wwy40	352	20	.	.	.
cord-016197-y69wwy40	353	1	Policies	policy	NNS
cord-016197-y69wwy40	353	2	that	that	WDT
cord-016197-y69wwy40	353	3	relate	relate	VBP
cord-016197-y69wwy40	353	4	to	to	IN
cord-016197-y69wwy40	353	5	development	development	NN
cord-016197-y69wwy40	353	6	activities	activity	NNS
cord-016197-y69wwy40	353	7	and	and	CC
cord-016197-y69wwy40	353	8	labelling	labelling	NN
cord-016197-y69wwy40	353	9	have	have	VBP
cord-016197-y69wwy40	353	10	the	the	DT
cord-016197-y69wwy40	353	11	potential	potential	NN
cord-016197-y69wwy40	353	12	to	to	TO
cord-016197-y69wwy40	353	13	increase	increase	VB
cord-016197-y69wwy40	353	14	development	development	NN
cord-016197-y69wwy40	353	15	costs	cost	NNS
cord-016197-y69wwy40	353	16	,	,	,
cord-016197-y69wwy40	353	17	restrict	restrict	VB
cord-016197-y69wwy40	353	18	use	use	NN
cord-016197-y69wwy40	353	19	,	,	,
cord-016197-y69wwy40	353	20	and	and	CC
cord-016197-y69wwy40	353	21	limit	limit	VB
cord-016197-y69wwy40	353	22	the	the	DT
cord-016197-y69wwy40	353	23	ability	ability	NN
cord-016197-y69wwy40	353	24	to	to	TO
cord-016197-y69wwy40	353	25	differentiate	differentiate	VB
cord-016197-y69wwy40	353	26	benefits	benefit	NNS
cord-016197-y69wwy40	353	27	.	.	.
cord-016197-y69wwy40	354	1	Collectively	collectively	RB
cord-016197-y69wwy40	354	2	policies	policy	NNS
cord-016197-y69wwy40	354	3	are	be	VBP
cord-016197-y69wwy40	354	4	negatively	negatively	RB
cord-016197-y69wwy40	354	5	impacting	impact	VBG
cord-016197-y69wwy40	354	6	big	big	JJ
cord-016197-y69wwy40	354	7	Pharma	Pharma	NNP
cord-016197-y69wwy40	354	8	's	's	POS
cord-016197-y69wwy40	354	9	willingness	willingness	NN
cord-016197-y69wwy40	354	10	to	to	TO
cord-016197-y69wwy40	354	11	continue	continue	VB
cord-016197-y69wwy40	354	12	investment	investment	NN
cord-016197-y69wwy40	354	13	in	in	IN
cord-016197-y69wwy40	354	14	this	this	DT
cord-016197-y69wwy40	354	15	field	field	NN
cord-016197-y69wwy40	354	16	.	.	.
cord-016197-y69wwy40	355	1	The	the	DT
cord-016197-y69wwy40	355	2	combined	combined	JJ
cord-016197-y69wwy40	355	3	and	and	CC
cord-016197-y69wwy40	355	4	cumulative	cumulative	JJ
cord-016197-y69wwy40	355	5	effects	effect	NNS
cord-016197-y69wwy40	355	6	of	of	IN
cord-016197-y69wwy40	355	7	the	the	DT
cord-016197-y69wwy40	355	8	various	various	JJ
cord-016197-y69wwy40	355	9	policy	policy	NN
cord-016197-y69wwy40	355	10	items	item	NNS
cord-016197-y69wwy40	355	11	related	relate	VBN
cord-016197-y69wwy40	355	12	to	to	IN
cord-016197-y69wwy40	355	13	surveillance	surveillance	NN
cord-016197-y69wwy40	355	14	,	,	,
cord-016197-y69wwy40	355	15	use	use	NN
cord-016197-y69wwy40	355	16	,	,	,
cord-016197-y69wwy40	355	17	clinical	clinical	JJ
cord-016197-y69wwy40	355	18	trial	trial	NN
cord-016197-y69wwy40	355	19	guidelines	guideline	NNS
cord-016197-y69wwy40	355	20	,	,	,
cord-016197-y69wwy40	355	21	product	product	NN
cord-016197-y69wwy40	355	22	labelling	labelling	NN
cord-016197-y69wwy40	355	23	,	,	,
cord-016197-y69wwy40	355	24	and	and	CC
cord-016197-y69wwy40	355	25	promotion	promotion	NN
cord-016197-y69wwy40	355	26	require	require	VBP
cord-016197-y69wwy40	355	27	a	a	DT
cord-016197-y69wwy40	355	28	broad	broad	JJ
cord-016197-y69wwy40	355	29	,	,	,
cord-016197-y69wwy40	355	30	collaborative	collaborative	JJ
cord-016197-y69wwy40	355	31	,	,	,
cord-016197-y69wwy40	355	32	and	and	CC
cord-016197-y69wwy40	355	33	global	global	JJ
cord-016197-y69wwy40	355	34	view	view	NN
cord-016197-y69wwy40	355	35	of	of	IN
cord-016197-y69wwy40	355	36	the	the	DT
cord-016197-y69wwy40	355	37	impact	impact	NN
cord-016197-y69wwy40	355	38	on	on	IN
cord-016197-y69wwy40	355	39	Pharma	Pharma	NNP
cord-016197-y69wwy40	355	40	R&D.	R&D.	NNP
cord-016197-y69wwy40	355	41	Collaboration	Collaboration	NNP
cord-016197-y69wwy40	355	42	is	be	VBZ
cord-016197-y69wwy40	355	43	required	require	VBN
cord-016197-y69wwy40	355	44	to	to	TO
cord-016197-y69wwy40	355	45	identify	identify	VB
cord-016197-y69wwy40	355	46	agreed	agree	VBN
cord-016197-y69wwy40	355	47	and	and	CC
cord-016197-y69wwy40	355	48	mutually	mutually	RB
cord-016197-y69wwy40	355	49	acceptable	acceptable	JJ
cord-016197-y69wwy40	355	50	ways	way	NNS
cord-016197-y69wwy40	355	51	to	to	TO
cord-016197-y69wwy40	355	52	streamline	streamline	VB
cord-016197-y69wwy40	355	53	development	development	NN
cord-016197-y69wwy40	355	54	,	,	,
cord-016197-y69wwy40	355	55	implement	implement	VB
cord-016197-y69wwy40	355	56	appropriate	appropriate	JJ
cord-016197-y69wwy40	355	57	prescribing	prescribing	NN
cord-016197-y69wwy40	355	58	,	,	,
cord-016197-y69wwy40	355	59	demonstrate	demonstrate	VB
cord-016197-y69wwy40	355	60	and	and	CC
cord-016197-y69wwy40	355	61	promote	promote	VB
cord-016197-y69wwy40	355	62	product	product	NN
cord-016197-y69wwy40	355	63	benefits	benefit	NNS
cord-016197-y69wwy40	355	64	,	,	,
cord-016197-y69wwy40	355	65	and	and	CC
cord-016197-y69wwy40	355	66	maintain	maintain	VB
cord-016197-y69wwy40	355	67	financial	financial	JJ
cord-016197-y69wwy40	355	68	incentives	incentive	NNS
cord-016197-y69wwy40	355	69	.	.	.
cord-016197-y69wwy40	356	1	Antibacterial	antibacterial	JJ
cord-016197-y69wwy40	356	2	discovery	discovery	NN
cord-016197-y69wwy40	356	3	,	,	,
cord-016197-y69wwy40	356	4	development	development	NN
cord-016197-y69wwy40	356	5	,	,	,
cord-016197-y69wwy40	356	6	and	and	CC
cord-016197-y69wwy40	356	7	use	use	NN
cord-016197-y69wwy40	356	8	are	be	VBP
cord-016197-y69wwy40	356	9	related	relate	VBN
cord-016197-y69wwy40	356	10	within	within	IN
cord-016197-y69wwy40	356	11	a	a	DT
cord-016197-y69wwy40	356	12	dynamic	dynamic	JJ
cord-016197-y69wwy40	356	13	environment	environment	NN
cord-016197-y69wwy40	356	14	that	that	WDT
cord-016197-y69wwy40	356	15	includes	include	VBZ
cord-016197-y69wwy40	356	16	bacteria	bacteria	NNS
cord-016197-y69wwy40	356	17	,	,	,
cord-016197-y69wwy40	356	18	their	-PRON-	PRP$
cord-016197-y69wwy40	356	19	resistances	resistance	NNS
cord-016197-y69wwy40	356	20	,	,	,
cord-016197-y69wwy40	356	21	and	and	CC
cord-016197-y69wwy40	356	22	policies	policy	NNS
cord-016197-y69wwy40	356	23	.	.	.
cord-016197-y69wwy40	357	1	As	as	IN
cord-016197-y69wwy40	357	2	with	with	IN
cord-016197-y69wwy40	357	3	any	any	DT
cord-016197-y69wwy40	357	4	dynamic	dynamic	JJ
cord-016197-y69wwy40	357	5	environment	environment	NN
cord-016197-y69wwy40	357	6	,	,	,
cord-016197-y69wwy40	357	7	change	change	NN
cord-016197-y69wwy40	357	8	will	will	MD
cord-016197-y69wwy40	357	9	alter	alter	VB
cord-016197-y69wwy40	357	10	the	the	DT
cord-016197-y69wwy40	357	11	balance	balance	NN
cord-016197-y69wwy40	357	12	(	(	-LRB-
cord-016197-y69wwy40	357	13	Figure	figure	NN
cord-016197-y69wwy40	357	14	3	3	CD
cord-016197-y69wwy40	357	15	)	)	-RRB-
cord-016197-y69wwy40	357	16	.	.	.
cord-016197-y69wwy40	358	1	Policies	policy	NNS
cord-016197-y69wwy40	358	2	are	be	VBP
cord-016197-y69wwy40	358	3	contributing	contribute	VBG
cord-016197-y69wwy40	358	4	to	to	IN
cord-016197-y69wwy40	358	5	a	a	DT
cord-016197-y69wwy40	358	6	change	change	NN
cord-016197-y69wwy40	358	7	and	and	CC
cord-016197-y69wwy40	358	8	a	a	DT
cord-016197-y69wwy40	358	9	negative	negative	JJ
cord-016197-y69wwy40	358	10	impact	impact	NN
cord-016197-y69wwy40	358	11	on	on	IN
cord-016197-y69wwy40	358	12	the	the	DT
cord-016197-y69wwy40	358	13	potential	potential	NN
cord-016197-y69wwy40	358	14	and	and	CC
cord-016197-y69wwy40	358	15	willingness	willingness	NN
cord-016197-y69wwy40	358	16	of	of	IN
cord-016197-y69wwy40	358	17	Pharma	Pharma	NNP
cord-016197-y69wwy40	358	18	to	to	TO
cord-016197-y69wwy40	358	19	develop	develop	VB
cord-016197-y69wwy40	358	20	new	new	JJ
cord-016197-y69wwy40	358	21	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	358	22	.	.	.
cord-016197-y69wwy40	359	1	While	while	IN
cord-016197-y69wwy40	359	2	change	change	NN
cord-016197-y69wwy40	359	3	may	may	MD
cord-016197-y69wwy40	359	4	require	require	VB
cord-016197-y69wwy40	359	5	adaptation	adaptation	NN
cord-016197-y69wwy40	359	6	for	for	IN
cord-016197-y69wwy40	359	7	survival	survival	NN
cord-016197-y69wwy40	359	8	and	and	CC
cord-016197-y69wwy40	359	9	success	success	NN
cord-016197-y69wwy40	359	10	,	,	,
cord-016197-y69wwy40	359	11	careful	careful	JJ
cord-016197-y69wwy40	359	12	consideration	consideration	NN
cord-016197-y69wwy40	359	13	and	and	CC
cord-016197-y69wwy40	359	14	collaboration	collaboration	NN
cord-016197-y69wwy40	359	15	is	be	VBZ
cord-016197-y69wwy40	359	16	needed	need	VBN
cord-016197-y69wwy40	359	17	by	by	IN
cord-016197-y69wwy40	359	18	all	all	DT
cord-016197-y69wwy40	359	19	parties	party	NNS
cord-016197-y69wwy40	359	20	to	to	TO
cord-016197-y69wwy40	359	21	help	help	VB
cord-016197-y69wwy40	359	22	to	to	TO
cord-016197-y69wwy40	359	23	ensure	ensure	VB
cord-016197-y69wwy40	359	24	that	that	IN
cord-016197-y69wwy40	359	25	insurmountable	insurmountable	JJ
cord-016197-y69wwy40	359	26	hurdles	hurdle	NNS
cord-016197-y69wwy40	359	27	are	be	VBP
cord-016197-y69wwy40	359	28	not	not	RB
cord-016197-y69wwy40	359	29	created	create	VBN
cord-016197-y69wwy40	359	30	leading	lead	VBG
cord-016197-y69wwy40	359	31	to	to	IN
cord-016197-y69wwy40	359	32	the	the	DT
cord-016197-y69wwy40	359	33	inability	inability	NN
cord-016197-y69wwy40	359	34	of	of	IN
cord-016197-y69wwy40	359	35	Pharma	Pharma	NNP
cord-016197-y69wwy40	359	36	to	to	TO
cord-016197-y69wwy40	359	37	survive	survive	VB
cord-016197-y69wwy40	359	38	and	and	CC
cord-016197-y69wwy40	359	39	succeed	succeed	VB
cord-016197-y69wwy40	359	40	in	in	IN
cord-016197-y69wwy40	359	41	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	359	42	R&D.	R&D.	NNP
cord-016197-y69wwy40	359	43	Failure	failure	NN
cord-016197-y69wwy40	359	44	of	of	IN
cord-016197-y69wwy40	359	45	Pharma	Pharma	NNPS
cord-016197-y69wwy40	359	46	to	to	TO
cord-016197-y69wwy40	359	47	deliver	deliver	VB
cord-016197-y69wwy40	359	48	new	new	JJ
cord-016197-y69wwy40	359	49	antibacterials	antibacterial	NNS
cord-016197-y69wwy40	359	50	would	would	MD
cord-016197-y69wwy40	359	51	lead	lead	VB
cord-016197-y69wwy40	359	52	to	to	IN
cord-016197-y69wwy40	359	53	"	"	``
cord-016197-y69wwy40	359	54	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	359	55	extinction	extinction	NN
cord-016197-y69wwy40	359	56	.	.	.
cord-016197-y69wwy40	359	57	"	"	''
cord-016197-y69wwy40	360	1	Pharmaceutical	Pharmaceutical	NNP
cord-016197-y69wwy40	360	2	Company	Company	NNP
cord-016197-y69wwy40	360	3	Approach	Approach	NNP
cord-016197-y69wwy40	360	4	697	697	CD
cord-016197-y69wwy40	360	5	Bacterial	bacterial	JJ
cord-016197-y69wwy40	360	6	resistance	resistance	NN
cord-016197-y69wwy40	360	7	concerns	concern	NNS
cord-016197-y69wwy40	361	1	The	the	DT
cord-016197-y69wwy40	361	2	relationship	relationship	NN
cord-016197-y69wwy40	361	3	between	between	IN
cord-016197-y69wwy40	361	4	the	the	DT
cord-016197-y69wwy40	361	5	volume	volume	NN
cord-016197-y69wwy40	361	6	of	of	IN
cord-016197-y69wwy40	361	7	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	361	8	consumption	consumption	NN
cord-016197-y69wwy40	361	9	in	in	IN
cord-016197-y69wwy40	361	10	human	human	JJ
cord-016197-y69wwy40	361	11	communities	community	NNS
cord-016197-y69wwy40	361	12	and	and	CC
cord-016197-y69wwy40	361	13	the	the	DT
cord-016197-y69wwy40	361	14	frequency	frequency	NN
cord-016197-y69wwy40	361	15	of	of	IN
cord-016197-y69wwy40	361	16	resistance	resistance	NN
cord-016197-y69wwy40	361	17	Antibiotic	antibiotic	JJ
cord-016197-y69wwy40	361	18	therapy	therapy	NN
cord-016197-y69wwy40	361	19	of	of	IN
cord-016197-y69wwy40	361	20	community	community	NN
cord-016197-y69wwy40	361	21	respiratory	respiratory	JJ
cord-016197-y69wwy40	361	22	tract	tract	NN
cord-016197-y69wwy40	361	23	infections	infection	NNS
cord-016197-y69wwy40	361	24	:	:	:
cord-016197-y69wwy40	361	25	Strategies	strategy	NNS
cord-016197-y69wwy40	361	26	for	for	IN
cord-016197-y69wwy40	361	27	optimal	optimal	JJ
cord-016197-y69wwy40	361	28	outcomes	outcome	NNS
cord-016197-y69wwy40	361	29	and	and	CC
cord-016197-y69wwy40	361	30	minimized	minimize	VBN
cord-016197-y69wwy40	361	31	resistance	resistance	NN
cord-016197-y69wwy40	361	32	emergence	emergence	NN
cord-016197-y69wwy40	361	33	Surveillance	surveillance	NN
cord-016197-y69wwy40	361	34	of	of	IN
cord-016197-y69wwy40	361	35	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	361	36	resistance	resistance	NN
cord-016197-y69wwy40	361	37	-	-	,
cord-016197-y69wwy40	361	38	what	what	WP
cord-016197-y69wwy40	361	39	,	,	,
cord-016197-y69wwy40	361	40	how	how	WRB
cord-016197-y69wwy40	361	41	and	and	CC
cord-016197-y69wwy40	361	42	whither	whither	WP
cord-016197-y69wwy40	361	43	?	?	.
cord-016197-y69wwy40	362	1	Antibiotic	antibiotic	JJ
cord-016197-y69wwy40	362	2	clinical	clinical	JJ
cord-016197-y69wwy40	362	3	trials-	trials-	NN
cord-016197-y69wwy40	363	1	the	the	DT
cord-016197-y69wwy40	363	2	Witley	Witley	NNP
cord-016197-y69wwy40	363	3	Park	Park	NNP
cord-016197-y69wwy40	363	4	Symposium	Symposium	NNP
cord-016197-y69wwy40	363	5	Moving	move	VBG
cord-016197-y69wwy40	363	6	from	from	IN
cord-016197-y69wwy40	363	7	recommendation	recommendation	NN
cord-016197-y69wwy40	363	8	to	to	IN
cord-016197-y69wwy40	363	9	implementation	implementation	NN
cord-016197-y69wwy40	363	10	and	and	CC
cord-016197-y69wwy40	363	11	audit	audit	NN
cord-016197-y69wwy40	363	12	:	:	:
cord-016197-y69wwy40	364	1	Part	part	NN
cord-016197-y69wwy40	364	2	1	1	CD
cord-016197-y69wwy40	364	3	.	.	.
cord-016197-y69wwy40	365	1	Current	current	JJ
cord-016197-y69wwy40	365	2	recommendations	recommendation	NNS
cord-016197-y69wwy40	365	3	and	and	CC
cord-016197-y69wwy40	365	4	programs	program	NNS
cord-016197-y69wwy40	365	5	:	:	:
cord-016197-y69wwy40	365	6	a	a	DT
cord-016197-y69wwy40	365	7	critical	critical	JJ
cord-016197-y69wwy40	365	8	commentary	commentary	NN
cord-016197-y69wwy40	365	9	Politiques	Politiques	NNP
cord-016197-y69wwy40	365	10	d'antibiothérapie	d'antibiothérapie	NNP
cord-016197-y69wwy40	365	11	a	a	DT
cord-016197-y69wwy40	365	12	l'échelon	l'échelon	NNP
cord-016197-y69wwy40	365	13	national	national	NNP
cord-016197-y69wwy40	365	14	dans	dans	FW
cord-016197-y69wwy40	365	15	divers	divers	NNPS
cord-016197-y69wwy40	365	16	pays	pay	VBZ
cord-016197-y69wwy40	365	17	Moving	move	VBG
cord-016197-y69wwy40	365	18	from	from	IN
cord-016197-y69wwy40	365	19	recommendation	recommendation	NN
cord-016197-y69wwy40	365	20	to	to	IN
cord-016197-y69wwy40	365	21	implementation	implementation	NN
cord-016197-y69wwy40	365	22	and	and	CC
cord-016197-y69wwy40	365	23	audit	audit	NN
cord-016197-y69wwy40	365	24	:	:	:
cord-016197-y69wwy40	366	1	Part	part	NN
cord-016197-y69wwy40	366	2	2	2	CD
cord-016197-y69wwy40	366	3	.	.	.
cord-016197-y69wwy40	367	1	Review	Review	NNP
cord-016197-y69wwy40	367	2	of	of	IN
cord-016197-y69wwy40	367	3	interventions	intervention	NNS
cord-016197-y69wwy40	367	4	and	and	CC
cord-016197-y69wwy40	367	5	audit	audit	NN
cord-016197-y69wwy40	368	1	Antibiotic	antibiotic	JJ
cord-016197-y69wwy40	368	2	policies	policy	NNS
cord-016197-y69wwy40	369	1	Oxazolidinones	Oxazolidinones	NNP
cord-016197-y69wwy40	369	2	:	:	:
cord-016197-y69wwy40	370	1	A	a	DT
cord-016197-y69wwy40	370	2	review	review	NN
cord-016197-y69wwy40	370	3	European	European	NNP
cord-016197-y69wwy40	370	4	Conference	Conference	NNP
cord-016197-y69wwy40	370	5	on	on	IN
cord-016197-y69wwy40	370	6	Antibiotic	Antibiotic	NNP
cord-016197-y69wwy40	370	7	Use	Use	NNP
cord-016197-y69wwy40	370	8	in	in	IN
cord-016197-y69wwy40	370	9	Europe	Europe	NNP
cord-016197-y69wwy40	370	10	.	.	.
cord-016197-y69wwy40	371	1	15	15	CD
cord-016197-y69wwy40	371	2	-	-	SYM
cord-016197-y69wwy40	371	3	17	17	CD
cord-016197-y69wwy40	371	4	Surveillance	surveillance	NN
cord-016197-y69wwy40	371	5	of	of	IN
cord-016197-y69wwy40	371	6	resistance	resistance	NN
cord-016197-y69wwy40	371	7	in	in	IN
cord-016197-y69wwy40	371	8	bacteria	bacteria	NNS
cord-016197-y69wwy40	371	9	causing	cause	VBG
cord-016197-y69wwy40	371	10	community	community	NN
cord-016197-y69wwy40	371	11	-	-	HYPH
cord-016197-y69wwy40	371	12	acquired	acquire	VBN
cord-016197-y69wwy40	371	13	respiratory	respiratory	JJ
cord-016197-y69wwy40	371	14	tract	tract	NN
cord-016197-y69wwy40	371	15	infections	infection	NNS
cord-016197-y69wwy40	372	1	A	a	DT
cord-016197-y69wwy40	372	2	critical	critical	JJ
cord-016197-y69wwy40	372	3	assessment	assessment	NN
cord-016197-y69wwy40	372	4	of	of	IN
cord-016197-y69wwy40	372	5	published	publish	VBN
cord-016197-y69wwy40	372	6	guidelines	guideline	NNS
cord-016197-y69wwy40	372	7	and	and	CC
cord-016197-y69wwy40	372	8	other	other	JJ
cord-016197-y69wwy40	372	9	decision	decision	NN
cord-016197-y69wwy40	372	10	-	-	HYPH
cord-016197-y69wwy40	372	11	support	support	NN
cord-016197-y69wwy40	372	12	systems	system	NNS
cord-016197-y69wwy40	372	13	for	for	IN
cord-016197-y69wwy40	372	14	the	the	DT
cord-016197-y69wwy40	372	15	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	372	16	treatment	treatment	NN
cord-016197-y69wwy40	372	17	of	of	IN
cord-016197-y69wwy40	372	18	community	community	NN
cord-016197-y69wwy40	372	19	-	-	HYPH
cord-016197-y69wwy40	372	20	acquired	acquire	VBN
cord-016197-y69wwy40	372	21	respiratory	respiratory	JJ
cord-016197-y69wwy40	372	22	tract	tract	NN
cord-016197-y69wwy40	372	23	infections	infection	NNS
cord-016197-y69wwy40	373	1	The	the	DT
cord-016197-y69wwy40	373	2	evolution	evolution	NN
cord-016197-y69wwy40	373	3	of	of	IN
cord-016197-y69wwy40	373	4	anti	anti	JJ
cord-016197-y69wwy40	373	5	-	-	JJ
cord-016197-y69wwy40	373	6	microbic	microbic	JJ
cord-016197-y69wwy40	373	7	drugs	drug	NNS
cord-016197-y69wwy40	373	8	A	a	DT
cord-016197-y69wwy40	373	9	review	review	NN
cord-016197-y69wwy40	373	10	of	of	IN
cord-016197-y69wwy40	373	11	the	the	DT
cord-016197-y69wwy40	373	12	role	role	NN
cord-016197-y69wwy40	373	13	of	of	IN
cord-016197-y69wwy40	373	14	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	373	15	policies	policy	NNS
cord-016197-y69wwy40	373	16	in	in	IN
cord-016197-y69wwy40	373	17	the	the	DT
cord-016197-y69wwy40	373	18	control	control	NN
cord-016197-y69wwy40	373	19	of	of	IN
cord-016197-y69wwy40	373	20	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	373	21	resistance	resistance	NN
cord-016197-y69wwy40	373	22	Minimum	Minimum	NNP
cord-016197-y69wwy40	373	23	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	373	24	stewardship	stewardship	NN
cord-016197-y69wwy40	373	25	measures	measure	NNS
cord-016197-y69wwy40	374	1	The	the	DT
cord-016197-y69wwy40	374	2	current	current	JJ
cord-016197-y69wwy40	374	3	status	status	NN
cord-016197-y69wwy40	374	4	of	of	IN
cord-016197-y69wwy40	374	5	surveillance	surveillance	NN
cord-016197-y69wwy40	374	6	of	of	IN
cord-016197-y69wwy40	374	7	resistance	resistance	NN
cord-016197-y69wwy40	374	8	to	to	IN
cord-016197-y69wwy40	374	9	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	374	10	agents	agent	NNS
cord-016197-y69wwy40	374	11	:	:	:
cord-016197-y69wwy40	374	12	Report	report	VB
cord-016197-y69wwy40	374	13	on	on	IN
cord-016197-y69wwy40	374	14	a	a	DT
cord-016197-y69wwy40	374	15	meeting	meeting	NN
cord-016197-y69wwy40	374	16	Abstracts	abstract	NNS
cord-016197-y69wwy40	374	17	of	of	IN
cord-016197-y69wwy40	374	18	the	the	DT
cord-016197-y69wwy40	374	19	42nd	42nd	JJ
cord-016197-y69wwy40	374	20	Interscience	Interscience	NNP
cord-016197-y69wwy40	374	21	Conference	Conference	NNP
cord-016197-y69wwy40	374	22	on	on	IN
cord-016197-y69wwy40	374	23	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	374	24	Agents	Agents	NNPS
cord-016197-y69wwy40	374	25	and	and	CC
cord-016197-y69wwy40	374	26	Chemotherapy	Chemotherapy	NNP
cord-016197-y69wwy40	374	27	Abstracts	abstract	NNS
cord-016197-y69wwy40	374	28	of	of	IN
cord-016197-y69wwy40	374	29	the	the	DT
cord-016197-y69wwy40	374	30	43rd	43rd	JJ
cord-016197-y69wwy40	374	31	Interscience	Interscience	NNP
cord-016197-y69wwy40	374	32	Conference	Conference	NNP
cord-016197-y69wwy40	374	33	on	on	IN
cord-016197-y69wwy40	374	34	Antimicrobial	Antimicrobial	NNP
cord-016197-y69wwy40	374	35	Agents	Agents	NNPS
cord-016197-y69wwy40	374	36	and	and	CC
cord-016197-y69wwy40	374	37	Chemotherapy	Chemotherapy	NNP
cord-016197-y69wwy40	375	1	The	the	DT
cord-016197-y69wwy40	375	2	future	future	NN
cord-016197-y69wwy40	375	3	of	of	IN
cord-016197-y69wwy40	375	4	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	375	5	drug	drug	NN
cord-016197-y69wwy40	375	6	availability	availability	NN
cord-016197-y69wwy40	375	7	:	:	:
cord-016197-y69wwy40	375	8	An	an	DT
cord-016197-y69wwy40	375	9	impending	impending	JJ
cord-016197-y69wwy40	375	10	crisis	crisis	NN
cord-016197-y69wwy40	375	11	Measuring	measure	VBG
cord-016197-y69wwy40	375	12	the	the	DT
cord-016197-y69wwy40	375	13	pace	pace	NN
cord-016197-y69wwy40	375	14	of	of	IN
cord-016197-y69wwy40	375	15	new	new	JJ
cord-016197-y69wwy40	375	16	drug	drug	NN
cord-016197-y69wwy40	375	17	development	development	NN
cord-016197-y69wwy40	375	18	in	in	IN
cord-016197-y69wwy40	375	19	the	the	DT
cord-016197-y69wwy40	375	20	user	user	NN
cord-016197-y69wwy40	375	21	fee	fee	NN
cord-016197-y69wwy40	375	22	era	era	NN
cord-016197-y69wwy40	375	23	How	how	WRB
cord-016197-y69wwy40	375	24	many	many	JJ
cord-016197-y69wwy40	375	25	genes	gene	NNS
cord-016197-y69wwy40	375	26	can	can	MD
cord-016197-y69wwy40	375	27	make	make	VB
cord-016197-y69wwy40	375	28	a	a	DT
cord-016197-y69wwy40	375	29	cell	cell	NN
cord-016197-y69wwy40	375	30	:	:	:
cord-016197-y69wwy40	375	31	the	the	DT
cord-016197-y69wwy40	375	32	minimal	minimal	JJ
cord-016197-y69wwy40	375	33	-	-	HYPH
cord-016197-y69wwy40	375	34	gene	gene	NN
cord-016197-y69wwy40	375	35	-	-	HYPH
cord-016197-y69wwy40	375	36	set	set	VBN
cord-016197-y69wwy40	375	37	concept	concept	NN
cord-016197-y69wwy40	375	38	Antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	375	39	resistance	resistance	NN
cord-016197-y69wwy40	375	40	surveillance	surveillance	NN
cord-016197-y69wwy40	375	41	:	:	:
cord-016197-y69wwy40	375	42	Methods	method	NNS
cord-016197-y69wwy40	375	43	will	will	MD
cord-016197-y69wwy40	375	44	depend	depend	VB
cord-016197-y69wwy40	375	45	on	on	IN
cord-016197-y69wwy40	375	46	objectives	objective	NNS
cord-016197-y69wwy40	375	47	The	the	DT
cord-016197-y69wwy40	375	48	role	role	NN
cord-016197-y69wwy40	375	49	of	of	IN
cord-016197-y69wwy40	375	50	genomics	genomic	NNS
cord-016197-y69wwy40	375	51	in	in	IN
cord-016197-y69wwy40	375	52	antimicrobial	antimicrobial	JJ
cord-016197-y69wwy40	375	53	discovery	discovery	NN
cord-016197-y69wwy40	376	1	The	the	DT
cord-016197-y69wwy40	376	2	patient	patient	NN
cord-016197-y69wwy40	376	3	,	,	,
cord-016197-y69wwy40	376	4	the	the	DT
cord-016197-y69wwy40	376	5	doctor	doctor	NN
cord-016197-y69wwy40	376	6	,	,	,
cord-016197-y69wwy40	376	7	the	the	DT
cord-016197-y69wwy40	376	8	regulator	regulator	NN
cord-016197-y69wwy40	376	9	and	and	CC
cord-016197-y69wwy40	376	10	the	the	DT
cord-016197-y69wwy40	376	11	profit	profit	NN
cord-016197-y69wwy40	376	12	maker	maker	NN
cord-016197-y69wwy40	376	13	:	:	:
cord-016197-y69wwy40	376	14	Conflicts	conflict	NNS
cord-016197-y69wwy40	376	15	and	and	CC
cord-016197-y69wwy40	376	16	possible	possible	JJ
cord-016197-y69wwy40	376	17	solutions	solution	NNS
cord-016197-y69wwy40	376	18	Do	do	VBP
cord-016197-y69wwy40	376	19	guidelines	guideline	NNS
cord-016197-y69wwy40	376	20	for	for	IN
cord-016197-y69wwy40	376	21	communityacquired	communityacquired	JJ
cord-016197-y69wwy40	376	22	pneumonia	pneumonia	NN
cord-016197-y69wwy40	376	23	improve	improve	VB
cord-016197-y69wwy40	376	24	the	the	DT
cord-016197-y69wwy40	376	25	cost	cost	NN
cord-016197-y69wwy40	376	26	-	-	HYPH
cord-016197-y69wwy40	376	27	effectiveness	effectiveness	NN
cord-016197-y69wwy40	376	28	of	of	IN
cord-016197-y69wwy40	376	29	hospital	hospital	NN
cord-016197-y69wwy40	376	30	care	care	NN
cord-016197-y69wwy40	376	31	?	?	.
cord-016197-y69wwy40	377	1	Antibacterial	antibacterial	JJ
cord-016197-y69wwy40	377	2	drug	drug	NN
cord-016197-y69wwy40	377	3	discovery	discovery	NN
cord-016197-y69wwy40	377	4	:	:	:
cord-016197-y69wwy40	378	1	What	what	WP
cord-016197-y69wwy40	378	2	's	be	VBZ
cord-016197-y69wwy40	378	3	in	in	IN
cord-016197-y69wwy40	378	4	the	the	DT
cord-016197-y69wwy40	378	5	pipeline	pipeline	NN
cord-016197-y69wwy40	378	6	?	?	.
cord-016197-y69wwy40	379	1	BSAC	BSAC	NNP
cord-016197-y69wwy40	379	2	Respiratory	Respiratory	NNP
cord-016197-y69wwy40	379	3	Resistance	Resistance	NNP
cord-016197-y69wwy40	379	4	Surveillance	Surveillance	NNP
cord-016197-y69wwy40	379	5	Programme	Programme	NNP
cord-016197-y69wwy40	379	6	:	:	:
cord-016197-y69wwy40	380	1	First	first	JJ
cord-016197-y69wwy40	380	2	results	result	NNS
cord-016197-y69wwy40	380	3	of	of	IN
cord-016197-y69wwy40	380	4	the	the	DT
cord-016197-y69wwy40	380	5	winter	winter	NN
cord-016197-y69wwy40	380	6	1999	1999	CD
cord-016197-y69wwy40	380	7	-	-	SYM
cord-016197-y69wwy40	380	8	2000	2000	CD
cord-016197-y69wwy40	380	9	collection	collection	NN
cord-016197-y69wwy40	380	10	Impact	impact	NN
cord-016197-y69wwy40	380	11	of	of	IN
cord-016197-y69wwy40	380	12	registration	registration	NN
cord-016197-y69wwy40	380	13	procedures	procedure	NNS
cord-016197-y69wwy40	380	14	on	on	IN
cord-016197-y69wwy40	380	15	antibiotic	antibiotic	JJ
cord-016197-y69wwy40	380	16	policies	policy	NNS
cord-016197-y69wwy40	380	17	Strategic	strategic	JJ
cord-016197-y69wwy40	380	18	and	and	CC
cord-016197-y69wwy40	380	19	regulatory	regulatory	JJ
cord-016197-y69wwy40	380	20	considerations	consideration	NNS
cord-016197-y69wwy40	380	21	in	in	IN
cord-016197-y69wwy40	380	22	the	the	DT
cord-016197-y69wwy40	380	23	clinical	clinical	JJ
cord-016197-y69wwy40	380	24	development	development	NN
cord-016197-y69wwy40	380	25	of	of	IN
cord-016197-y69wwy40	380	26	anti	anti	JJ
cord-016197-y69wwy40	380	27	-	-	JJ
cord-016197-y69wwy40	380	28	infectives	infectives	JJ
cord-016197-y69wwy40	380	29	Molecular	molecular	JJ
cord-016197-y69wwy40	380	30	structure	structure	NN
cord-016197-y69wwy40	380	31	of	of	IN
cord-016197-y69wwy40	380	32	nucleic	nucleic	JJ
cord-016197-y69wwy40	380	33	acids	acid	NNS
cord-016197-y69wwy40	380	34	:	:	:
cord-016197-y69wwy40	380	35	A	a	DT
cord-016197-y69wwy40	380	36	structure	structure	NN
cord-016197-y69wwy40	380	37	for	for	IN
cord-016197-y69wwy40	380	38	deoxyribose	deoxyribose	JJ
cord-016197-y69wwy40	380	39	nucleic	nucleic	JJ
cord-016197-y69wwy40	380	40	acid	acid	NN
cord-016197-y69wwy40	380	41	 	 	_SP
cord-016197-y69wwy40	380	42	Figure	Figure	NNP
cord-016197-y69wwy40	380	43	3	3	CD
cord-016197-y69wwy40	380	44	.	.	.
cord-016197-y69wwy40	381	1	A	a	DT
cord-016197-y69wwy40	381	2	question	question	NN
cord-016197-y69wwy40	381	3	of	of	IN
cord-016197-y69wwy40	381	4	balance	balance	NN
cord-016197-y69wwy40	381	5	:	:	:
cord-016197-y69wwy40	381	6	increasing	increase	VBG
cord-016197-y69wwy40	381	7	and	and	CC
cord-016197-y69wwy40	381	8	decreasing	decrease	VBG
cord-016197-y69wwy40	381	9	factors	factor	NNS
cord-016197-y69wwy40	381	10	in	in	IN
cord-016197-y69wwy40	381	11	the	the	DT
cord-016197-y69wwy40	381	12	environment	environment	NN
cord-016197-y69wwy40	381	13	of	of	IN
cord-016197-y69wwy40	381	14	antibacterial	antibacterial	JJ
cord-016197-y69wwy40	381	15	resistance	resistance	NN
cord-016197-y69wwy40	381	16	,	,	,
cord-016197-y69wwy40	381	17	usage	usage	NN
cord-016197-y69wwy40	381	18	,	,	,
cord-016197-y69wwy40	381	19	discovery	discovery	NN
cord-016197-y69wwy40	381	20	,	,	,
cord-016197-y69wwy40	381	21	and	and	CC
cord-016197-y69wwy40	381	22	development	development	NN
cord-016197-y69wwy40	381	23	.	.	.